<?xml version="1.0" encoding="UTF-8"?>
<registryObjects xmlns="http://ands.org.au/standards/rif-cs/registryObjects" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://ands.org.au/standards/rif-cs/registryObjects https://researchdata.edu.au/documentation/rifcs/schema/registryObjects.xsd">
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014703</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014703</identifier>
<identifier type="nhmrc">2014703</identifier>
<name type="primary"><namePart>SMARTERscreen: A randomised controlled trial of patient SMS messaging in general practice to increase participation in the National Bowel Cancer Screening Program</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | preventive medicine | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </subject>
<subject type="local">colorectal cancer prevention</subject>
<subject type="local">bowel cancer screening</subject>
<subject type="local">patient participation</subject>
<subject type="local">primary care</subject>
<subject type="local">behaviour change</subject>
<description type="Chief Investigator">Prof Mark Jenkins</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Most people invited to take part in free screening for bowel cancer do not participate. We will test whether a personalised SMS from the doctor, to their patients phone, will people completing and returning the home test kit sent. The SMS will contain a message from the person's doctor recommending they do it, a video testimonial from someone affected by bowel cancer, a link to the website of the screening program for more information, and an animation of how to complete the home test kit.</description>
<description type="fundingAmount">$1,595,838.95</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014837</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014837</identifier>
<identifier type="nhmrc">2014837</identifier>
<name type="primary"><namePart>A breakthrough approach to define screening gaps in priority groups to target screening</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">cancer screening</subject>
<subject type="local">mammogram screening</subject>
<subject type="local">data linkage</subject>
<subject type="local">data analysis</subject>
<subject type="local">aboriginal health</subject>
<description type="Chief Investigator">Dr Elizabeth Buckley</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Improving breast screening participation requires accurate data of screening rates including within priority groups such as Aboriginal and Torres Strait Islander women, women from diverse cultural and language backgrounds and with different levels of educational attainment and income. Linkage between Census and NSW screening records can provide best evidence of screening rates overall, within priority groups, and following the impact of COVID and previous attempts to improve screening.</description>
<description type="fundingAmount">$601,260.25</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014908</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014908</identifier>
<identifier type="nhmrc">2014908</identifier>
<name type="primary"><namePart>Embedding community driven models to increase cervical screening via HPV self-collection to improve cervical cancer outcomes for Aboriginal and Torres Strait Islander people</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | public health and health services | primary health care | public health and health services | preventive medicine | </subject>
<subject type="local">indigenous health</subject>
<subject type="local">cervical screening</subject>
<subject type="local">community-based</subject>
<subject type="local">implementation</subject>
<subject type="local">equity</subject>
<description type="Chief Investigator">Assoc Prof Lisa Whop</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Aboriginal and Torres Strait Islander people face an unfair burden of cervical cancer. A new screening option lets people take their own sample; this may make screening easier. Working with communities and health services dedicated to Aboriginal and Torres Strait Islander health needs we will co-design ways services can use self-collection and other strategies that best suit them and their communities. This work will engage more people to participate in screening in a culturally safe environment.</description>
<description type="fundingAmount">$1,579,683.10</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014964</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014964</identifier>
<identifier type="nhmrc">2014964</identifier>
<name type="primary"><namePart>MAIL, GP, and SCALE: Mobilising nAtIonaL bowel cancer screeninG Program participation through combining individual, health ServiCe, and populAtion Level intervEntions</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | primary health care | </subject>
<subject type="local">bowel cancer screening</subject>
<subject type="local">general practice</subject>
<subject type="local">intervention study</subject>
<subject type="local">disease modelling</subject>
<subject type="local">mass media</subject>
<description type="Chief Investigator">Dr Eleonora Feletto</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We aim to better understand how Australians are screening for bowel cancer and design a new method for GPs to advocate for the National Bowel Cancer Screening Program, especially for people who screen outside the program but should not and those who have never or forgotten to screen. This project will take new and existing information on ways in which we can improve screening for bowel cancer and assess how they could be combined most effectively to prevent the greatest number of deaths.</description>
<description type="fundingAmount">$1,749,059.70</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015178</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015178</identifier>
<identifier type="nhmrc">2015178</identifier>
<name type="primary"><namePart>It’s a gamechanger” – using HPV self-collection to improve equity and participation in Australia's National Cervical Screening Program</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | primary health care | public health and health services | preventive medicine | public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">human papillomavirus (hpv)</subject>
<subject type="local">cervical cancer</subject>
<subject type="local">equity</subject>
<subject type="local">implementation</subject>
<subject type="local">health care evaluation</subject>
<description type="Chief Investigator">Dr Claire Nightingale</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Integrating self-collection into Australia’s National Cervical Screening Program has game-changing potential to increase participation. We know that healthcare providers need more support to offer this option, and women need information to support decision-making. Our project will enable innovative solutions to support providers, women, and the scale-up of self-collection, and create an enabling environment for the consideration of models of care to increase access and equity.</description>
<description type="fundingAmount">$1,408,759.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015215</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015215</identifier>
<identifier type="nhmrc">2015215</identifier>
<name type="primary"><namePart>Overcoming Inequity: Increasing Cervical Screening Participation for People with Intellectual Disability (CIRCE)</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02y0cs367</identifier><title>Family Planning NSW</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | care for disabled | public health and health services | health promotion | public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">cervical cancer</subject>
<subject type="local">intellectual disability</subject>
<subject type="local">cancer screening</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">informed decision making</subject>
<description type="Chief Investigator">Prof Deborah Bateson</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">Hospitals and Health Services</description>
<description type="full">People with intellectual disability (PWID) are under-screened for cervical cancer in Australia. Through a qualitative process, this project seeks to identify facilitators and barriers to screening. A cluster randomised controlled trial will be undertaken to test the effectiveness of a co-designed, co-produced suite of resources designed to support informed decision making and increase access and uptake of screening in the National Cervical Screening Program for PWID.</description>
<description type="fundingAmount">$1,433,806.71</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015286</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015286</identifier>
<identifier type="nhmrc">2015286</identifier>
<name type="primary"><namePart>BreastScreenPlus: A novel intervention targeting obesity-related barriers to mammographic screening</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | epidemiology | </subject>
<subject type="local">breast cancer</subject>
<subject type="local">mammogram screening</subject>
<subject type="local">obesity</subject>
<subject type="local">intervention study</subject>
<subject type="local">service delivery</subject>
<description type="Chief Investigator">Assoc Prof Jennifer Stone</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Eight breast cancer deaths are prevented for every 1,000 women aged 50-74 years who undergo biennial mammographic screening. However, despite the demonstrated benefits of (free) screening, many women fail to return for screening when next due. This project will evaluate a novel intervention nested within BreastScreen WA to improve the screening experience for both obese women and service delivery staff and thereby, increase rescreening participation in women with obesity.</description>
<description type="fundingAmount">$819,444.70</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015290</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015290</identifier>
<identifier type="nhmrc">2015290</identifier>
<name type="primary"><namePart>A preference-informed model to improve access and equity in bowel screening for Australia’s First Nations people through home care services</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">indigenous health</subject>
<subject type="local">cancer screening</subject>
<subject type="local">bowel cancer screening</subject>
<subject type="local">health services research</subject>
<subject type="local">consumer preferences</subject>
<description type="Chief Investigator">Prof Gail Garvey</description>
<description type="Date Announced">2022-01-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bowel cancer is the third-most common cancer affecting Aboriginal and Torres Strait Islander Australians. Participation in the National Bowel Cancer Screening Program by Aboriginal and Torres Strait Islander people is lower than for non-Indigenous Australians. This project aims to increase participation among the Aboriginal and Torres Strait Islander Home Care Clients by co-developing and implementing a bowel cancer screening program that is informed by their preferences and values.</description>
<description type="fundingAmount">$994,552.30</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2007402</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007402</identifier>
<identifier type="nhmrc">2007402</identifier>
<name type="primary"><namePart>Identifying the predictors and consequences of disparities in the uptake of HIV prevention and treatment programs in Australia: a national data linkage study</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | epidemiology | </subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">disease prevention</subject>
<subject type="local">infectious diseases</subject>
<subject type="local">sexual health</subject>
<subject type="local">infectious diseases</subject>
<description type="Chief Investigator">Dr Skye McGregor</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will create a national e-cohort of people with HIV, linking HIV diagnoses from 1997-2025 with nine other national datasets. This comprehensive dataset will enable us to achieve our aims of tracking and analysing: missed clinical opportunities for HIV testing, PrEP uptake and usage, HIV treatment uptake and adherence, and HIV-related morbidity and mortality. Outcomes will be used by Partner Organisations to develop tailored HIV programs, to achieve elimination of HIV transmission in Australia.</description>
<description type="fundingAmount">$1,216,847.15</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2013921</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013921</identifier>
<identifier type="nhmrc">2013921</identifier>
<name type="primary"><namePart>A national program to scale-up point-of-care hepatitis C testing and treatment</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | infectious diseases | public health and health services | epidemiology | </subject>
<subject type="local">hepatitis c infection</subject>
<subject type="local">liver disease</subject>
<subject type="local">treatment strategies</subject>
<subject type="local">access</subject>
<subject type="local">treatment strategies</subject>
<description type="Chief Investigator">Prof Jason Grebely</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hepatitis C testing and treatment has declined in Australia, slowing elimination progress. Our team evaluated a new point-of-care test for detection of active hepatitis C infection in one hour, enabling same-visit diagnosis and treatment. This test is now approved in Australia and has changed how testing and treatment can be delivered. This Partnership Project will evaluate a national program funded by the Australian government to scale-up point-of-care hepatitis C testing in Australia.</description>
<description type="fundingAmount">$1,498,085.85</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014633</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014633</identifier>
<identifier type="nhmrc">2014633</identifier>
<name type="primary"><namePart>A non-surgical alternative to hysterectomy for the treatment of endometrial cancer</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">endometrial cancer</subject>
<subject type="local">biomarkers</subject>
<subject type="local">predictive</subject>
<subject type="local">molecular biology</subject>
<subject type="local">predictive</subject>
<description type="Chief Investigator">Prof Andreas Obermair</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to develop a personalised treatment decision tool used to counsel endometrial cancer patients about their surgical and non-surgical (hormonal) treatment options. It will take into account key attributes of importance such as fertility preservation, risk of surgical morbidity, risk of relapse, genetic factors, quality of life, patient values and treatment preferences. This work is of critical importance for patients with early onset endometrial cancer, and for frail patients.</description>
<description type="fundingAmount">$739,425.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014684</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014684</identifier>
<identifier type="nhmrc">2014684</identifier>
<name type="primary"><namePart>Novel strategies to improve protection for pregnant women and medically at risk children from influenza and COVID-19</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">public health and health services | health promotion | </subject>
<subject type="local">pregnancy</subject>
<subject type="local">young children</subject>
<subject type="local">influenza</subject>
<subject type="local">covid-19</subject>
<subject type="local">influenza</subject>
<description type="Chief Investigator">Prof Helen Marshall</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pregnant women and children with chronic medical conditions are at increased risk of hospitalisation, intensive care admission and death from influenza and COVID-19 infections. However, there appears to be a high level of vaccine hesitancy among women of reproductive age. We will develop “nudge” interventions to improve influenza and COVID vaccine uptake among pregnant women and medically at risk children and test the effectiveness of the interventions using randomised controlled trials.</description>
<description type="fundingAmount">$964,165.35</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014821</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014821</identifier>
<identifier type="nhmrc">2014821</identifier>
<name type="primary"><namePart>Optimising functional and social independence and safety of older people living with dementia in care homes: Implementation research</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | aged health care | </subject>
<subject type="local">dementia care</subject>
<subject type="local">rehabilitation</subject>
<subject type="local">aged care</subject>
<subject type="local">implementation</subject>
<subject type="local">aged care</subject>
<description type="Chief Investigator">Prof Yun-Hee Jeon</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program builds on true collaboration with the project partner organisations and decades of the research team's track records in promoting evidence informed best practice in dementia care, leveraging their extensive network of partners in research and the aged-care industry. The outcomes will inform researchers, service providers and policymakers working in the aged care sector about implementation of person centred, reablement approaches to dementia care, nationally and internationally.</description>
<description type="fundingAmount">$1,206,733.71</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015197</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015197</identifier>
<identifier type="nhmrc">2015197</identifier>
<name type="primary"><namePart>An integrated platform for the early diagnosis and treatment of biotoxin-related illnesses in Australia like Chronic Inflammatory Response Syndrome</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | infectious diseases |</subject>
<subject type="local">fungal infection </subject>
<subject type="local">biomarkers </subject>
<subject type="local">chronic inflammatory disease </subject>
<subject type="local">fungal diagnosis </subject>
<subject type="local">immune response </subject>
<description type="Chief Investigator">Prof Gilles Guillemin</description>
<description type="Date Announced">2022-02-22T00:00:00</description>
<description type="Sector">University</description>
<description type="full">While many studies now suggest that living in dampness and mould can adversely affect the immune system in some people, few studies define tests that doctors could use to diagnose and treat affected individuals. This research project will study both affected individuals and healthy controls, examining their blood, urine, and sweat along with other tests such as brain scans and environmental testing in their homes, in order to identify appropriate diagnostic tests that doctors can use.</description>
<description type="fundingAmount">$1,063,797.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014696</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014696</identifier>
<identifier type="nhmrc">2014696</identifier>
<name type="primary"><namePart>The Indigenous Australian HPV Cohort Study 2; continuation 5 to 10 years</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">indigenous australians</subject>
<subject type="local">human papillomavirus (hpv)</subject>
<subject type="local">cancer epidemiology</subject>
<subject type="local">cohort study</subject>
<subject type="local">cost-effectiveness</subject>
<description type="Chief Investigator">Ms Joanne Hedges</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Continuing a large, representative Indigenous adult cohort through which to track oral HPV infection, monitor early throat cancer and estimate cost-effectiveness of extensive HPV vaccination coverage in culturally safe ways is essential to yield critical information to include in the management armamentarium of health and wellbeing recommendations for Australia’s First Peoples.</description>
<description type="fundingAmount">$3,107,613.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014723</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014723</identifier>
<identifier type="nhmrc">2014723</identifier>
<name type="primary"><namePart>INTErGenerational intervention to Reduce fraIlTY trial (INTEGRITY).</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aged health care | </subject>
<subject type="local">frailty</subject>
<subject type="local">older people</subject>
<subject type="local">multiple risk factors</subject>
<subject type="local">community intervention</subject>
<subject type="local">community participation</subject>
<description type="Chief Investigator">Assoc Prof Ruth Peters</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The recent ABC TV show ‘Old People’s Home For Four Year Olds’ shows on-screen benefits of bringing together older adults and pre-schoolers. This has enormous potential to benefit our ageing society and similar programs are becoming popular. but a TV show is not the same as everyday life. We now need to establish how these benefits work in a realistic everyday setting. We will test this using a community-based clinical trial: the INTErGenerational Intervention to Reduce fraIlTY trial (INTEGRITY).</description>
<description type="fundingAmount">$3,711,897.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014729</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014729</identifier>
<identifier type="nhmrc">2014729</identifier>
<name type="primary"><namePart>Making Inroads: RCT of a web-based early intervention to interrupt the vicious cycle of co-occurring anxiety and hazardous alcohol use among young adults</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | mental health | </subject>
<subject type="local">anxiety</subject>
<subject type="local">alcohol abuse</subject>
<subject type="local">cognitive behaviour therapy</subject>
<subject type="local">young adults</subject>
<subject type="local">early intervention</subject>
<description type="Chief Investigator">Assoc Prof Lexine Stapinski</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Anxiety and alcohol disorders often co-occur, fueling each other in a self-perpetuating cycle. Early intervention is crucial to engage people with effective management strategies when problematic symptoms first emerge, and before anxiety and alcohol use disorders become entrenched. This study will evaluate the Inroads program, an online early intervention to empower young adults, enhance coping skills, and interrupt the vicious cycle between anxiety and hazardous alcohol use.</description>
<description type="fundingAmount">$1,295,748.84</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014740</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014740</identifier>
<identifier type="nhmrc">2014740</identifier>
<name type="primary"><namePart>Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CALIPSO): multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | infectious diseases | clinical sciences | surgery | clinical sciences | anaesthesiology | </subject>
<subject type="local">prophylaxis</subject>
<subject type="local">cardiac surgery</subject>
<subject type="local">infection control</subject>
<subject type="local">clinical trial</subject>
<subject type="local">antimicrobial resistance</subject>
<description type="Chief Investigator">Assoc Prof Trisha Peel</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Infections following surgery lead to significant patient suffering and healthcare costs. The administration of antibiotics at the time of surgery is an important strategy to prevent infections. In patients undergoing heart surgery we do not know whether there is an additional benefit to giving longer courses of antibiotics following surgery to help prevent infections or if this will lead to patient harm, such as drug-resistant infections. This project will answer these important questions.</description>
<description type="fundingAmount">$4,343,709.10</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014750</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014750</identifier>
<identifier type="nhmrc">2014750</identifier>
<name type="primary"><namePart>PRECeDe: Prevention of neonatal Respiratory morbidity with antenatal corticosteroids prior to Elective Caesarean section in women with Diabetes: A Randomised trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | obstetrics and gynaecology | </subject>
<subject type="local">caesarean section</subject>
<subject type="local">neonatal respiratory distress syndrome</subject>
<subject type="local">gestational diabetes</subject>
<subject type="local">transient neonatal hyperglycaemia</subject>
<subject type="local">corticosteroids</subject>
<description type="Chief Investigator">Assoc Prof Joanne Said</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research trial will determine whether giving corticosteroid injections to pregnant women with diabetes before elective Caesarean section between 35+0 and 39+6 weeks reduces the rate of breathing problems in their babies. We will study the short-term benefits and side effects in the mothers and babies, and also determine whether giving corticosteroid injections is good value for money.</description>
<description type="fundingAmount">$3,409,951.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014763</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014763</identifier>
<identifier type="nhmrc">2014763</identifier>
<name type="primary"><namePart>Epigenetic Protection Predicts Risk Diabetic Nephropathy (EPICENTRE)</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">genetics | epigenetics (incl. genome methylation and epigenomics) | </subject>
<subject type="local">diabetes mellitus</subject>
<subject type="local">renal disease</subject>
<subject type="local">diabetic nephropathy</subject>
<subject type="local">dna methylation</subject>
<subject type="local">epigenetics</subject>
<description type="Chief Investigator">Prof Assam El-Osta</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Diabetes affects over 1 million Australians and disproportionately affects Indigenous Australians. We have established an international EPICENTRE consortium now seek to explore the potential role of epigenetic modifications to explain the development of diabetic renal disease. Over the last decade we have developed contemporary genomic technologies and new approaches that specifically characterise epigenetic modifications using overt renal disease as the primary outcome.</description>
<description type="fundingAmount">$4,897,328.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014800</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014800</identifier>
<identifier type="nhmrc">2014800</identifier>
<name type="primary"><namePart>Personalised Selection of Medication for Newly Diagnosed Adult Epilepsy – the PERSONAL Trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">neurosciences | central nervous system | </subject>
<subject type="local">epilepsy</subject>
<subject type="local">decision support</subject>
<subject type="local">antiepileptic drugs</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">artificial neural networks</subject>
<description type="Chief Investigator">Prof Patrick Kwan</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We have trained a machine learning prediction model that can assist neurologists to select the most effective initial antiseizure medication for individual patients with newly diagnosed epilepsy. We propose a randomised controlled trial (PERSONAL) to evaluate whether incorporating the machine learning model in initial drug selection can render more patients seizure-free compared to usual care. A total of 234 patients will be recruited from 14 epilepsy centres across all six states of Australia.</description>
<description type="fundingAmount">$2,459,115.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014833</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014833</identifier>
<identifier type="nhmrc">2014833</identifier>
<name type="primary"><namePart>A primary care provider intervention to improve early child neurodevelopment in Urban Aboriginal children</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05jhnwe22</identifier><title>Edith Cowan University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">child development</subject>
<subject type="local">aboriginal child</subject>
<subject type="local">community child health</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">maternal mental health</subject>
<description type="Chief Investigator">Assoc Prof Daniel McAullay</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite a high level of developmental issues in Aboriginal babies, there has been no primary health care delivered early child development program starting in the first 4 weeks of life. We will address Aboriginal child’s development by improving primary health care’s ability to deliver child development services. We will do this by seeing if the CCD program commenced in the first 4-weeks of life will improves a child’s developmental needs in the first year of life.</description>
<description type="fundingAmount">$2,992,864.40</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014841</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014841</identifier>
<identifier type="nhmrc">2014841</identifier>
<name type="primary"><namePart>The LifeTrack Project: Population-based longitudinal cohort study to understand suicidal transitions</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | mental health | </subject>
<subject type="local">suicide prevention</subject>
<subject type="local">suicide risk</subject>
<subject type="local">population-based</subject>
<subject type="local">longitudinal cohort study</subject>
<subject type="local">psychiatric epidemiology</subject>
<description type="Chief Investigator">Prof Philip Batterham</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We don't understand why some people who think about suicide go on to make a suicide attempt, while others recover. There have been very few studies following individuals at risk of suicide over an extended time period. We will test a group of people with suicidal thoughts for three years to work out whether there are certain types of people who are more resistant to suicide attempt. We will use the information from the study to identify new ways to reduce suicide risk in the population.</description>
<description type="fundingAmount">$1,062,723.20</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014868</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014868</identifier>
<identifier type="nhmrc">2014868</identifier>
<name type="primary"><namePart>The FLIRT-TB study: A fluoroquinolone-based regimen to treat the commonest form of drug-resistant tuberculosis</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | infectious diseases | </subject>
<subject type="local">mycobacterium tuberculosis</subject>
<subject type="local">drug resistance</subject>
<subject type="local">infectious diseases</subject>
<subject type="local">clinical trial</subject>
<subject type="local">tuberculosis</subject>
<description type="Chief Investigator">Prof Gregory Fox</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Tuberculosis (TB) is an infectious respiratory disease affecting 10 million people each year worldwide. Resistance to isoniazid, one of the most important first-line antibiotics used to treat TB, leads to increased mortality and more advanced drug resistance. We will undertake the first clinical trial to evaluate the effectiveness of new-generation fluoroquinolones antibiotics in treating isoniazid-resistant TB. This trial will be conducted in Australia, Vietnam and Canada.</description>
<description type="fundingAmount">$4,773,516.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014896</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014896</identifier>
<identifier type="nhmrc">2014896</identifier>
<name type="primary"><namePart>Are calcium channel blockers associated with breast cancer? Assessing the impact of long-term use in large longitudinal cohorts</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02n415q13</identifier><title>Curtin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">breast cancer</subject>
<subject type="local">pharmacoepidemiology</subject>
<subject type="local">high blood pressure</subject>
<subject type="local">data linkage</subject>
<subject type="local">longitudinal cohort study</subject>
<description type="Chief Investigator">Prof Rachael Moorin</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Breast cancer is the commonest cancer in women. Calcium channel blockers (CCBs) are frequently used worldwide to treat high blood pressure. A link between use of CCBs and breast cancer has been proposed with mixed findings in North American, European and Asian women. No data exist for Australian women or across populations. Since 1 in 8 Australian women will be diagnosed with breast cancer by age 85 years, it is important to determine whether this risk is increased by the use of CCBs.</description>
<description type="fundingAmount">$1,107,757.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014899</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014899</identifier>
<identifier type="nhmrc">2014899</identifier>
<name type="primary"><namePart>Perinatal depression and antidepressants treatment: wave 7 follow up of the MPEWS longitudinal cohort study</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02stey378</identifier><title>The University of Notre Dame Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | psychiatry (incl. psychotherapy) | </subject>
<subject type="local">cohort study</subject>
<subject type="local">longitudinal study</subject>
<subject type="local">maternal depression</subject>
<subject type="local">antidepressants</subject>
<subject type="local">child development</subject>
<description type="Chief Investigator">Prof Megan Galbally</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">When examining the longer term outcomes from pregnancy treatment with antidepressants on maternal depression and on child developmental outcomes, randomized controlled trials for antidepressants are not ethically possible and as such cohort data are required. Currently there remains uncertainty about antidepressant treatment in pregnancy for clinicians and women. We will address this gap in cohort studies through undertaking a follow up wave of a prospective longitudinal pregnancy cohort study.</description>
<description type="fundingAmount">$1,585,413.80</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014900</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014900</identifier>
<identifier type="nhmrc">2014900</identifier>
<name type="primary"><namePart>SNAP-PY: Staphylococcus aureus Network Adaptive Platform trial for Paediatrics and Youth</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | infectious diseases | </subject>
<subject type="local">staphylococcus aureus</subject>
<subject type="local">antibiotic therapy</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">bacteraemia</subject>
<subject type="local">paediatric</subject>
<description type="Chief Investigator">Assoc Prof Asha Bowen</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Staphylococcus aureus is the most common cause of bloodstream infections resulting in hospital admission for children. The best antibiotic treatments for children are not known. The Staph aureus Network Adaptive Platform trial for Paediatrics and Youth (SNAP-PY) will find out the best antibiotic treatments for children and adolescents. This will optimise antibiotic treatment for children with Staph aureus bloodstream infections and reduce premature deaths.</description>
<description type="fundingAmount">$2,045,957.40</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014930</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014930</identifier>
<identifier type="nhmrc">2014930</identifier>
<name type="primary"><namePart>Translatable Evidence To Improve Lung Health Outcomes In First Nations People – A Cohort Study From Birth to 6 Years</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">cardiorespiratory medicine and heamatology | respiratory diseases | public health and health services | aboriginal and torres strait islander health | paediatrics and reproductive medicine | paediatrics | </subject>
<subject type="local">lung function assessment</subject>
<subject type="local">disease prevention</subject>
<subject type="local">indigenous health</subject>
<subject type="local">aboriginal child</subject>
<subject type="local">cohort study</subject>
<description type="Chief Investigator">Dr Danielle Wurzel</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Good lung health as an adult depends on how healthy we are as children. Good lung health predicts future heart health and how long we live. First Nations children have unacceptably high rates of lung disease which means poorer adult health. There are certain exposures or events in childhood that can be protective or damaging to our lungs. This research will look at a range of these exposures and events and study them in detail to discover ways to help improve the health of FirstN People.</description>
<description type="fundingAmount">$3,723,567.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014932</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014932</identifier>
<identifier type="nhmrc">2014932</identifier>
<name type="primary"><namePart>Can mass drug administration reduce the incidence of adverse perinatal outcomes and other health consequences of endemic sexually transmitted infections? A community effectiveness trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | pacific peoples health | public health and health services | preventive medicine | paediatrics and reproductive medicine | obstetrics and gynaecology | </subject>
<subject type="local">population health</subject>
<subject type="local">sexual health</subject>
<subject type="local">gonorrhoea</subject>
<subject type="local">chlamydia</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Lucia Romani</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Sexual and reproductive health is an urgent global public health priority in Fiji and the Pacific region, where curable sexually transmitted infections (STIs) are endemic. This world first trial will use mass drug administration with azithromycin to reduce the prevalence of chlamydia and gonorrhoeae in a population of &gt;180,000 people in Fiji and will be the first to measure the effect of MDA on serious complications of STIs in the general population.</description>
<description type="fundingAmount">$2,148,887.90</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014936</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014936</identifier>
<identifier type="nhmrc">2014936</identifier>
<name type="primary"><namePart>ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">oncology</subject>
<subject type="local">clinical trial</subject>
<subject type="local">ovarian cancer</subject>
<subject type="local">targeted therapy</subject>
<subject type="local">survival rate</subject>
<description type="Chief Investigator">Prof Linda Mileshkin</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In Australia ovarian cancer is the most common cause of gynaecological cancer death. Despite surgery and chemotherapy 80% of affected women have cancer relapse which is ultimately fatal. This international randomised clinical trial examines if combining 2 targeted therapies, cediranib and olaparib tablets taken after finishing chemotherapy, will help women live longer without cancer progression. The trial will complete recruitment in 2022 and this funding will ensure patient follow-up continues</description>
<description type="fundingAmount">$494,131.60</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014937</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014937</identifier>
<identifier type="nhmrc">2014937</identifier>
<name type="primary"><namePart>Resuscitation in Paediatric Septic Shock using Mega-Dose Vitamin C and Hydrocortisone - A Randomised Controlled Multicentre Trial (RESPOND study)</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | </subject>
<subject type="local">clinical trial</subject>
<subject type="local">paediatric</subject>
<subject type="local">septic shock</subject>
<subject type="local">intensive care</subject>
<subject type="local">ascorbic acid</subject>
<description type="Chief Investigator">Assoc Prof Kristen Gibbons</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Globally, a child dies from sepsis every 10 seconds; in Australia, a child dies every week. Many surviving children experience long term adverse outcomes. Australian states are implementing mandates for sepsis treatment. Yet, the evidence for sepsis treatment other than antibiotics is limited. We will perform an international study for children with sepsis which will test the use of mega-dose vitamin C and steroids - a promising treatment that has already shown some benefit in adults.</description>
<description type="fundingAmount">$1,305,172.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014952</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014952</identifier>
<identifier type="nhmrc">2014952</identifier>
<name type="primary"><namePart>Understanding intergenerational change in the health and well-being of older adults and its effects: The Sydney Memory and Ageing Study 2.</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aged health care | </subject>
<subject type="local">aged health</subject>
<subject type="local">cognition</subject>
<subject type="local">physical health</subject>
<subject type="local">mental health</subject>
<subject type="local">social health issues</subject>
<description type="Chief Investigator">Prof Henry Brodaty</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Has there been a generational change in health of older Australians? We aim to compare the cognitive, physical, psychological and social health of current older Australians and those from 17 years ago. Each generation undergoes different experiences compared to previous ones; these can effect health. We will repeat and expand (using new technology) on our 2005+ survey of 1037 70-90 year olds to answer this question. Answers will shed light on protective factors and inform health planning.</description>
<description type="fundingAmount">$3,304,760.16</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014954</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014954</identifier>
<identifier type="nhmrc">2014954</identifier>
<name type="primary"><namePart>AAT-APP Trial: A RCT of alcohol approach-avoidance training to reduce heavy drinking in people with alcohol use disorders</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">psychology | psychology not elsewhere classified | public health and health services | mental health | </subject>
<subject type="local">alcohol use disorders</subject>
<subject type="local">addiction treatment</subject>
<subject type="local">impulsivity</subject>
<subject type="local">health service utilisation</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<description type="Chief Investigator">Assoc Prof Victoria Manning</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">When people undergoing alcohol treatment are given computerised training to avoid alcohol images, and approach positive images instead, it reduces their likelihood of relapsing. We have developed and tested the world’s first smartphone app that delivers a personalised version of this “approach/avoidance training” (“AAT-App”). We now aim to determine how effective AAT-App is at reducing alcohol use and craving in a large sample of people with alcohol dependence who are not receiving treatment.</description>
<description type="fundingAmount">$948,498.04</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014960</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014960</identifier>
<identifier type="nhmrc">2014960</identifier>
<name type="primary"><namePart>SODA-BIC: Sodium Bicarbonate For Decompensated Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | intensive care | </subject>
<subject type="local">intensive care</subject>
<subject type="local">critical care medicine</subject>
<subject type="local">metabolic acidosis</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Ary Serpa Neto</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Metabolic acidosis is a term that means that the blood is acidic. Patients with this condition are typically very ill and may die. No specific therapy exists, but sodium bicarbonate (a cheap and widely available drug) may improve the condition of these patients. We will randomly (like tossing a coin) treat severe patients with either sodium bicarbonate or inactive fluid given into a vein by continuous drip. We will compare the mortality rate and the use of haemodialysis within the first 30 days.</description>
<description type="fundingAmount">$1,920,486.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2014980</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014980</identifier>
<identifier type="nhmrc">2014980</identifier>
<name type="primary"><namePart>A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | clinical sciences not elsewhere classified | clinical sciences | psychiatry (incl. psychotherapy) | public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">cannabis</subject>
<subject type="local">substance use disorders</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">addiction treatment</subject>
<subject type="local">aboriginal mental health</subject>
<description type="Chief Investigator">Prof Nicholas Lintzeris</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cannabis use is increasing in Australia, yet there are few effective treatments for cannabis dependence. This study will evaluate cannabidiol (CBD) combined with counselling to reduce illicit cannabis use and improve health and social outcomes, compared to placebo in a randomised trial with 250 participants across services in NSW and Victoria. Aboriginal people comprise 20% of people in treatment for cannabis, and we will purposively examine their outcomes and experiences in the study.</description>
<description type="fundingAmount">$2,120,137.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015020</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015020</identifier>
<identifier type="nhmrc">2015020</identifier>
<name type="primary"><namePart>Magnetic Resonance imaging outcomes in the Colchicine After Stroke to Prevent Event Recurrence (MR-CASPER) trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">post-stroke dementia</subject>
<subject type="local">ischaemic stroke</subject>
<subject type="local">neuroinflammation</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">cognition</subject>
<description type="Chief Investigator">Prof Mark Parsons</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">MR-CASPER is a multi-centre, prospective, randomised, double-blind trial of the anti-inflammatory agent colchicine to prevent recurrent stroke and rapid progression of atherosclerotic disease. The trial uses novel, serial Magnetic Resonance Imaging (MRI) of the brain and cerebral blood vessels to measure outcomes alongside cognitive, mood and quality of life assessments. MR-CASPER will give crucial mechanistic insights into the effects of colchicine on brain and blood vessel inflammation.</description>
<description type="fundingAmount">$1,535,098.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015060</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015060</identifier>
<identifier type="nhmrc">2015060</identifier>
<name type="primary"><namePart>Childhood febrile convulsions - do treatment patterns determine the risk of early recurrence?</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | emergency medicine | </subject>
<subject type="local">child health</subject>
<subject type="local">emergency medicine</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">seizures</subject>
<subject type="local">caregivers</subject>
<description type="Chief Investigator">Prof Simon Craig</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">A febrile convulsion in a young child is incredibly stressful. Parents often think their child is dying. Currently, no specific treatment is offered to parents when their child is discharged from hospital. Our research, to be conducted across 25 hospitals, will compare the current "wait and see" approach to treatment recommendations for regular doses of paracetamol or ibuprofen to control fevers. We hope to test if the new treatment reduces the risk of more seizures occurring in the same illness</description>
<description type="fundingAmount">$3,490,416.30</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015100</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015100</identifier>
<identifier type="nhmrc">2015100</identifier>
<name type="primary"><namePart>Accelerating clot lysis in ischemic stroke with dornase alfa in an Umbrella Bayesian Optimised Phase 2 trial</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">neurosciences | central nervous system | </subject>
<subject type="local">ischaemic stroke</subject>
<subject type="local">alternative thrombolytic agents</subject>
<subject type="local">haematology</subject>
<subject type="local">rural and remote health</subject>
<subject type="local">telemedicine</subject>
<description type="Chief Investigator">Prof Bruce Campbell</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Stroke remains a major cause of disability. Clot-dissolving medicines targeting fibrin can be rapidly delivered at most Australian hospitals. DNA extruded by white blood cells is another key structural component of clot. Dornase, an approved medicine for other diseases, dissolves DNA and we showed accelerated clot dissolving when combined with standard treatment. Our trial will test whether dornase can accelerate restoration of blood flow to improve outcomes in up to 300 patients with stroke.</description>
<description type="fundingAmount">$1,453,336.70</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015133</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015133</identifier>
<identifier type="nhmrc">2015133</identifier>
<name type="primary"><namePart>Avatar-mediated therapy for hallucinations: superiority trial (AMETHYST)</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/031rekg67</identifier><title>Swinburne University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | health, clinical and counselling psychology | </subject>
<subject type="local">psychosis</subject>
<subject type="local">schizophrenia and related disorders</subject>
<subject type="local">cognitive behaviour therapy</subject>
<subject type="local">clinical psychology</subject>
<subject type="local">psychological treatment</subject>
<description type="Chief Investigator">Assoc Prof Neil Thomas</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing hostile and critical voices is a highly distressing experience that characterises psychosis. Current treatments have limited impact, and more potent therapies are urgently needed. A promising new approach uses virtual reality technology to recreate the voices the person hears as digital avatars, used in therapy sessions to help overcome this experience. This clinical trial will determine whether this therapy offers a more powerful therapeutic option than current recommended treatment.</description>
<description type="fundingAmount">$1,746,774.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015140</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015140</identifier>
<identifier type="nhmrc">2015140</identifier>
<name type="primary"><namePart>A Surfactant Treatment Method for Modern Neonatal Care: SURFactant by SUPraglottic Airway (The SURFSUP RCT)</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | </subject>
<subject type="local">very preterm birth</subject>
<subject type="local">lung surfactant</subject>
<subject type="local">neonatal respiratory distress syndrome</subject>
<subject type="local">continuous positive airway pressure (cpap)</subject>
<subject type="local">neonatal intensive care (nicu)</subject>
<description type="Chief Investigator">Dr Calum Roberts</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This trial will assess a new method of giving surfactant treatment into the lungs of premature babies with breathing difficulties. 'Supraglottic airway' are soft plastic devices that are easier to insert and more comfortable than current methods, which are challenging to learn and not possible for some neonatal units. We will test the effectiveness of supraglottic airway surfactant treatment, which will allow all babies who need surfactant to receive it in their birth hospital without delay.</description>
<description type="fundingAmount">$1,707,835.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015146</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015146</identifier>
<identifier type="nhmrc">2015146</identifier>
<name type="primary"><namePart>EFFECT OF A VAPORISED NICOTINE PRODUCT vs VARENICLINE ON SMOKING CESSATION FOR LOW-SOCIOECONOMIC STATUS SMOKERS: A RANDOMISED TRIAL</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">smoking cessation</subject>
<subject type="local">smoking intervention</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">intervention study</subject>
<subject type="local">social disadvantage</subject>
<description type="Chief Investigator">Dr Ryan Courtney</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Smoking cessation aids can support long-term smoking cessation, but quit rates from current approaches remain low. VNPs are one such approach that has shown some promise for cessation, but government and regulatory bodies have called for more trial evidence. Newer generation pod VNPs have not been evaluated in a clinical trial despite their popularity and wide use globally. Trial findings will have immediate practical applications and provide much needed evidence on a new alternative quit aid.</description>
<description type="fundingAmount">$2,659,251.03</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015147</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015147</identifier>
<identifier type="nhmrc">2015147</identifier>
<name type="primary"><namePart>ORVAC Stage 2 - Optimising Rotavirus Vaccine in Aboriginal Children: a double-blind, randomised, placebo-controlled, adaptive clinical trial of a third scheduled dose of oral rotavirus vaccine for Australian Aboriginal children.</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">rotavirus</subject>
<subject type="local">diarrhoeal disease</subject>
<subject type="local">vaccine strategy</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<description type="Chief Investigator">Prof Thomas Snelling</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Rotavirus can cause such bad diarrhoea in children that they need to be hospitalised. Aboriginal children in remote and rural parts of Australia are up to 20 times more likely to need hospitalisation with rotavirus than non-Indigenous children. There is a vaccine for rotavirus. Optimising Rotavirus Vaccination in Aboriginal Children (ORVAC) will test whether giving Aboriginal children aged 6-11 months an extra (booster) dose of rotavirus vaccine will give them better protection from rotavirus.</description>
<description type="fundingAmount">$2,561,907.70</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015173</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015173</identifier>
<identifier type="nhmrc">2015173</identifier>
<name type="primary"><namePart>NUDG-ED: Trial of behavioural ‘nudging’ interventions to reduce unnecessary care for low back pain in the Emergency Department</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | health promotion | clinical sciences | emergency medicine | public health and health services | health information systems (incl. surveillance) | </subject>
<subject type="local">quality of care</subject>
<subject type="local">low back pain</subject>
<subject type="local">behavioural intervention</subject>
<subject type="local">communications/social research</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Adrian Traeger</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In 2018 over 120 000 people went to an emergency department in Australia because of low back pain. Most had 'simple' low back pain, where medical care such as diagnostic imaging (x-Ray, CT, MRI) and strong opioid medicines offer little benefit. Yet 3 in every 4 patients still received this kind of care. Unnecessary care can harm patients and diverts substantial resources from where they are most needed. This project tests a new way to reduce unnecessary care in Australian hospitals.</description>
<description type="fundingAmount">$1,119,327.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015177</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015177</identifier>
<identifier type="nhmrc">2015177</identifier>
<name type="primary"><namePart>Improving health outcomes in people with a dual diagnosis released from prison: a multi-jurisdictional, prospective cohort study</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | mental health | </subject>
<subject type="local">prison population</subject>
<subject type="local">health inequalities</subject>
<subject type="local">health service utilisation</subject>
<subject type="local">data linkage</subject>
<subject type="local">dual diagnosis</subject>
<description type="Chief Investigator">Prof Stuart Kinner</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">People released from prison have poor health and die at a rate much higher than the general community. Among this already vulnerable group, people with co-occurring mental health and substance use problems (‘dual diagnosis’) are particularly at risk. This study will examine health and health service outcomes for 4,232 adults released from prisons in QLD, WA, NSW and VIC, and followed for more than 9 years through data linkage. The findings will inform improvements to throughcare nationally.</description>
<description type="fundingAmount">$1,466,784.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015203</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015203</identifier>
<identifier type="nhmrc">2015203</identifier>
<name type="primary"><namePart>Maternal and early life origins of adolescent menstrual disorders and pelvic pain</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | public health and health services | epidemiology | </subject>
<subject type="local">menstruation</subject>
<subject type="local">adolescent</subject>
<subject type="local">dysmenorrhoea</subject>
<subject type="local">maternal health</subject>
<subject type="local">early childhood</subject>
<description type="Chief Investigator">Prof Gita Mishra</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Menstrual disorders – irregular, heavy, or painful periods – and pelvic pain are common among adolescent girls and disrupt life activities. Not enough is known about the maternal and early life factors linked with these conditions. This study addresses evidence gaps with new data on menstruation in adolescence, combined with previous data available from these girls and their mothers. The new knowledge on the development of these conditions will inform and guide their prevention and management.</description>
<description type="fundingAmount">$1,475,456.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015208</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015208</identifier>
<identifier type="nhmrc">2015208</identifier>
<name type="primary"><namePart>‘The Next Generation Aboriginal Youth Cohort Study’: Co-designing a strengths-based study to identify evidence-based, culturally strong, implementable strategies to improve youth health outcomes</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | public health and health services | epidemiology | public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">indigenous health</subject>
<subject type="local">youth</subject>
<subject type="local">wellbeing</subject>
<subject type="local">aboriginal mental health</subject>
<subject type="local">resilience</subject>
<description type="Chief Investigator">Prof Sandra Eades</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The project aims to undertake two waves of follow-up of young Aboriginal people from the 'Next Generation Youth Wellbeing study' in partnership with young people, their families and Aboriginal Community organisations. The study will examine changes in key health outcomes (social and emotional wellbeing, cardiovascular risk factors and avoidable injury) and factors that impact on those outcomes such as connection to culture, health behaviours and social challenges.</description>
<description type="fundingAmount">$2,619,818.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015248</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015248</identifier>
<identifier type="nhmrc">2015248</identifier>
<name type="primary"><namePart>Testing an implementable strategy to improve infant skin barrier to prevent asthma and preserve lung function: a 4-year follow-up of the existing PEBBLES RCT</namePart></name>
<name type="alternative"><namePart>Clinical Trials and Cohort Studies</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | preventive medicine | </subject>
<subject type="local">allergy prevention</subject>
<subject type="local">lung development</subject>
<subject type="local">asthma</subject>
<subject type="local">allergic airways disease</subject>
<subject type="local">neonatal</subject>
<description type="Chief Investigator">Assoc Prof Adrian Lowe</description>
<description type="Date Announced">2022-05-18T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will test if improving the infant skin barrier by using daily regular skincare treatment can reduce early life asthma and lung function deficits. This trial may change infant skincare practices and reduce the amount of respiratory disease in our community. This is a follow-on study of our large NHMRC funded trial, testing if this intervention can improve skin barrier, and reduce the incidence of allergic sensitisation and food allergy.</description>
<description type="fundingAmount">$756,239.42</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015584</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015584</identifier>
<identifier type="nhmrc">2015584</identifier>
<name type="primary"><namePart>Centre for Safe Air</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | epidemiology | public health and health services | environmental and occupational health and safety | applied economics | health economics | </subject>
<subject type="local">environmental epidemiology</subject>
<subject type="local">mathematical modelling</subject>
<subject type="local">risk assessment</subject>
<subject type="local">cost-effectiveness</subject>
<subject type="local">public health policy</subject>
<description type="Chief Investigator">Prof Fay Johnston</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Outdoor air hazards like allergens, traffic emissions, and smoke cause a substantial health burden by contributing to diseases of the lungs, heart and brain. Some threats, like bushfire smoke, are increasing but research and policy responses remain fragmented across health and environmental fields. We will bring together experts, policymakers, and consumers to create synergistic, innovative solutions for protecting community health in the face of existing and escalating airborne threats.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015587</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015587</identifier>
<identifier type="nhmrc">2015587</identifier>
<name type="primary"><namePart>Violence Perpetration: Profiling, Prediction and Prevention</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">domestic violence</subject>
<subject type="local">aggression</subject>
<subject type="local">antisocial behaviour</subject>
<subject type="local">social and behavioural research</subject>
<subject type="local">childhood</subject>
<description type="Chief Investigator">Prof Tony Butler</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Violence is a major public health issue. It is a major cause of death, suffering and economic loss worldwide. The focus of this CRE is to better understand violence perpetration, and to facilitate improvements in its prediction and prevention. Eleven projects will observe individual factors such as early life experiences, cognition and medication use, and consider broader issues such as sentencing practices in court and how to optimize the collection and use of large violence-related data.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015611</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015611</identifier>
<identifier type="nhmrc">2015611</identifier>
<name type="primary"><namePart>CRE for STrengthening Health Systems in Remote Australia (CRESTRA)</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006mbby82</identifier><title>Menzies School of Health Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | primary health care | </subject>
<subject type="local">health service accessibility</subject>
<subject type="local">health services research</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">remote communities</subject>
<subject type="local">rural and remote health services</subject>
<description type="Chief Investigator">Prof John Wakerman</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The Centre of Research Excellence for Strengthening Health Systems in Remote Australia brings together Australia’s leading remote health researchers and remote primary care services across four states to carry out a program of research that will ensure: (1) stable and competent staffing; (2) fair funding; and (3) well-coordinated health services, thereby improving access to high quality health services in remote areas, reducing hospitalisations and improving health outcomes at a lesser cost.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015613</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015613</identifier>
<identifier type="nhmrc">2015613</identifier>
<name type="primary"><namePart>CRE for Interstitial Lung Disease - towards Individualised Care</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">cardiorespiratory medicine and heamatology | respiratory diseases | </subject>
<subject type="local">pulmonary fibrosis</subject>
<subject type="local">individualising management</subject>
<subject type="local">disease aetiology</subject>
<subject type="local">phenotype</subject>
<subject type="local">drug discovery</subject>
<description type="Chief Investigator">Assoc Prof Tamera Corte</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The Centre for Research Excellence in Interstitial Lung Disease (ILD) – towards Individualised Care (CRE-ILD) aims to transform and extend the lives of people with ILD, through effective, personalised approaches to identify and manage ILD. Building on our successful CRE for pulmonary fibrosis, exceptional national platforms and multidisciplinary expert team, CRE-ILD will broaden our focus to all ILD, in a personalised approach specifically addressing our patients’ identified research priorities.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015615</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015615</identifier>
<identifier type="nhmrc">2015615</identifier>
<name type="primary"><namePart>Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | rheumatology and arthritis | </subject>
<subject type="local">clinical effectiveness</subject>
<subject type="local">evidence-based health care</subject>
<subject type="local">capacity building</subject>
<subject type="local">implementation</subject>
<subject type="local">translation</subject>
<description type="Chief Investigator">Prof Rachelle Buchbinder</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trial Network was established in 2015 to address the immense burden of musculoskeletal conditions. With the aid of NHMRC-CRE investment (2018-22) we have already driven improvements in care. Our new CRE will significantly extend our reach, scope, depth and impact. Three new foci will be to bridge the bench to bedside gap, state-of-the-art trials of complex interventions, embedded in usual care, and 3) globalisation of our work.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015622</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015622</identifier>
<identifier type="nhmrc">2015622</identifier>
<name type="primary"><namePart>Science Translation for e-Psychological Perinatal Supports (STePPS CRE)</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00ymae584</identifier><title>Institute for Breathing and Sleep</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | health, clinical and counselling psychology | psychology | developmental psychology and ageing | public health and health services | primary health care | </subject>
<subject type="local">maternal depression</subject>
<subject type="local">anxiety disorders</subject>
<subject type="local">psychological treatment</subject>
<subject type="local">mother-infant interaction</subject>
<subject type="local">internet service delivery</subject>
<description type="Chief Investigator">Prof Jeannette Milgrom</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Over 300,000 women give birth in Australia each year and 20% experience clinical depression, often with severe anxiety, either in pregnancy or the first postnatal year. By bringing together cutting edge Australian and international research in perinatal mental health, the goal is to reduce the burden of mental health difficulties on families and future generations. This CRE will produce better Knowledge, better Interventions and e-mental health treatments, Improved access and treatment uptake.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015705</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015705</identifier>
<identifier type="nhmrc">2015705</identifier>
<name type="primary"><namePart>A Centre of Research Excellence to Accelerate Stroke Trial Innovation and Translation</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">neurosciences | cellular nervous system | </subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">stroke</subject>
<subject type="local">telemedicine</subject>
<subject type="local">public health impact</subject>
<subject type="local">public health policy</subject>
<description type="Chief Investigator">Prof Richard Lindley</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Stroke remains a serious medical problem affecting tens of thousands of Australians each year. This CRE application will deliver better healthcare for those with stroke, by co-designing new stroke trials with consumers, and using new technology to deliver stroke interventions in rural and remote Australia. Our 'whole of system" approach will speed up translation of new treatments and we will build a new generation of clinician researchers to increase future stroke research capacity.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015724</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015724</identifier>
<identifier type="nhmrc">2015724</identifier>
<name type="primary"><namePart>Towards eradicating food allergy: from population to precision prevention, early intervention and management</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | </subject>
<subject type="local">food allergy</subject>
<subject type="local">paediatric</subject>
<subject type="local">population health</subject>
<subject type="local">allergy prevention</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Assoc Prof Kirsten Perrett</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Australia has the world’s highest rate of food allergy. We have made significant progress understanding strategies to prevent food allergy and are testing these in large clinical trials. We now aim to understand who will benefit from these strategies, to reduce the number of children developing allergies, how best to treat and manage allergy to improve the lives of those living with food allergy, and to rapidly transfer research findings into public health policy and clinical practice changes.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015727</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015727</identifier>
<identifier type="nhmrc">2015727</identifier>
<name type="primary"><namePart>Translational Centre for Speech Disorders</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics and reproductive medicine not elsewhere classified | </subject>
<subject type="local">developmental disorders</subject>
<subject type="local">speech</subject>
<subject type="local">child development</subject>
<subject type="local">clinical genetics</subject>
<subject type="local">brain development</subject>
<description type="Chief Investigator">Prof Angela Morgan</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">One in 5 children have a speech or language disorder at school entry, with lifelong deficits in psychosocial, academic and employment outcomes. Current speech pathology management is severely limited because it focuses on symptoms and ignores critical growing evidence on underlying genetic and neural aetiologies. The vision of our CRE is to transform speech pathology, by identifying, understanding and targeting the underlying aetiology that results in the symptomatology.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015739</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015739</identifier>
<identifier type="nhmrc">2015739</identifier>
<name type="primary"><namePart>Centre for Research Excellence in Cervical Cancer Control (C4)</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | preventive medicine | </subject>
<subject type="local">cervical screening</subject>
<subject type="local">vaccination</subject>
<subject type="local">cervical cancer</subject>
<subject type="local">human papillomavirus (hpv)</subject>
<subject type="local">screening</subject>
<description type="Chief Investigator">Prof Karen Canfell</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This proposal will continue the work of our successful Centre of Research Excellence in Cervical Cancer Control - “C4”. To realise the elimination goal of cervical cancer, we will tackle the enormous inequities in access to cervical cancer control interventions, through implementation activities focused on achieving high and equitable participation in HPV vaccination, cervical screening, triage and treatment, including developing and evaluating new pathways for HPV self-collection for screening.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015747</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015747</identifier>
<identifier type="nhmrc">2015747</identifier>
<name type="primary"><namePart>The Centre of Research Excellence in Bipolar Disorder (CORE-BD)</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">public health and health services | mental health | </subject>
<subject type="local">bipolar affective disorder</subject>
<subject type="local">clinical trial</subject>
<subject type="local">early intervention</subject>
<subject type="local">quality of care</subject>
<subject type="local">quality of life</subject>
<description type="Chief Investigator">Prof Susan Cotton</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bipolar disorder (BD) is a pervasive and debilitating disorder. The Centre of Research Excellence in Bipolar Disorders (CORE-BD) presents a unique opportunity for Australia to position itself as an international leader in BD research, spanning early detection and intervention, through to helping those with chronic BD. By growing workforce capacity, we will ensure research findings are implemented into practice in order to help reduce the burden experienced by those impacted by BD.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015820</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015820</identifier>
<identifier type="nhmrc">2015820</identifier>
<name type="primary"><namePart>Centre of Research Excellence in Urban Indigenous Health</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">aboriginal health</subject>
<subject type="local">access to health care</subject>
<subject type="local">community health care</subject>
<subject type="local">health systems</subject>
<subject type="local">social determinants of health</subject>
<description type="Chief Investigator">Prof James Ward</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Unmet health needs for urban Indigenous Australians are well documented, alongside a persistent gap in health research conducted with this population. Australia’s first Centre of Research Excellence in Urban Indigenous Health will drive innovative research aimed at achieving excellence in health care delivery. Our CRE will harness existing partnerships and infrastructure to develop the next generation of health researchers to drive Australia's first urban Indigenous health research agenda.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015821</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015821</identifier>
<identifier type="nhmrc">2015821</identifier>
<name type="primary"><namePart>Frailty ADD: Improving Hospital Outcomes for Frail Patients Across Different Disciplines</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | geriatrics and gerontology | public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">frailty</subject>
<subject type="local">hospitals</subject>
<subject type="local">multidisciplinary</subject>
<subject type="local">medical education</subject>
<subject type="local">clinical practice</subject>
<description type="Chief Investigator">Prof Ruth Hubbard</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Frail patients are often harmed in hospitals. This CRE will improve hospital outcomes for frail patients by helping healthcare systems understand the impact of frailty on outcomes and costs, developing clinical practice guidelines for frailty informed care across multiple disciplines, developing a core outcome set for frail patients, and upskilling the next generation of researchers and clinicians to continue the legacy of this CRE.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015843</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015843</identifier>
<identifier type="nhmrc">2015843</identifier>
<name type="primary"><namePart>DRIVE CP: Directing Research In Very Early Cerebral Palsy</namePart></name>
<name type="alternative"><namePart>Centres of Research Excellence</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | health and community services | public health and health services | care for disabled | </subject>
<subject type="local">cerebral palsy</subject>
<subject type="local">cerebral palsy treatments</subject>
<subject type="local">allied health</subject>
<subject type="local">implementation</subject>
<subject type="local">translation</subject>
<description type="Chief Investigator">Prof Iona Novak</description>
<description type="Date Announced">2022-09-01T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cerebral Palsy (CP) is common (1 in 700) and the cost is immense (0.14% GDP). The rate has fallen by 30% meaning more is possible. Our CRE is co-designed with consumers to directly address the priorities set by consumers in our National CP strategy. Together we will diagnose CP early through a national screening program, then develop and transmit new early interventions, that reduce severity and improve independence. We will use artificial intelligence to automate screening for diagnosis.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015501</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015501</identifier>
<identifier type="nhmrc">2015501</identifier>
<name type="primary"><namePart>Pathway Of Low Anterior Resection syndrome relief after Surgery (POLARiS) trial</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">cancer</subject>
<subject type="local">clinical trial</subject>
<subject type="local">rectum</subject>
<subject type="local">gastrointestinal surgery</subject>
<subject type="local">quality of life</subject>
<description type="Chief Investigator">Dr Kheng-Seong Ng</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Disease-free survival is usually regarded as the most important consideration after rectal cancer surgery. As survival outcomes have improved, there is increasing focus on ‘survivorship’ and QoL. One important determinant of QoL is post-operative bowel function which can be deleteriously impacted by surgery. Optimal management of bowel dysfunction following surgery (LARS) remains unclear. This trial will compare 3 interventions for LARS, and assess their influence on QoL and cost-effectiveness.</description>
<description type="fundingAmount">$1,106,974.40</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015726</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015726</identifier>
<identifier type="nhmrc">2015726</identifier>
<name type="primary"><namePart>The clinical and cost-effectiveness of lumbar fusion surgery for patients with persistent, severe low back pain: FusiOn veRsus bEst coNServative Care (the FORENSIC trial)</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | orthopaedics | clinical sciences | physiotherapy | clinical sciences | surgery | </subject>
<subject type="local">orthopaedic surgery</subject>
<subject type="local">back pain</subject>
<subject type="local">physiotherapy</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">health economics</subject>
<description type="Chief Investigator">Prof Nadine Foster</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Lumbar fusion is an operation in which bones in the spine (vertebrae) are fixed together to try to help patients who have persistent low back pain that is thought to be related to specific spine changes seen on scans. We do not know whether this type of surgery for these patients is better than offering further high quality non-surgical care. We will conduct a large trial to test whether lumbar fusion surgery is better for patients and the healthcare system than high quality non-surgical care.</description>
<description type="fundingAmount">$2,373,198.49</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017548</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017548</identifier>
<identifier type="nhmrc">2017548</identifier>
<name type="primary"><namePart>Youth-GEMs: Gene Environment interactions in Mental health trajectories of Youth</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | psychiatry (incl. psychotherapy) | </subject>
<subject type="local">prediction </subject>
<subject type="local">longitudinal cohort study </subject>
<subject type="local">adolescent health </subject>
<subject type="local">child health </subject>
<subject type="local">biomarkers </subject>
<description type="Chief Investigator">Prof Christel Middeldorp</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mental disorders in children and adolescents have a large impact on the individuals, their families and society. This project aims to improve prediction of mental health trajectories by including biological markers as that will facilitate targeted intervention. We will make use of already collected data in various cohorts in the general population, but will also collect longitudinal data in at risk clinical populations, presenting to emergency departments.</description>
<description type="fundingAmount">$499,332.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017566</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017566</identifier>
<identifier type="nhmrc">2017566</identifier>
<name type="primary"><namePart>Clinical validation of Artificial Intelligence for providing a personalized motor clinical profile assessment and rehabilitation of upper limb in children with unilateral Cerebral Palsy</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | neurosciences | central nervous system | clinical sciences | rehabilitation and therapy (excl. physiotherapy) | </subject>
<subject type="local">cerebral palsy </subject>
<subject type="local">hemiplegic cerebral palsy </subject>
<subject type="local">cerebral palsy treatments </subject>
<subject type="local">neuroscience </subject>
<subject type="local">stroke rehabilitation </subject>
<description type="Chief Investigator">Prof Roslyn Boyd</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cerebral Palsy is the most common physical disability in childhood (1 in 700) and Hemiplegia is the most common form (40%). Children with hemiplegia have impairments to hand function and mobility that impact self care, participation in school and leisure and long term vocational aspirations. Accurate diagnosis is important for accessing tailored interventions, individualised rehabilitation and prognosis for education, employment and independent living.</description>
<description type="fundingAmount">$499,778.84</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017666</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017666</identifier>
<identifier type="nhmrc">2017666</identifier>
<name type="primary"><namePart>PREFERABLE-II - Personalised Exercise-Oncology for improvement of supportive care: a super umbrella trial to demonstrate the (cost)effectiveness of live-remote exercise in cancer survivors</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00qbkg805</identifier><title>Cabrini Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | human movement and sports science | exercise physiology | </subject>
<subject type="local">exercise </subject>
<subject type="local">supportive care </subject>
<subject type="local">quality of life </subject>
<subject type="local">side-effects </subject>
<subject type="local">cancer </subject>
<description type="Chief Investigator">Dr Eva Zopf</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">Hospitals and Health Services</description>
<description type="full">Cancer and its treatment can lead to sustained deleterious side effects. Exercise can improve long-term cancer side effects and quality of life; yet, access to high-quality exercise support is not routinely available. PREFERABLE-II evaluates the (cost)-effectiveness of a convenient, live-remote exercise intervention that targets common cancer-related side effects. The project aims to improve the accessibility of best-practice exercise to all cancer survivors and improve supportive cancer care.</description>
<description type="fundingAmount">$457,547.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017786</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017786</identifier>
<identifier type="nhmrc">2017786</identifier>
<name type="primary"><namePart>Improvement of school indoor air quality and children's health</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | environmental and occupational health and safety | public health and health services | epidemiology | public health and health services | preventive medicine | </subject>
<subject type="local">indoor air pollution </subject>
<subject type="local">environmental epidemiology </subject>
<subject type="local">child </subject>
<subject type="local">environmental intervention </subject>
<subject type="local">environmental health </subject>
<description type="Chief Investigator">Prof Yuming Guo</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This Australian project will conduct short-term controlled trials to assess the effect of change in indoor air quality in primary schools on the health and cognitive outcomes of children in Melbourne. Together with InChildHealth supported by H2020, this project will fill information gaps for the indoor air quality legal framework, providing guidelines and recommendations that support health promotion and disease prevention for children in the schools.</description>
<description type="fundingAmount">$499,557.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017837</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017837</identifier>
<identifier type="nhmrc">2017837</identifier>
<name type="primary"><namePart>Identification of chemical and biological determinants, their sources, and strategies to promote healthier homes in Europe (INQUIRE)</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | environmental and occupational health and safety | </subject>
<subject type="local">indoor air pollution </subject>
<subject type="local">air pollution </subject>
<subject type="local">environmental health </subject>
<subject type="local">chemical exposure </subject>
<subject type="local">exposure assessment </subject>
<description type="Chief Investigator">Prof Kevin Thomas</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">While Australians are estimated to spend roughly 90% of their time indoors, we understand little about the air pollutants that may be present in homes. As part of a broader European study, this project aims to assess air and dust samples from Australian homes, along with urine samples from residents, to characterise indoor air pollutants, map their sources, and determine impacts on health. This knowledge can be used to guide policy and industry towards approaches to improve indoor air quality.</description>
<description type="fundingAmount">$499,818.80</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018124</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018124</identifier>
<identifier type="nhmrc">2018124</identifier>
<name type="primary"><namePart>Risk and Resilience in Developmental Diversity and Mental Health</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">genetics | genomics | </subject>
<subject type="local">behaviour genetics </subject>
<subject type="local">molecular genetics </subject>
<subject type="local">speech and language development </subject>
<subject type="local">developmental disorders </subject>
<subject type="local">mental health </subject>
<description type="Chief Investigator">Prof Angela Morgan</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Mental health problems affect a staggering 20% of the Australian population and cost our government $11 billion dollars in 2019-2020. Within any 12 month period, over half a million Australian children experience a mental disorder and prevalence is highest for those with pre-existing neurodevelopmental disorders. Current management is failing as it focuses entirely on mental health risk. Our pioneering work will move the field to understand and promote resilience in EU and Australian contexts.</description>
<description type="fundingAmount">$499,734.30</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018165</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018165</identifier>
<identifier type="nhmrc">2018165</identifier>
<name type="primary"><namePart>PSYCH-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | psychiatry (incl. psychotherapy) | medicinal and biomolecular chemistry | molecular medicine | genetics | genetics not elsewhere classified | </subject>
<subject type="local">psychiatry </subject>
<subject type="local">drug treatment </subject>
<subject type="local">drug resistance </subject>
<subject type="local">schizophrenia </subject>
<subject type="local">mood disorders </subject>
<description type="Chief Investigator">Assoc Prof Klaus Oliver Schubert</description>
<description type="Date Announced">2022-09-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">About 30% of people suffering from mental illnesses such as schizophrenia, bipolar disorder, and major depression don't benefit from treatment with standard medicines and have "treatment resistance" (TR). TR leads to great individual suffering and often to a sense of "failure". The vision of PsychSTRATA is to pave the way for a shift from the current step-wise trial-and-error paradigm of psychiatric therapies towards targeted early introduction of intensive treatments for people at risk of TR.</description>
<description type="fundingAmount">$498,335.30</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015018</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015018</identifier>
<identifier type="nhmrc">2015018</identifier>
<name type="primary"><namePart>TRANSMIT: A multifaceted knowledge TRANslation Strategy iMprovIng funcTion in children and youth with cerebral palsy</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | </subject>
<subject type="local">cerebral palsy</subject>
<subject type="local">evidence-based clinical practice</subject>
<subject type="local">translational research</subject>
<subject type="local">neurological disability</subject>
<subject type="local">allied health</subject>
<description type="Chief Investigator">Prof Iona Novak</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">One third of children with cerebral palsy (CP) will never walk, and one quarter will never talk. These children receive ineffective treatments 43% of the time, lowering their chance of employment. We will build a mobile health aide that filters effective intervention options for children with CP, that overcomes the need to understand complex health information, and that supports consumers to choose, clinicians to provide, and policymakers to reimburse effective treatments.</description>
<description type="fundingAmount">$1,420,252.40</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015440</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015440</identifier>
<identifier type="nhmrc">2015440</identifier>
<name type="primary"><namePart>Promoting CHANGE (Community Health And Nutrition, and Government Engagement): a Randomised Controlled Trial to accelerate healthy food retail in local government settings</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02czsnj07</identifier><title>Deakin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">nutrition and dietics | public nutrition intervention | </subject>
<subject type="local">nutrition</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">health policy</subject>
<subject type="local">capacity building</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Dr Miranda Blake</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This grant will test if an intervention to support retail outlets in Local Government settings (e.g. community sports centres) to improve availability and promotion of healthy food and drink is effective and delivers good value for money. The study will provide evidence from a rigorous randomised controlled trial to support the creation of healthier food environments. Ultimately this will improve what people eat and help reduce the risk of diet-related diseases in an effective and sustained way.</description>
<description type="fundingAmount">$1,169,876.49</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015462</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015462</identifier>
<identifier type="nhmrc">2015462</identifier>
<name type="primary"><namePart>BUBs Quit study: Clinical Midwife Specialist to assist pregnant women to quit smoking using counselling and embedded technology</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">nursing | midwifery | public health and health services | preventive medicine | </subject>
<subject type="local">midwifery</subject>
<subject type="local">pregnancy</subject>
<subject type="local">smoking intervention</subject>
<subject type="local">translational research</subject>
<subject type="local">policy development</subject>
<description type="Chief Investigator">Prof Robyn Richmond</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This study will determine the effectiveness of the BUBs Quit smoking cessation intervention delivered by trained midwives compared to usual care in assisting pregnant women to quit during pregnancy and maintain abstinence at 6 months post-birth. We will explore factors affecting integration of the intervention into usual maternity care. We expect that the BUBs Quit intervention will reduce smoking rates among pregnant women compared to the comparison group by at least 8.5% and be cost effective.</description>
<description type="fundingAmount">$1,245,561.55</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015470</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015470</identifier>
<identifier type="nhmrc">2015470</identifier>
<name type="primary"><namePart>Delivering a population-based intervention to reduce young driver crashes</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">road safety</subject>
<subject type="local">injury epidemiology</subject>
<subject type="local">accident prevention</subject>
<subject type="local">evaluation</subject>
<subject type="local">population health</subject>
<description type="Chief Investigator">Prof Mark Stevenson</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Road crashes are a leading cause of injury mortality and morbidity. As a consequence of advances in telematics technology, there is an opportunity to deliver a unique prevention strategy that will influence a drivers’ risk taking and hence crash propensity. We propose a randomised controlled trial to assess the effects of personalised safety feedback and financial incentives, delivered using a smartphone application, on reducing motor vehicle crashes over the first 6-months of driving</description>
<description type="fundingAmount">$865,506.36</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015514</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015514</identifier>
<identifier type="nhmrc">2015514</identifier>
<name type="primary"><namePart>MenoPROMPT: a co-designed, comprehensive, evidence-based program to improve the care of women at and after menopause.</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | clinical sciences not elsewhere classified | </subject>
<subject type="local">women's health</subject>
<subject type="local">menopause</subject>
<subject type="local">disease prevention</subject>
<subject type="local">primary care</subject>
<subject type="local">clinical practice guidelines</subject>
<description type="Chief Investigator">Prof Susan Davis</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Menopausal symptoms are frequently debilitating. Despite readily available, safe therapy, most severely symptomatic women are not receiving evidenced-based therapy. We will develop a simple menopause assessment and decision-making tool, that will be integrated into general practitioner (GP) software, so that key information is immediately accessible to GPs, together with a pre-consultation women’s health self-assessment tool, delivered by SMS, to ensure menopausal symptoms are not overlooked.</description>
<description type="fundingAmount">$1,096,144.35</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015532</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015532</identifier>
<identifier type="nhmrc">2015532</identifier>
<name type="primary"><namePart>The PeriWarm Trial: Transforming perioperative temperature management for better patient outcomes</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03pnv4752</identifier><title>Queensland University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">nursing | clinical nursing: secondary (acute care) | clinical sciences | anaesthesiology | clinical sciences | surgery | </subject>
<subject type="local">implementation</subject>
<subject type="local">hypothermia</subject>
<subject type="local">anaesthesia</subject>
<subject type="local">surgery</subject>
<subject type="local">multidisciplinary</subject>
<description type="Chief Investigator">Dr Judith Munday</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Perioperative hypothermia occurs when patients undergoing surgery lose body heat. As well as discomfort, heat loss also causes other adverse health outcomes including wound infection, increased blood loss, longer hospital stays and increased costs. Although guidance to prevent perioperative hypothermia is available, this guidance is not widely used. This project seeks to reduce perioperative hypothermia through assisting health care providers to use guidance and improve patient outcomes.</description>
<description type="fundingAmount">$1,145,483.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015544</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015544</identifier>
<identifier type="nhmrc">2015544</identifier>
<name type="primary"><namePart>Smarter hospitals: Unlocking the promise of virtual models of care through infrastructure innovation in Australian healthcare facilities</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | health and community services | </subject>
<subject type="local">health systems</subject>
<subject type="local">quality of care</subject>
<subject type="local">access to health care</subject>
<subject type="local">hospitals</subject>
<subject type="local">electronic health information</subject>
<description type="Chief Investigator">Assoc Prof Reema Harrison</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Virtual models of care can improve patient health outcomes and their healthcare experience, at a reduced cost in comparison to face-to-face care. Significant evidence gaps remain about how to design healthcare facilities to integrate virtual care, how to ensure equitable health outcomes when using virtual care, and how to support workforce change management. Our program of work provides the evidence and solutions required by our Partner Organisations and health services nationally.</description>
<description type="fundingAmount">$1,276,987.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015744</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015744</identifier>
<identifier type="nhmrc">2015744</identifier>
<name type="primary"><namePart>RELEASE: REdressing Long-tErm Antidepressant uSE in general practice</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | primary health care | </subject>
<subject type="local">general practice</subject>
<subject type="local">quality of care</subject>
<subject type="local">prescribing</subject>
<subject type="local">mental health services</subject>
<subject type="local">patient safety</subject>
<description type="Chief Investigator">Prof Katharine Wallis</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Our aim is to improve Australian health outcomes by decreasing unnecessary and potentially harmful long-term (&amp;gt;12 months) prescribing of antidepressants in general practice. The outcomes of our research will include a validated antidepressant discontinuation model and proven implementation strategies, including practical resources where currently there are none, to foster sustainable improvement in primary mental health care, including for urban and rural general practice.</description>
<description type="fundingAmount">$652,769.80</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015751</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015751</identifier>
<identifier type="nhmrc">2015751</identifier>
<name type="primary"><namePart>Digitally Enhancing Youth Mental Health Services across Australia: cluster RCT of an Adaptive, TaiLored, and behAvioural Science-informed (ATLAS) Implementation Strategy</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | psychiatry (incl. psychotherapy) | </subject>
<subject type="local">mental health services</subject>
<subject type="local">early intervention</subject>
<subject type="local">implementation</subject>
<subject type="local">health services research</subject>
<subject type="local">psychological treatment</subject>
<description type="Chief Investigator">Prof Mario Alvarez-Jimenez</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The mental health system is overwhelmed and has catastrophically failed to meet the needs of those with mental-ill health. Despite the potential for digital technology to be a pillar of a modern, sustainable, and adaptive mental health system, digital interventions have not been integrated into mental health services. This aim of this project is to address this global failure by integrating a fully-funded, evidenced-based digital platform (MOST) in a large network of mental health services.</description>
<description type="fundingAmount">$1,306,238.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015773</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015773</identifier>
<identifier type="nhmrc">2015773</identifier>
<name type="primary"><namePart>Strengthening Healthcare Systems with Patient Reported Outcome Measures (PROMs)</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">quality of care</subject>
<subject type="local">patient/doctor communication</subject>
<subject type="local">quality of life</subject>
<subject type="local">health systems</subject>
<subject type="local">health surveys</subject>
<description type="Chief Investigator">Prof Rachael Morton</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The collection and use of Patient Reported Outcome Measures (PROMs) enhances two way communication between patients and clinicians, resulting in improved outcomes and quality of life for patients. This research aims to understand what makes PROMs acceptable to clinicians and consumers, when they should be collected, and how PRO data can best be displayed for quality assurance and care. This will facilitate use of PROMs in healthcare, driving change at an individual, service and system level.</description>
<description type="fundingAmount">$1,166,592.10</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015783</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015783</identifier>
<identifier type="nhmrc">2015783</identifier>
<name type="primary"><namePart>Optimising public health notification systems to achieve hepatitis C elimination in Australia</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | health information systems (incl. surveillance) | </subject>
<subject type="local">hepatitis c infection</subject>
<subject type="local">health surveillance</subject>
<subject type="local">diagnostic test</subject>
<subject type="local">treatment strategies</subject>
<subject type="local">public health impact</subject>
<description type="Chief Investigator">Prof Mark Stoove</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Australia can eliminate hepatitis C as a public health threat by sustaining high rates of hepatitis C treatment. But Australia’s rates of hepatitis C treatment have stalled over recent years. All hepatitis C diagnoses are notified to health departments and this partnership project will implement and evaluate a series of strategies across all states and territories and identify the most effective ways of following up notifications to enhance rates of hepatitis C treatment and cure in Australia.</description>
<description type="fundingAmount">$1,383,550.42</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015784</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015784</identifier>
<identifier type="nhmrc">2015784</identifier>
<name type="primary"><namePart>Bipolar Early intervention using New Digital technologies: a hybrid effectiveness-implementation trial of a multi-component model of evidence-based care</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | psychiatry (incl. psychotherapy) | </subject>
<subject type="local">bipolar affective disorder</subject>
<subject type="local">clinical effectiveness</subject>
<subject type="local">implementation</subject>
<subject type="local">early intervention</subject>
<subject type="local">relapse prevention</subject>
<description type="Chief Investigator">Dr Aswin Ratheesh</description>
<description type="Date Announced">2022-09-16T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Early intervention for young people with serious mood problems like Bipolar Disorder is largely unavailable in Australia. To address this, we have developed an innovative model of care that combines three effective interventions (BLEND). In this project, we will evaluate how effective the BLEND model is in improving young people’s quality of life, compared with standard mental health care. We will also aim to understand whether the strategies used to implement BLEND are acceptable and feasible.</description>
<description type="fundingAmount">$1,423,795.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016268</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016268</identifier>
<identifier type="nhmrc">2016268</identifier>
<name type="primary"><namePart>RBR E3 ubiquitin ligases in health and disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | enzymes | biological sciences | biochemistry and cell biology | signal transduction</subject>
<subject type="local">ubiquitination </subject>
<subject type="local">protein biochemistry</subject>
<subject type="local">enzyme activity</subject>
<subject type="local">cell biology</subject>
<subject type="local">intracellular signal transduction</subject>
<description type="Chief Investigator">Dr Bernhard Lechtenberg</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cells in the human body constantly process signals to react to changes in their environment. Errors in cellular signalling cause diseases like cancers and neurodegeneration. One key signalling molecule is the small protein ubiquitin. My program will develop tools to uncover how the processes involved in ubiquitin signalling occur normally and how they can cause disease. This provides new opportunities to understand basic biology, discover and exploit new drug targets, and develop novel medicines.</description>
<description type="fundingAmount">$1,476,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016274</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016274</identifier>
<identifier type="nhmrc">2016274</identifier>
<name type="primary"><namePart>More accurate disease assessment and improved clinical decision-making for patients with urothelial cancers</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies</subject>
<subject type="local">bladder cancer </subject>
<subject type="local">diagnostic marker</subject>
<subject type="local">clinical research</subject>
<subject type="local">minimal residual disease</subject>
<subject type="local">treatment evaluation</subject>
<description type="Chief Investigator">Prof Ian Davis</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancers of the bladder and similar tissues (“urothelial cancers”) can cause major health issues, including shortened survival and significant loss of quality of life. Some patients can benefit from more aggressive treatment while others will not, but we cannot yet tell who. We have developed a simple, quick, and easy method to look for urothelial cancer DNA in the blood. This project will test that method to see if it can help predict who might need more treatment and for whom it can be spared.</description>
<description type="fundingAmount">$2,468,555.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016277</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016277</identifier>
<identifier type="nhmrc">2016277</identifier>
<name type="primary"><namePart>Leveraging big data to maximise the impact of pharmacists on medicines safety in aged care</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | health sciences | health services and systems | aged health care</subject>
<subject type="local">pharmacoepidemiology </subject>
<subject type="local">pharmacy</subject>
<subject type="local">aged care</subject>
<subject type="local">health services research</subject>
<subject type="local">medications</subject>
<description type="Chief Investigator">Dr Janet Sluggett</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The recent Aged Care Royal Commission recommended urgent action to improve medicines use in aged care services. This project will tell us more about the effects of medicines when they are used by people receiving aged care services, so that health professionals can make improvements. It will also establish a system to guide best practice for pharmacists who work in aged care settings and monitor for improvements in medicines use, health and wellbeing among people who receive aged care services.</description>
<description type="fundingAmount">$1,261,112.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016279</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016279</identifier>
<identifier type="nhmrc">2016279</identifier>
<name type="primary"><namePart>"No Place to Grow Old": Advancing health care and management of Australia's ageing prisoners</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">prison population </subject>
<subject type="local">health inequalities</subject>
<subject type="local">health literacy</subject>
<subject type="local">health outcomes</subject>
<subject type="local">ageing population</subject>
<description type="Chief Investigator">Dr Ye In (Jane) Hwang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research was designed in response to the rapid ageing of Australia’s prisoner population, which is creating new, unique and expensive challenges to criminal justice and public health. The research aims to generate important data regarding the health and functioning status of older prisoners. It also aims to inform better health and service provision upon release from prison, where older prisoners are at particular risk of adverse outcomes.</description>
<description type="fundingAmount">$630,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016283</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016283</identifier>
<identifier type="nhmrc">2016283</identifier>
<name type="primary"><namePart>Detailing epigenetic mechanisms in cancer evolution for improved patient outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours</subject>
<subject type="local">dna methylation </subject>
<subject type="local">epigenetics</subject>
<subject type="local">acute myeloid leukaemia (aml)</subject>
<subject type="local">cancer biology</subject>
<subject type="local">sequencing</subject>
<description type="Chief Investigator">Dr Heather Lee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancers are very difficult to cure because they can adapt to therapy, become resistant and recur. The ability to evade treatment is linked to the diversity of cells in a cancer: the more keys a cancer has, the more likely it is to unlock resistance and escape therapy. This research project will explore cell diversity and cancer adaptation in a devastating blood cancer, revealing new treatments that can delay or prevent recurrence.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016286</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016286</identifier>
<identifier type="nhmrc">2016286</identifier>
<name type="primary"><namePart>Improving access to non-pharmacological treatment in chronic respiratory disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | allied health and rehabilitation science | physiotherapy</subject>
<subject type="local">telemedicine </subject>
<subject type="local">rehabilitation</subject>
<subject type="local">chronic obstructive pulmonary disease (copd)</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Dr Narelle Cox</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">For people with chronic lung disease, pulmonary rehabilitation improves symptoms and function, and helps reduce healthcare costs. Yet very few (less than 10%) people who would benefit from pulmonary rehabilitation have ever done a program. This work will explore new ways to deliver pulmonary rehabilitation, including directly to people’s homes, to make access to programs easier. If more people can access and thus benefit from pulmonary rehabilitation, health system costs could be reduced.</description>
<description type="fundingAmount">$1,526,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016301</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016301</identifier>
<identifier type="nhmrc">2016301</identifier>
<name type="primary"><namePart>Stemming the rising tide of youth mental health problems: prevention through social connection</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">mental health </subject>
<subject type="local">mental health promotion</subject>
<subject type="local">adolescence</subject>
<subject type="local">substance misuse</subject>
<subject type="local">prevention</subject>
<description type="Chief Investigator">Dr Louise Birrell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mental health problems, such as depression and anxiety, are rising in recent cohorts of adolescents. This research aims to generate new knowledge about effective prevention for these problems. It will utilise large-scale longitudinal data, include a world-first RCT and generate practical guidelines for the implementation of effective prevention within secondary school settings.</description>
<description type="fundingAmount">$621,850.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016308</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016308</identifier>
<identifier type="nhmrc">2016308</identifier>
<name type="primary"><namePart>Structure-function relationships in drug transport and inhibition of membrane proteins</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</subject>
<subject type="local">structural biology </subject>
<subject type="local">membrane protein</subject>
<subject type="local">electron microscopy</subject>
<subject type="local">bioenergetics</subject>
<subject type="local">drug transport</subject>
<description type="Chief Investigator">Dr Alastair Stewart</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will study how drugs interact with bacterial targets and drug transporters. This work is instrumental in antimicrobial drug development and will also potentially increase current drug potency and effectiveness.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016324</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016324</identifier>
<identifier type="nhmrc">2016324</identifier>
<name type="primary"><namePart>Improving critically ill patient outcomes through randomised trials and registries in intensive care</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care</subject>
<subject type="local">intensive care medicine </subject>
<subject type="local">critical illness</subject>
<subject type="local">traumatic brain injury (tbi)</subject>
<subject type="local">blood transfusion</subject>
<subject type="local">respiratory failure</subject>
<description type="Chief Investigator">Prof David J. (Jamie) Cooper</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Around 50% of Australians will be admitted to an intensive care unit in their lifetime, with more than 175,000 intensive care admissions each year. As a global leader in intensive care, including founding binational infrastructure, my research program using the gold standard of phase III multicentre, randomised, controlled trials and registries will continue to deliver improvements in clinical decision-making and outcomes for critically ill patients, as well as significant healthcare savings.</description>
<description type="fundingAmount">$3,487,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016330</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016330</identifier>
<identifier type="nhmrc">2016330</identifier>
<name type="primary"><namePart>Investigations into phage biology directed at therapies for antimicrobial resistant (AMR) infections</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | infectious agents</subject>
<subject type="local">bacteriophage </subject>
<subject type="local">klebsiella</subject>
<subject type="local">bacterial pathogen</subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">antibiotic resistance</subject>
<description type="Chief Investigator">Prof Trevor Lithgow</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The rise of drug-resistant superbugs is a global problem with a bleak outlook. A projected increase to 10 million human deaths per year here and around the world can only be addressed with new, sustainable solutions. My vision applies computational and structural biology as well as biochemistry and microbiology to evaluate and optimize the properties of viruses called "phages" to either resolve infections directly or re-sensitize bacteria in infection sites to existing drugs in clinical use.</description>
<description type="fundingAmount">$3,937,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016334</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016334</identifier>
<identifier type="nhmrc">2016334</identifier>
<name type="primary"><namePart>The Microbiota-Growth Hormone Axis - From Metabolic Function to Liver Disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | systems biology</subject>
<subject type="local">circadian rhythms </subject>
<subject type="local">liver</subject>
<subject type="local">control of gene expression</subject>
<subject type="local">signalling pathways</subject>
<subject type="local">endocrine</subject>
<description type="Chief Investigator">Dr Benjamin Weger</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease. If left untreated, it can progress to advanced scarring, liver failure or cancer. Current therapies are limited and for many patients, ineffective. This project will investigate the involvement of gut microbes in the development of NAFLD and whether their targeted modulation could provide new treatment options.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016338</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016338</identifier>
<identifier type="nhmrc">2016338</identifier>
<name type="primary"><namePart>Genetic basis for skeletal muscle formation and regeneration in development and disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination)</subject>
<subject type="local">muscle </subject>
<subject type="local">muscular dystrophy</subject>
<subject type="local">zebrafish</subject>
<subject type="local">stem cells</subject>
<subject type="local">muscle regeneration</subject>
<description type="Chief Investigator">Prof Peter Currie</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I am a biomedical scientist who focuses on understanding how skeletal muscle is made and maintained, and how this process is perturbed in diseases of childhood such as muscular dystrophies. I study muscle formation and growth and the role of muscle stem cells during injury and disease, collaborating widely with an international and national clinical networks and with industry. My main research tool is the zebrafish model, where the processes I study can be dissected in living muscle tissue.</description>
<description type="fundingAmount">$2,537,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016346</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016346</identifier>
<identifier type="nhmrc">2016346</identifier>
<name type="primary"><namePart>Right care, first time: delivering technology-enabled mental health care to young people at scale</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | mental health services</subject>
<subject type="local">mental health services </subject>
<subject type="local">youth</subject>
<subject type="local">health policy</subject>
<subject type="local">access to health care</subject>
<subject type="local">health outcomes</subject>
<description type="Chief Investigator">Prof Ian Hickie</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Providing highly-personalised mental health care to young people, as early as possible in an illness, is a global priority. COVID-19 has been particularly harsh on the mental health of youth. This program (‘Right Care, First Time') uses digital technologies, new health planning tools, early intervention services and socio-economic policies to drive local delivery. These approaches require detailed studies to test whether they can deliver better health and economic outcomes.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016379</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016379</identifier>
<identifier type="nhmrc">2016379</identifier>
<name type="primary"><namePart>Reducing maternal and newborn deaths: Transforming midwifery in the Asia-Pacific region through research and innovation</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified</subject>
<subject type="local">midwifery </subject>
<subject type="local">maternal health</subject>
<subject type="local">newborn</subject>
<subject type="local">maternal and child health</subject>
<subject type="local">nursing</subject>
<description type="Chief Investigator">Prof Caroline Homer</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">A reduction in maternal and newborn deaths and stillbirths in the Asia-Pacific region is urgently needed. Midwives can save lives; there are, however, significant gaps in the knowledge-base about how best to strengthen midwifery. This Investigator Grant will support primary research across the region to improve maternal and newborn health post COVID-19. The outcomes will ensure that maternal and newborn health services can withstand future shocks such as pandemics and natural disasters.</description>
<description type="fundingAmount">$3,437,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016380</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016380</identifier>
<identifier type="nhmrc">2016380</identifier>
<name type="primary"><namePart>Improving Outcomes in Paracetamol Poisoning</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | toxicology (incl. clinical toxicology)</subject>
<subject type="local">poisoning </subject>
<subject type="local">paracetamol toxicity</subject>
<subject type="local">acute liver injury</subject>
<subject type="local">clinical practice guidelines</subject>
<subject type="local">toxicology</subject>
<description type="Chief Investigator">Dr Angela Chiew</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Each year paracetamol leads to &gt;10,000 hospital presentations following deliberate self-poisoning and accidental overdose in Australia. It is also the leading cause of acute liver failure. This study aims to improve the management of paracetamol poisoning through evaluating the use and outcomes from updated 2020 guidelines and clinical studies on new tests and treatments. Outcomes from this research will aim to improve management and decrease the rate of liver injury from paracetamol poisoning.</description>
<description type="fundingAmount">$327,575.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016381</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016381</identifier>
<identifier type="nhmrc">2016381</identifier>
<name type="primary"><namePart>Sewers to cures: Bacteriophages as a targeted treatment for Group B Streptococcal infections</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology</subject>
<subject type="local">bacteriophage </subject>
<subject type="local">streptococcus agalactiae</subject>
<subject type="local">perinatal</subject>
<subject type="local">therapeutic agents</subject>
<subject type="local">molecular biology</subject>
<description type="Chief Investigator">Dr Lucy Furfaro</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Group B Streptococci are bacteria that can transfer from mother to baby during birth and cause severe disease. Mothers who carry these bacteria receive antibiotics, which kill the bacteria but also affects the baby’s natural beneficial bacteria. My research will investigate a century old treatment using phages, viruses that kill specific bacteria. I will use advanced genetic techniques to achieve a targeted, safe and effective treatment as a future alternative to antibiotic use in pregnancy.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016390</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016390</identifier>
<identifier type="nhmrc">2016390</identifier>
<name type="primary"><namePart>Optimising lifelong health and development for our most immature newborns</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology</subject>
<subject type="local">prematurity </subject>
<subject type="local">follow-up</subject>
<subject type="local">developmental outcomes</subject>
<subject type="local">risk prediction</subject>
<subject type="local">extremely low birth weight</subject>
<description type="Chief Investigator">Prof Jeanie Cheong</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Extremely preterm births, before 28 weeks of pregnancy, carry lifelong risks to health and development. Many unanswered questions posing barriers to optimising their health and development will be addressed in this proposal. These include outcomes in their mid -30s, and outcomes after change in care practices, and the COVID pandemic. I will advance ways to predict individuals at highest risk, and implement a surveillance program to ensure consistency and best care for this vulnerable group.</description>
<description type="fundingAmount">$2,505,432.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016391</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016391</identifier>
<identifier type="nhmrc">2016391</identifier>
<name type="primary"><namePart>Tools to curb drug resistance in malaria parasites</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | microbial genetics | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical microbiology | medical parasitology</subject>
<subject type="local">antimalarial </subject>
<subject type="local">malaria drug resistance</subject>
<subject type="local">malaria transmission</subject>
<subject type="local">malaria therapy</subject>
<subject type="local">resistance spread</subject>
<description type="Chief Investigator">Prof Geoffrey McFadden</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Drug resistance is a major challenge to controlling malaria. Resistant parasites emerge, spread geographically &amp; eventually render our drugs useless. We have been on a treadmill of using, then losing, malaria drugs for decades. I will identify antimalarial compounds to stem the spread of drug resistance. I exploit the fact that malaria must spread via mosquitoes. I find drugs for which resistant parasites get trapped in the mosquito stopping them infecting new people &amp; spreading resistance.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016394</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016394</identifier>
<identifier type="nhmrc">2016394</identifier>
<name type="primary"><namePart>Preventing harm from central venous catheters for children treated for cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | nursing | acute care</subject>
<subject type="local">paediatric </subject>
<subject type="local">adverse incidents including complications</subject>
<subject type="local">nursing practice</subject>
<subject type="local">cancer care</subject>
<subject type="local">health service decision making</subject>
<description type="Chief Investigator">Prof Amanda Ullman</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Children with cancer often need a central line, which is a plastic tube that delivers medicine to directly to their bloodstream. Unfortunately, these tubes can also cause significant harm, like infections and blood clots. My research aims to change clinical practice by testing new technologies and educating healthcare workers to deliver best practice care. We expect outcomes will improve the experience and safety of care for children with cancer.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016396</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016396</identifier>
<identifier type="nhmrc">2016396</identifier>
<name type="primary"><namePart>Translational studies in infectious diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified</subject>
<subject type="local">acute infective illnesses </subject>
<subject type="local">clinical trial</subject>
<subject type="local">clinical malaria</subject>
<subject type="local">clinical microbiology</subject>
<subject type="local">antimicrobial therapy</subject>
<description type="Chief Investigator">Prof James McCarthy</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Testing new drugs and vaccines for infectious diseases has been impeded by difficulties in finding out how well these work in humans. I have developed a system where healthy human volunteers are experimentally infected with a microbe to test drugs or vaccines in controlled conditions. This has accelerated the development of drugs and vaccines to treat these infectious diseases. In this Program I will extend this work and establish new challenge systems to deliver new vaccines and treatments.</description>
<description type="fundingAmount">$1,968,555.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016399</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016399</identifier>
<identifier type="nhmrc">2016399</identifier>
<name type="primary"><namePart>The IVCare adaptive platform trial: Towards zero bloodstream infections in IV catheters</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | nursing | acute care</subject>
<subject type="local">nursing practice </subject>
<subject type="local">infection control</subject>
<subject type="local">bacteraemia</subject>
<subject type="local">hospitals</subject>
<subject type="local">acute care</subject>
<description type="Chief Investigator">Prof Claire Rickard</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Life-saving medical treatments are delivered into the bloodstream via intravenous (IV) catheters. This risks bacteria also entering the bloodstream through the catheter and causing a deadly whole-body infection. My research will use an advanced clinical trial design to test new medical equipment and decision support tools to block bacteria entering catheters and avoid infections during IV therapy. This will make patients safer and improve hospital care in developed and developing countries.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016406</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016406</identifier>
<identifier type="nhmrc">2016406</identifier>
<name type="primary"><namePart>Optimising radiopharmaceutical therapy to improve clinical outcomes in advanced prostate cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies</subject>
<subject type="local">prostate cancer </subject>
<subject type="local">radiopharmaceuticals</subject>
<subject type="local">biomarkers</subject>
<subject type="local">hormone-refractory prostate cancer</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Assoc Prof Arun Azad</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I will lead innovative clinical trials using radiopharmaceuticals to target a protein called PSMA (prostate-specific membrane antigen), which is found on most prostate cancer cells. Using scans from these trials and tiny fragments of DNA called circulating tumour DNA (ctDNA), I will try to understand why some patients respond better to PSMA radiopharmaceuticals than others. This study will lead to better and more effective treatments for advanced prostate cancer.</description>
<description type="fundingAmount">$1,802,716.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016407</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016407</identifier>
<identifier type="nhmrc">2016407</identifier>
<name type="primary"><namePart>Evaluation of antenatal vaccines and vaccination programs in pregnancy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance</subject>
<subject type="local">influenza </subject>
<subject type="local">pertussis</subject>
<subject type="local">vaccination</subject>
<subject type="local">pregnancy</subject>
<subject type="local">indigenous australians</subject>
<description type="Chief Investigator">Dr Lisa McHugh</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Antenatal influenza, pertussis and now COVID vaccines reduce the severity of these illnesses and prevent deaths in pregnancy and young babies. We need to know the uptake, safety and effectiveness of these vaccines in pregnancy using large study numbers and gold standard methods. First we must ensure the way we currently collect vaccination information in pregnancy in Australia is valid. Results will be used to advocate including pregnancy status in the Australian Immunisation Register.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016410</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016410</identifier>
<identifier type="nhmrc">2016410</identifier>
<name type="primary"><namePart>From structural mechanisms of endosomal trafficking to therapies for neurodegenerative diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology | biological sciences | biochemistry and cell biology | protein trafficking | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</subject>
<subject type="local">endosomes </subject>
<subject type="local">structural biology</subject>
<subject type="local">membrane trafficking</subject>
<subject type="local">alzheimer disease</subject>
<subject type="local">parkinson disease</subject>
<description type="Chief Investigator">Prof Brett Collins</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Disruption of the endolysosomal system is directly linked to neurological dysfunction leading to dementia and other neurodegenerative disorders for which no effective treatments are available. This proposal will build on my world-leading studies of Retromer to better understand its mechanism of action and its role in sporadic and inherited neurodegenerative disorders, and to ultimately deliver new molecular therapies that can promote Retromer’s neuroprotective functions.</description>
<description type="fundingAmount">$3,132,170.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016415</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016415</identifier>
<identifier type="nhmrc">2016415</identifier>
<name type="primary"><namePart>Ensuring equitable access to care for migrants living with HIV in sub-Saharan Africa: Lessons learnt from an evaluation of Botswana’s migrant inclusive program</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">migrant health </subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">access to health care</subject>
<subject type="local">patient satisfaction</subject>
<subject type="local">surveillance</subject>
<description type="Chief Investigator">Dr Tafireyi Marukutira</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Migration is a key consideration in controlling the spread of HIV. There is no formal evaluation of national HIV public health programs that are inclusive of migrants. Botswana a country in sub-Saharan Africa, the epicentre of the HIV epidemic has run a migrant inclusive public program since 2020. My research will evaluate Botswana's program to document lessons learnt and explore the practicality of implementing a linked HIV surveillance system to track progress to HIV elimination.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016420</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016420</identifier>
<identifier type="nhmrc">2016420</identifier>
<name type="primary"><namePart>Enhancing motor recovery after stroke using a discovery pipeline approach</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation</subject>
<subject type="local">stroke rehabilitation </subject>
<subject type="local">clinical studies</subject>
<subject type="local">translational research</subject>
<subject type="local">rehabilitation</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Kathryn Hayward</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Our emergency response to stroke has significantly improved. Nevertheless, many people are still left with disability, and current rehabilitation interventions have limited impact. This Investigator Grant will improve rehabilitation options by advancing the way these options are developed. My work will help establish a higher standard for trials, led by Australia, for global use. Taken together, this research will ultimately drive the most promising rehabilitation interventions into practice.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016432</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016432</identifier>
<identifier type="nhmrc">2016432</identifier>
<name type="primary"><namePart>Water injections: Transforming childbirth pain management for any woman, anywhere.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | midwifery | clinical midwifery</subject>
<subject type="local">labour </subject>
<subject type="local">birth</subject>
<subject type="local">pain management</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Dr Nigel Lee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Medical options for relief of childbirth pain are unavailable to many women in rural Australia. My previous research has proven that small injections of water are effective in reducing labour back pain with minimal side effects. My research aim is to develop a water injection technique that reduces abdominal labour pain that can be used safely in childbirth . This will provide a safe, effective and low cost option for labour pain management for women in rural and other birthing settings.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016438</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016438</identifier>
<identifier type="nhmrc">2016438</identifier>
<name type="primary"><namePart>Personalised Dementia Prevention: Clinical Trials, Advanced Modelling &amp; Biomarker Discovery</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">dementia </subject>
<subject type="local">alzheimer disease</subject>
<subject type="local">primary prevention</subject>
<subject type="local">biomarkers</subject>
<subject type="local">epigenetics</subject>
<description type="Chief Investigator">Assoc Prof Joanne Ryan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is no cure for dementia but understanding why some individuals are more likely to develop dementia, will enable the implementation of effective strategies and treatments to help reduce the risk. This research program will use clinical trials to test new drug treatments for dementia prevention, and large studies in communities of older Australians to better understand who is most at risk and why. Together this research program will deliver major advances in dementia prevention.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016461</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016461</identifier>
<identifier type="nhmrc">2016461</identifier>
<name type="primary"><namePart>Drug Discovery and Chemical Biology of cell Death processes: Novel Insights and First-in-Class Therapeutics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | biochemistry and cell biology | cell development, proliferation and death | chemical sciences | medicinal and biomolecular chemistry | biomolecular modelling and design</subject>
<subject type="local">drug discovery </subject>
<subject type="local">drug development</subject>
<subject type="local">anti-inflammatory agents</subject>
<subject type="local">ocular disease</subject>
<subject type="local">anticancer drug</subject>
<description type="Chief Investigator">Prof Guillaume Lessene</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cell death processes are key for our development and our health. Most diseases are linked to cell death deregulation, either allowing rogue cells to survive (as in cancer) or inducing the death of healthy cells (inflammatory conditions). This program of work is focussed on developing new small molecules that modulate cell death to achieve two goals: the creation of new medicines for cancer and inflammatory diseases and the provision of new probes to better understand cell death biology.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016464</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016464</identifier>
<identifier type="nhmrc">2016464</identifier>
<name type="primary"><namePart>Childhood cancer precision diagnostics and therapeutics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified</subject>
<subject type="local">tumour targeting </subject>
<subject type="local">cancer research</subject>
<subject type="local">drug delivery systems</subject>
<subject type="local">drug resistance</subject>
<subject type="local">nanotechnology</subject>
<description type="Chief Investigator">Prof Maria Kavallaris</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is the lead cause of disease-related death in children in Australia and other developed countries. Resistance to therapy, toxic side effects of treatment, and delivery of effective doses of drugs to aggressive cancers are a major obstacle to cure. Our research will identify the right treatment for the right patient and target treatment delivery to cancer cells, reducing toxicity to healthy tissue. This will provide better treatment options for patients with aggressive cancer.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016491</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016491</identifier>
<identifier type="nhmrc">2016491</identifier>
<name type="primary"><namePart>Immunity, Vaccines and Therapeutics for pandemic viruses</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">infectious diseases </subject>
<subject type="local">humoral immunity</subject>
<subject type="local">cellular immunology</subject>
<subject type="local">virus</subject>
<subject type="local">vaccination immunology</subject>
<description type="Chief Investigator">Prof Stephen Kent</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Major ongoing global viral pandemics have swept the world in recent decades, including SARS-CoV-2, influenza and HIV. I present 3 inter-related research themes to address control of SARS-CoV-2, influenza and HIV. My overall vision is to bring our understanding of immunity to SARS-CoV-2, influenza and HIV to the point where we can improve vaccination strategies and treatment paradigms for these viruses.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016501</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016501</identifier>
<identifier type="nhmrc">2016501</identifier>
<name type="primary"><namePart>Preventing suicide by improving mass media reporting of suicide in South Asia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | human society | anthropology | medical anthropology | health sciences | public health | social determinants of health</subject>
<subject type="local">suicide prevention </subject>
<subject type="local">mental health</subject>
<subject type="local">social determinants of health</subject>
<subject type="local">interdisciplinary</subject>
<subject type="local">social environment</subject>
<description type="Chief Investigator">Dr Gregory Armstrong</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Responsible media reporting of suicide is a core suicide prevention intervention. Yet, there is a profound lack of robust evidence globally on the impacts of optimised media reporting. My proposed research in the South Asia region represents a rare opportunity to conduct trials to address global evidence gaps around the impact of media interventions, given the baseline context of extremely poor-quality reporting, high suicide rates and limited prior suicide prevention activity.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016513</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016513</identifier>
<identifier type="nhmrc">2016513</identifier>
<name type="primary"><namePart>Understanding the physiological and pathological roles for Transient Receptor Potential (TRP) channels in the mammalian cortex</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | central nervous system | biomedical and clinical sciences | neurosciences | sensory systems</subject>
<subject type="local">cerebral cortex </subject>
<subject type="local">calcium signalling</subject>
<subject type="local">intracellular calcium</subject>
<subject type="local">sensory systems</subject>
<subject type="local">neurodegenerative disorders</subject>
<description type="Chief Investigator">Dr Ehsan Kheradpezhouh</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My recent discovery that transient receptor potential Ankyrin 1 (TRPA1) is expressed in rodent cortical neurons has shed light on its role in the mammalian brain. Recent studies have proposed a role for cortical TRPA1 in Alzheimer’s disease and Multiple Sclerosis, and further suggested that its activation leads to neuronal death. I will investigate the physiological and pathological roles of cortical TRPA1, focusing on its activation mechanisms to develop targeted therapies for these diseases.</description>
<description type="fundingAmount">$630,150.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016530</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016530</identifier>
<identifier type="nhmrc">2016530</identifier>
<name type="primary"><namePart>Leveraging Polygenic Risk and Genetics for Pre-clinical Discovery in Cardiometabolic Disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical physiology | systems physiology</subject>
<subject type="local">lipotoxicity </subject>
<subject type="local">mitochondrial function</subject>
<subject type="local">complex genetic disease</subject>
<subject type="local">muscle physiology</subject>
<subject type="local">fatty liver disease</subject>
<description type="Chief Investigator">Assoc Prof Brian Drew</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cardiometabolic diseases such as obesity, diabetes and cardiovascular disease, account for more deaths in the developed world than any other condition. Our genes play a major part in the development of these conditions, however the specific causal genes remain unknown. This proposal will engage new genetic technologies to identify these specific genes, whilst validation studies in lab based models and exclusive access to human datasets will ensure translational and commercial relevance.</description>
<description type="fundingAmount">$1,806,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016545</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016545</identifier>
<identifier type="nhmrc">2016545</identifier>
<name type="primary"><namePart>Integrated genetic approaches to improve glaucoma diagnosis and management</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | ophthalmology</subject>
<subject type="local">glaucoma </subject>
<subject type="local">genetic testing</subject>
<subject type="local">genetic counselling</subject>
<subject type="local">clinical patient management</subject>
<subject type="local">consumer participation</subject>
<description type="Chief Investigator">Dr Emmanuelle Souzeau</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Glaucoma robs individuals of their vision; however, genetic testing can identify at-risk individuals early and influence management. My research program will advance knowledge on genes and variants for glaucoma, develop novel genetic testing reporting strategies for glaucoma in clinical practice, and assess current genetic testing services. This work will improve glaucoma diagnosis and clinical management, access to genetic services and support for patients and their families.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016547</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016547</identifier>
<identifier type="nhmrc">2016547</identifier>
<name type="primary"><namePart>Pioneering data analysis methods to decrypt the cancer transcriptome</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | bioinformatics and computational biology | genomics and transcriptomics</subject>
<subject type="local">bioinformatics </subject>
<subject type="local">gene transcription</subject>
<subject type="local">data analysis</subject>
<subject type="local">sequence analysis</subject>
<subject type="local">alternative splicing</subject>
<description type="Chief Investigator">Dr Nadia Davidson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Recent advances in technology mean that RNA, the functional read-out of DNA, can be sequenced to a new level of detail. However, this technology results in masses of information that we do not yet have the capacity to analyse. My program will develop computational methods that will analyse RNA in cancer. This will enable us to understand the cellular events that allow cancers to develop and spread and how these can be targeted to accelerate development of new cancer therapies.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016566</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016566</identifier>
<identifier type="nhmrc">2016566</identifier>
<name type="primary"><namePart>Improving prognosis and quality of life in children with muco-obstructive lung disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</subject>
<subject type="local">respiratory medicine </subject>
<subject type="local">child health</subject>
<subject type="local">cystic fibrosis</subject>
<subject type="local">bronchiectasis</subject>
<subject type="local">lung function</subject>
<description type="Chief Investigator">Dr Kathryn Ramsey</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cystic fibrosis and bronchiectasis are life-shortening lung conditions that develop in childhood and progress throughout life. My research is focused on early detection, monitoring, and treatment of these conditions to improve outcomes. Through the analysis of biological samples, we can examine the early pathways associated with worse outcomes later in life. This work can identify new targets for therapies to prevent and slow disease progression, and ultimately improve health outcomes.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016596</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016596</identifier>
<identifier type="nhmrc">2016596</identifier>
<name type="primary"><namePart>An integrated approach to antigen discovery in autoimmunity and cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | immunology | cellular immunology</subject>
<subject type="local">mass spectrometry </subject>
<subject type="local">peptides</subject>
<subject type="local">antigen processing</subject>
<subject type="local">antigen presentation</subject>
<subject type="local">vaccine candidate molecules</subject>
<description type="Chief Investigator">Prof Anthony Purcell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Understanding the targets of immune recognition provides insight into the molecular basis of disease; including vaccine and immunotherapy targets for infections and cancer, as well as insights into aberrant immune recognition leading to autoimmune conditions. As a world leader in antigen discovery, I will apply and further develop technologies to address immune specificity in a variety of cancers and autoimmune diseases to improve vaccine design, immune monitoring and immunotherapies.</description>
<description type="fundingAmount">$2,537,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016598</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016598</identifier>
<identifier type="nhmrc">2016598</identifier>
<name type="primary"><namePart>Improving the psychosocial wellbeing of adults with hearing loss through a mHealth intervention</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02n415q13</identifier><title>Curtin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | allied health and rehabilitation science | audiology | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | mental health services</subject>
<subject type="local">psychosocial </subject>
<subject type="local">wellbeing</subject>
<subject type="local">hearing loss</subject>
<subject type="local">communications/social research</subject>
<subject type="local">psychosocial adjustment</subject>
<description type="Chief Investigator">Dr Rebecca Bennett</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing loss is common in Australia. People with hearing loss often avoid social situations for fear of mishearing. They can feel left out and disconnected. Hearing aids alone are not enough. Audiologists are well-placed to help people cope with these feelings. My research will develop an App to provide effective emotional support for people with hearing loss. Audiologists will be trained to support client’s using the App within routine audiological care.</description>
<description type="fundingAmount">$574,120.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016627</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016627</identifier>
<identifier type="nhmrc">2016627</identifier>
<name type="primary"><namePart>Role of testosterone in preventing major morbidity in women</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology</subject>
<subject type="local">women's health </subject>
<subject type="local">sex hormones</subject>
<subject type="local">testosterone</subject>
<subject type="local">postmenopausal</subject>
<subject type="local">androgen-response</subject>
<description type="Chief Investigator">Prof Susan Davis</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research will determine if the hormone testosterone (often considered a male hormone) can serve as a new therapy to protect against the leading causes of ill health in older women, namely muscle wasting, heart failure and loss of brain function. We will establish whether this same intervention can prevent premature bone loss and sexual dysfunction in younger women with premature ovarian insufficiency. These are all conditions for which there are no proven preventive interventions.</description>
<description type="fundingAmount">$3,937,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016629</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016629</identifier>
<identifier type="nhmrc">2016629</identifier>
<name type="primary"><namePart>Super smart Smartphones: Sensing changes in mental health and delivering just-in-time adaptive interventions</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology</subject>
<subject type="local">mental health </subject>
<subject type="local">internet</subject>
<subject type="local">health promotion</subject>
<subject type="local">body image</subject>
<subject type="local">mass media</subject>
<description type="Chief Investigator">Dr Gemma Sharp</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Body image concerns impact more than a third of young people and are linked with eating disorders, anxiety, depression and suicidality. This program of research will harness the popularity of smartphones to predict when young people are struggling with their body image from the way they are using their phones, and provide the right level of personalised support via “just in time” online interventions. If effective, this work will translate into improved body image for at-risk young people.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016641</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016641</identifier>
<identifier type="nhmrc">2016641</identifier>
<name type="primary"><namePart>Reducing infectious complications in kidney transplant recipients</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology</subject>
<subject type="local">population health </subject>
<subject type="local">microbial infections</subject>
<subject type="local">kidney disease</subject>
<subject type="local">transplantation</subject>
<subject type="local">clinical epidemiology</subject>
<description type="Chief Investigator">Dr Samuel Chan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Infections commonly occur following kidney transplantation and are associated with significant morbidity and mortality. My research program addresses this public health burden by designing clinical trials that are of critical importance to patients, caregivers and healthcare professionals. My aim is to ensure views of patients and caregivers are addressed so that my research is relevant to our nephrology community. My research program will benefit patients both in Australia and also globally.</description>
<description type="fundingAmount">$393,090.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016647</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016647</identifier>
<identifier type="nhmrc">2016647</identifier>
<name type="primary"><namePart>Reducing antibiotic overprescribing in dentistry</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | dentistry | dental therapeutics, pharmacology and toxicology</subject>
<subject type="local">dentistry </subject>
<subject type="local">therapeutics</subject>
<subject type="local">medical informatics</subject>
<subject type="local">qualitative research</subject>
<subject type="local">antibiotic use</subject>
<description type="Chief Investigator">Dr Leanne Teoh</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Dentists prescribe over 800,000 antibiotic prescriptions yearly and 55% are overprescribed. The aim of this multimodal study is to improve dental prescribing by determining the patient factors that influence dental antibiotic prescribing and providing dentists with a clinical decision prescribing tool, Drugs4dent, to improve prescribing. The outcome is aimed to be improved dental antibiotic use, and transforming the access to drug knowledge for dentists.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016662</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016662</identifier>
<identifier type="nhmrc">2016662</identifier>
<name type="primary"><namePart>Improving Outcomes for Preterm Infants Through Randomised Clinical Trials</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology</subject>
<subject type="local">very preterm birth </subject>
<subject type="local">neonatal intensive care (nicu)</subject>
<subject type="local">neonatal respiratory distress syndrome</subject>
<subject type="local">neonatology</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Assoc Prof Brett Manley</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Babies who are born early (premature) can face many health challenges. My research focuses on ways to improve how we care for premature babies in the first days and weeks of life, especially by supporting their breathing. I also want to explore new ways of doing research studies in premature babies so that we can get better at answering the most important questions. By improving the way we care for premature babies early in their lives, we can improve their health into childhood and even beyond.</description>
<description type="fundingAmount">$2,354,074.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016667</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016667</identifier>
<identifier type="nhmrc">2016667</identifier>
<name type="primary"><namePart>Implementation research to improve hepatitis C testing and treatment in rural and regional Australia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | implementation science and evaluation</subject>
<subject type="local">hepatitis c virus </subject>
<subject type="local">population health</subject>
<subject type="local">primary care</subject>
<subject type="local">access to health care</subject>
<subject type="local">cost-effectiveness</subject>
<description type="Chief Investigator">Dr Amanda Wade</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">I will use implementation research to increase access to hepatitis C testing and treatment in primary care in Western Victoria, and eliminate hepatitis C as a public health threat. Using data from this and a similar project in Cairns, I will determine which interventions are cost-effective in regional settings. Finally, I will help underserved regional areas in Australia to have better access to cost-effective testing and treatment in primary care, especially for people who inject drugs.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016668</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016668</identifier>
<identifier type="nhmrc">2016668</identifier>
<name type="primary"><namePart>Identifying opportunities to reverse the diabetes epidemic: surveillance of diabetes, its complications and mortality</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance</subject>
<subject type="local">diabetic complications </subject>
<subject type="local">diabetic vascular complications</subject>
<subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">end-stage kidney disease</subject>
<description type="Chief Investigator">Prof Dianna Magliano</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Diabetes is a serious disease causing deadly, disabling and costly complications. We need data to help us manage this pandemic. My research will tell us which complications are increasing and who are most at risk, in Australia and worldwide. It will also tell us which interventions are most effective. Together, this understanding will improve care for people with diabetes. It will ensure that interventions are well targeted which will in turn limit the global health expenditure on diabetes.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016686</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016686</identifier>
<identifier type="nhmrc">2016686</identifier>
<name type="primary"><namePart>Harnessing long noncoding RNAs for cancer diagnosis and treatment</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</subject>
<subject type="local">cell biology </subject>
<subject type="local">cancer cell biology</subject>
<subject type="local">cancer research</subject>
<subject type="local">rna</subject>
<subject type="local">colon cancer mechanisms</subject>
<description type="Chief Investigator">Prof Xu Dong Zhang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer cells exploit a newly discovered class of molecules for their growth and resistance to treatment. This research program will develop a better understanding of how these molecules influence cancer initiation, progression, and treatment response. It will also uncover new biomarkers that reveal the presence of cancer, as well as new molecular targets for anti-cancer drugs. Findings from this research will pave the way towards earlier detection of cancer and more effective cancer treatments.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016688</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016688</identifier>
<identifier type="nhmrc">2016688</identifier>
<name type="primary"><namePart>Targeted neuroprotective treatments for fetal and neonatal brain injury</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | infant and child health</subject>
<subject type="local">cerebral palsy </subject>
<subject type="local">cerebral palsy treatments</subject>
<subject type="local">very preterm birth</subject>
<subject type="local">fetal growth restriction</subject>
<subject type="local">low birth weight infant</subject>
<description type="Chief Investigator">Prof Suzanne Miller</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Neonatal brain injury is common in infants born preterm, with fetal growth restriction, or who suffer a severe lack of oxygen at birth. Having previously identified the neuropathology specific to these complications, I will now examine targeted neuroprotective treatments that address the specific mechanisms of brain injury. The results of my preclinical studies will inform clinical trials offering new therapies to reduce neonatal brain injury and prevent life-long neurodevelopment deficits.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016695</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016695</identifier>
<identifier type="nhmrc">2016695</identifier>
<name type="primary"><namePart>Improving alcohol and other drug policy by focussing on values</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">human society | policy and administration | public policy | human society | policy and administration | health policy | health sciences | health services and systems | health systems</subject>
<subject type="local">public health policy </subject>
<subject type="local">substance use</subject>
<subject type="local">illicit drug use</subject>
<subject type="local">policy analysis</subject>
<subject type="local">ethical issues</subject>
<description type="Chief Investigator">Prof Alison Ritter</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">What should governments do about alcohol and illicit drugs? The policies that are chosen need to be informed by evidence and reflect the goals and values of communities. This program of work on the role of values in policy development will result in more effective and value-aligned alcohol and illicit drug policies such that the harms experienced across communities from these substances can be reduced.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016698</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016698</identifier>
<identifier type="nhmrc">2016698</identifier>
<name type="primary"><namePart>Strengthening Australian Infectious Disease Clinical Research with a focus on vulnerable populations</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">hepatitis c infection </subject>
<subject type="local">hepatitis b infection</subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">covid-19</subject>
<subject type="local">injecting drug use</subject>
<description type="Chief Investigator">Prof Gail Matthews</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research aims to study treatments for infectious diseases that affect particularly vulnerable communities including people who inject drugs and people living with HIV. It focuses on finding solutions that will aid progress towards elimination of hepatitis B and C, and towards managing the pandemics of HIV and COVID-19, through the establishment of high quality international collaborative clinical research.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016706</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016706</identifier>
<identifier type="nhmrc">2016706</identifier>
<name type="primary"><namePart>Alcohol's harm to others</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">human society | policy and administration | health policy</subject>
<subject type="local">alcohol </subject>
<subject type="local">health surveys</subject>
<subject type="local">health services research</subject>
<subject type="local">family studies</subject>
<subject type="local">child maltreatment</subject>
<description type="Chief Investigator">Dr Anne-Marie Laslett</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to measure alcohol's harms to others, beyond the drinker, within families, communities, societies and public services. Using a new Australian survey, in-depth interviews and health, crime and welfare system datasets, the project will study how individuals, health and social services, systems and policies respond to problems caused by others’ drinking. The study will model how reduced heavy drinking will decrease harm from others' drinking, in Australia and internationally.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016719</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016719</identifier>
<identifier type="nhmrc">2016719</identifier>
<name type="primary"><namePart>Transforming health literacy in Australia: a partnership approach</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | other health sciences | other health sciences not elsewhere classified</subject>
<subject type="local">health literacy </subject>
<subject type="local">shared clinical decision making</subject>
<subject type="local">decision support</subject>
<subject type="local">evidence-based health care</subject>
<subject type="local">public health</subject>
<description type="Chief Investigator">Prof Kirsten McCaffery</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program will develop interventions to build health literacy and shared decision making. It will also improve the health system’s capacity to meet the communication needs of people with low health literacy. This program will produce co-designed and tested evidence-based interventions that combine behavioural science with digital innovation and knowledge translation for scalable interventions to improve health literacy nationally and internationally.</description>
<description type="fundingAmount">$2,882,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016726</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016726</identifier>
<identifier type="nhmrc">2016726</identifier>
<name type="primary"><namePart>P. vivax Serological Testing &amp; Treatment: a novel intervention to facilitate malaria elimination</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiology not elsewhere classified</subject>
<subject type="local">plasmodium </subject>
<subject type="local">malaria control</subject>
<subject type="local">diagnostic applications</subject>
<subject type="local">relapse prevention</subject>
<subject type="local">mathematical modelling</subject>
<description type="Chief Investigator">Prof Ivo Mueller</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">This research program aims to develop the diagnostic tools and clinical trials evidence to prove that a new public health intervention, P. vivax Serological Test and Treat (SeroTAT) can facilitate PV elimination in vivax endemic countries world-wide. To achieve this, we will develop a new class of malaria point-of-care sero-diagnostic test that can identify those most at risk of recurrent vivax malaria, and prove that treating these people will significantly reduce P. vivax transmission.</description>
<description type="fundingAmount">$2,249,688.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016729</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016729</identifier>
<identifier type="nhmrc">2016729</identifier>
<name type="primary"><namePart>Improving Labour Induction Outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology</subject>
<subject type="local">induction of labour </subject>
<subject type="local">obstetrics</subject>
<subject type="local">birth</subject>
<subject type="local">perinatal</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Wentao Li</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">About 1 in 3 Australian women have an induction of labour - an artificial intervention to stimulate the onset of labour when indicated. We know who should have induction of labour and when, but not much about how (which method to use) and where (stay in hospital or at home) to induce labour. In this program, I will lead one international collaborative project, one pragmatic multi-centre clinical trial, and one multi-centre observational study to provide unequivocal answers to these questions.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016730</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016730</identifier>
<identifier type="nhmrc">2016730</identifier>
<name type="primary"><namePart>Screening of athletes for cardiovascular disesase and prevention of sudden death</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">preventive screening </subject>
<subject type="local">athlete training programs</subject>
<subject type="local">cardiac arrhythmia</subject>
<subject type="local">electrocardiogram (ecg)</subject>
<subject type="local">sports medicine</subject>
<description type="Chief Investigator">Dr Jessica Orchard</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Sudden cardiac death (SCD) in athletes is a rare but tragic event. Screening programs to prevent SCD are recommended but data are lacking for some groups (indigenous Australians, female athletes) and across sports. The project will develop Australia’s first national registry of athlete screening ECGs, focus on under-represented groups, and make comparisons across sports. The ultimate goal is to improve the accuracy and quality of screening programs to prevent SCD.</description>
<description type="fundingAmount">$635,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016732</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016732</identifier>
<identifier type="nhmrc">2016732</identifier>
<name type="primary"><namePart>Leveraging Nanoparticle Platforms to Advance Nanomedicine</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | industrial biotechnology | nanobiotechnology | biomedical and clinical sciences | medical biotechnology | nanomedicine | engineering | nanotechnology | nanomaterials</subject>
<subject type="local">nanotechnology </subject>
<subject type="local">biomaterials</subject>
<subject type="local">drug delivery systems</subject>
<subject type="local">cellular interactions</subject>
<subject type="local">protein interactions</subject>
<description type="Chief Investigator">Prof Frank Caruso</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Nanoparticles (NPs) afford a revolutionary approach of packaging and delivering medicines to target specific sites within patients. This proposal will address current limitations in NP-based medicines, by understanding and engineering the performance of NPs, and through their reproducible and scalable synthesis. With a focus on cancer, and infectious and neurological diseases, this research will progress nanomedicines towards preclinical studies and commercialisation to improve health outcomes.</description>
<description type="fundingAmount">$2,137,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016756</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016756</identifier>
<identifier type="nhmrc">2016756</identifier>
<name type="primary"><namePart>N-3 (Omega-3) precision nutrition: preventing prematurity and enhancing cognitive development of very preterm children</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</subject>
<subject type="local">maternal and child health </subject>
<subject type="local">omega-3 fatty acids</subject>
<subject type="local">pregnancy</subject>
<subject type="local">nutritional therapy</subject>
<subject type="local">premature infant</subject>
<description type="Chief Investigator">Prof Maria Makrides</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Being born too soon can be devastating for children and their families. My work is designed to overcome omega-3 deficiency in Australian pregnant women to prevent some of those early births. For babies born more than 11 weeks before their due date, my research aims to maximise developmental benefits by feeding extra omega-3 fats in the neonatal unit to match what would have been received in the womb.</description>
<description type="fundingAmount">$3,525,097.84</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016792</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016792</identifier>
<identifier type="nhmrc">2016792</identifier>
<name type="primary"><namePart>Malaria volunteer infection studies for the advancement of antimalarial therapeutics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">malaria </subject>
<subject type="local">clinical trial</subject>
<subject type="local">clinical research</subject>
<subject type="local">antimalarial</subject>
<subject type="local">disease pathogenesis</subject>
<description type="Chief Investigator">Assoc Prof Bridget Barber</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">At QIMR Berghofer I will lead malaria volunteer infection studies to advance the development of antimalarial therapeutics. This will include studies to characterise the PK/PD profile of existing antimalarials to optimise dose selection, evaluate the transmission blocking activity of new and existing antimalarials, and evaluate strategies to boost antimalarial immunity. These studies will inform antimalarial treatment strategies worldwide.</description>
<description type="fundingAmount">$1,345,834.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016801</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016801</identifier>
<identifier type="nhmrc">2016801</identifier>
<name type="primary"><namePart>Prevention of cardiometabolic conditions in diverse populations</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">cardiovascular disease prevention </subject>
<subject type="local">diabetes prevention</subject>
<subject type="local">chronic heart failure (chf)</subject>
<subject type="local">women's health</subject>
<subject type="local">pharmacotherapy</subject>
<description type="Chief Investigator">Prof Anushka Patel</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cardiometabolic conditions (including heart disease and diabetes) are a leading cause of premature death and poor health in Australia and globally. My research will focus on identifying effective preventive treatments and methods to deliver these treatments to high-risk populations in Australia and other countries in our region, particularly to groups that have not previously had their needs adequately addressed. A focus will be on novel use of affordable and effective preventive drug therapies.</description>
<description type="fundingAmount">$1,762,266.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016803</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016803</identifier>
<identifier type="nhmrc">2016803</identifier>
<name type="primary"><namePart>Alzheimer's disease: causes, natural history, early diagnosis and prevention</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | central nervous system</subject>
<subject type="local">alzheimer disease </subject>
<subject type="local">dementia</subject>
<subject type="local">genetic risk factors</subject>
<subject type="local">amyloid beta-protein</subject>
<subject type="local">neurodegeneration</subject>
<description type="Chief Investigator">Prof Colin Masters</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Alzheimer’s disease (AD) is a devastating illness for a large number of people in our aging community. We have discovered the major causes of AD from our work over the past 40 years. We are now poised to develop disease modifying therapies (both pharmacological and non-pharmacological) and apply these therapies for prevention. We have defined when and where in the brain AD starts. Armed with this knowledge, we can implement diagnostic and therapeutic strategies for prevention.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016819</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016819</identifier>
<identifier type="nhmrc">2016819</identifier>
<name type="primary"><namePart>Dietary protein to improve outcomes from critical illness</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | biomedical and clinical sciences | clinical sciences | intensive care</subject>
<subject type="local">intensive care medicine </subject>
<subject type="local">critical care medicine</subject>
<subject type="local">enteral nutrition</subject>
<subject type="local">metabolism</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<description type="Chief Investigator">Assoc Prof Adam Deane</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Critically ill patients are admitted to an intensive care unit (ICU) to receive life support therapies but suffer rapid and severe muscle wasting. Dr Deane will evaluate whether increasing dietary protein using existing formula or specific amino acid supplements reduces muscle wasting. This program will determine whether there is a pragmatic and inexpensive solution for a condition that results in considerable mortality and morbidity to a large number of Australians each year.</description>
<description type="fundingAmount">$2,029,753.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016820</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016820</identifier>
<identifier type="nhmrc">2016820</identifier>
<name type="primary"><namePart>Deregulated epigenetics and transcription in cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</subject>
<subject type="local">epigenetics </subject>
<subject type="local">cancer biology</subject>
<subject type="local">cancer immunology</subject>
<subject type="local">gene transcription</subject>
<subject type="local">cancer therapy</subject>
<description type="Chief Investigator">Prof Ricky Johnstone</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The Investigator grant will support Prof. Ricky Johnstone, a world leader in cancer research. His work focusses on how genes are regulated in normal and cancer cells through a process called epigenetics, and how de-regulated gene expression can result in cancer onset and progression. He and his team will determine how manipulating the proteins and pathways that control the expression of genes can inhibit cancer cell growth and survival, and regulate how our immune system responds to cancer.</description>
<description type="fundingAmount">$1,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016822</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016822</identifier>
<identifier type="nhmrc">2016822</identifier>
<name type="primary"><namePart>Translating Genomics into Improved Care of Inherited Heart Disease and Sudden Death Families</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">cardiovascular disease </subject>
<subject type="local">sudden cardiac death</subject>
<subject type="local">cardiomyopathy</subject>
<subject type="local">genetics</subject>
<subject type="local">inherited</subject>
<description type="Chief Investigator">Prof Christopher Semsarian</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inherited heart diseases are caused by errors in genes we are born with. These genetic errors can lead to heart muscle and rhythm disorders, which can cause sudden cardiac death in the young. This proposed research will use the latest clinical, genetic, and cellular approaches to identify what these genetic errors are, how these errors cause these clinical diseases, and how we can use this new knowledge to improve the care of patients with inherited heart diseases and prevent sudden death.</description>
<description type="fundingAmount">$2,099,688.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016825</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016825</identifier>
<identifier type="nhmrc">2016825</identifier>
<name type="primary"><namePart>Improving Knowledge and Interventions to reduce and prevent substance use related harms</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified | health sciences | epidemiology | major global burdens of disease</subject>
<subject type="local">addiction </subject>
<subject type="local">data linkage</subject>
<subject type="local">behavioural epidemiology</subject>
<subject type="local">adolescent health</subject>
<subject type="local">mental health</subject>
<description type="Chief Investigator">Prof Louisa Degenhardt</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I will study the epidemiology of illicit drug use, and improve estimates of substance use and mental disorders and health burden; and study prospective associations between disorders and harms. I will lead globally focused work on the epidemiology and harms of illicit drugs, and coverage of interventions to reduce harm; and examine interventions to address drug use, including treatment of opioid dependence and other interventions to reduce harm among people who use illicit drugs.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016826</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016826</identifier>
<identifier type="nhmrc">2016826</identifier>
<name type="primary"><namePart>Illuminating the dark genome in cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics</subject>
<subject type="local">functional genomics </subject>
<subject type="local">rna</subject>
<subject type="local">somatic mutation</subject>
<subject type="local">genetic association</subject>
<subject type="local">enhancer elements</subject>
<description type="Chief Investigator">Assoc Prof Juliet French</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Research into the genetic basis of cancer has largely focused on the 2% of human DNA that codes for proteins (what most people refer to as "genes"). In the last decade, it has become clear that a large proportion of DNA outside these genes (referred to as noncoding regions) is functional and can harbour genetic and epigenetic alterations that can promote the development of cancer. This research program will explore the contribution of these noncoding regions to cancer development.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016827</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016827</identifier>
<identifier type="nhmrc">2016827</identifier>
<name type="primary"><namePart>Capturing atomic snapshots to visualise epigenetic silencing machinery for identification of novel therapeutic targets</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</subject>
<subject type="local">structural biology </subject>
<subject type="local">electron microscopy</subject>
<subject type="local">protein structure</subject>
<subject type="local">epigenetics</subject>
<subject type="local">gene silencing</subject>
<description type="Chief Investigator">Dr Shabih Shakeel</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Heterochromatin, a tightly packed form of DNA prevents genes from being turned on. We know very little about heterochromatin biology at molecular level, despite its critical role in gene silencing. Through cryo-electron microscopy (cryoEM), I will study the protein complexes that lead to heterochromatin formation and maintenance. This information will enable the rational design of a targeted drug discovery program to treat diseases caused by epigenetic dysregulation.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016833</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016833</identifier>
<identifier type="nhmrc">2016833</identifier>
<name type="primary"><namePart>Using MRI tools to map and mitigate brain harms in chronic cannabis use</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04cxm4j25</identifier><title>Australian Catholic University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | biological psychology not elsewhere classified</subject>
<subject type="local">cannabis </subject>
<subject type="local">addictive behaviours</subject>
<subject type="local">hippocampus</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">mental health</subject>
<description type="Chief Investigator">Assoc Prof Valentina Lorenzetti</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Australia has one of the highest rates of cannabis dependence, and 28% of users report high distress and mental illness. Yet, the neurobiology of cannabis use is unclear. I will fill this knowledge gap by combining advanced brain imaging tools with large longitudinal datasets to map the brain mechanisms which predate, predict and underpin chronic cannabis use, and by trialling new interventions that directly target and mitigate brain dysfunction in chronic cannabis use.</description>
<description type="fundingAmount">$1,115,278.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016841</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016841</identifier>
<identifier type="nhmrc">2016841</identifier>
<name type="primary"><namePart>Understanding the autoimmune response against the brain to improve diagnosis and therapy of neuroimmunological disorders</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system</subject>
<subject type="local">neuroimmunology </subject>
<subject type="local">antibody</subject>
<subject type="local">diagnostic assay</subject>
<subject type="local">multiple sclerosis (ms)</subject>
<subject type="local">sars-cov-2</subject>
<description type="Chief Investigator">Assoc Prof Fabienne Brilot</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Neuroimmunological disorders include neurological and psychiatric disorders affecting the brain, spinal cord, and nerves. Overall, they can affect up to 1% of the human population. They almost always result in a poor quality of life for children and adults and are a high cost burden for the community. The research program will explore the dysregulation of the immune system in these patients and will design new diagnostic and therapeutic approaches.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016851</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016851</identifier>
<identifier type="nhmrc">2016851</identifier>
<name type="primary"><namePart>Optimising strategies for control of neglected tropical diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | rural and remote health services | health sciences | epidemiology | disease surveillance | health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">epidemiology </subject>
<subject type="local">population health</subject>
<subject type="local">tropical disease</subject>
<subject type="local">infectious diseases</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Lucia Romani</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Neglected tropical diseases (NTDs) are a group of health conditions that affect the poorest of the poor, particularly in remote and rural areas. They affect the most vulnerable communities and cause substantial, chronic health harms impairing personal and social development. Several debilitating NTDs are common in remote indigenous communities and Pacific islands. I propose a series of studies to investigate new strategies to control NTDs in large populations where these diseases are endemic.</description>
<description type="fundingAmount">$1,493,326.67</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016866</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016866</identifier>
<identifier type="nhmrc">2016866</identifier>
<name type="primary"><namePart>A pathway to new symptomatic drug therapies in dementia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | cognitive neuroscience | psychology | biological psychology  | psychopharmacology | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases</subject>
<subject type="local">dementia </subject>
<subject type="local">cognitive neuroscience</subject>
<subject type="local">brain imaging</subject>
<subject type="local">neuropharmacology</subject>
<subject type="local">noradrenaline</subject>
<description type="Chief Investigator">Dr Claire O'Callaghan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The cognitive symptoms of dementia can be devastating for patients and their families. The drugs that are currently available to treat these symptoms are limited and they do not work for everyone. My program will identify new drug treatment options for cognitive symptoms, and, establish faster ways to help us translate these drugs into clinical practice – so that people with dementia can benefit from novel treatment options as soon as possible.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016876</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016876</identifier>
<identifier type="nhmrc">2016876</identifier>
<name type="primary"><namePart>Repetitive Neurotrauma and the Risk for Dementia in Former Athletes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | other health sciences | other health sciences not elsewhere classified</subject>
<subject type="local">ageing </subject>
<subject type="local">cognition</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">dementia</subject>
<subject type="local">neurotrauma</subject>
<description type="Chief Investigator">Assoc Prof Andrew Gardner</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Contact and collision sports have been popular in Australia for generations, and many millions of people, worldwide, played these sports during their youth. There is tremendous societal concern about whether exposure to concussions and repetitive blows to the head during youth leads to accelerated brain aging and risk for neurological disease later in life. This project will make important advancements in medical and scientific knowledge relating to the long-term brain health of former athletes.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016884</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016884</identifier>
<identifier type="nhmrc">2016884</identifier>
<name type="primary"><namePart>Building RNA therapies to re-program gene expression.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics</subject>
<subject type="local">messenger rna (mrna) </subject>
<subject type="local">rna</subject>
<subject type="local">gene expression</subject>
<subject type="local">rna processing</subject>
<subject type="local">gene therapy</subject>
<description type="Chief Investigator">Assoc Prof Timothy Mercer</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Gene mutations cause a wide range of inherited diseases. The delivery of mRNA therapies can replace mutated genes. However, mRNA therapies must be correctly expressed in the diseased tissue and match the expression of the mutated gene. I propose to build a toolkit of RNA structures that control expression of mRNA therapies in different tissues. This will allow their correct expression of mRNA therapies in disease tissues and a new opportunity to treat these currently incurable diseases.</description>
<description type="fundingAmount">$2,756,790.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016894</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016894</identifier>
<identifier type="nhmrc">2016894</identifier>
<name type="primary"><namePart>Using advanced structural biology to exploit BCL2 effector proteins for new tailored therapies.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</subject>
<subject type="local">structural biology </subject>
<subject type="local">apoptosis</subject>
<subject type="local">bcl-2</subject>
<subject type="local">bax</subject>
<subject type="local">mitochondria</subject>
<description type="Chief Investigator">Dr Richard Birkinshaw</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">This research aims to identify new cancer drugs like venetoclax, which has revolutionised leukemia therapy by targeting one of eight BCL2 family proteins involved in cell death. Using Australia’s leading facilities, eg. the National Drug Discovery Center and Australian Synchrotron, this research will investigate the structure and function of three additional BCL2 proteins. This is expected to lead to new classes of drugs that can treat diseases where current therapies fail.</description>
<description type="fundingAmount">$1,476,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016907</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016907</identifier>
<identifier type="nhmrc">2016907</identifier>
<name type="primary"><namePart>BREATHE EASY - respiratory protection against airborne threats</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health systems</subject>
<subject type="local">respiratory viruses </subject>
<subject type="local">biological sciences</subject>
<subject type="local">infectious diseases</subject>
<subject type="local">population health</subject>
<subject type="local">occupational health and safety</subject>
<description type="Chief Investigator">Prof Raina MacIntyre</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">MacIntyre is a leading international researcher &amp; woman with a 15-year track record of mask research. This will enable critical research on masks; aerosols &amp; how they are blocked by masks; and development of a novel, sustainable mask to meet global needs. These are seamlessly connected within a new NHMRC CRE, BREATHE on mitigation of airborne threats to health, which she leads. She has strong policy and industry links to ensure this research results in global solutions in respiratory protection.</description>
<description type="fundingAmount">$2,390,896.36</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016908</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016908</identifier>
<identifier type="nhmrc">2016908</identifier>
<name type="primary"><namePart>Antibody-based therapies against infectious diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | infectious agents</subject>
<subject type="local">falciparum malaria </subject>
<subject type="local">coronavirus</subject>
<subject type="local">antibody therapy</subject>
<subject type="local">structural biology</subject>
<subject type="local">host/pathogen interaction</subject>
<description type="Chief Investigator">Prof Wai-Hong Tham</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Infectious diseases have resulted in devastating mortality in human populations throughout history. Antibody-based therapies have revolutionised modern medicine and will be important for the prevention and treatment of diseases caused by some of the world’s deadliest pathogens. Our program builds on a deep understanding of the molecular interactions between human and pathogen and leverages advanced antibody platforms to develop novel antibody therapies against malaria and COVID-19.</description>
<description type="fundingAmount">$2,105,736.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016909</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016909</identifier>
<identifier type="nhmrc">2016909</identifier>
<name type="primary"><namePart>Optimising the investment in real-time prescription drug monitoring</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">opioid analgesia </subject>
<subject type="local">opioid dependence</subject>
<subject type="local">addiction prevention</subject>
<subject type="local">health policy</subject>
<subject type="local">public health</subject>
<description type="Chief Investigator">Ms Louisa Picco</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Opioid prescribing has increased substantially in recent times and is associated with significant harms. Various approaches have been adopted to prevent these harms, however research has shown some approaches add to harms. This research aims to better understand the impact of prescription drug monitoring programs on clinical decision-making and how these impact patient and population level outcomes.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016930</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016930</identifier>
<identifier type="nhmrc">2016930</identifier>
<name type="primary"><namePart>Anti-fibrotic targeting and biosensor imaging in pancreatic cancer (PC): taking cancer targeting to new dimensions</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall)</subject>
<subject type="local">pancreatic cancer </subject>
<subject type="local">fibrosis</subject>
<subject type="local">imaging</subject>
<subject type="local">extracellular matrix</subject>
<subject type="local">biosensor</subject>
<description type="Chief Investigator">Prof Paul Timpson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pancreatic cancer is a devastating disease in which high levels of dense tissue (otherwise know as fibrosis) surrounds the tumour and effectively protects the tumour from efficient drug delivery and penetrance, causing poor drug response. In this program of work, we outline how we can target this dense impenetrable fibrotic tissue to effectively improve drug delivery and response in this aggressive disease.</description>
<description type="fundingAmount">$2,882,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016947</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016947</identifier>
<identifier type="nhmrc">2016947</identifier>
<name type="primary"><namePart>Preventing pulmonary complications after major surgery</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | anaesthesiology | biomedical and clinical sciences | clinical sciences | surgery | health sciences | allied health and rehabilitation science | physiotherapy</subject>
<subject type="local">pre-operative care </subject>
<subject type="local">respiratory infection</subject>
<subject type="local">physiotherapy</subject>
<subject type="local">surgical outcomes research</subject>
<subject type="local">patient education</subject>
<description type="Chief Investigator">Dr Ianthe Boden</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Contracting a chest infection after major surgery can be catastrophic. Despite the seriousness of this complication, we know little about how common it is, how much it costs hospitals, and how it impacts a person’s recovery after surgery. My research will provide world-first data on the impact of chest infections after major surgery, treatment guidelines for clinicians, and online methods to deliver breathing training before surgery - a treatment known to prevent chest infections after surgery.</description>
<description type="fundingAmount">$574,120.00</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016951</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016951</identifier>
<identifier type="nhmrc">2016951</identifier>
<name type="primary"><namePart>Phosphoinositide signalling in disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified</subject>
<subject type="local">phosphoinositide 3-kinase </subject>
<subject type="local">endosomes</subject>
<subject type="local">breast cancer</subject>
<subject type="local">receptor trafficking</subject>
<subject type="local">signal transduction</subject>
<description type="Chief Investigator">Prof Christina Mitchell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Breast cancer is the most common cancer in women. Current treatment protocols are initially effective; however, more than half of patients experience relapse presenting an urgent need for new therapies. Lipid signals within cells can be hyperactivated in breast cancer promoting tumour growth and spread. We have discovered genes that regulate these signals, that when altered lead to poor outcomes in breast cancer. Here we will investigate these events to identify new biomarkers and therapies.</description>
<description type="fundingAmount">$1,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016969</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016969</identifier>
<identifier type="nhmrc">2016969</identifier>
<name type="primary"><namePart>Antigen Presentation and Adaptive Immunity</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | protein trafficking | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | innate immunity</subject>
<subject type="local">antigen presentation </subject>
<subject type="local">t cell immunity</subject>
<subject type="local">protein trafficking</subject>
<subject type="local">inflammation</subject>
<subject type="local">metabolism</subject>
<description type="Chief Investigator">Prof Jose Villadangos</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The research program I will carry out during this fellowship will characterise how the immune system detects and starts responses against pathogens and cancer cells. I will describe proteins and intracellular processes required to fulfil this function, which may be harnessed to develop more effective vaccines against infections, protect critically ill patients from hospital acquired infections, prevent autoimmunity and fight cancer.</description>
<description type="fundingAmount">$3,749,688.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016991</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016991</identifier>
<identifier type="nhmrc">2016991</identifier>
<name type="primary"><namePart>Patient-Specific CT-Derived Computational Modelling to Optimise Outcomes in Aortic Stenosis</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">aortic stenosis </subject>
<subject type="local">computed tomography</subject>
<subject type="local">coronary blood flow</subject>
<subject type="local">computer simulation</subject>
<subject type="local">heart valve disease</subject>
<description type="Chief Investigator">Dr Abdul Rahman Ihdayhid</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Transcatheter aortic valve replacement (TAVR) has revolutionised the treatment of aortic stenosis by offering a less invasive alternative to open heart surgery. This study aims to use non-invasive images from cardiac CT to develop a novel, personalised technique that allow clinicians to perform 3D simulation of aortic valve implantation that predicts short and long term clinical outcomes. These results will provide new tools to make TAVR safer, more durable and accessible to more patients.</description>
<description type="fundingAmount">$444,472.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016995</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016995</identifier>
<identifier type="nhmrc">2016995</identifier>
<name type="primary"><namePart>A multidisciplinary approach to reducing complications with extracorporeal membrane oxygenation</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | medical devices</subject>
<subject type="local">biomedical engineering </subject>
<subject type="local">blood flow</subject>
<subject type="local">task-related training</subject>
<subject type="local">left ventricular assist device (lvad)</subject>
<subject type="local">cardiopulmonary bypass</subject>
<description type="Chief Investigator">Assoc Prof Shaun Gregory</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Critically-ill patients with heart and/or lung failure (including COVID19) may require advanced life support using a device called ECMO. Current ECMO systems are riddled with complications related to the patient-device interface, such as a poor surgical connection and a lack of regular and life-like clinical training. This project will improve the ECMO-patient interface through better devices and improved clinical training, and measure improvements in patient outcomes using large databases.</description>
<description type="fundingAmount">$1,376,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017001</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017001</identifier>
<identifier type="nhmrc">2017001</identifier>
<name type="primary"><namePart>Discovery and validation of antifibrotic therapies for kidney disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology</subject>
<subject type="local">fibrosis </subject>
<subject type="local">kidney disease</subject>
<subject type="local">diabetic nephropathy</subject>
<subject type="local">tubulointerstitial inflammation</subject>
<subject type="local">kidney failure</subject>
<description type="Chief Investigator">Prof Carol Pollock</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Kidney failure is increasing by 6-12% annually, directly costing up to $1.8B pa. Despite optimum treatment of patients with chronic kidney disease, dialysis, kidney transplant or premature death ensues. This program will assess new treatments for which we have promising preliminary data &amp; dissect differences in the processes leading to kidney recovery vs irreparable damage after kidney injury. Consequently, new therapies will be developed and the next generation of scientists will be trained.</description>
<description type="fundingAmount">$2,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017012</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017012</identifier>
<identifier type="nhmrc">2017012</identifier>
<name type="primary"><namePart>Smart technology for hip osteoarthritis: a personalised real-world ‘move’ into the future</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | rehabilitation engineering | health sciences | sports science and exercise | biomechanics | biomedical and clinical sciences | clinical sciences | orthopaedics</subject>
<subject type="local">osteoarthritis </subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">biomechanics</subject>
<subject type="local">musculoskeletal disorders</subject>
<subject type="local">activities of daily living</subject>
<description type="Chief Investigator">Dr Laura Diamond</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My program will design and test a new treatment for hip osteoarthritis (OA). The team I lead has proven that people with hip OA load their hip in a detrimental way during daily activities, and that hip load can be improved with laboratory-based movement retraining. To translate changes into everyday life, retraining must now happen in the real-world. My program will partner authentically with stakeholders to co-develop a body-worn smart device for personalised self-management in the real-world.</description>
<description type="fundingAmount">$630,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017023</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017023</identifier>
<identifier type="nhmrc">2017023</identifier>
<name type="primary"><namePart>Statistical bioinformatics at single cell resolution</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">mathematical sciences | statistics | statistical data science | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biological sciences | bioinformatics and computational biology | bioinformatic methods development</subject>
<subject type="local">bioinformatics </subject>
<subject type="local">applied statistics</subject>
<subject type="local">gene expression</subject>
<subject type="local">biomarkers</subject>
<subject type="local">information processing and learning</subject>
<description type="Chief Investigator">Prof Jean Yang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program will generate a framework and innovative bioinformatics tools to extract disease-associated signatures from multiple-modality single cell platforms for large cohort studies. Our strategy is based on contextual focus machine learning methods and novel statistical models to identify stable relationships among clinical and molecular measurements with robust predictive power across multiple platforms. This will accelerate the process of translational significant biomedical research.</description>
<description type="fundingAmount">$2,682,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017033</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017033</identifier>
<identifier type="nhmrc">2017033</identifier>
<name type="primary"><namePart>Optimising novel therapies to improve lymphoma patient outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours</subject>
<subject type="local">lymphoma </subject>
<subject type="local">non-hodgkin lymphoma</subject>
<subject type="local">cancer immunotherapy</subject>
<subject type="local">molecular biology</subject>
<subject type="local">diagnostic imaging</subject>
<description type="Chief Investigator">Assoc Prof Eliza Hawkes</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Lymphomas are blood cancers that can be cured in some patients, but current treatments cause major side effects and many patients still die from this devastating disease. My research brings together clinical trials testing new therapies that manipulate the immune system, studies of blood and biopsy abnormalities, and new types of scans, in patients receiving these and standard treatments, with studies of real-world registry data, to improve treatment options and outcomes for lymphoma patients.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017060</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017060</identifier>
<identifier type="nhmrc">2017060</identifier>
<name type="primary"><namePart>Circulating tumour DNA informed management of early-stage colorectal cancer and pancreas cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers</subject>
<subject type="local">colorectal cancer </subject>
<subject type="local">pancreatic cancer</subject>
<subject type="local">adjuvant therapy</subject>
<subject type="local">biomarkers</subject>
<subject type="local">cancer prognosis</subject>
<description type="Chief Investigator">Prof Peter Gibbs</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Colorectal or pancreas cancer is treated with surgery, then potentially chemotherapy, with that decision informed by examination of the cancer tissue that has been removed. This remains an imprecise way of estimating risk of recurrence and possible benefit from chemotherapy. My initial studies show that a blood test for circulating tumour DNA is a far more precise way of determining recurrence risk. I am leading 4 randomised studies looking to prove the benefit of ctDNA informed management.</description>
<description type="fundingAmount">$3,529,302.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017070</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017070</identifier>
<identifier type="nhmrc">2017070</identifier>
<name type="primary"><namePart>Using muscle-directed gene delivery to study and treat disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical physiology | cell physiology</subject>
<subject type="local">musculoskeletal disorders </subject>
<subject type="local">cell signalling</subject>
<subject type="local">gene therapy</subject>
<subject type="local">skeletal muscle hypertrophy</subject>
<subject type="local">skeletal muscle wasting</subject>
<description type="Chief Investigator">Assoc Prof Paul Gregorevic</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Effective therapeutics are urgently required to combat the debilitating effects of skeletal muscle-related disease. This program of research will examine how cellular mechanisms control the functionality of skeletal muscle in health and disease, to pursue the development of innovative muscle-directed therapeutics to eradicate the loss of skeletal muscle mass and function as a cause of morbidity and early death, and combat other serious non-muscle diseases.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017080</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017080</identifier>
<identifier type="nhmrc">2017080</identifier>
<name type="primary"><namePart>Improving Outcomes for People with Bone Metastases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | sports medicine | health sciences | allied health and rehabilitation science | rehabilitation | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</subject>
<subject type="local">bone metastasis </subject>
<subject type="local">breast cancer</subject>
<subject type="local">prostate cancer</subject>
<subject type="local">exercise therapy</subject>
<subject type="local">rehabilitation</subject>
<description type="Chief Investigator">Dr Nicolas Hart</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">MOST people with advanced cancer will develop bone metastases – where cancer spreads to bone. This leads to devastating physical and mental problems including bone fragility, bone pain and muscle weakness, along with distress, anxiety and depression. My previous work has proven that carefully prescribed exercise is SAFE for these high-risk people. Now, I aim to establish the clinical effectiveness of supervised and targeted exercise to strengthen muscle, rescue bone loss, and improve function.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017081</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017081</identifier>
<identifier type="nhmrc">2017081</identifier>
<name type="primary"><namePart>Improving outcomes for ICU survivors with anaemia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care</subject>
<subject type="local">critical care </subject>
<subject type="local">critical illness</subject>
<subject type="local">anaemia</subject>
<subject type="local">intensive care</subject>
<subject type="local">intensive care medicine</subject>
<description type="Chief Investigator">Assoc Prof Edward Litton</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">More than 170,000 Australians require intensive care treatment each year. At discharge, nearly half are anaemic. This impairs recovery, increasing the risk of prolonged and repeated hospitalisation. My research has identified promising anaemia treatments. This Fellowship will allow me to generate high quality evidence to guide practice and policy with the aim of improving recovery after ICU. I will also develop new blood tests that will enable these treatments to be personalised.</description>
<description type="fundingAmount">$1,129,998.28</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017086</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017086</identifier>
<identifier type="nhmrc">2017086</identifier>
<name type="primary"><namePart>Mechanistic and pharmacological insights into peripheral sensory neuron function in physiological and pathological pain</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology</subject>
<subject type="local">ion channels </subject>
<subject type="local">nociceptive system</subject>
<subject type="local">electrophysiology</subject>
<subject type="local">peptides</subject>
<subject type="local">sensory nerves</subject>
<description type="Chief Investigator">Prof Irina Vetter</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic pain is a major health issue in Australia and globally. Many currently used pain killers are associated with serious side effects or do not provide adequate relief for patients. One promising approach to develop better drugs is to directly modify activity of peripheral pain-sensing nerves, which often respond abnormally in pain states. This proposal seeks to better understand the molecular mechanisms of pain to facilitate future development of mechanism-based therapeutics.</description>
<description type="fundingAmount">$1,956,790.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017125</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017125</identifier>
<identifier type="nhmrc">2017125</identifier>
<name type="primary"><namePart>Fear extinction as an experimental model for PTSD treatments and course</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03pnv4752</identifier><title>Queensland University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | biological psychology not elsewhere classified | psychology | biological psychology  | psychophysiology | psychology | clinical and health psychology | clinical psychology</subject>
<subject type="local">fear </subject>
<subject type="local">posttraumatic stress disorder (ptsd)</subject>
<subject type="local">conditioning</subject>
<subject type="local">memory</subject>
<subject type="local">psychological treatment</subject>
<description type="Chief Investigator">Dr Luke Ney</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Treating psychiatric disorders such as posttraumatic stress disorder (PTSD) is challenging because the biological and cognitive processes involved in the disorders are unclear. This project will benchmark current experimental models of PTSD against real world clinical outcomes, such as treatment success and disease course. The project will design new and data-informed methods for experimentally modelling processes involved PTSD, leading to novel tools that will help to improve PTSD treatments.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017131</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017131</identifier>
<identifier type="nhmrc">2017131</identifier>
<name type="primary"><namePart>Development of a bench to bedside platform for novel therapy development for psychiatric disorders</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02czsnj07</identifier><title>Deakin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology</subject>
<subject type="local">psychiatric disorders </subject>
<subject type="local">bipolar affective disorder</subject>
<subject type="local">depression</subject>
<subject type="local">bipolar depression</subject>
<subject type="local">schizophrenia and related disorders</subject>
<description type="Chief Investigator">Prof Michael Berk</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My vision for the next five years is to conceptualise, coordinate and lead a program for the bench to bedside development, validation and translation of new, evidence-based therapies for the most prevalent and disabling neuropsychiatric disorders, in particular depression, bipolar disorder, and schizophrenia.</description>
<description type="fundingAmount">$3,249,688.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017138</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017138</identifier>
<identifier type="nhmrc">2017138</identifier>
<name type="primary"><namePart>Extracellular vesicles-based drug delivery for cancer therapy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified</subject>
<subject type="local">breast cancer </subject>
<subject type="local">cancer metastasis</subject>
<subject type="local">cell-cell communication</subject>
<subject type="local">chemotherapy</subject>
<subject type="local">drug delivery</subject>
<description type="Chief Investigator">Dr Pamali Fonseka</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research program aims to develop a novel treatment for metastatic breast cancer with the use of milk derived packages, an agent with anti-cancer properties. Late-stage breast cancer patients suffer from treatment failure and severe side effects from chemotherapy. Loading drugs into these packages will enhance the delivery, treatment response and limit the side effects. This will ultimately result in positive impact on the quality of life of cancer patients.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017139</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017139</identifier>
<identifier type="nhmrc">2017139</identifier>
<name type="primary"><namePart>Optimising metabolic and mental health in the management of adolescent obesity</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</subject>
<subject type="local">diets for weight loss </subject>
<subject type="local">sub-clinical eating disorders</subject>
<subject type="local">binge eating</subject>
<subject type="local">dietary intervention</subject>
<subject type="local">dietary lifestyle</subject>
<description type="Chief Investigator">Dr Hiba Jebeile</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Effective treatment for adolescent obesity is vital. However, a subset of adolescents with obesity are vulnerable to eating disorders. This research brings together a collaboration of obesity and eating disorder researchers, clinicians and consumers to understand: 1) The prevalence of mental health concerns in adolescents with obesity; 2) How to identify adolescents at risk of developing an eating disorder; and 3) How to optimise obesity treatment to improve both physical and mental health</description>
<description type="fundingAmount">$605,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017140</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017140</identifier>
<identifier type="nhmrc">2017140</identifier>
<name type="primary"><namePart>Advancing dynamic MRI to enable adaptive lung radiotherapy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">physical sciences | medical and biological physics | medical physics</subject>
<subject type="local">magnetic resonance imaging (mri) </subject>
<subject type="local">lung cancer</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">radiotherapy</subject>
<subject type="local">medical imaging</subject>
<description type="Chief Investigator">Dr David Waddington</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">MRI-Linacs are cutting-edge treatment machines that use magnetic resonance imaging (MRI) to image tumour anatomy and biological function with unrivalled quality while radiation therapy is performed with a linear accelerator (Linac). This program will use MRI technology to dynamically track moving lung tumours and identify radioresistant tumour tissue responsible for treatment failure. MRI-Linac advances will enable lung cancer radiation treatments with unprecedented accuracy and efficacy.</description>
<description type="fundingAmount">$628,510.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017170</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017170</identifier>
<identifier type="nhmrc">2017170</identifier>
<name type="primary"><namePart>Implementation research: Delivering impact at the health-food retail interface for healthy food environments, with Indigenous communities</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | social determinants of health | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander diet and nutrition</subject>
<subject type="local">indigenous health </subject>
<subject type="local">nutrition</subject>
<subject type="local">population</subject>
<subject type="local">food</subject>
<subject type="local">translational research</subject>
<description type="Chief Investigator">Assoc Prof Julie Brimblecombe</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">How food is promoted, priced and made available in food retail impacts consumer behaviour and subsequently population health. In partnership with communities, Aboriginal health services, the retail sector and policy-makers, I will generate new knowledge on determinants of, and effective strategies to address, dietary inequity for Aboriginal and Torres Strait Islander Peoples through a focus on the remote store environment, practice and policy, and establish a global remote store collaborative.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017176</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017176</identifier>
<identifier type="nhmrc">2017176</identifier>
<name type="primary"><namePart>Understanding the Genetic Basis of Treatment Response for Depression</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">mental health </subject>
<subject type="local">depression</subject>
<subject type="local">pharmacogenomics</subject>
<subject type="local">clinical psychology</subject>
<subject type="local">statistical genetics</subject>
<description type="Chief Investigator">Dr Brittany Mitchell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Depression is the most common psychiatric disorder and is most commonly trated with antidepressant medicationd and psychological therapy. However, many people discontinue treatment due to experiencing adverse side effects or experiencing no remission in symptoms. I aim to identify genetic factors that influence depression treatment response by analyzing large-scale genetic data. These insights could be used to understand who is most likely to benefit from certain types of treatment.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017197</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017197</identifier>
<identifier type="nhmrc">2017197</identifier>
<name type="primary"><namePart>A Metagenomics Platform to Prevent Future Pandemics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology</subject>
<subject type="local">virology </subject>
<subject type="local">genomics</subject>
<subject type="local">emerging diseases</subject>
<subject type="local">evolution</subject>
<subject type="local">bioinformatics</subject>
<description type="Chief Investigator">Prof Edward Holmes</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Genome sequence data has transformed the study of emerging diseases. However, large-scale metagenomic data are cumbersome to analyse and have not been widely used for virus surveillance. This research programme will transform our understanding of the disease threat to Australian and global populations by developing a new bioinformatics pipeline to rapidly and identify viruses of potential public health impact and by performing a metagenomic survey of viruses at the animal-human interface.</description>
<description type="fundingAmount">$3,937,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017220</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017220</identifier>
<identifier type="nhmrc">2017220</identifier>
<name type="primary"><namePart>Neural regulation of immunity</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | immunology | cellular immunology</subject>
<subject type="local">sympathetic nervous system </subject>
<subject type="local">neuroimmunology</subject>
<subject type="local">immune response</subject>
<subject type="local">cellular interactions</subject>
<subject type="local">t cells</subject>
<description type="Chief Investigator">Prof Scott Mueller</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Immune responses are essential for the body to fight infections and cancer. It is well appreciated that communication occurs between the nervous system and the immune system, but how this occurs is unclear. Using new tools, genomics and highly advanced imaging, this project will define interactions between the nervous system and the immune system that can be precisely targeted to improve therapies and vaccines for infectious diseases and cancer.</description>
<description type="fundingAmount">$3,582,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017223</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017223</identifier>
<identifier type="nhmrc">2017223</identifier>
<name type="primary"><namePart>Innovative screening and treatment approaches for diabetic complications</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology</subject>
<subject type="local">diabetic complications </subject>
<subject type="local">diabetic vascular complications</subject>
<subject type="local">diabetic nephropathy</subject>
<subject type="local">atherosclerosis</subject>
<subject type="local">biomarkers</subject>
<description type="Chief Investigator">Prof Karin Jandeleit-Dahm</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Diabetes is complicated by damage to the kidney leading to kidney failure and injury to blood vessels leading to heart attacks, strokes and amputations. My program will validate novel biomarkers for earlier detection and will develop novel and better treatments for diabetic complications, including in the Indigenous population. I will initiate clinical trials and translate into practice. As a clinician/ scientist my mission is to reduce the high health burden of diabetes and its complications.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017225</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017225</identifier>
<identifier type="nhmrc">2017225</identifier>
<name type="primary"><namePart>Detection and treatment of brain injury in growth restricted newborns</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified</subject>
<subject type="local">fetal growth restriction </subject>
<subject type="local">neuroprotection</subject>
<subject type="local">brain injury</subject>
<subject type="local">inflammation</subject>
<subject type="local">newborn</subject>
<description type="Chief Investigator">Dr Julie Wixey</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Babies that grow slowly before birth are more likely to suffer brain damage. There is no way to prevent this brain damage, it is difficult to detect, and there are no treatments. These babies often face a challenging life, with many problems including autism, ADHD, or cerebral palsy. My work will provide new knowledge on not only tests to detect brain damage to identify these babies earlier, this project will also explore treatments to improve life-long outcomes for these children.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017229</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017229</identifier>
<identifier type="nhmrc">2017229</identifier>
<name type="primary"><namePart>Improving strategies to combat preventable infections</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">infectious diseases </subject>
<subject type="local">gastrointestinal infections</subject>
<subject type="local">qualitative methods</subject>
<subject type="local">travel health</subject>
<subject type="local">preventive health</subject>
<description type="Chief Investigator">Dr Sarah McGuinness</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">People living in and visiting resource-poor settings are at increased risk of exposure to infections spread through food, water, mosquitoes and the environment. Preventive strategies that should reduce infection exposure often have limited success in the real world. My research aims to understand and overcome the barriers that limit the effectiveness and uptake of key preventive strategies (such as improved water supplies and vaccination), to improve health outcomes in vulnerable populations.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017233</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017233</identifier>
<identifier type="nhmrc">2017233</identifier>
<name type="primary"><namePart>Functional amplification of stem cells for tissue repair</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall)</subject>
<subject type="local">adult stem cells </subject>
<subject type="local">tropoelastin</subject>
<subject type="local">elastin</subject>
<subject type="local">extracellular matrix</subject>
<subject type="local">tissue repair</subject>
<description type="Chief Investigator">Dr Giselle Yeo</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Stem cells are increasingly being used to treat a diverse range of diseases. However, for such therapies to be clinically feasible and widely accessible, a large supply of quality stem cells are needed. Current methods of manufacturing stem cells are inadequate and expensive. This work aims to develop a safe, cost-effective, robust and more efficient way of propagating and preparing stem cells, by exploiting the potent, versatile actions of a human elastic protein on cell lifespan and behaviour.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017256</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017256</identifier>
<identifier type="nhmrc">2017256</identifier>
<name type="primary"><namePart>Unlocking precision medicine for 'incurable' child cancers</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers</subject>
<subject type="local">combination therapy </subject>
<subject type="local">biomarkers</subject>
<subject type="local">drug discovery</subject>
<subject type="local">molecular diagnostics</subject>
<subject type="local">molecular oncology</subject>
<description type="Chief Investigator">Prof Michelle Haber</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Although personalised medicine programs for children with cancer are better matching drugs to their molecular targets, the outlook remains dismal for patients with aggressive high-risk disease. I will develop new optimised combination therapies for treating these children, develop a new drug to prevent and treat childhood cancer, and develop new diagnostics to better predict treatment response and optimise personalised therapy, with the singular goal of improving patient outcomes.</description>
<description type="fundingAmount">$1,500,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017257</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017257</identifier>
<identifier type="nhmrc">2017257</identifier>
<name type="primary"><namePart>Building best-in-class bioinformatics tools to drive next generation biomedical research</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | bioinformatic methods development | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches)</subject>
<subject type="local">bioinformatics </subject>
<subject type="local">genomics</subject>
<subject type="local">gene expression</subject>
<subject type="local">data analysis</subject>
<subject type="local">sequencing</subject>
<description type="Chief Investigator">Assoc Prof Matthew Ritchie</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">To get a complete picture of disease, the analysis of data obtained from cutting edge biotechnologies applied to clinical samples is essential. To do this successfully, advanced statistical methods are needed. I will develop new software tools and curate large collections of molecular information to improve understanding of healthy ageing and disease processes. The tools will be freely available to researchers anywhere and will drive new discoveries and disease treatments.</description>
<description type="fundingAmount">$3,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017267</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017267</identifier>
<identifier type="nhmrc">2017267</identifier>
<name type="primary"><namePart>Beyond translation: Integrating clinical trials and intelligent health systems for stroke</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">acute stroke </subject>
<subject type="local">ischaemic stroke</subject>
<subject type="local">stroke outcome</subject>
<subject type="local">telemedicine</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Assoc Prof Andrew Bivard</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Over the next 5 years my research will generate new knowledge with new clinical trials, novel AI-driven stroke assessment tools , and integrated telehealth technologies to enhance rural and regional stroke care. My research will leverage globally unique imaging and biobank data capabilities and my extensive national and international clinical trials network. These will drive the next phase of my successful track record of clinical translation.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017278</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017278</identifier>
<identifier type="nhmrc">2017278</identifier>
<name type="primary"><namePart>Evaluation and implementation of a digital health literacy tool to improve written health information</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | implementation science and evaluation | health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">health literacy </subject>
<subject type="local">patient education</subject>
<subject type="local">health services research</subject>
<subject type="local">health care worker education</subject>
<subject type="local">health informatics</subject>
<description type="Chief Investigator">Dr Julie Ayre</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Providing health information that all people can easily understand is a key step towards a fair and safe public health system, and one that empowers people to become active participants in their own health care. However, we currently lack sophisticated and scalable tools to achieve this goal. This project will evaluate a new online text-editing tool that helps health care providers write health information more simply, and provide strategies to increase its uptake within health organisations.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017279</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017279</identifier>
<identifier type="nhmrc">2017279</identifier>
<name type="primary"><namePart>Biomarker discovery informs precision medicine in childhood epilepsy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system</subject>
<subject type="local">epilepsy </subject>
<subject type="local">genetic testing</subject>
<subject type="local">biomarkers</subject>
<subject type="local">inflammatory cytokines</subject>
<subject type="local">epilepsy surgery</subject>
<description type="Chief Investigator">Dr Kavitha Kothur</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Epilepsy is a common problem affecting 3% of the general population, and is associated with comorbidities, affects the quality of life and poses safety risks. However, if diagnosed and treated appropriately, seizures can be reversed, improving morbidity and mortality. My program will generate novel biomarkers on a large clinical registry of refractory epilepsy patients to increase understanding of underlying disease processes and to provide patient specific precision medicine.</description>
<description type="fundingAmount">$605,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017282</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017282</identifier>
<identifier type="nhmrc">2017282</identifier>
<name type="primary"><namePart>Linking Brains: Histology, MRI, Connectivity and Functional Maps of Humans and Mice</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified</subject>
<subject type="local">neuroanatomy </subject>
<subject type="local">neuroanatomical connections</subject>
<subject type="local">neuroimaging</subject>
<subject type="local">neuroanatomical tracing</subject>
<subject type="local">neuroscience</subject>
<description type="Chief Investigator">Prof George Paxinos</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project uses imaging techniques to produce a new generation of brain atlases. It will advance our understanding of the organisation and connections of the human brain as well as that of the most commonly used animal to model human disease––the mouse. The atlases will inform the development of psychotherapeutic drugs and result in more accurate interventions on the human brain. The new maps will assist those who study the brain of patients with diseases such as Alzheimer’s and Parkinson’s.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017284</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017284</identifier>
<identifier type="nhmrc">2017284</identifier>
<name type="primary"><namePart>Evolutionary genomics to inform outbreak responses</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | biological sciences | evolutionary biology | phylogeny and comparative analysis | biological sciences | bioinformatics and computational biology | bioinformatic methods development</subject>
<subject type="local">genetic epidemiology </subject>
<subject type="local">infectious diseases</subject>
<subject type="local">evolution</subject>
<subject type="local">genomics</subject>
<subject type="local">bioinformatics</subject>
<description type="Chief Investigator">Dr Sebastian Duchene</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Genomics has been essential to track recent pandemics, including those of COVID-19, Ebola, and drug-resistant bacteria. This project will develop methods to integrate epidemiological and genomic data, for a comprehensive system of infectious disease surveillance that will constantly update estimates of pathogen introductions and infectious spread. Implementation of these techniques in public health will dramatically increase the value of information for pandemic preparedness and mitigation.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017289</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017289</identifier>
<identifier type="nhmrc">2017289</identifier>
<name type="primary"><namePart>Determining cellular competency in the mammary gland</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death</subject>
<subject type="local">calcium signalling </subject>
<subject type="local">calcium channels</subject>
<subject type="local">calcium imaging</subject>
<subject type="local">lactation</subject>
<subject type="local">mammary gland cancer</subject>
<description type="Chief Investigator">Dr Valentina Rodriguez Paris</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">A mother’s ability to produce a nutritionally complete source of food for her baby is of central importance to human health. However, we understand very little about the cells in the breast that produce and secrete milk. I will visualise and quantify the function of individual cells in this tissue to better understand their behaviours and to improve our knowledge of the cellular functions and characteristics that can contribute to the development and progression of breast cancers.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017295</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017295</identifier>
<identifier type="nhmrc">2017295</identifier>
<name type="primary"><namePart>One size does not fit all: achieving patient-centred deprescribing through evidence-based, individualised interventions</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">prescribing </subject>
<subject type="local">patient/doctor communication</subject>
<subject type="local">patient preference</subject>
<subject type="local">decision making</subject>
<subject type="local">communication</subject>
<description type="Chief Investigator">Dr Kristie Weir</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Reducing medicines (deprescribing) through stopping medicines or taking less medicines is a positive intervention that improves health outcomes. Deprescribing should be tailored and patient-centred, but it is complex and unclear how this can be achieved. This body of work will explore and develop evidence-based tools to enable individualised communication about deprescribing. This will ensure patients and GPs make good decisions about medicines use in older age.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017299</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017299</identifier>
<identifier type="nhmrc">2017299</identifier>
<name type="primary"><namePart>Deciphering the rules of T cell residency across intestinal compartments</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified</subject>
<subject type="local">cd8 t cells </subject>
<subject type="local">t cell memory</subject>
<subject type="local">t cell development</subject>
<subject type="local">mucosal immunology</subject>
<subject type="local">gastrointestinal infections</subject>
<description type="Chief Investigator">Dr Maximilien Evrard</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Tissue-resident memory T cells (TRM) are key for immune protection against infection at barrier sites such as the gut. While much of our understanding of gut TRM comes from studies on the small intestine, how these cells develop and function in the large intestine is unknown. This project aims to identify and modulate molecular pathways by which the intestinal microenvironment influences TRM development specifically in the small or large intestine to enhance immune protection against infections.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017302</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017302</identifier>
<identifier type="nhmrc">2017302</identifier>
<name type="primary"><namePart>Dietitian-led intervention for physical health disparities in people living with severe mental illness</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | mental health services | biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</subject>
<subject type="local">mental illness </subject>
<subject type="local">early psychosis</subject>
<subject type="local">nutrition</subject>
<subject type="local">clinical dietetic practice</subject>
<subject type="local">body weight changes</subject>
<description type="Chief Investigator">Dr Scott Teasdale</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Nutrition is a critical underlying issue for the significantly higher rates of chronic diseases, such as heart disease, experienced by people living with severe mental illness. Best practice nutrition intervention is yet to be determined. This project builds on promising pilot projects to determine the most effective interventions and to translate this into practice by formalising a clinical care process for dietitians and a resource for consumers to advocate for best practice nutrition support.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017325</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017325</identifier>
<identifier type="nhmrc">2017325</identifier>
<name type="primary"><namePart>Delivering Precision Medicine to Population-based Cancer Prevention</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics</subject>
<subject type="local">breast cancer </subject>
<subject type="local">prostate cancer</subject>
<subject type="local">inheritance</subject>
<subject type="local">biological risk factors</subject>
<subject type="local">risk prediction</subject>
<description type="Chief Investigator">Prof Melissa Southey</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My program will build upon my landmark studies that have demonstrated cancer risk factors that are modifications of DNA (epigenomic) rather than mutation of DNA (genomic) by building new, accurate prediction tools for cancer risk in the general population. This research program will advance cancer risk screening by including both epigenomic and genomic assessment and make it widely available in Australia to prevent cases of cancer and to develop new medicines for those who do develop cancer.</description>
<description type="fundingAmount">$3,249,688.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017335</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017335</identifier>
<identifier type="nhmrc">2017335</identifier>
<name type="primary"><namePart>Gatekeepers of optimal T cell immune function in health and aging-related decline</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | immunology | cellular immunology | biological sciences | biochemistry and cell biology | signal transduction</subject>
<subject type="local">t cells </subject>
<subject type="local">ageing</subject>
<subject type="local">t cell receptor</subject>
<subject type="local">t cell activation</subject>
<subject type="local">receptor signalling</subject>
<description type="Chief Investigator">Prof Nicole La Gruta</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">T cells protect from infectious disease and cancers, and boosting T cell activation is the goal of current immunotherapies. In older individuals, T cells become dysfunctional placing the elderly at much greater risk. However, precisely what is required for effective T cell activation, and what goes wrong in older individuals, remains poorly understood. This study will advance fundamental knowledge around T cell activation, critical for the ongoing development and optimisation of immunotherapies.</description>
<description type="fundingAmount">$2,682,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017353</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017353</identifier>
<identifier type="nhmrc">2017353</identifier>
<name type="primary"><namePart>Uncovering new targets for cancer immunotherapy through multiplexed genomic screens in cytotoxic T cells</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology</subject>
<subject type="local">cancer immunotherapy </subject>
<subject type="local">cancer immunology</subject>
<subject type="local">haematological malignancy</subject>
<subject type="local">solid tumours</subject>
<subject type="local">cellular immunology</subject>
<description type="Chief Investigator">Dr Emily Lelliott</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Immunotherapy is a modern approach to treat cancer and works by training the immune system, particularly T cells, to attack cancer cells. Immunotherapies are proving to be very successful in treating certain cancers, however, not all patients respond positively to this treatment for reasons that are still unclear. This project will identify the genetic factors that determine whether T cells have the capacity to fight cancer and discover new ways to improve patient responses to immunotherapy.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017370</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017370</identifier>
<identifier type="nhmrc">2017370</identifier>
<name type="primary"><namePart>Fallopian tube on-a-chip for understanding human reproduction</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | reproduction | engineering | fluid mechanics and thermal engineering | microfluidics and nanofluidics | engineering | biomedical engineering | biomedical instrumentation</subject>
<subject type="local">fertility </subject>
<subject type="local">reproduction</subject>
<subject type="local">epithelial cells</subject>
<subject type="local">sperm function</subject>
<subject type="local">cell culture</subject>
<description type="Chief Investigator">Dr Reza Nosrati</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Infertility is on the rise, affecting &gt;180 million individuals worldwide. However, our knowledge of fertilisation is still insufficient and advances in treatment methods are infrequent. This project aims to develop new microfluidic technologies that closely represent the physiology and function of the female fallopian tube to directly study human reproduction. The project expects to bring new insights into unknown causes of infertility and improve treatment methods worldwide.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017373</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017373</identifier>
<identifier type="nhmrc">2017373</identifier>
<name type="primary"><namePart>Reducing the Breast Cancer Burden in Young Women</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified</subject>
<subject type="local">breast cancer aetiology </subject>
<subject type="local">epidemiology</subject>
<subject type="local">cancer epidemiology</subject>
<subject type="local">risk assessment</subject>
<subject type="local">risk factors</subject>
<description type="Chief Investigator">Dr Shuai Li</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I aim to reduce the breast cancer burden in young women by finding out the causes of breast cancer in young women and how cancer risk can be accurately predicted and prevented. I will also investigate the future health of young women diagnosed with breast cancer so that health support is provided to young survivors.</description>
<description type="fundingAmount">$638,056.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017382</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017382</identifier>
<identifier type="nhmrc">2017382</identifier>
<name type="primary"><namePart>Targeting the gut microbiota to treat cardiovascular disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">blood pressure </subject>
<subject type="local">metabolites</subject>
<subject type="local">dietary fibre</subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">diet</subject>
<description type="Chief Investigator">Assoc Prof Francine Marques</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">After four decades of research, we now know the association between fibre intake and lower blood pressure is dependent on our gut microbes. While our bodies are incapable of digesting some types of fibre, it feeds the community of ‘good’ bacteria, resulting in the release of substances that can lower blood pressure. In the next 5 years, I will establish how these substances lower blood pressure and test their use to treat patients.</description>
<description type="fundingAmount">$815,278.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017383</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017383</identifier>
<identifier type="nhmrc">2017383</identifier>
<name type="primary"><namePart>A comprehensive vaccine-based strategy to combat gonorrhoea</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology</subject>
<subject type="local">neisseria gonorrhoeae </subject>
<subject type="local">sexually-transmitted infections (sti)</subject>
<subject type="local">vaccine development</subject>
<subject type="local">antibody</subject>
<subject type="local">vaccination immunology</subject>
<description type="Chief Investigator">Prof Kate Seib</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The sexually transmitted infection gonorrhoea has a significant impact on global health, with 100 million cases/year, many of which are associated with infertility and increased HIV transmission. Due to increasing antimicrobial resistance and the absence of a vaccine, the WHO has classified gonorrhoea an urgent threat to public health that requires immediate action. My research aims to develop a vaccine to prevent gonorrhoea from becoming an untreatable ‘superbug’ in the near future.</description>
<description type="fundingAmount">$2,082,170.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017388</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017388</identifier>
<identifier type="nhmrc">2017388</identifier>
<name type="primary"><namePart>Sickly sweet: managing high blood glucose during and post critical illness</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care</subject>
<subject type="local">hyperglycaemia </subject>
<subject type="local">diabetes mellitus</subject>
<subject type="local">critical care medicine</subject>
<subject type="local">intensive care medicine</subject>
<subject type="local">diabetes prevention</subject>
<description type="Chief Investigator">Dr Mark Plummer</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">High blood sugar levels occur frequently during critical illness even in patients without a history of diabetes. High blood sugar levels are associated with increased mortality in ICU and an increased risk of developing diabetes in survivors. My research will; (i) determine the efficacy of a new drug to manage high sugar levels in the ICU, (ii) identify mechanisms of how high blood sugar levels in ICU lead to diabetes, and, (iii) determine whether this can be prevented with screening programs.</description>
<description type="fundingAmount">$447,128.72</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017404</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017404</identifier>
<identifier type="nhmrc">2017404</identifier>
<name type="primary"><namePart>Developing microbiome-based interventions to improve vaccine immunogenicity</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | biological sciences | biochemistry and cell biology | systems biology | biological sciences | microbiology | microbial ecology</subject>
<subject type="local">systems biology </subject>
<subject type="local">bioinformatics</subject>
<subject type="local">microbial ecology</subject>
<subject type="local">genomics</subject>
<subject type="local">vaccine biology</subject>
<description type="Chief Investigator">Dr Feargal Ryan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Effective vaccination is critical for combating infectious disease. However, vaccine immune responses are highly variable between individuals and populations (e.g. lower in the elderly). New evidence suggests bacteria in our gut microbiome may be responsible. This program of work will allow us to understand how gut bacteria modulate activity of the immune system in response to vaccination. This knowledge will be crucial to both future vaccine development and improving vaccines currently in use.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017405</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017405</identifier>
<identifier type="nhmrc">2017405</identifier>
<name type="primary"><namePart>Better health outcomes after road traffic injury</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified</subject>
<subject type="local">motor vehicle accidents </subject>
<subject type="local">whiplash injuries</subject>
<subject type="local">neck pain</subject>
<subject type="local">rehabilitation</subject>
<subject type="local">pain</subject>
<description type="Chief Investigator">Prof Michele Sterling</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic pain is the leading cause of disability worldwide with 30% caused by a road traffic injury. My research will produce new knowledge under three aims. To: 1) Gain new insights into the development of chronic pain, 2) Test novel early treatments to prevent chronic pain after road traffic injury and 3) Implement early risk-screening models of care in the clinical and injury compensation environments. The outcomes will drive change in the assessment and treatment of road traffic injury.</description>
<description type="fundingAmount">$2,351,142.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017417</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017417</identifier>
<identifier type="nhmrc">2017417</identifier>
<name type="primary"><namePart>Applying communication and social science to improve vaccine confidence and uptake</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | health promotion | health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation</subject>
<subject type="local">vaccination </subject>
<subject type="local">community intervention</subject>
<subject type="local">social and behavioural research</subject>
<subject type="local">health promotion</subject>
<subject type="local">measurement</subject>
<description type="Chief Investigator">Dr Jessica Kaufman</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">COVID-19 has put vaccination in the spotlight like never before. It is more important than ever to understand why some people don't vaccinate and what to do about it. This research will: 1) Use surveys to understand access and acceptance barriers to vaccination, and 2) Provide tools and training for community leaders to use to advocate for vaccination. The outcome will be to help more people feel comfortable about getting routine and COVID-19 vaccines in Australia and the Western Pacific Region.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017420</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017420</identifier>
<identifier type="nhmrc">2017420</identifier>
<name type="primary"><namePart>Targeting T cell differentiation and function to treat cancer and chronic disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">t cells </subject>
<subject type="local">molecular biology</subject>
<subject type="local">immunotherapy</subject>
<subject type="local">gene transcription</subject>
<subject type="local">cell differentiation</subject>
<description type="Chief Investigator">Prof Axel Kallies</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic diseases, including persistent viral infections and cancer, are major health burdens and among the most difficult to treat. T cells play a central role in disease control; however, their function is often impaired by a process termed ‘exhaustion’. Immunotherapies aimed at reinvigorating exhausted T cells have revolutionised cancer treatment. In this project, I will identify molecular pathways that control T cells with the goal to pave the way for new immunotherapies for chronic diseases.</description>
<description type="fundingAmount">$3,494,678.07</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017436</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017436</identifier>
<identifier type="nhmrc">2017436</identifier>
<name type="primary"><namePart>Addressing the threat of emerging zoonotic malaria in our region</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006mbby82</identifier><title>Menzies School of Health Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">malaria </subject>
<subject type="local">zoonotic infectious disease</subject>
<subject type="local">epidemiology</subject>
<subject type="local">malaria transmission</subject>
<subject type="local">zoonotic disease</subject>
<description type="Chief Investigator">Assoc Prof Matthew Grigg</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The monkey malaria parasite P. knowlesi (Pk) increasingly infects humans across Southeast Asia. A multidisciplinary approach will evaluate why Pk cases are rising, improve laboratory detection methods, assess preventative treatments, and inform public health programs. Pk genetic analyses will explore causes of severe disease and geographical infection patterns. Evaluating human interaction with mosquitos, monkeys, and land-use, will generate regional Pk risk prediction maps for targeted control.</description>
<description type="fundingAmount">$1,526,800.96</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017438</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017438</identifier>
<identifier type="nhmrc">2017438</identifier>
<name type="primary"><namePart>Innovative interventions to reduce the personal and societal burden of food allergy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | paediatrics | infant and child health | health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">food allergy </subject>
<subject type="local">treatment strategies</subject>
<subject type="local">clinical trial</subject>
<subject type="local">immunotherapy</subject>
<subject type="local">translational research</subject>
<description type="Chief Investigator">Prof Mimi Tang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Food allergy causes severely reduced quality of life and psychological distress for allergic children and their families. My vision is to free children and families from the burdens of living with food allergy. This 5 year program of research will: (i) identify and evaluate new treatments that induce remission of allergy, bringing a long-term solution that will transform the lives of allergic children and families; (ii) deliver innovative tools that improve the way food allergy is managed now.</description>
<description type="fundingAmount">$1,710,808.85</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017450</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017450</identifier>
<identifier type="nhmrc">2017450</identifier>
<name type="primary"><namePart>Improving equity, access, and quality of cardiac rehabilitation services</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | allied health and rehabilitation science | allied health and rehabilitation science not elsewhere classified</subject>
<subject type="local">telemedicine </subject>
<subject type="local">cardiac rehabilitation</subject>
<subject type="local">implementation</subject>
<subject type="local">translational research</subject>
<subject type="local">secondary prevention</subject>
<description type="Chief Investigator">Dr Emma Thomas</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cardiac rehabilitation (CR) enables people who have suffered a heart event to self-manage their condition and improve their quality of life.However, many eligible patients (70%) do not attend. Telehealth-delivered CR can reduce access barriers, is safe, effective and is well-liked by patients. However, there is a practice-gap in translating these findings into practice. This project aims to provide a major health system impact by supporting the expanded use of telehealth across CR services.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017461</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017461</identifier>
<identifier type="nhmrc">2017461</identifier>
<name type="primary"><namePart>New Toxin Tools for Dissecting Pain</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology</subject>
<subject type="local">pain </subject>
<subject type="local">toxins</subject>
<subject type="local">peptides</subject>
<subject type="local">ion channels</subject>
<subject type="local">receptors</subject>
<description type="Chief Investigator">Dr Samuel Robinson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is worldwide demand for new and creative pain treatment strategies. The aim of my research is to identify new pain-causing toxins from animal venoms and to use them as tools to improve our understanding and, ultimately treatment, of pain.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017463</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017463</identifier>
<identifier type="nhmrc">2017463</identifier>
<name type="primary"><namePart>Novel approaches to understand and treat human allergic diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | immunology | cellular immunology</subject>
<subject type="local">cd4 </subject>
<subject type="local">t cells</subject>
<subject type="local">th2 differentiation</subject>
<subject type="local">cellular immunology</subject>
<subject type="local">lymphocyte differentiation</subject>
<description type="Chief Investigator">Assoc Prof Cindy Ma</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Allergic diseases affect ~1 in 3 Australians and carry significant health and financial burdens. Primary immunodeficiencies (PIDs) result from damaging mutations in genes that affect the development and function of immune cells. In addition to life-threatening infections, PID patients often suffer from severe allergies. I will investigate immune cells from PID patients and patients with allergy to reveal mechanisms of disease and novel approaches to understand and treat these conditions.</description>
<description type="fundingAmount">$2,756,790.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017476</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017476</identifier>
<identifier type="nhmrc">2017476</identifier>
<name type="primary"><namePart>Prolonging survival in glioblastoma through targeting of quiescent glioma stem cells.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</subject>
<subject type="local">adult stem cells </subject>
<subject type="local">glioma</subject>
<subject type="local">combination therapy</subject>
<subject type="local">cell proliferation</subject>
<subject type="local">chemotherapy</subject>
<description type="Chief Investigator">Dr Lachlan Harris</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Most people diagnosed with the brain cancer glioblastoma die within 15-months. The cancer is so deadly because of slowly dividing cancer stem cells that resist treatment and cause patient relapse. My strategy is to eliminate these resistant cells by focusing on unique features of their biology, for example, by targeting the fact that these cells have increased expression of surface proteins. This project will test targeted molecules to establish an evidence base for Phase 1 trials.</description>
<description type="fundingAmount">$605,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017477</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017477</identifier>
<identifier type="nhmrc">2017477</identifier>
<name type="primary"><namePart>An immunogenomic approach to breast cancer in young women</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | solid tumours</subject>
<subject type="local">breast cancer </subject>
<subject type="local">translational research</subject>
<subject type="local">genomics</subject>
<subject type="local">microenvironment</subject>
<subject type="local">oncology</subject>
<description type="Chief Investigator">Dr Peter Savas</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Breast cancer causes the highest number of disease related deaths in adult women under the age of 45. It is a difficult problem that is also becoming more common. To understand this disease better, we need a comprehensive and detailed approach. Using samples taken from real patients, we will apply the most sophisticated technologies available to us for revealing how and why a cancer develops. This will ultimately lead to better ways to treat, detect and prevent breast cancer in young women.</description>
<description type="fundingAmount">$574,120.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017479</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017479</identifier>
<identifier type="nhmrc">2017479</identifier>
<name type="primary"><namePart>Transforming Outcomes for Pulmonary Fibrosis</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</subject>
<subject type="local">pulmonary fibrosis </subject>
<subject type="local">respiratory</subject>
<subject type="local">lung disease</subject>
<subject type="local">disease progression</subject>
<subject type="local">individualising management</subject>
<description type="Chief Investigator">Assoc Prof Tamera Corte</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pulmonary Fibrosis (PF) is a group of devastating conditions with scarring of the lung tissue - the most common has a survival of only 2-5 years. This research program will develop new techniques to understand the causes of PF; improve early and accurate diagnosis; correctly identify patients whose PF is more likely to progress rapidly, and those most likely to respond to treatment; and optimise delivery of PF care across Australia. This will enable more personalised approaches to treatment.</description>
<description type="fundingAmount">$1,954,074.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017481</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017481</identifier>
<identifier type="nhmrc">2017481</identifier>
<name type="primary"><namePart>The impact of chronic viral infections on molecular ageing processes and associated clinical outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">clinical research </subject>
<subject type="local">prospective cohort study</subject>
<subject type="local">viral infection</subject>
<subject type="local">ageing</subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<description type="Chief Investigator">Dr Nila Dharan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Older people with certain chronic virus infections age more quickly and have more ageing-related medical problems than people without chronic virus infections. This research will study key chronic virus infections – HIV and cytomegalovirus (a very common virus) – to better understand the biological processes that increase the risk of ageing-related medical conditions. The aim of this research is to discover novel screening and prevention measures to promote healthy ageing.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017485</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017485</identifier>
<identifier type="nhmrc">2017485</identifier>
<name type="primary"><namePart>Eliminating Malaria in the Asia-Pacific</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance</subject>
<subject type="local">malaria </subject>
<subject type="local">implementation</subject>
<subject type="local">immune surveillance</subject>
<subject type="local">epidemiology</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<description type="Chief Investigator">Prof Freya Fowkes</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">In the Asia-Pacific, more than two billion people are at risk of malaria, a parasitic disease transmitted by mosquitoes. I will work with malaria endemic partners to provide evidence for the most effective malaria prevention strategies and improve surveillance so that every last malaria infection is detected, treated and eliminated. My program aims to change policy and advance progress towards the goal of malaria elimination in the Asia-Pacific by 2030.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017498</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017498</identifier>
<identifier type="nhmrc">2017498</identifier>
<name type="primary"><namePart>A program of substantive and methodological research and capacity building in biostatistics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">mathematical sciences | statistics | applied statistics</subject>
<subject type="local">clinical trial </subject>
<subject type="local">biostatistics</subject>
<subject type="local">neonatal</subject>
<subject type="local">applied statistics</subject>
<subject type="local">paediatric</subject>
<description type="Chief Investigator">Prof Katherine Lee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Adaptive platform designs are revolutionising how clinical trials are conducted. The proposed program of biostatistical and substantive research and capacity building in these study designs will not only lead to advances in statistical methodology and child health, but will ensure that Australia has the biostatistical skills and understanding to support cutting-edge clinical and public health research into the future.</description>
<description type="fundingAmount">$2,219,468.85</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017499</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017499</identifier>
<identifier type="nhmrc">2017499</identifier>
<name type="primary"><namePart>Single molecular antigen rapid test (SMART)</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03f0f6041</identifier><title>University of Technology Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | biomedical imaging | engineering | biomedical engineering | medical devices</subject>
<subject type="local">nanotechnology </subject>
<subject type="local">optical imaging</subject>
<subject type="local">diagnostic techniques</subject>
<subject type="local">instrumentation</subject>
<subject type="local">covid-19</subject>
<description type="Chief Investigator">Assoc Prof Jiajia Zhou</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to investigate the role of the spike protein of the COVID-19 virus in binding antibodies and host cells. The project will use new knowledge to develop a Single Molecular Antigen Rapid Test (SMART). Expected outcomes include a better understanding of virus functions and their structural correlation at the molecular level, being able to visualise spike-induced cellular interactions, and a device that can detect multiple virus antigens, sensitively and very efficiently.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017504</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017504</identifier>
<identifier type="nhmrc">2017504</identifier>
<name type="primary"><namePart>Novel approaches to improve blood pressure control</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">hypertension </subject>
<subject type="local">control of blood pressure</subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">dietary salt</subject>
<description type="Chief Investigator">Prof Aletta Schutte</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">High blood pressure (BP) is the top killer of people in Australia, but only 1 in 3 adults with high BP has it under control. My vision is to rapidly improve BP control using four novel scalable approaches. My program will evaluate the effectiveness of highly promising interventions to lower BP: a salt substitute; a BP awareness campaign in hardware stores; using wearable cuffless BP monitoring; and a simplified treatment model with single pill combination therapy in primary care.</description>
<description type="fundingAmount">$3,382,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017506</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017506</identifier>
<identifier type="nhmrc">2017506</identifier>
<name type="primary"><namePart>Protecting physical &amp; mental health of trauma-exposed populations</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | health promotion</subject>
<subject type="local">physical activity </subject>
<subject type="local">traumatic stress</subject>
<subject type="local">exercise</subject>
<subject type="local">refugee health</subject>
<subject type="local">posttraumatic stress disorder (ptsd)</subject>
<description type="Chief Investigator">Assoc Prof Simon Rosenbaum</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Traumatic experiences are a risk factor for poor physical and mental health. This research program will generate critical knowledge on how lifestyle factors (physical activity, diet and sleep) impact mental and physical health, in people exposed to trauma. This includes emergency service workers, veterans and people from refugee and asylum seeker backgrounds. Results will inform how lifestyle programs can be integrated into routine care of people exposed to trauma (with, and at risk of PTSD).</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017515</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017515</identifier>
<identifier type="nhmrc">2017515</identifier>
<name type="primary"><namePart>Multi-omic landscape of platelet function in disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genetics not elsewhere classified</subject>
<subject type="local">mitochondria </subject>
<subject type="local">mitochondrial dna (mtdna)</subject>
<subject type="local">energy metabolism</subject>
<subject type="local">platelet activation</subject>
<subject type="local">platelet function</subject>
<description type="Chief Investigator">Dr Tara Richman</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Platelets enable blood clotting and would healing during vascular injury requiring high levels of energy to be maintained during circulation in preparation for activation. The energy centre of the cell is packaged within platelets but its function is not well defined. This project will uncover how dysfunction in the energy centre affects the platelets and how this can be translated to diagnosis and treatments for patients with excessive bleeding or clotting leading to stroke or heart attack.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017517</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017517</identifier>
<identifier type="nhmrc">2017517</identifier>
<name type="primary"><namePart>New method to identify disease-associated drug targets</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | proteomics and metabolomics | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | biochemistry and cell biology | receptors and membrane biology</subject>
<subject type="local">therapeutic target </subject>
<subject type="local">mass spectrometry</subject>
<subject type="local">membrane protein</subject>
<subject type="local">drug targeting</subject>
<subject type="local">protein targeting</subject>
<description type="Chief Investigator">Dr Miaomiao Liu</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to develop mass spectrometry-based methods to identify or characterise new targets for drug discovery. The application of the methods in target identification will allow finding of unknown protein targets for bioactive compounds and will revolutionise and dramatically accelerate the drug discovery process. Furthermore, adapting to studying membrane proteins will result in finding novel therapeutic ligands that target MPs, the most important class of drug targets.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017521</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017521</identifier>
<identifier type="nhmrc">2017521</identifier>
<name type="primary"><namePart>Targeting anhedonia to improve clinical and functional outcomes in depression</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology | psychology | cognitive and computational psychology | learning, motivation and emotion</subject>
<subject type="local">depression </subject>
<subject type="local">antidepressants</subject>
<subject type="local">emotion</subject>
<subject type="local">learning</subject>
<subject type="local">mood disorders</subject>
<description type="Chief Investigator">Dr Alexis Whitton</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Anhedonia (loss of pleasure) is a key driver of disability in people with depression because it impairs functioning and responds poorly to treatment. This research aims to improve our understanding of anhedonia’s underlying causes and will evaluate whether a novel intervention improves symptoms and functioning for people with anhedonic depression. By informing new treatment approaches for anhedonia, the findings would make significant progress toward reducing the global burden of depression.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017527</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017527</identifier>
<identifier type="nhmrc">2017527</identifier>
<name type="primary"><namePart>Next Generation Therapeutic Brain Stimulation for Depression and beyond</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">neuroimaging </subject>
<subject type="local">transcranial magnetic stimulation (tms)</subject>
<subject type="local">neuropsychiatry</subject>
<subject type="local">functional magnetic resonance imaging (fmri)</subject>
<subject type="local">treatment-resistant</subject>
<description type="Chief Investigator">Dr Robin Cash</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">With millions of people suffering from depression and other mental illnesses, there is an urgent need for more effective treatments. I aspire to make possible a future in which dysfunctional brain circuits are routinely delineated using a person’s brain scans and treated using innovative brain stimulation therapeutics. My program will fundamentally advance the brain stimulation personalisation technology that I have developed and accelerate its clinical translation to improve patient outcomes.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017537</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017537</identifier>
<identifier type="nhmrc">2017537</identifier>
<name type="primary"><namePart>Averting suicide contagion and suicide clusters in young people</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | health sciences | health services and systems | health and community services</subject>
<subject type="local">suicide prevention </subject>
<subject type="local">youth</subject>
<subject type="local">mental health services</subject>
<subject type="local">health surveillance</subject>
<subject type="local">health services research</subject>
<description type="Chief Investigator">Dr Nicole Hill</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Suicide is the leading cause of death in young Australians. Young people who are exposed to suicide are at significant risk of suicide themselves. The proposed research will transform suicide prevention policy by building the evidence base identifying who is at risk of suicide contagion and clusters and building a suite of practical resources that can be implemented and utilised by stakeholders and decision makers to avert further deaths in communities impacted by multiple suicide losses.</description>
<description type="fundingAmount">$642,052.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017538</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017538</identifier>
<identifier type="nhmrc">2017538</identifier>
<name type="primary"><namePart>Improving outcomes after high-risk surgery</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | anaesthesiology</subject>
<subject type="local">chronic pain </subject>
<subject type="local">surgical outcomes research</subject>
<subject type="local">systemic inflammation</subject>
<subject type="local">risk prediction</subject>
<subject type="local">anaesthesia</subject>
<description type="Chief Investigator">Dr Andrew Toner</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Complications after operations are common and can result in chronic health problems or death. In this project, a large clinical trial will test whether treatment with a local anaesthetic drug, lidocaine, reduces the development of chronic pain one year after high-risk breast cancer surgery. Parallel studies will also assess the impact of enhanced ward monitoring after all types of high-risk operations and the role of inflammation in driving poor surgical outcomes.</description>
<description type="fundingAmount">$452,575.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017575</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017575</identifier>
<identifier type="nhmrc">2017575</identifier>
<name type="primary"><namePart>Scalable Survivorship Support after Cancer (CanSupport): Evaluation of a co-designed and automated eHealth intervention to support cancer survivors in primary care</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | digital health</subject>
<subject type="local">public health </subject>
<subject type="local">health services research</subject>
<subject type="local">health promotion</subject>
<subject type="local">electronic health information</subject>
<subject type="local">population health</subject>
<description type="Chief Investigator">Dr Anna Singleton</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">After cancer treatment, survivors need ongoing health support but access is limited. As an emerging survivorship researcher, my vision is to improve survivors’ access to support and health. I will expand my earlier breast cancer work to co-design a new support program for prostate, colorectal and lung cancer survivors sent via text messages called CanSupport, test if it improves support access and health in a primary care clinical trial and collect information to inform national roll-out.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017578</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017578</identifier>
<identifier type="nhmrc">2017578</identifier>
<name type="primary"><namePart>Structural biology and protein engineering to accelerate rational development of novel antipsychotics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology</subject>
<subject type="local">membrane protein </subject>
<subject type="local">molecular pharmacology</subject>
<subject type="local">schizophrenia</subject>
<subject type="local">structural biology</subject>
<subject type="local">drug discovery</subject>
<description type="Chief Investigator">Dr Christopher Draper-Joyce</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Schizophrenia is a debilitating psychiatric disorder that affects ~1% of the population, with a projected global economic burden of ~US$6trillion by 2030. Unfortunately, most schizophrenia patients discontinue antipsychotic treatment within the initial months of starting due to two key reasons: debilitating side effects and lack of efficacy. My research program is focused on solving these major bottlenecks with cutting-edge techniques and platforms for drug discovery at both new and old targets.</description>
<description type="fundingAmount">$605,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017580</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017580</identifier>
<identifier type="nhmrc">2017580</identifier>
<name type="primary"><namePart>Improving sepsis outcomes using precision medicine</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care</subject>
<subject type="local">intensive care medicine </subject>
<subject type="local">sepsis</subject>
<subject type="local">immune modulation</subject>
<subject type="local">corticosteroids</subject>
<subject type="local">resuscitation</subject>
<description type="Chief Investigator">Prof Simon Finfer</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Sepsis occurs when your body’s response to infection damages its own tissues and organs, if not prevented or treated promptly it may be fatal. It affects 55,000 Australians each year causing 7,000 deaths. Survivors commonly suffer long term health problems. My research focusses on improving the design and conduct of clinical trials that will match the right treatments to the right patients at the right time thus reducing death and disability from sepsis.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017583</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017583</identifier>
<identifier type="nhmrc">2017583</identifier>
<name type="primary"><namePart>Fair resource allocation decisions in old age – enhancing the quality-adjusted life year (QALY) framework</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | aged health care | economics | applied economics | health economics</subject>
<subject type="local">economic evaluation </subject>
<subject type="local">health economics</subject>
<subject type="local">ageing</subject>
<subject type="local">quality of life</subject>
<subject type="local">patient preference</subject>
<description type="Chief Investigator">Dr Lidia Engel</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">People aged 65 years and over, a rapidly growing age group, are significant users of health and aged care services. Funding decisions for services are guided by cost-effectiveness evidence, using quality-adjusted life years (QALYs) as a measure of effectiveness. Yet the methods used to derive QALYs in older adults are flawed. My research will provide evidence on how to improve the estimation of QALYs in older adults, promoting fairer and socially accepted funding decisions for older adults.</description>
<description type="fundingAmount">$553,973.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017605</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017605</identifier>
<identifier type="nhmrc">2017605</identifier>
<name type="primary"><namePart>Improving Emergency Department Identification and Care for Children with Sepsis</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | emergency medicine</subject>
<subject type="local">emergency medicine </subject>
<subject type="local">sepsis</subject>
<subject type="local">paediatric</subject>
<subject type="local">young children</subject>
<subject type="local">infection</subject>
<description type="Chief Investigator">Prof Franz Babl</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Sepsis is a severe infection of major national concern due to its morbidity and mortality. Early identification and optimal management of children at risk of sepsis in emergency departments are yet to be determined. My program will develop methods to identify these children, expand our understanding of sepsis causes and identify the most efficacious intravenous fluid for management. The goal is to improve sepsis care for children by filling evidence gaps for national/international guidelines.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017609</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017609</identifier>
<identifier type="nhmrc">2017609</identifier>
<name type="primary"><namePart>Integration of Pre-hospital and Hospital cardiac clinical registries to investigate novel therapeutics and systems of care in cardiac emergencies</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">acute myocardial infarction (ami) </subject>
<subject type="local">cardiac arrest</subject>
<subject type="local">shock</subject>
<subject type="local">acute coronary syndromes</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Assoc Prof Dion Stub</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The cardiac emergencies of cardiac arrest and heart attack continue to be a major challenge, with unacceptably high mortality and morbidity. Best outcomes are seen when systems of care integrating pre-hospital and hospital care are optimized. My research team involves the collaboration of Ambulance Victoria, with hospital based cardiac clinical registries, allowing for the unique opportunity to perform pragmatic clinical trials, to improve therapies in patients who currently have poor outcomes.</description>
<description type="fundingAmount">$1,461,112.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017628</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017628</identifier>
<identifier type="nhmrc">2017628</identifier>
<name type="primary"><namePart>Targeting death anxiety with an online intervention to improve outcomes in anxiety-related disorders</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology</subject>
<subject type="local">anxiety disorders </subject>
<subject type="local">internet service delivery</subject>
<subject type="local">psychological treatment</subject>
<subject type="local">cognitive behaviour therapy</subject>
<subject type="local">treatment efficacy</subject>
<description type="Chief Investigator">Dr Rachel Menzies</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">High rates of anxiety disorders are a global issue, with dire need for scalable treatment. Death anxiety has been shown to underpin many anxiety-related disorders, making it a vital treatment target. This research program will examine the world's first online evidence-based intervention for death anxiety. It will provide evidence of whether interventions targeting death anxiety improve existing mental health symptoms, reduce relapse, and prevent development of new disorders.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017630</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017630</identifier>
<identifier type="nhmrc">2017630</identifier>
<name type="primary"><namePart>Innovative public health strategies for the elimination of malaria and lymphatic filariasis</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance</subject>
<subject type="local">malaria </subject>
<subject type="local">filariasis</subject>
<subject type="local">health surveillance</subject>
<subject type="local">clinical trial</subject>
<subject type="local">vector control</subject>
<description type="Chief Investigator">Prof Leanne Robinson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">My vision is to improve the health of communities that have a high, yet often unrecognised, burden of parasitic vector-borne diseases, particularly malaria and lymphatic filariasis. My collaborative program of research will reduce the burden of these chronic debilitating infections in low-income countries, especially Papua New Guinea, by developing and testing new public health strategies and directly informing policy to target these infections more accurately, efficiently and effectively.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017642</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017642</identifier>
<identifier type="nhmrc">2017642</identifier>
<name type="primary"><namePart>Digital health to support behaviour change and chronic disease prevention in the community: What works, for whom, and in what context?</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | health sciences | health services and systems | general practice | health sciences | health services and systems | digital health</subject>
<subject type="local">health informatics </subject>
<subject type="local">health behaviours</subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">primary care</subject>
<subject type="local">population health</subject>
<description type="Chief Investigator">Dr Liliana Laranjo</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The use of technology like apps to support health care and lifestyle behaviours is becoming increasingly common. However, the research to date is either non-existent or unclear as to which ones work best to improve health outcomes. I will address this gap by synthesising existing research and evaluating novel technologies such as artificial intelligence to better understand how digital technologies can be best used to improve health behaviours and prevent chronic disease in the community.</description>
<description type="fundingAmount">$636,434.15</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017646</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017646</identifier>
<identifier type="nhmrc">2017646</identifier>
<name type="primary"><namePart>Novel approaches to the treatment and monitoring of patients with incurable haematological cancers</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | immunology | tumour immunology</subject>
<subject type="local">non-hodgkin lymphoma </subject>
<subject type="local">t cell immunotherapy</subject>
<subject type="local">targeted therapy</subject>
<subject type="local">cancer immunotherapy</subject>
<subject type="local">haematological malignancy</subject>
<description type="Chief Investigator">Prof Miles Prince</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will focus on 2 largely incurable forms of blood cancer; T cell lymphoma (TCL) and acute myeloid leukemia (AML). We will join international collaborators contributing to large databases to examine the causes and predictors of outcome of TCL. I will undertake completely novel clinical trials using non-chemotherapy therapies which will include the scale-up in our laboratory of genetically engineered human immune cells called CART cells specifically designed for treating TCL and AML.</description>
<description type="fundingAmount">$974,844.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017651</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017651</identifier>
<identifier type="nhmrc">2017651</identifier>
<name type="primary"><namePart>Translating Epilepsy Genetics Advances into Improved Patient Care</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases</subject>
<subject type="local">epilepsy </subject>
<subject type="local">neuroscience</subject>
<subject type="local">genetics</subject>
<subject type="local">antiepileptic drugs</subject>
<subject type="local">epilepsy surgery</subject>
<description type="Chief Investigator">Assoc Prof Piero Perucca</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Many epilepsies are now known to be genetic. The time has come to use this knowledge in the management of people with epilepsy to improve their treatment outcomes. I will develop a research program that will translate the progress in epilepsy genetics in the past 20 years into better patient care by using genetic data to accurately classify epilepsies of unknown type and guide epilepsy surgery. I will also set up a platform to study therapies targeting genetic abnormalities causing epilepsy.</description>
<description type="fundingAmount">$1,376,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017661</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017661</identifier>
<identifier type="nhmrc">2017661</identifier>
<name type="primary"><namePart>Optimised Outpatient Parenteral Antimicrobial Therapy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">antimicrobial resistance </subject>
<subject type="local">antimicrobial therapy</subject>
<subject type="local">bacterial infection</subject>
<subject type="local">clinical pharmacology</subject>
<subject type="local">community care</subject>
<description type="Chief Investigator">Assoc Prof Benjamin Rogers</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Treatment of many complicated infections can now occur in the community rather than hospital. The approach of giving antibiotics in the home setting is preferred by patients and health services. However, practical challenges impact on which antibiotics are available for use in the home setting. Further, as this is a relatively new field, research on the best possible treatments and strategies to overcome practical challenges to antibiotic administration in the home setting are urgently needed.</description>
<description type="fundingAmount">$440,075.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017679</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017679</identifier>
<identifier type="nhmrc">2017679</identifier>
<name type="primary"><namePart>Platform Technologies for Antibiotic Resistance Diagnostics at Single-Cell Resolution</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | fluid mechanics and thermal engineering | microfluidics and nanofluidics</subject>
<subject type="local">biomedical engineering </subject>
<subject type="local">biotechnology</subject>
<subject type="local">antibiotic resistance</subject>
<subject type="local">cell separation</subject>
<subject type="local">drug screening</subject>
<description type="Chief Investigator">Dr Ming Li</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My research aims to advance our understanding of antibiotic resistance in bacterial populations at the single-cell level. Examining the differences between individual bacterial cells in response to antibiotics is essential to provide fundamental insights into heterogeneous resistance, an important player precipitating the antibiotic crisis. Expected outcomes include improved knowledge of bacterial heterogeneity, informing antibiotic usage, and a new tool for more accurate resistance testing.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017694</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017694</identifier>
<identifier type="nhmrc">2017694</identifier>
<name type="primary"><namePart>Design and evaluation of novel interventions for infectious diseases of global importance</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">infectious diseases </subject>
<subject type="local">community intervention study</subject>
<subject type="local">epidemiology</subject>
<subject type="local">evaluation studies</subject>
<subject type="local">social disadvantage</subject>
<description type="Chief Investigator">Prof John Kaldor</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I will set up a new centre to conduct studies on how to prevent sexually transmitted infections and neglected tropical diseases in the countries most affected by these conditions. I will trial novel uses and new agents for mass drug administration, which involves treating whole populations when disease rates are high, rather than trying to find those with the infection. I will also evaluate innovative methods for tracking the impact of programs and strategies aimed at control of these diseases.</description>
<description type="fundingAmount">$2,633,294.56</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017719</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017719</identifier>
<identifier type="nhmrc">2017719</identifier>
<name type="primary"><namePart>Transforming Injury for Aboriginal and Torres Strait Islander Children through Innovative Knowledge Gain and Co-designed Intervention</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | injury prevention | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing</subject>
<subject type="local">aboriginal health </subject>
<subject type="local">aboriginal child</subject>
<subject type="local">injury</subject>
<subject type="local">injury prevention</subject>
<subject type="local">injury epidemiology</subject>
<description type="Chief Investigator">Dr Courtney Ryder</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Indigenous children have high rates of injury, these rates are not decreasing and create burden in the community. My research program will address this through collaborating with Indigenous communities in South Australia and working with Big Data to understand the injury burden for Indigenous children, detect areas for improvement, and co-design an injury intervention for Indigenous children to decrease injury and improve health and wellbeing.</description>
<description type="fundingAmount">$642,650.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017734</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017734</identifier>
<identifier type="nhmrc">2017734</identifier>
<name type="primary"><namePart>Lungs for life: a programme of clinical trials to improve respiratory outcomes for premature babies</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology</subject>
<subject type="local">prematurity </subject>
<subject type="local">premature infant</subject>
<subject type="local">bronchopulmonary dysplasia</subject>
<subject type="local">respiratory distress syndrome (rds)</subject>
<subject type="local">resuscitation</subject>
<description type="Chief Investigator">Assoc Prof Louise Owen</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Almost 1 in 10 babies in Australia are born early (preterm). They often need help to breathe at birth, and for days and weeks afterwards. Some will go on to have long-term problems with their lungs. My research looks at how we can improve the outlook for preterm babies, by finding better ways to support their breathing, right from their first breath. Improving how we care for preterm babies immediately after birth can improve their lung health, as newborns, as children and through to adulthood.</description>
<description type="fundingAmount">$1,345,834.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017742</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017742</identifier>
<identifier type="nhmrc">2017742</identifier>
<name type="primary"><namePart>Large scale evidence, microsimulation and translation to address contemporary challenges in tobacco control and cardiovascular disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care</subject>
<subject type="local">chronic illness prevention </subject>
<subject type="local">cigarette smoking</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">survivorship</subject>
<description type="Chief Investigator">Prof Emily Banks</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic diseases, including cardiovascular disease (CVD), cancer, dementia, chronic kidney disease and chronic lung disease, are highly preventable and threaten Australia's continuing improvements in life expectancy. The proposed research will generate and translate large-scale evidence to drive improvement in tobacco control, electronic cigarettes and CVD, for the general and Aboriginal and Torres Strait Islander populations, including through creation of an enduring CVD microsimulation model.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017774</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017774</identifier>
<identifier type="nhmrc">2017774</identifier>
<name type="primary"><namePart>Advanced intravascular optical imaging in vivo for future precise diagnosis and treatment therapies</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | engineering | nanotechnology | nanophotonics | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">diagnostic imaging </subject>
<subject type="local">optical imaging</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">lens development</subject>
<description type="Chief Investigator">Prof Yuerui Lu</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This interdisciplinary project aims to develop a new optical imaging modality using the high-speed and focus-tunable micro-lenses I recently invented. The device will be small enough to be inserted into blood vessels to provide high-quality images with unprecedented resolution and image depth. Artificial intelligence will be implemented for high-speed and real-time image processing. This will help specialists better visualise and understand the causes of heart attacks and how to prevent them.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017798</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017798</identifier>
<identifier type="nhmrc">2017798</identifier>
<name type="primary"><namePart>Managing the First Pillar for Atrial Fibrillation and Stroke</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">atrial fibrillation </subject>
<subject type="local">stroke</subject>
<subject type="local">lifestyle factors</subject>
<subject type="local">cardiac arrhythmia</subject>
<subject type="local">embolism</subject>
<description type="Chief Investigator">Prof Prashanthan Sanders</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program will develop and evaluate a standardised approach to the management of lifestyle/risk factors for atrial fibrillation (AF) and stroke. Management of AF is currently not standardised and therefore leads to highly variable patient outcomes. Advancing risk factor modification as the primary AF management pillar, this program seeks to establish a new paradigm of upstream interventions for the prevention and treatment of AF and stroke, and formulate optimal delivery strategies for care.</description>
<description type="fundingAmount">$2,117,519.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017818</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017818</identifier>
<identifier type="nhmrc">2017818</identifier>
<name type="primary"><namePart>A holistic approach to achieving best health outcomes through culturally appropriate self-determined pathways into employment for Aboriginal and Torres Strait Islander people</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander peoples, society and community | aboriginal and torres strait islander community-based research | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | indigenous studies | aboriginal and torres strait islander education | embedding aboriginal and torres strait islander knowledges, histories, culture, country, perspectives and ethics in education</subject>
<subject type="local">indigenous health </subject>
<subject type="local">social determinants of health</subject>
<subject type="local">employment</subject>
<subject type="local">community intervention study</subject>
<subject type="local">public health</subject>
<description type="Chief Investigator">Dr Bobby Porykali</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will achieve best health outcomes for Aboriginal and Torres Strait Islander peoples by developing holistic culturally appropriate pathways into self-determined employment. The longer people remain unemployed the more likely they suffer from a range of health problems and premature deaths. By improving employment outcomes, we will improve the set of circumstances that individuals, families, and communities are born, grow, live and work. This will promote good health and wellbeing.</description>
<description type="fundingAmount">$666,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017828</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017828</identifier>
<identifier type="nhmrc">2017828</identifier>
<name type="primary"><namePart>Turning the tide: co-developing drowning prevention interventions</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | behavioural epidemiology | health sciences | public health | injury prevention | health sciences | health services and systems | implementation science and evaluation</subject>
<subject type="local">injury prevention </subject>
<subject type="local">health policy</subject>
<subject type="local">injury control</subject>
<subject type="local">health inequalities</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Dr Jagnoor Jagnoor</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Drowning is a leading cause of injury deaths. In the last 30 years, we have developed a good understanding of how we can prevent drowning incidents and deaths, but we have not implemented our knowledge to its full potential. Using robust methods and through a consultative process, I will work with communities and policy stakeholders in Australia and India to develop and implement, evidence-led drowning prevention solutions for populations most susceptible to drowning.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017844</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017844</identifier>
<identifier type="nhmrc">2017844</identifier>
<name type="primary"><namePart>Understanding and reducing hip osteoarthritis burden in young adults and adolescents</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | rheumatology and arthritis | health sciences | allied health and rehabilitation science | physiotherapy | biomedical and clinical sciences | clinical sciences | sports medicine</subject>
<subject type="local">hip replacement </subject>
<subject type="local">arthritis</subject>
<subject type="local">physiotherapy</subject>
<subject type="local">sports medicine</subject>
<subject type="local">musculoskeletal disorders</subject>
<description type="Chief Investigator">Dr Joanne Kemp</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hip pain is common in young adults, causing substantial burden and representing early hip arthritis. My research program will reduce the burden of hip pain in younger adults at risk of/with early hip arthritis. I will capture the natural history of hip disease and develop effective interventions, determining how to best treat hip pain in younger adult, and identify who is at risk of hip arthritis to stop the progression of hip pain to hip osteoarthritis and the need for hip replacement.</description>
<description type="fundingAmount">$1,576,390.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017876</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017876</identifier>
<identifier type="nhmrc">2017876</identifier>
<name type="primary"><namePart>Harnessing innovative digital technologies to enhance youth mental health care</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">adolescent health </subject>
<subject type="local">clinical psychology</subject>
<subject type="local">internet service delivery</subject>
<subject type="local">mental health</subject>
<subject type="local">psychological treatment</subject>
<description type="Chief Investigator">Dr Imogen Bell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is a growing youth mental health crisis. Mental ill-health remains the leading cause of death in young people. Of the one in four who suffer, only a quarter receive adequate care. To overcome this crisis, more accessible and effective treatments need to be developed. My research program will develop, evaluate and implement a new generation of treatments that harness advanced digital technologies to provide better care to young people.</description>
<description type="fundingAmount">$648,985.62</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017877</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017877</identifier>
<identifier type="nhmrc">2017877</identifier>
<name type="primary"><namePart>Targeted regulatory T cells to treat autoimmune diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | autoimmunity</subject>
<subject type="local">autoimmunity </subject>
<subject type="local">t cells</subject>
<subject type="local">regulatory t cells</subject>
<subject type="local">autoimmune disease</subject>
<subject type="local">cell therapy</subject>
<description type="Chief Investigator">Dr Joshua Ooi</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Autoimmune diseases occur when the immune system attacks a person's own body. These diseases affect more than a million Australians and hundreds of millions worldwide. There are no cures and current treatments cause significant side effects. This novel research program will use genetic engineering to develop a potent cell-based therapy that specifically treats the cause of disease. This new therapy has the potential to cure autoimmune diseases and restore the lives of many patients.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017879</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017879</identifier>
<identifier type="nhmrc">2017879</identifier>
<name type="primary"><namePart>Improving outcomes for children with anxiety disorders</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | mental health services | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">primary school-aged children </subject>
<subject type="local">anxiety disorders</subject>
<subject type="local">mental health</subject>
<subject type="local">internet service delivery</subject>
<subject type="local">early intervention</subject>
<description type="Chief Investigator">Prof J Hudson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Children whose mental health difficulties are identified early, and effectively addressed, reap the benefits across their lifespan. This has profound benefits for the child and the child’s family as well as significant social benefits. We need to invest in improving outcomes for children with anxiety to make an enduring difference to the mental health of all Australians. This work will improve access to, and delivery of evidence-based care and will improve treatments for children with anxiety.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017897</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017897</identifier>
<identifier type="nhmrc">2017897</identifier>
<name type="primary"><namePart>Translating new therapeutics and diagnostics for stillbirth and preeclampsia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology | biomedical and clinical sciences | reproductive medicine | reproduction</subject>
<subject type="local">pre-eclampsia </subject>
<subject type="local">stillbirth</subject>
<subject type="local">biomarkers</subject>
<subject type="local">pregnancy</subject>
<subject type="local">fetal growth restriction</subject>
<description type="Chief Investigator">Prof Stephen Tong</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Stillbirth and preeclampsia are terrible diseases of pregnancy that can claim the life of the mother, or her unborn baby. Here, I propose large programs of research that will avidly hunt for new treatments and diagnostics to tackle both conditions. We will develop a blood test that may save babies from stillbirth. We will find new drugs in the laboratory to treat preeclampsia and test them in successive international clinical trials - mainly South Africa where the disease is sadly rife.</description>
<description type="fundingAmount">$2,500,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017898</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017898</identifier>
<identifier type="nhmrc">2017898</identifier>
<name type="primary"><namePart>Novel Therapeutic Strategies for Childhood Brain Cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</subject>
<subject type="local">brain tumours </subject>
<subject type="local">anti-tumour drugs</subject>
<subject type="local">oncology</subject>
<subject type="local">paediatric</subject>
<subject type="local">tumour biology</subject>
<description type="Chief Investigator">Assoc Prof David Ziegler</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Brain cancer is the single disease causing the most deaths in childhood, as well as significant disability and long-term health problems for survivors, warranting urgent improvement to treatments. My program seeks to improve outcomes for children with the most aggressive brain tumours by developing new targeted treatment strategies, investigating immunotherapies, and developing strategies to allow effective drugs to penetrate into the brain.</description>
<description type="fundingAmount">$1,878,395.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017903</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017903</identifier>
<identifier type="nhmrc">2017903</identifier>
<name type="primary"><namePart>Harnessing novel lymph-resident targets and lymph-specific therapeutics to fight inflammation</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences</subject>
<subject type="local">pharmaceutics </subject>
<subject type="local">drug delivery</subject>
<subject type="local">lymphatics</subject>
<subject type="local">obesity</subject>
<subject type="local">inflammation</subject>
<description type="Chief Investigator">Dr Enyuan Cao</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The mesenteric lymphatic system plays vital roles in regulating dietary lipid transport and immune activation. Lymphatic dysfunction impairs these processes, and is detrimental in both obesity-associated metabolic disease and inflammatory bowel disease. This proposal will uncover the mechanisms driving mesenteric lymphatic dysfunction and associated inflammation. This knowledge will be used to establish lymph-specific therapeutics to enhance treatment outcomes in chronic inflammation.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017912</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017912</identifier>
<identifier type="nhmrc">2017912</identifier>
<name type="primary"><namePart>Linking microbiome, inflammation, HIV target cells</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology</subject>
<subject type="local">human immunodeficiency virus (hiv) </subject>
<subject type="local">mucosal immunity</subject>
<subject type="local">dendritic cell</subject>
<subject type="local">t cells</subject>
<subject type="local">epidermal barrier</subject>
<description type="Chief Investigator">Dr Kirstie Bertram</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">New HIV infections are now clearly associated with an inflamed genital tract (in both females and males) and the microbiome of these sites. What is unclear is the immune cell constitution of these inflamed tissues that may be the main drivers of increased disease. I have developed in my lab techniques to isolate and interrogate immune cells from human genital tissue and how they interact with HIV. I will connect the immune cell environment with inflammation and the microbiome.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017916</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017916</identifier>
<identifier type="nhmrc">2017916</identifier>
<name type="primary"><namePart>Tumour-stroma crosstalk in breast cancer: Deciphering and disrupting communications between cancer cells and cancer-associated fibroblasts</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | biological sciences | biochemistry and cell biology | signal transduction</subject>
<subject type="local">fibroblasts </subject>
<subject type="local">stromal cells</subject>
<subject type="local">breast cancer</subject>
<subject type="local">calcium signalling</subject>
<subject type="local">drug discovery</subject>
<description type="Chief Investigator">Dr Krystyna Gieniec</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Breast cancer can be described as a play with many acts and actors. For approx. 20% of women diagnosed with this disease, there are no targeted therapies and for many more, recurrence and metastasis are major obstacles. Whilst tumour cells take centre stage in the diagnosis and treatment of this disease, it is now understood that fibroblasts play an important supporting role. Using novel methods to view and study this disease, my work will help to define the next generation of cancer therapies.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017929</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017929</identifier>
<identifier type="nhmrc">2017929</identifier>
<name type="primary"><namePart>Investigating the interplay between cell death and inflammation in human diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | innate immunity | biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | biochemistry and cell biology | signal transduction</subject>
<subject type="local">cell death </subject>
<subject type="local">cell signalling</subject>
<subject type="local">tissue necrosis factor (tnf)</subject>
<subject type="local">inflammation</subject>
<subject type="local">mouse models</subject>
<description type="Chief Investigator">Dr Najoua Lalaoui</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cell death is a mechanism that allows old cells to be replaced by new cells or occurs during tissue damage. In some contexts, dying cells release inflammatory molecules that can be beneficial or detrimental to the body. This proposal aims to study the complex interplay between cell death and inflammation. Understanding the involvement of these processes in cancer and inflammatory diseases is essential to identify novel treatment strategies.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017942</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017942</identifier>
<identifier type="nhmrc">2017942</identifier>
<name type="primary"><namePart>Developing and Applying Mendelian Randomization Methods to Facilitate Drug Discovery and Solve Intractable Problems in Medical Research</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiological methods | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics</subject>
<subject type="local">statistical genetics </subject>
<subject type="local">genetic epidemiology</subject>
<subject type="local">complex disease</subject>
<subject type="local">genetic association</subject>
<subject type="local">biostatistics</subject>
<description type="Chief Investigator">Prof David Evans</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mendelian randomization is a way of using genetic data to test whether particular environmental exposures, biological molecules or drug targets cause disease. The purpose of this Investigator Award is to create new statistical methods and software that use Mendelian randomization to facilitate drug discovery, and to use the Mendelian randomization paradigm to solve high value questions in medical research that have so far proven intractable to other research approaches.</description>
<description type="fundingAmount">$2,307,786.44</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017952</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017952</identifier>
<identifier type="nhmrc">2017952</identifier>
<name type="primary"><namePart>Innovating pathways to embed novel RNA technologies into clinical practise</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics)</subject>
<subject type="local">clinical genetics </subject>
<subject type="local">cancer predisposition</subject>
<subject type="local">molecular diagnostics</subject>
<subject type="local">splicing</subject>
<subject type="local">aboriginal health</subject>
<description type="Chief Investigator">Prof Sandra Cooper</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Genetic rare disorders affect 1 in 100 individuals. A precise genetic diagnosis is the key to personalised healthcare, disease prevention, and sometimes a cure or treatment. For the 50% of families undiagnosed after DNA testing, the answer can lie in their RNA. I will lead an evidence-based national strategy to embed RNA diagnostics in clinical practise, vastly improving diagnoses of families living with genetic rare disorders and revolutionising their personalised health care options.</description>
<description type="fundingAmount">$2,287,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017962</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017962</identifier>
<identifier type="nhmrc">2017962</identifier>
<name type="primary"><namePart>Identifying clinically relevant neurobiological markers of depression and suicidal behaviours</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">depression </subject>
<subject type="local">suicide</subject>
<subject type="local">neuroimaging</subject>
<subject type="local">prediction</subject>
<subject type="local">longitudinal</subject>
<description type="Chief Investigator">Assoc Prof Lianne Schmaal</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Depression and suicide have a devastating impact on lives and communities. To develop more effective treatments, we need to gain a better understanding of the biological mechanisms underlying depression and suicide. This research program aims to identify brain markers that can assist in the diagnosis of depression and suicidal thoughts and behaviours and predict who is at risk for poor clinical outcomes over time.</description>
<description type="fundingAmount">$2,256,790.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017971</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017971</identifier>
<identifier type="nhmrc">2017971</identifier>
<name type="primary"><namePart>Using advanced CRISPR tools to improve clinical therapies for poor prognostic lymphomas</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biological sciences | biochemistry and cell biology | cell development, proliferation and death</subject>
<subject type="local">genetic screening </subject>
<subject type="local">bcl-2</subject>
<subject type="local">lymphoma</subject>
<subject type="local">tumour suppression</subject>
<subject type="local">oncogenes</subject>
<description type="Chief Investigator">Prof Marco Herold</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Treatment outcomes for certain aggressive blood cancers have not improved in recent years. Many patients do not respond and novel treatments are desperately required. My program aims to fill this gap by using sophisticated lymphoma models and unique molecular tools to discover new treatments and therapy resistance factors, and to test a new drug for clinical application. Outcomes of this work could improve life quality and chances for a cure for blood cancer patients.</description>
<description type="fundingAmount">$2,205,736.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017974</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017974</identifier>
<identifier type="nhmrc">2017974</identifier>
<name type="primary"><namePart>Fighting Cancer Relapse: Developing an Oral Cancer Vaccine Generating Memory T Cells</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | nanotechnology | nanomaterials | engineering | biomedical engineering | biomaterials</subject>
<subject type="local">nanotechnology </subject>
<subject type="local">vaccine vectors</subject>
<subject type="local">adjuvant</subject>
<subject type="local">colorectal cancer prevention</subject>
<subject type="local">oral administration</subject>
<description type="Chief Investigator">Dr Jie Tang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Colorectal cancer (CRC) is the world's second most fatal cancer with a high rate of relapse. This project aims to develop an oral vaccine for preventing CRC recurrence by boosting the local gut immune response, which is at the frontline in powerful anti-cancer defence. This oral vaccine is based on cutting-edge research in immunology and nanomaterials, enabling robust and persistent protection against CRC recurrence, and enables convenient oral intake for maximal patient acceptance.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018015</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018015</identifier>
<identifier type="nhmrc">2018015</identifier>
<name type="primary"><namePart>Increasing the impact of food policy research in Australia and globally</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">public health policy </subject>
<subject type="local">dietary sodium</subject>
<subject type="local">community development</subject>
<subject type="local">food</subject>
<subject type="local">public health impact</subject>
<description type="Chief Investigator">Prof Jacqui Webster</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My research will identify the critical factors required to support adoption and implementation of food policies by governments in Australia and globally. It will inform strategies to support researchers to strengthen the impact of future food policy research. This will ensure that evidence-based policies are to improve diets are adopted and implemented reducing the health and economic burden of diet-related diseases and meaning government funding for food policy research is well spent.</description>
<description type="fundingAmount">$1,932,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018064</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018064</identifier>
<identifier type="nhmrc">2018064</identifier>
<name type="primary"><namePart>Advancing perinatal health in Australia through international randomised studies to reduce death and disability.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiology not elsewhere classified</subject>
<subject type="local">clinical trial </subject>
<subject type="local">perinatal</subject>
<subject type="local">neonatal</subject>
<subject type="local">meta-analysis</subject>
<subject type="local">obstetrics</subject>
<description type="Chief Investigator">Prof William Tarnow-Mordi</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Clinical trials have made big advances in treatment in all areas in Australia and worldwide. However most trials for high-risk babies and their mothers are too small to find improvements in healthy survival as quickly as we would like. We will work with stakeholders across the world to create a new kind of trial that will run at least ten times larger and faster, at one tenth the cost, saving thousands more lives and millions more dollars in Australia and overseas</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018071</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018071</identifier>
<identifier type="nhmrc">2018071</identifier>
<name type="primary"><namePart>Early intervention for therapeutic benefit in AML: a national program of clinical trials</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</subject>
<subject type="local">acute myeloid leukaemia (aml) </subject>
<subject type="local">targeted therapy</subject>
<subject type="local">myeloid leukaemia</subject>
<subject type="local">clinical trial</subject>
<subject type="local">drug resistance</subject>
<description type="Chief Investigator">Prof Andrew Wei</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">AML is a lethal blood cancer capable of developing resistance to therapy. Relapsing disease is the major barrier to improving outcome. I will build on my success in delivering new AML therapies by developing a national program of trials using technologies to detect returning disease at its earliest stages complemented by novel drugs to target AML with precision intent. A multidisciplinary team will elucidate mechanisms of resistance and validate alternative approaches to extend patient survival.</description>
<description type="fundingAmount">$3,029,302.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018077</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018077</identifier>
<identifier type="nhmrc">2018077</identifier>
<name type="primary"><namePart>Saving lives with better blood pressure measurement</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">blood pressure </subject>
<subject type="local">hypertension</subject>
<subject type="local">cardiovascular physiology</subject>
<subject type="local">bioinformatics</subject>
<subject type="local">reliability</subject>
<description type="Chief Investigator">Dr Dean Picone</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The research program aims to address problems related to inaccurate measurement of blood pressure (BP). I will use advanced analysis techniques to develop a better way to measure BP. Other program elements include examining the accuracy of BP measurement in high-risk patients and promotion best practice measurement methods and devices through translational research. Overall, the aim of the program is to minimise the burden of preventable cardiovascular disease in Australia and globally.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018081</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018081</identifier>
<identifier type="nhmrc">2018081</identifier>
<name type="primary"><namePart>New therapies for skeletal dysplasia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics)</subject>
<subject type="local">translational research </subject>
<subject type="local">clinical genetics</subject>
<subject type="local">skeletal dysplasia</subject>
<subject type="local">clinical trial</subject>
<subject type="local">individualising management</subject>
<description type="Chief Investigator">Prof Ravi Savarirayan</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Inherited disorders of the skeleton are common with significant health impacts. My research has enabled treatment of these conditions at their genetic source. This program will assess whether drug treatment of infants with achondroplasia will decrease the 50-fold higher risk of sudden death by relieving pressure on the spinal cord, and assess whether treatment of children with metaphyseal dysplasia will relieve pain, improve skeletal deformity and eliminate the need for invasive surgery.</description>
<description type="fundingAmount">$2,605,432.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018082</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018082</identifier>
<identifier type="nhmrc">2018082</identifier>
<name type="primary"><namePart>Estimating the health equity and productivity impacts of dietary salt reduction in people with chronic kidney disease in Australia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiological modelling | health sciences | public health | preventative health care</subject>
<subject type="local">hypertension </subject>
<subject type="local">dietary sodium</subject>
<subject type="local">kidney disease</subject>
<subject type="local">burden of disease</subject>
<subject type="local">health economics</subject>
<description type="Chief Investigator">Dr Leopold Aminde</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Excess salt intake increases blood pressure and puts persons at risk of complications like chronic kidney disease (CKD) that kills one in ten Australians. CKD contributes to health inequalities and has a major impact on quality of life and productivity, and the future impacts in Australia are unknown. This project will evaluate long-term impacts of strategies to reduce population salt intake on CKD burden, to guide policies that improve the quality of life of all Australians.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018098</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018098</identifier>
<identifier type="nhmrc">2018098</identifier>
<name type="primary"><namePart>Understanding and exploiting A-to-I RNA editing</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02k3cxs74</identifier><title>St Vincents Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genetics not elsewhere classified</subject>
<subject type="local">rna binding proteins </subject>
<subject type="local">rna</subject>
<subject type="local">innate immunity</subject>
<subject type="local">mouse genetics</subject>
<subject type="local">cell biology</subject>
<description type="Chief Investigator">Prof Carl Walkley</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">This project will determine how changes to a type of RNA modification, termed Adenosine-to-Inosine (A-to-I) RNA editing, cause disease. Reduced A-to-I editing causes development of autoimmune disease and brain diseases. Too much editing is seen in cancer. I will use animal models to understand how changes in A-to-I editing cause disease. This will be important to provide knowledge of how these diseases occur and identify new ways to treat them.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018101</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018101</identifier>
<identifier type="nhmrc">2018101</identifier>
<name type="primary"><namePart>Scaling the effects of salt substitute on cardiovascular risk reduction population-wide</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">dietary salt </subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">high blood pressure</subject>
<subject type="local">modelling</subject>
<subject type="local">control of blood pressure</subject>
<description type="Chief Investigator">Dr Liping Huang</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In a world-first trial, we showed that switching regular salt for a reduced-sodium, added-potassium ‘salt substitute’ can lower blood pressure and prevent premature death. ‘Salt substitutes’ are safe and low-cost but are not widely used. Over the next 5-years I will do the work required to upscale their use in Australia and around the world. I will do this by building tools that show governments the health gains, cost-benefits and practical ways they can scale national uptake of salt substitute.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018105</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018105</identifier>
<identifier type="nhmrc">2018105</identifier>
<name type="primary"><namePart>Decoding the instructions for immune cell function</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death</subject>
<subject type="local">macrophage biology </subject>
<subject type="local">t cells</subject>
<subject type="local">breast cancer</subject>
<subject type="local">confocal microscopy</subject>
<subject type="local">immune regulation</subject>
<description type="Chief Investigator">Dr Caleb Dawson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Each organ sends many different signals to its immune cells to instruct them in varied and critical functions that impact health and disease. These signals are complex and there is a lack of tools to study them, so how they act to instruct immune cell function remains largely unknown. I will combine cutting-edge molecular and imaging technologies to discover how the breast instructs its immune cells and reveal new ways to control breast cancer, treat inflammation and improve infant health.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018108</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018108</identifier>
<identifier type="nhmrc">2018108</identifier>
<name type="primary"><namePart>Harnessing big data to improve access to care and outcomes in REcent Migrants And Refugees diagnosed with Cancer (REMARC)</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health services and systems not elsewhere classified</subject>
<subject type="local">cancer control </subject>
<subject type="local">refugee health</subject>
<subject type="local">equity</subject>
<subject type="local">migrant health</subject>
<subject type="local">radiotherapy</subject>
<description type="Chief Investigator">Dr Mei Ling Yap</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is one of the leading causes of death in Australia. There have been 4.5 million migrants and refugees to Australia in the last 30 years. This research program uses big data to study whether recent migrants and refugees diagnosed with cancer access the right treatments and the impacts of a cancer diagnosis on these people’s lifespan and employment. Our research will highlight current gaps and the policy changes needed to improve the lives of people diagnosed with cancer in this population.</description>
<description type="fundingAmount">$493,090.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018114</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018114</identifier>
<identifier type="nhmrc">2018114</identifier>
<name type="primary"><namePart>Investigating the epigenetic control of female-biased autoimmune disorders</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b3dvp57</identifier><title>Garvan Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</subject>
<subject type="local">epigenetics </subject>
<subject type="local">dna methylation</subject>
<subject type="local">autoimmune disease</subject>
<subject type="local">x chromosome inactivation</subject>
<subject type="local">b cells</subject>
<description type="Chief Investigator">Dr Ksenia Skvortsova</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Our immune system is a complex network of cells that defend us from infections. In 5-8% of people, the immune system goes awry and mistakenly attacks the body’s healthy tissues, leading to autoimmune disease. Remarkably, 80% of autoimmunity patients are women, however, the molecular mechanisms behind this bias remain unknown. Using cutting-edge technologies, I will define female-specific mechanisms leading to autoimmunity, which will provide tools for diagnostics and drug target prioritisation.</description>
<description type="fundingAmount">$574,120.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018118</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018118</identifier>
<identifier type="nhmrc">2018118</identifier>
<name type="primary"><namePart>Food, mood and microbes: Improving mental health through diet</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02czsnj07</identifier><title>Deakin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</subject>
<subject type="local">mental health </subject>
<subject type="local">diet</subject>
<subject type="local">molecular microbiology</subject>
<subject type="local">dietary intervention</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Heidi Staudacher</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mental health conditions like depression are a major cause of reduced quality of life. Unfortunately, medications are suboptimal for many people with the condition. Research shows changing your diet can improve depression. A Mediterranean diet rich in wholegrain cereals, fruit, vegetables and olive oil is particularly beneficial. However, we do not know how this diet improves depression symptoms and we need to identify ways to provide clear information about it to the people who need it most.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018144</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018144</identifier>
<identifier type="nhmrc">2018144</identifier>
<name type="primary"><namePart>Driving change in the health sector to reduce the impact of intergenerational trauma and family violence</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | social determinants of health | health sciences | epidemiology | social epidemiology | health sciences | health services and systems | implementation science and evaluation</subject>
<subject type="local">trauma </subject>
<subject type="local">aboriginal mental health</subject>
<subject type="local">refugee health</subject>
<subject type="local">domestic violence</subject>
<subject type="local">lived experiences</subject>
<description type="Chief Investigator">Prof Stephanie Brown</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Intergenerational trauma and family violence are global public health issues with major impacts on the health and wellbeing of children, families and communities. My research will provide robust evidence about lived experiences of intergenerational trauma and family violence in priority populations to inform early intervention and health system reform. Co-designed intervention studies will provide evidence about ways to embed culturally safe, trauma-informed approaches into practice.</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018157</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018157</identifier>
<identifier type="nhmrc">2018157</identifier>
<name type="primary"><namePart>Harnessing digital technologies to improve the quality of youth mental health services</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | mental health services</subject>
<subject type="local">youth </subject>
<subject type="local">computer-based decision support</subject>
<subject type="local">prediction</subject>
<subject type="local">mood disorders</subject>
<subject type="local">outcomes research</subject>
<description type="Chief Investigator">Dr Frank Iorfino</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mental disorders are the leading cause of disability and death among young people. While youth mental health services have improved access to care, many challenges contribute to ongoing service inefficiencies and poor clinical outcomes at high costs to society. This research program aims to address these challenges by making use of modern digital technologies to provide services with decision-support tools designed to make youth mental health care more personalised, dynamic and proactive.</description>
<description type="fundingAmount">$574,564.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018163</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018163</identifier>
<identifier type="nhmrc">2018163</identifier>
<name type="primary"><namePart>Atrial fibrillation: improving outcomes through lifestyle and ablation</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">atrial fibrillation </subject>
<subject type="local">atrial arrhythmias</subject>
<subject type="local">congestive heart failure</subject>
<subject type="local">obesity</subject>
<subject type="local">alcohol</subject>
<description type="Chief Investigator">Prof Peter Kistler</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Atrial fibrillation(AF) is the most common heart rhythm disorder and an epidemic of cardiovascular disease. AF is associated with stroke, mortality and heart failure. Ablation involves passing wires into the heart and delivering tiny burns to cure AF. Increasingly lifestyle factors such as weight loss and alcohol reduction have also been shown to reduce AF. The research plan explores yoga, medicated weight loss and new ablation techniques to improve outcomes in people with AF.</description>
<description type="fundingAmount">$1,941,085.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018167</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018167</identifier>
<identifier type="nhmrc">2018167</identifier>
<name type="primary"><namePart>Targeting crosstalk in the tumour microenvironment for precision cancer therapy</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets</subject>
<subject type="local">metastatic progression </subject>
<subject type="local">breast cancer</subject>
<subject type="local">prostate cancer</subject>
<subject type="local">microenvironment</subject>
<subject type="local">interferon (ifn)</subject>
<description type="Chief Investigator">Assoc Prof Belinda Parker</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer spread remains very difficult to target therapeutically. My research focus has been modelling the cellular interactions that occur during cell spread to develop markers that predict the effectiveness of existing therapies and to uncover new biological targets for treating aggressive cancer types. I now aim to drive this research into the clinical setting by utilising unique humanised models and interrogating patient samples to enable science-guided therapies for cancer patients.</description>
<description type="fundingAmount">$2,082,170.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018182</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018182</identifier>
<identifier type="nhmrc">2018182</identifier>
<name type="primary"><namePart>Musculoskeletal pain: getting the right patient to the right treatment at the right time</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis | health sciences | allied health and rehabilitation science | physiotherapy</subject>
<subject type="local">musculoskeletal disorders </subject>
<subject type="local">clinical trial</subject>
<subject type="local">health economics</subject>
<subject type="local">low back pain</subject>
<subject type="local">osteoarthritis</subject>
<description type="Chief Investigator">Prof Nadine Foster</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Common painful conditions affecting the bones and joints such as low back pain and arthritis cause more disability than any other condition, and the scale of the problem is rising. Health care is struggling to meet the demand, commonly offering treatments of limited value to patients who don't need them, whilst not providing access to effective care for those who do. This program will reduce uncertainty about treatment effectiveness and ensure patients get access to the care they need.</description>
<description type="fundingAmount">$2,832,580.96</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018187</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018187</identifier>
<identifier type="nhmrc">2018187</identifier>
<name type="primary"><namePart>Leveraging liver-derived extracellular vesicles to identify new therapies for type 2 diabetes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell metabolism</subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </subject>
<subject type="local">endocrine factors</subject>
<subject type="local">lipid metabolism</subject>
<subject type="local">insulin resistance</subject>
<subject type="local">fatty liver disease</subject>
<description type="Chief Investigator">Dr Paula Miotto</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Type 2 diabetes is characterised by impairments in glycemic control, compromised insulin secretion, and insulin resistance. There is an urgent clinical need to develop new strategies to normalise blood glucose levels. This investigator grant aims to identify novel insulin-independent therapeutic targets that can improve glycemic control. This project will use preclinical models to validate the efficacy of these targets, setting the stage for the development of new treatments for type 2 diabetes.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018194</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018194</identifier>
<identifier type="nhmrc">2018194</identifier>
<name type="primary"><namePart>Innovative solutions towards reducing heart attacks- beyond classical risk factors</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">coronary artery disease </subject>
<subject type="local">atherosclerosis</subject>
<subject type="local">biomarkers</subject>
<subject type="local">drug discovery</subject>
<subject type="local">heart attack</subject>
<description type="Chief Investigator">Prof Gemma Figtree</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">I am a cardiologist driven by the increasing number of heart attack patients who ask “why me?”. Fourteen-27% of patients with life-threatening heart attacks have no standard modifiable risk factors. By focussing on this growing group with no risk factors, I will discover and translate new biomarkers, develop new drugs to reduce heart attacks, derive new clinical pathways, and improve outcomes with broader benefits to all patients susceptible to coronary artery disease and heart attack.</description>
<description type="fundingAmount">$2,029,302.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018204</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018204</identifier>
<identifier type="nhmrc">2018204</identifier>
<name type="primary"><namePart>Advancing Refugee Mental Health</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">psychology | clinical and health psychology | clinical psychology</subject>
<subject type="local">refugee health </subject>
<subject type="local">posttraumatic stress disorder (ptsd)</subject>
<subject type="local">traumatic stress</subject>
<subject type="local">psychological treatment</subject>
<subject type="local">cognitive behaviour therapy</subject>
<description type="Chief Investigator">Prof Angela Nickerson</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The number of refugees worldwide has reached unprecedented levels. Refugees show high rates of psychological disorders due to exposure to war, trauma and persecution. Despite this, many do not seek help or fail to respond to treatment. This research program proposes to increase knowledge about the factors contributing to PTSD and help-seeking. This will lead to the development of two new interventions to improve mental health outcomes in refugees.</description>
<description type="fundingAmount">$2,756,790.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018214</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018214</identifier>
<identifier type="nhmrc">2018214</identifier>
<name type="primary"><namePart>Reconstructing the megakaryocyte lipidome to control platelet production: Applications for thrombocytopenia or thrombocytosis</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death</subject>
<subject type="local">platelets </subject>
<subject type="local">lipids</subject>
<subject type="local">haematopoiesis</subject>
<subject type="local">thrombocytopenia</subject>
<subject type="local">stem cell biology</subject>
<description type="Chief Investigator">Dr Man Lee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Platelets are cell fragments critical for blood clotting. Too few, results in bleeding disorders and too many, can block blood supply to organs. Both are life threatening. Current treatments are limited and have side effects. There is an urgent need to identify new ways to counteract both extreme conditions. We recently identified important lipids that are needed for platelet production. Here, we aim to increase or decrease these lipid levels to determine if we can control platelet production.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018220</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018220</identifier>
<identifier type="nhmrc">2018220</identifier>
<name type="primary"><namePart>Optimizing strategies for control of neglected tropical diseases</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiological methods | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | public health not elsewhere classified</subject>
<subject type="local">tropical disease </subject>
<subject type="local">community intervention study</subject>
<subject type="local">helminth infection</subject>
<subject type="local">scabies</subject>
<subject type="local">trachoma</subject>
<description type="Chief Investigator">Assoc Prof Susana Nery</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My research program will optimize strategies for control of neglected tropical diseases which are closely associated with poverty, affecting 2 billion of people globally. The specific aims of this research program are: 1) optimising programs for control of intestinal worms; 2) integration of control programs to increase their impact and 3) defining the public health role of a new and promising medication, moxidectin. Findings will be used to inform policy makers and improve existing guidelines.</description>
<description type="fundingAmount">$2,756,790.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018222</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018222</identifier>
<identifier type="nhmrc">2018222</identifier>
<name type="primary"><namePart>Pathogen Genomics Dual Utility to Deliver Personalised Medicine and Precision Public Health</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases</subject>
<subject type="local">functional genomics </subject>
<subject type="local">medical virology</subject>
<subject type="local">molecular virology</subject>
<subject type="local">public health</subject>
<subject type="local">respiratory infection</subject>
<description type="Chief Investigator">Dr Rebecca Rockett (nee Sedwell)</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Novel treatments for COVID-19 have rapidly been developed and are used to prevent severe SARS-CoV-2 infection in patients with underlying health conditions. The SARS-CoV-2 virus is evolving rapidly and this has led to variants that can reduce the effectiveness of novel antiviral treatments. This grant will develop genomic tools to predict the optimal SARS-CoV-2 therapeutic needed whilst monitoring for viral resistance in patients that fail antiviral therapy.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018244</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018244</identifier>
<identifier type="nhmrc">2018244</identifier>
<name type="primary"><namePart>Leveraging genomics to unravel tumour complexity and improve patient outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | sequence analysis</subject>
<subject type="local">dna sequencing </subject>
<subject type="local">bioinformatics</subject>
<subject type="local">medical genomics</subject>
<subject type="local">cancer</subject>
<subject type="local">tumour-specific targeting</subject>
<description type="Chief Investigator">Dr Nicola Waddell</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cancer is the cause of 1 in 8 deaths worldwide. Cancer occurs due to errors or mutations in the DNA of normal cells. I will identify the mutations in tumour cells to determine: i) How a tumour develops and how complex it is ii) How a tumour may be treated to kill the cancer The work studies a variety of cancer types including mesothelioma, melanoma, oesophageal and breast cancer. The overall vision is to apply some of the research findings or approaches into patient care to improve patient survival</description>
<description type="fundingAmount">$2,382,170.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018256</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018256</identifier>
<identifier type="nhmrc">2018256</identifier>
<name type="primary"><namePart>A rapid synthetic molecular evolution platform for novel antimicrobials against infections</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | chemical sciences | medicinal and biomolecular chemistry | proteins and peptides</subject>
<subject type="local">antibiotic resistance </subject>
<subject type="local">drug discovery</subject>
<subject type="local">novel therapeutic agents</subject>
<subject type="local">synthetic peptides</subject>
<subject type="local">mechanism of action</subject>
<description type="Chief Investigator">Dr Wenyi Li</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Infections caused by antimicrobial resistant bacteria are rapidly increasing worldwide, with 106 million new cases annually. Antimicrobial peptides are a promising therapeutic to tackle the shortage of antibiotics. However, conventional development of antimicrobial peptides is limited by inadequate preparation of large parallel libraries and ineffective bioactivity tests. I will develop novel approaches via computational modelling and smart synthesis to identify therapeutic to combat infections.</description>
<description type="fundingAmount">$630,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018340</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018340</identifier>
<identifier type="nhmrc">2018340</identifier>
<name type="primary"><namePart>Breakthrough research paving the way for the development of transformative immunotherapies for SLE.</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | autoimmunity</subject>
<subject type="local">gut immunity </subject>
<subject type="local">autoantibodies</subject>
<subject type="local">lupus</subject>
<subject type="local">metabolites</subject>
<subject type="local">pathology</subject>
<description type="Chief Investigator">Prof Fabienne Mackay</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Lupus is a debilitating autoimmune disease which is very hard to treat. Patients with lupus have a leaky gut but the role of this medical anomaly in driving disease is not known. Breakthrough data from our group showed that modifying the biology of immune cells in the gut, restores gut health and protects against lupus. We propose to harness the biological mechanisms underpinning this new therapeutic effect for the development of transformative and much needed new therapies for lupus.</description>
<description type="fundingAmount">$1,500,000.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018360</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018360</identifier>
<identifier type="nhmrc">2018360</identifier>
<name type="primary"><namePart>Improving the genetic diagnosis of cardiovascular disease</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics</subject>
<subject type="local">medical genomics </subject>
<subject type="local">bioinformatics</subject>
<subject type="local">dna sequencing</subject>
<subject type="local">cardiovascular disease</subject>
<subject type="local">gene mutations</subject>
<description type="Chief Investigator">Assoc Prof Eleni Giannoulatou</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cardiovascular disease (CVD) claims 17.9 million lives each year and has remained the leading cause of death globally for the last 20 years. Using genomic technologies and novel computational methodology, I will improve the rate of genetic diagnosis of cardiovascular disease and provide better understanding of the disease mechanism. This research program will enable personalised management and treatment, and improved risk assessment for CVD patients and their families.</description>
<description type="fundingAmount">$1,526,390.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018363</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018363</identifier>
<identifier type="nhmrc">2018363</identifier>
<name type="primary"><namePart>RNA-level gene regulation</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biological sciences | genetics | genome structure and regulation</subject>
<subject type="local">messenger rna (mrna) </subject>
<subject type="local">rna binding proteins</subject>
<subject type="local">rna processing</subject>
<subject type="local">rrna</subject>
<subject type="local">protein synthesis</subject>
<description type="Chief Investigator">Prof Thomas Preiss</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Genetic information resides in the DNA of our genome; however, to use this information it must be transcribed into chemically related RNA molecules, collectively known as the transcriptome. While different body cells carry the same genome, they differ widely in their transcriptome composition. To understand how cells properly utilise their transcriptomes, I will characterise the marks and binding partners found on RNA in the context of cardiac and cancer biology.</description>
<description type="fundingAmount">$2,437,110.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018376</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018376</identifier>
<identifier type="nhmrc">2018376</identifier>
<name type="primary"><namePart>Development of novel ablation technologies for the treatment of ventricular tachycardia</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</subject>
<subject type="local">microwave </subject>
<subject type="local">ionising radiation</subject>
<subject type="local">ventricular tachycardia</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">sympathetic nerves</subject>
<description type="Chief Investigator">Dr Pierre Qian</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Rhythm disorders from the main pumping chambers of the heart (ventricular arrhythmias, VA) cause 1 in4 of all deaths from heart disease. VA can be treated effectively by finding and destroying the circuits within heart scar tissue that perpetuate VA (ablation). The study innovates new technology and minimally invasive approaches to reduce the risk of VA for patients with heart disease, prolonging longevity and improving quality of life.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018383</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018383</identifier>
<identifier type="nhmrc">2018383</identifier>
<name type="primary"><namePart>Simplified Immunotherapies for Global Oncology</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</subject>
<subject type="local">human papillomavirus (hpv) </subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">kaposi's sarcoma</subject>
<subject type="local">epstein-barr virus (ebv)</subject>
<subject type="local">cancer genetics</subject>
<description type="Chief Investigator">Prof Mark Polizzotto</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Around 1 in 5 cancers worldwide are caused by infections. These are particularly important in the developing world, where they account for the majority of cancer cases and deaths, often in young people. This grant continues my world-leading work in developing drugs to treat and prevent cancers caused by infections, and in understanding their origins. I focus on simple but effective drugs that can be used in developing countries, to ensure my new treatments can be used by those in greatest need.</description>
<description type="fundingAmount">$2,878,395.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018391</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018391</identifier>
<identifier type="nhmrc">2018391</identifier>
<name type="primary"><namePart>Addressing unmet needs in chronic disease through innovations in trial design and delivery</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology</subject>
<subject type="local">clinical trial </subject>
<subject type="local">kidney disease</subject>
<subject type="local">chronic diseases</subject>
<subject type="local">chronic cardiovascular disease</subject>
<subject type="local">quality assurance</subject>
<description type="Chief Investigator">Prof Meg Jardine</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program will utilise innovative designs and new digital capabilities to address some of the challenges in completing randomized trials in chronic disease. Trial designs will be informed by clinical practice and a good understanding of clinician and consumer attitudes to proposed trials. These approaches will facilitate large, simple randomized quality assurance studies and trials embedded in clinical practice, leading to improvements in clinical outcomes.</description>
<description type="fundingAmount">$3,257,170.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018420</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018420</identifier>
<identifier type="nhmrc">2018420</identifier>
<name type="primary"><namePart>Expanding genetic causal inference analyses to evaluate cancer risk factors in diverse populations</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | statistical and quantitative genetics</subject>
<subject type="local">complex genetic disease </subject>
<subject type="local">genetic analysis</subject>
<subject type="local">genetic risk factors</subject>
<subject type="local">genetic susceptibility</subject>
<subject type="local">genetic epidemiology</subject>
<description type="Chief Investigator">Dr Jue Sheng Ong</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">My research studies the use of statistical models applied to large-scale genetic data to help us understand what causes diseases such as cancers. Using these models, I investigate whether the genetic background underlying cancers can give us clues about whether the observed relationship between a range of putatively modifiable risk factors and common cancers is causal in European populations. I am also investigating whether the same genetic relationship is present in other populations.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018431</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018431</identifier>
<identifier type="nhmrc">2018431</identifier>
<name type="primary"><namePart>Towards improved clinical outcomes for common brain disorders using large-scale statistical genomics</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | neurogenetics | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics</subject>
<subject type="local">statistical genetics </subject>
<subject type="local">autism spectrum disorders</subject>
<subject type="local">parkinson disease</subject>
<subject type="local">neurogenetics</subject>
<subject type="local">genomics</subject>
<description type="Chief Investigator">Dr Jacob Gratten</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The social and economic costs of common brain disorders, such as autism spectrum disorder and Parkinson’s disease, are enormous. My research aims to generate new knowledge on these conditions by using advanced statistical methods to integrate large-scale genetics and genomics with deep clinical and lifestyle data. Ultimately, this is expected to underpin improved clinical outcomes and quality of life through prevention, earlier diagnosis, and safer evidence-based treatments.</description>
<description type="fundingAmount">$2,356,790.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018432</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018432</identifier>
<identifier type="nhmrc">2018432</identifier>
<name type="primary"><namePart>Characterisation of the genetic architecture of autoimmune disease at single-cell resolution</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology)</subject>
<subject type="local">control of gene expression </subject>
<subject type="local">autoimmune disease</subject>
<subject type="local">genetic variation</subject>
<subject type="local">bioinformatics</subject>
<subject type="local">functional genomics</subject>
<description type="Chief Investigator">Jose Alquicira Hernandez</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Autoimmune disorders represent a considerable burden for the healthcare system, affecting up to 9% of the human population. Genetic factors are the most significant contributors to autoimmune disease risk; however, their effects on individual immune cells remain unknown. My research seeks to characterise the functional impact of genetic factors in pathological cell states and their role in mediating autoimmunity to ultimately improve the treatment of autoimmune conditions.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018440</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018440</identifier>
<identifier type="nhmrc">2018440</identifier>
<name type="primary"><namePart>Dissecting the cellular ecosystems and therapeutic vulnerabilities of breast cancer</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | systems biology</subject>
<subject type="local">breast cancer </subject>
<subject type="local">cancer biology</subject>
<subject type="local">gene expression</subject>
<subject type="local">cancer immunology</subject>
<subject type="local">cancer treatment</subject>
<description type="Chief Investigator">Assoc Prof Alexander Swarbrick</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Solid cancers are complex cellular ‘ecosystems’ in which the growth and drug response of the tumour is controlled by cell interactions. We will use single cell genomics to understand the nature and interactions of cells that make up breast cancers. This will help us to better understand the role of specific cell types in the development of cancers and find improved ways to treat cancer.</description>
<description type="fundingAmount">$2,205,736.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018461</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018461</identifier>
<identifier type="nhmrc">2018461</identifier>
<name type="primary"><namePart>Engineering protein diagnostics/therapeutics via next-generation enzymatic and genetic code expansion approaches</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | synthetic biology | biological sciences | biochemistry and cell biology | enzymes</subject>
<subject type="local">antibody engineering </subject>
<subject type="local">protein engineering</subject>
<subject type="local">drug conjugation</subject>
<subject type="local">protein expression</subject>
<subject type="local">molecular pharmacology</subject>
<description type="Chief Investigator">Dr Fabian Rehm</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The use of protein conjugates for therapeutic or diagnostic applications is widespread. However, currently employed protein modifying technologies are largely non-specific and result in a mixture of conjugates. It is difficult to predict how such mixtures perform in a clinical setting and typically a substantial fraction underperforms. To address these issues, the proposed project aims to establish a platform for generating new types of highly defined protein conjugates.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018465</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018465</identifier>
<identifier type="nhmrc">2018465</identifier>
<name type="primary"><namePart>Supporting healing and recovery for Aboriginal and Torres Strait Islander survivors of childhood sexual abuse</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing</subject>
<subject type="local">trauma </subject>
<subject type="local">sexual abuse</subject>
<subject type="local">recovery</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">wellbeing</subject>
<description type="Chief Investigator">Dr Graham Gee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Child sexual abuse is a form of violence that occurs across nations and cultures worldwide. Collective efforts are being made to address this issue within Victorian Aboriginal and Torres Strait Islander communities. This research will generate new knowledge about survivors lived experiences of healing and recovery, identify current therapeutic practices, and build training and education resources that support Aboriginal organisations to better meet the healing and recovery needs of survivors.</description>
<description type="fundingAmount">$1,568,756.02</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018477</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018477</identifier>
<identifier type="nhmrc">2018477</identifier>
<name type="primary"><namePart>Transforming Care and Outcomes for Patients with Pleural Effusion</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</subject>
<subject type="local">adult respiratory diseases </subject>
<subject type="local">mesothelioma</subject>
<subject type="local">respiratory infection</subject>
<subject type="local">respiratory medicine</subject>
<subject type="local">lung neoplasms</subject>
<description type="Chief Investigator">Prof Y C Gary Lee</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My world-leading program brings together clinicians, scientists and allied health researchers to advance knowledge and care of pleural effusions (fluid build-up in the chest), a neglected condition that affects 60,000 Australians a year. Our consumer-driven research will use multicentre randomised trials, multidisciplinary (diet, exercise, psychology) approaches and cutting-edge laboratory techniques to improve diagnosis and treatment of pleural effusions esp those from cancer and infection.</description>
<description type="fundingAmount">$2,205,736.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018497</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018497</identifier>
<identifier type="nhmrc">2018497</identifier>
<name type="primary"><namePart>Microvascular dysfunction in acute ischemic stroke: The next frontier in stroke reperfusion</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified</subject>
<subject type="local">cerebral ischaemia </subject>
<subject type="local">ischaemia/reperfusion</subject>
<subject type="local">treatment</subject>
<subject type="local">microvascular</subject>
<subject type="local">recovery</subject>
<description type="Chief Investigator">Dr Felix Ng</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Ischemic stroke is due to an abrupt blockage in a major brain artery. Over half of patients who receive acute treatment do not improve for unclear reasons. We will study how dysfunction of microcirculation (microscopic vessels in the brain) leads to complications and reduces treatment effectiveness. Ultimately, the aim is to develop a new therapy targeting the microvessels that can augment the benefit of reperfusion treatments in stroke.</description>
<description type="fundingAmount">$655,150.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018514</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018514</identifier>
<identifier type="nhmrc">2018514</identifier>
<name type="primary"><namePart>Melanoma: Getting the Diagnosis and Treatment Right for Better Patient Outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers | biomedical and clinical sciences | clinical sciences | pathology (excl. oral pathology) | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis</subject>
<subject type="local">malignant melanoma </subject>
<subject type="local">oncology</subject>
<subject type="local">pathology</subject>
<subject type="local">diagnosis</subject>
<subject type="local">cancer treatment</subject>
<description type="Chief Investigator">Prof Richard Scolyer</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Melanoma is a major Australian health problem. Prevention, early diagnosis and appropriate treatment remain the linchpins of disease control. Over the past decade, new drug therapies have improved previously dismal outcomes for metastatic melanoma patients. This research proposal will integrate molecular and immune profiling with clinical and patient factors, and personalised treatment strategies, to transform melanoma diagnosis, risk prediction and treatment across all stages of the disease.</description>
<description type="fundingAmount">$3,937,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018534</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018534</identifier>
<identifier type="nhmrc">2018534</identifier>
<name type="primary"><namePart>Innovation for global lung health</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</subject>
<subject type="local">tuberculosis </subject>
<subject type="local">lung disease</subject>
<subject type="local">air pollution</subject>
<subject type="local">public health</subject>
<subject type="local">asthma</subject>
<description type="Chief Investigator">Prof Guy Marks</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program of work is dedicated to mitigating the global burden of ill-health due to lung disease. I have focused on the major respiratory diseases that are responsible for death and disability worldwide, noncommunicable chronic respiratory disease (asthma and COPD) and tuberculosis, and air pollution, a major environmental cause of ill-health.</description>
<description type="fundingAmount">$2,649,688.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018537</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018537</identifier>
<identifier type="nhmrc">2018537</identifier>
<name type="primary"><namePart>Innovative clinical trials: improving care and health outcomes</namePart></name>
<name type="alternative"><namePart>Investigator Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified</subject>
<subject type="local">clinical trial </subject>
<subject type="local">cardiovascular</subject>
<subject type="local">diabetes mellitus</subject>
<subject type="local">perinatal</subject>
<subject type="local">biomarkers</subject>
<description type="Chief Investigator">Prof Anthony Keech</description>
<description type="Date Announced">2022-10-12T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Ground-breaking clinical trials intended to advance care and improve health outcomes nationally and internationally will be undertaken. The focus will include trials and new methods in cardiovascular disease and diabetes particularly. Evidence synthesis for reliable guidelines and policy decisions will be conducted. Projects will link basic science research with clinical outcomes to improve our understanding of disease and treatment mechanisms.</description>
<description type="fundingAmount">$2,937,110.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015556</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015556</identifier>
<identifier type="nhmrc">2015556</identifier>
<name type="primary"><namePart>Hearing loss, the silent enemy of good health: Effectiveness, cost-effectiveness, and potential economic and social impact of interventions to promote treatment to facilitate improved hearing</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | preventive medicine | public health and health services | primary health care | applied economics | health economics | </subject>
<subject type="local">hearing loss</subject>
<subject type="local">hearing aids</subject>
<subject type="local">referral practices</subject>
<subject type="local">behavioural intervention</subject>
<subject type="local">health economics</subject>
<description type="Chief Investigator">Assoc Prof Julia Sarant</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing loss impacts many adults of all ages, and 7 in 10 adults aged over 70 years. Despite significant associated health, well-being and financial costs, referrals for hearing care, hearing aid adoption and use are very low. This project will identify barriers to medical referral for hearing care and barriers to hearing aid uptake and use and will design and evaluate the feasibility and cost-effectiveness of interventions to address these, leading to improved health outcomes for Australians.</description>
<description type="fundingAmount">$541,448.90</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015700</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015700</identifier>
<identifier type="nhmrc">2015700</identifier>
<name type="primary"><namePart>Improving access to the hearing services program for people from culturally and linguistically diverse backgrounds</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">other medical and health sciences | medical and health sciences not elsewhere classified | public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">hearing</subject>
<subject type="local">hearing aids</subject>
<subject type="local">health inequalities</subject>
<subject type="local">social and cultural issues</subject>
<subject type="local">access to health care</subject>
<description type="Chief Investigator">Prof Piers Dawes</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing loss affects 1 in 5 people, impacting communication, quality of life, education and employment, social activities, and physical and mental health. People can get effective help for hearing loss. But people from culturally and linguistically diverse communities are less likely to get help. We will work with people from culturally and linguistically diverse communities to co-design accessible, equitable and culturally safe hearing services to preserve and protect hearing health.</description>
<description type="fundingAmount">$902,757.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015711</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015711</identifier>
<identifier type="nhmrc">2015711</identifier>
<name type="primary"><namePart>Implementation and Evaluation of a Co-designed Program Targeting the Psychosocial and Emotional Impacts of Hearing Conditions in Adults</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | otorhinolaryngology | psychology | health, clinical and counselling psychology | </subject>
<subject type="local">hearing loss</subject>
<subject type="local">psychosocial adjustment</subject>
<subject type="local">audiology</subject>
<subject type="local">implementation</subject>
<subject type="local">mental health</subject>
<description type="Chief Investigator">Assoc Prof Christina Bryant</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing conditions have many psychosocial consequences and the most common forms of management (e.g., hearing aids) do not appropriately address these concerns. This project will develop an online Hearing Wellbeing Program (HWP) to improve the psychological, social, and emotional wellbeing of people with hearing conditions. The project will test the feasibility of implementing the HWP and then assess the program for its effectiveness in improving the wellbeing of people with hearing conditions.</description>
<description type="fundingAmount">$496,103.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015735</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015735</identifier>
<identifier type="nhmrc">2015735</identifier>
<name type="primary"><namePart>Building on newborn hearing screening success: towards national standards and data management</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">paediatrics and reproductive medicine | paediatrics | neurosciences | sensory systems | public health and health services | preventive medicine | </subject>
<subject type="local">databases</subject>
<subject type="local">hearing</subject>
<subject type="local">child</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">health outcomes</subject>
<description type="Chief Investigator">Assoc Prof Valerie Sung</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Australia’s universal newborn hearing screening enables early hearing loss identification, access to hearing devices and early intervention. But we do not know how hearing programs improve child outcomes, who do not access services, and whether postnatal screening occurs. We will establish the prerequisites of a national child hearing database to ensure screening/interventions improve child outcomes, ensure no deaf or hard-of-hearing child ‘falls through the cracks’, and facilitate research.</description>
<description type="fundingAmount">$1,436,994.31</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015748</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015748</identifier>
<identifier type="nhmrc">2015748</identifier>
<name type="primary"><namePart>Empowering adults with hearing loss by increasing informed choice, accessibility, and uptake of hearing healthcare</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02n415q13</identifier><title>Curtin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | otorhinolaryngology | </subject>
<subject type="local">audiology</subject>
<subject type="local">hearing aids</subject>
<subject type="local">aural rehabilitation</subject>
<subject type="local">computer-based decision support</subject>
<subject type="local">behaviour change</subject>
<description type="Chief Investigator">Assoc Prof Melanie Ferguson</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The problem. Four million Australians have hearing loss. Yet many do not seek help, and are unaware of the hearing healthcare options that are available. This leads to many people not obtaining the hearing healthcare they need. Our solution. We will co-create a tailored online decision aid to explain the pros and cons of available hearing health options. We anticipate this approach to decision-making will increase uptake of hearing healthcare and improve the lives of many adults with hearing loss.</description>
<description type="fundingAmount">$683,027.43</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015750</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015750</identifier>
<identifier type="nhmrc">2015750</identifier>
<name type="primary"><namePart>Prevalence of hearing loss in Aboriginal children caused by otitis media from birth to 5 years of age and evidence of the effectiveness of health promotion programs: evidence to inform national policy</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02n415q13</identifier><title>Curtin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">aboriginal health</subject>
<subject type="local">hearing loss</subject>
<subject type="local">otitis media</subject>
<subject type="local">child health</subject>
<subject type="local">health promotion</subject>
<description type="Chief Investigator">Assoc Prof Christopher Brennan-Jones</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will provide the first estimates of the number of Aboriginal children who have ear infections and hearing loss from 0 to 5 years of age and will demonstrate the feasibility of screening for ear infections and hearing loss from 2 months of age. It will also test, for the first time, the effectiveness of a health promotion intervention to resolve ear infections and prevent hearing loss without the need for surgery. If effective, this intervention can be implemented nationally.</description>
<description type="fundingAmount">$1,123,133.74</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015793</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015793</identifier>
<identifier type="nhmrc">2015793</identifier>
<name type="primary"><namePart>Pathways For Aboriginal and Torres Strait Islander Hearing Health: The PATHWAY Project</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">child health</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">otitis media</subject>
<subject type="local">referral practices</subject>
<subject type="local">public health</subject>
<description type="Chief Investigator">Dr Jacqueline Stephens</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">All children have the right to hear well, but Aboriginal and Torres Strait Islander children have inequitable access to hearing healthcare. Multifaceted strategies are needed which consider people’s first-hand experiences in the co-design of solutions. This project will generate evidence of culturally appropriate methods to build a strategy which optimises the complex and difficult to navigate hearing health patient pathway experienced by Aboriginal and Torres Strait Islander children.</description>
<description type="fundingAmount">$1,155,685.70</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015794</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015794</identifier>
<identifier type="nhmrc">2015794</identifier>
<name type="primary"><namePart>Hearables and behavioural activation for mental distress and social isolation in hearing impaired older adults</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">clinical sciences | otorhinolaryngology | clinical sciences | psychiatry (incl. psychotherapy) | clinical sciences | geriatrics and gerontology | </subject>
<subject type="local">hearing</subject>
<subject type="local">mental health promotion</subject>
<subject type="local">psychotherapy</subject>
<subject type="local">hearing aids</subject>
<subject type="local">depression</subject>
<description type="Chief Investigator">Dr Andrew Ford</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Age-related hearing loss is common and may lead to depression, social isolation, loneliness, and reduced quality of life. Hearing aids are expensive and simpler, cost-effective hearing amplification devices (hearables) may offer an alternative treatment strategy. This trial will test if hearables in addition to a pragmatic psychological intervention (behavioural activation) improves mood, quality of life, mental distress and social isolation in older adults with mild to moderate hearing loss.</description>
<description type="fundingAmount">$571,966.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015803</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015803</identifier>
<identifier type="nhmrc">2015803</identifier>
<name type="primary"><namePart>Improving the psychosocial and emotional well-being of adults with hearing loss through co-designed evidence-based services: ACE2.0</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">clinical sciences | rehabilitation and therapy (excl. physiotherapy) | </subject>
<subject type="local">hearing</subject>
<subject type="local">communication skills</subject>
<subject type="local">aural rehabilitation</subject>
<subject type="local">psychosocial</subject>
<subject type="local">qualitative methods</subject>
<description type="Chief Investigator">Assoc Prof Nerina Scarinci</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing loss affects a person’s ability to communicate and to socialise. Community members will partner with researchers to develop an innovative and contemporary education and support program to help adults with hearing loss and their family overcome the everyday communication, social, and emotional difficulties they experience. The solution will be rolled out and evaluated in hearing services across Australia and subsequently be made available to all Australians with hearing loss.</description>
<description type="fundingAmount">$527,012.40</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015740</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015740</identifier>
<identifier type="nhmrc">2015740</identifier>
<name type="primary"><namePart>Bridge to Better Health: A Cluster Randomised Controlled Trial for Capacity Building in Intellectual Disability Health for General Practice</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | care for disabled | nursing | clinical nursing: primary (preventative) | public health and health services | primary health care | </subject>
<subject type="local">intellectual disability</subject>
<subject type="local">general practice</subject>
<subject type="local">nursing</subject>
<subject type="local">health service accessibility</subject>
<subject type="local">health services research</subject>
<description type="Chief Investigator">Dr Catherine Franklin</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will improve preventive health outcomes for people with intellectual disability by supporting general practice nurses to do health assessments with their patients with intellectual disability. We will provide access to a specialist intellectual disability nurse, training on conducting a health assessment, intellectual disability health training and access to online resources. This intervention is designed to be able to be rolled out nationwide and will be evaluated using a randomised trial.</description>
<description type="fundingAmount">$1,497,939.40</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015753</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015753</identifier>
<identifier type="nhmrc">2015753</identifier>
<name type="primary"><namePart>GeneEQUAL: equitable and accessible genomic healthcare for people with intellectual disability</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">genetics | genomics | public health and health services | care for disabled | </subject>
<subject type="local">medical genomics</subject>
<subject type="local">genetic counselling</subject>
<subject type="local">intellectual disability</subject>
<subject type="local">health inequalities</subject>
<subject type="local">health literacy</subject>
<description type="Chief Investigator">Dr Elizabeth Palmer</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The GeneEQUAL team are: • self-advocates • researchers • clinicians. We will talk with: • people with intellectual disability • their families • their doctors. We will ask them about genomic health care. Genomic health care is genetic tests and genetic counselling. We will write guides and resources so that genomic healthcare will: • include everyone respectfully • help people make healthcare choices • help people understand about their health conditions • help people get the right treatments and support.</description>
<description type="fundingAmount">$1,556,865.18</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015902</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015902</identifier>
<identifier type="nhmrc">2015902</identifier>
<name type="primary"><namePart>Reducing potentially preventable hospitalisations and building health literacy for children and adolescents with intellectual disability</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">public health and health services | care for disabled | </subject>
<subject type="local">intellectual disability</subject>
<subject type="local">hospitalisation</subject>
<subject type="local">socioeconomic</subject>
<subject type="local">developmental disorders</subject>
<subject type="local">primary care</subject>
<description type="Chief Investigator">Assoc Prof Jenny Downs</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Children with intellectual disability have high health care needs but access to primary care services can be hampered by difficulties they and their carers face day to day, leading to potentially preventable hospitalisations. We will examine use of health services in hospital and primary care settings for these children, the enablers and barriers to using primary care services, and how health service use can be optimised for better care and be available across the community.</description>
<description type="fundingAmount">$1,537,414.30</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2015929</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015929</identifier>
<identifier type="nhmrc">2015929</identifier>
<name type="primary"><namePart>Equitable access to health and disability services for Aboriginal and Torres Strait Islander children with intellectual disability</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | public health and health services | care for disabled | </subject>
<subject type="local">intellectual disability</subject>
<subject type="local">child development</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">health services</subject>
<subject type="local">diagnosis</subject>
<description type="Chief Investigator">Prof Sandra Eades</description>
<description type="Date Announced">2022-10-21T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will improve the health and wellbeing of Indigenous children with intellectual disability (ID) by recommending effective models of care to ensure appropriate, timely diagnoses and access to high-quality health and disability services. National Disability Insurance Scheme data and interviews with families, adolescents with ID, and healthcare and disability services will be analysed to identify barriers and facilitators to meeting the healthcare needs of Indigenous children with ID.</description>
<description type="fundingAmount">$792,020.13</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021932</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021932</identifier>
<identifier type="nhmrc">2021932</identifier>
<name type="primary"><namePart>Natural killer cell immunotherapy in paediatric sarcomas</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">natural killer cells </subject>
<subject type="local">cancer immunotherapy</subject>
<subject type="local">cell therapy</subject>
<subject type="local">sarcoma</subject>
<subject type="local">paediatric</subject>
<description type="Chief Investigator">Dr Natacha Omer</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Sarcomas account for 10% of childhood cancers. It is a group of cancers arising from the bone or soft tissue with less than 30% chance of cure when it has spread or comes back despite intensive and possibly mutilating therapies. Natural killer (NK) cells are a type of immune cells known for their ability to kill cancer cells. This project aims to prove that our immune cells can be used to treat sarcomas by selecting the appropriate NK cells for the patients based on their receptor expression.</description>
<description type="fundingAmount">$102,238.25</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021941</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021941</identifier>
<identifier type="nhmrc">2021941</identifier>
<name type="primary"><namePart>Overweight and obesity in young adults with type 1 and type 2 diabetes: mortality, pregnancy outcomes, and novel glycaemic interventions</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology | </subject>
<subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">weight loss</subject>
<subject type="local">overweight/obesity</subject>
<subject type="local">pregnancy outcome</subject>
<description type="Chief Investigator">Dr Xi May Zhen</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to explore the impact of overweight and obesity on long-term outcomes and pregnancy outcomes in young people with type 1 diabetes, and to make comparisons with young-onset type 2 diabetes. Furthermore, this project aims to produce highly novel randomised trial data on the efficacy of novel glycaemic and obesity interventions in people with overweight/obesity and type 1 dabetes/young-onset type 2 diabetes.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021945</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021945</identifier>
<identifier type="nhmrc">2021945</identifier>
<name type="primary"><namePart>Evaluation and diagnosis of cardiac allograft vasculopathy post heart transplant using novel Cardiac CT techniques.</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">cardiac transplantation </subject>
<subject type="local">cardiac ischaemia</subject>
<subject type="local">functional computed tomography</subject>
<subject type="local">cardiac dysfunction</subject>
<subject type="local">microvascular disease</subject>
<description type="Chief Investigator">Dr Josephine Warren</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Heart transplantation is reserved for patients with terminal heart failure. Cardiac allograft vasculopathy (CAV) is a leading cause of death post-transplant, due to progressive narrowing in the heart arteries. As CAV is often asymptomatic, screening with invasive coronary angiography (ICA) is required. Non-invasive testing with Cardiac CT may be a suitable alternative to ICA in this population, and newer techniques examining the effect of blockages on blood flow may improve its accuracy.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021950</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021950</identifier>
<identifier type="nhmrc">2021950</identifier>
<name type="primary"><namePart>The ZEUs (ZopiclonE for acUte low back pain) trial: A multi-site, double blind, randomised controlled trial of zopiclone for acute low back pain</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | pain | </subject>
<subject type="local">low back pain </subject>
<subject type="local">sleep</subject>
<subject type="local">pain mechanisms</subject>
<subject type="local">pharmaceutical treatment</subject>
<subject type="local">primary care</subject>
<description type="Chief Investigator">Mr Harrison Hansford</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Low back pain (LBP) is the leading cause of disability globally and all commonly prescribed medications for acute LBP are not effective or cause serious side effects. Effective treatments for acute LBP are urgently needed. Muscle relaxants medicines such as Zopiclone, a safe sleep drug, appear to be safe and effective for acute LBP, although considerable uncertainty remains. My study, ZEUs, will be the definitive, double-blind placebo controlled randomised trial testing Zopiclone in acute LBP.</description>
<description type="fundingAmount">$85,964.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021953</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021953</identifier>
<identifier type="nhmrc">2021953</identifier>
<name type="primary"><namePart>Ethics of cancer trials phD</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">philosophy and religious studies | applied ethics | bioethics | philosophy and religious studies | applied ethics | medical ethics | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </subject>
<subject type="local">bioethics </subject>
<subject type="local">cancer</subject>
<subject type="local">cancer research</subject>
<subject type="local">clinical trial</subject>
<subject type="local">ethical issues</subject>
<description type="Chief Investigator">Dr Sarah Heynemann</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project seeks to understand how recent changes to the manner in which cancer research is designed and undertaken may influence the way research results are interpreted and used across the modern cancer treatment landscape. Interviews and surveys will be undertaken with research experts, cancer doctors and patients about their views on this topic and analysed with respect to new implications which emerge of an ethical nature as well as the way in which research contributes to new knowledge.</description>
<description type="fundingAmount">$117,310.58</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021964</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021964</identifier>
<identifier type="nhmrc">2021964</identifier>
<name type="primary"><namePart>Improving outcomes and experiences of Culturally and Linguistically Diverse patients affected by cancer participating in survivorship programs</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </subject>
<subject type="local">survivorship </subject>
<subject type="local">cancer follow-up</subject>
<subject type="local">migrant health</subject>
<subject type="local">patient outcomes</subject>
<subject type="local">qualitative research</subject>
<description type="Chief Investigator">Dr Lawrence Kasherman</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer survivors who have completed treatment are at risk of complications for several years. Although cancer survivorship clinics have been established around Australia, migrants of culturally and linguistically diverse (CALD) backgrounds, experience unique challenges in navigating local health systems in the survivorship setting. This research aims to highlight the substantial unmet needs specific to CALD populations that are yet to be addressed in the current Australian healthcare system.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021983</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021983</identifier>
<identifier type="nhmrc">2021983</identifier>
<name type="primary"><namePart>Clonal determinants of immune evasion to allogeneic stem cell transplant in acute myeloid leukaemia</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </subject>
<subject type="local">haematology </subject>
<subject type="local">cancer biology</subject>
<subject type="local">cancer genetics</subject>
<subject type="local">cancer immunology</subject>
<subject type="local">haematological malignancy</subject>
<description type="Chief Investigator">Dr Phillip Nguyen</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Patients with acute myeloid leukaemia (AML) who relapse after first line treatment have a very poor clinical outcome. A stem cell transplant offers the opportunity for cure, however up to half of patients receiving this cellular immunotherapy have disease resistance or recurrence. This project will use a cutting-edge barcoding technique to track the genetic and non-genetic changes in each leukaemia cell over time to determine the mechanisms of immune evasion by AML.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021986</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021986</identifier>
<identifier type="nhmrc">2021986</identifier>
<name type="primary"><namePart>Immune Related Adverse Events of the Gastrointestinal System and Investigation of Novel diagnostics and Therapeutics</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">colitis </subject>
<subject type="local">immunotherapy</subject>
<subject type="local">ultrasound</subject>
<subject type="local">faecal</subject>
<subject type="local">cancer immunotherapy</subject>
<description type="Chief Investigator">Dr Steven Nicolaides</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research project will explore the utility of intestinal ultrasound as a diagnostic tool of immune checkpoint inhibitor colitis. It will also explore the utility of faecal microbiota transplant in the management of immune checkpoint inhibitor colitis. It is expected that intestinal ultrasound will prove to provide an accurate and non invasive way of diagnosing this condition. It is also expected that faecal transplant will be effective in managing difficult to treat cases of this condition.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021994</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021994</identifier>
<identifier type="nhmrc">2021994</identifier>
<name type="primary"><namePart>Primary Aldosteronism: New Strategies for Diagnosis and Management</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">hypertension </subject>
<subject type="local">hyperaldosteronaemia</subject>
<subject type="local">cardiovascular disease</subject>
<subject type="local">adrenal endocrinology</subject>
<subject type="local">indigenous australians</subject>
<description type="Chief Investigator">Dr Elisabeth Ng</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Primary aldosteronism (PA) is a common and curable form of high blood pressure, requiring multiple tests for diagnosis. Lack of capacity for testing has led to delayed diagnosis and suboptimal outcomes, especially among Indigenous Australians whose rate of PA is unknown. Treatment options for PA are also limited at present. My research will establish modern tools, efficient pathways and novel therapies to improve health outcomes for all Australians with PA.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022019</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022019</identifier>
<identifier type="nhmrc">2022019</identifier>
<name type="primary"><namePart>Characterising the perinatal, neonatal and school-age childhood outcomes associated with diabetes in pregnancy</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health services and systems not elsewhere classified | </subject>
<subject type="local">gestational diabetes </subject>
<subject type="local">control of diabetes</subject>
<subject type="local">pregnancy complications</subject>
<subject type="local">early childhood</subject>
<subject type="local">diabetes mellitus</subject>
<description type="Chief Investigator">Dr Hannah Gordon</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Diabetes in pregnancy is common and can lead to complications for mother and baby. Using population-based data from Victoria, this dissertation seeks firstly to assess the long-term developmental and educational outcomes for children born to diabetic mothers. Management of diabetes confers improved perinatal outcomes, and so this thesis will secondarily assess the efficacy of lesser used medications, such as metformin, with the view to improving treatment of diabetes in pregnancy.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022072</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022072</identifier>
<identifier type="nhmrc">2022072</identifier>
<name type="primary"><namePart>Advanced magnetic resonance imaging (MRI) biomarkers for prediction of clinical outcomes after a first seizure</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">seizures </subject>
<subject type="local">epilepsy</subject>
<subject type="local">cognitive outcome</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">prediction</subject>
<description type="Chief Investigator">Dr Suyi Ooi</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">After someone has their first seizure, we are unable to accurately predict who will go on to have further seizures (e.g., epilepsy) despite routine investigations. Cognitive and social problems often predate the first seizure. This project will develop a prediction tool using MRI brain scan markers, that can be used in the clinic after someone experiences their first seizure. This may provide patients with a more accurate diagnosis, individualise treatment and prevent cognitive deterioration.</description>
<description type="fundingAmount">$102,238.25</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022097</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022097</identifier>
<identifier type="nhmrc">2022097</identifier>
<name type="primary"><namePart>CD8+ T cell tolerance within the tumour draining lymph node as a novel immunotherapy target in colorectal cancer</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">cancer immunology </subject>
<subject type="local">cancer immunotherapy</subject>
<subject type="local">immune tolerance</subject>
<subject type="local">colorectal cancer</subject>
<subject type="local">colorectal cancer treatment</subject>
<description type="Chief Investigator">Dr Avraham Travers</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Immunotherapy, a type of cancer treatment, achieves remarkable outcomes for some patients, though unfortunately not everyone benefits. An immune process called peripheral tolerance (PT) may be preventing the immune system from fighting cancer cells and reducing the benefit of immunotherapy. Our project aims to find out if PT is present in colorectal cancer and how it relates to patient outcomes. We will also define how to breach PT and explore new treatments in order to overcome this hurdle.</description>
<description type="fundingAmount">$94,702.08</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022099</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022099</identifier>
<identifier type="nhmrc">2022099</identifier>
<name type="primary"><namePart>The impact of gender affirming hormone therapy on scalp hair pattern and distribution</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | dermatology | </subject>
<subject type="local">gender </subject>
<subject type="local">testosterone</subject>
<subject type="local">estradiol</subject>
<subject type="local">hair cells</subject>
<subject type="local">hormone therapy</subject>
<description type="Chief Investigator">Dr Gia Tang</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Scalp hair loss in transgender individuals commencing testosterone for gender transition is poorly studied but has significant impacts on quality of life. Using novel artificial intelligence-assisted camera technology (HairMetrix), I will firstly document changes in scalp hair with gender affirming hormone therapy in trans men and in trans women. Following this, I will undertake the first randomised clinical trial to prevent hair loss in trans men starting testosterone therapy.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022102</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022102</identifier>
<identifier type="nhmrc">2022102</identifier>
<name type="primary"><namePart>Defining new therapeutic targets for ANCA-associated vasculitis</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | biomedical and clinical sciences | immunology | autoimmunity  | </subject>
<subject type="local">vasculitis </subject>
<subject type="local">neutrophils</subject>
<subject type="local">autoimmunity</subject>
<subject type="local">glomerulonephritis</subject>
<subject type="local">experimental glomerulonephritis</subject>
<description type="Chief Investigator">Dr Minh Huan Dang</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is an autoimmune disease that causes inflammation of small blood vessels. It often leads to severe kidney and lung inflammation and kidney impairment. While experimental disease models have identified new therapeutic options, they have multiple limitations that are hindering therapeutic progress. This work will optimise new disease models, define key mechanisms and identify new therapeutic targets in ANCA-associated vasculitis.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022109</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022109</identifier>
<identifier type="nhmrc">2022109</identifier>
<name type="primary"><namePart>Advancing precision therapies for epilepsy</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </subject>
<subject type="local">epilepsy </subject>
<subject type="local">clinical trial</subject>
<subject type="local">intractable epilepsy syndromes</subject>
<subject type="local">antiepileptic drugs</subject>
<subject type="local">neurogenetics</subject>
<description type="Chief Investigator">Dr Shuyu Wang</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Precision therapies targeting genetic abnormalities causing epilepsy may improve the outcomes of the medical treatment of epilepsy, which have remained unchanged for decades. My project will evaluate the existing information for precision therapies in epilepsy and study potential precision approaches in patients with two severe genetic epilepsies. The results of this project may provide a pathway to realising the promise of precision medicine, ultimately improving epilepsy treatment outcomes.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022116</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022116</identifier>
<identifier type="nhmrc">2022116</identifier>
<name type="primary"><namePart>The impact of post-school transitions on the mental health of young people with developmental disabilities</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | health equity | </subject>
<subject type="local">mental health </subject>
<subject type="local">disability</subject>
<subject type="local">school policies</subject>
<subject type="local">employment</subject>
<subject type="local">developmental disorders</subject>
<description type="Chief Investigator">Ms Stefanie Dimov</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Young people with developmental disabilities have poorer experiences of post-school transition and worse mental health compared to young people without disability. This PhD project will analyse survey data and conduct inclusive interviews with young people with development disabilities. The findings will provide evidence on the impact of post-school transitions on the mental health of young people with developmental disabilities.</description>
<description type="fundingAmount">$93,827.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022137</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022137</identifier>
<identifier type="nhmrc">2022137</identifier>
<name type="primary"><namePart>Novel approaches to transfusion to improve supportive care for patients with blood cancers</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </subject>
<subject type="local">haematological malignancy </subject>
<subject type="local">blood transfusion</subject>
<subject type="local">frailty</subject>
<subject type="local">cancer care</subject>
<subject type="local">supportive care</subject>
<description type="Chief Investigator">Dr Briony Shaw</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The burden of blood cancers is increasing with an ageing Australian population. With new treatments available, many older and more frail patients are accessing treatment for their disease. Transfusion is a mainstay of supportive care for people with blood cancers and one aspect of care that can be potentially be performed in the home. My research study involves the use of novel monitoring devices to monitor patients receiving transfusion, and to pilot a program to transfuse patients at home.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022142</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022142</identifier>
<identifier type="nhmrc">2022142</identifier>
<name type="primary"><namePart>Cardiovascular risk reduction in stroke survivors</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | health sciences | health services and systems | health systems | biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">cardiovascular disease prevention </subject>
<subject type="local">acute stroke</subject>
<subject type="local">health services</subject>
<subject type="local">stroke prevention</subject>
<subject type="local">clinical trial</subject>
<description type="Chief Investigator">Dr Rahul Muthalaly</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Many people who survive a stroke suffer heart disease in the next 10 years due to a high burden of vascular risk factors. Research in heart disease has identified effective ways to control these risk factors. Stroke survivors do not receive as much attention to these factors compared to heart attack survivors. The aim of our project is to implement a cardiologist-led clinic to reduce the risk of heart disease in stroke survivors. We will also classify risk in stroke survivors using new tools.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022150</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022150</identifier>
<identifier type="nhmrc">2022150</identifier>
<name type="primary"><namePart>Novel Insights into Ischemia and No Obstructive Coronary Artery Disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">coronary artery disease </subject>
<subject type="local">microvascular disease</subject>
<subject type="local">platelet function</subject>
<subject type="local">cardiac ischaemia</subject>
<subject type="local">vasospasm</subject>
<description type="Chief Investigator">Dr Rajan Rehan</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Patients with Ischemia and No Obstructive Coronary Artery Disease (INOCA) are under-diagnosed and under-treated in current clinical practice. These patients continue to experience recurrent angina, a poor quality of life and adverse cardiovascular outcomes. This project aims to improve our understanding of the burden of disease and the factors that drive its occurrence and progression. Our investigations will help inform future practice for INOCA patients, including a novel diagnostic pathway.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022155</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022155</identifier>
<identifier type="nhmrc">2022155</identifier>
<name type="primary"><namePart>Investigating methods to optimise and streamline transcatheter aortic valve implantation (TAVI)</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">aortic stenosis </subject>
<subject type="local">conduction block</subject>
<subject type="local">aged care</subject>
<subject type="local">cost-effectiveness</subject>
<subject type="local">pacemaker</subject>
<description type="Chief Investigator">Mr Karan Rao</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Transcatheter aortic valve implantation (TAVI) is a minimally invasive alternative to surgery for aortic valve narrowing. A common complication of TAVI is heart block (HB) requiring a pacemaker, which is hard to anticipate. This project investigates novel predictors of HB after TAVI, by monitoring patients for 2 years with an implantable heart monitor. Finally, we will evaluate the viability of safe &amp; early discharge in low risk patients, with aims to reduce length of stay, and streamline TAVI.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022156</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022156</identifier>
<identifier type="nhmrc">2022156</identifier>
<name type="primary"><namePart>Improving outcomes for children with complex communication needs</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | other health sciences | other health sciences not elsewhere classified | </subject>
<subject type="local">speech pathologist </subject>
<subject type="local">speech and language development</subject>
<subject type="local">motor speech disorders</subject>
<subject type="local">phenotype</subject>
<subject type="local">genetics</subject>
<description type="Chief Investigator">Lottie Morison</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Speech &amp; language disorders impact literacy, social &amp; work outcomes. The investigation of human genes can help us to understand why some children have speech &amp; language disorders. My projects are: 1) Describe the speech &amp; language profile of 2 genetic disorders (Batten Disease &amp; Kleefstra Syndrome) 2) Complete a high-tech speech therapy trial in the genetic disorder Angelman's Syndrome 3) Create a high-tech therapy decision-making resource for speech pathologists.</description>
<description type="fundingAmount">$99,112.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022163</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022163</identifier>
<identifier type="nhmrc">2022163</identifier>
<name type="primary"><namePart>Moving Towards Personalising Treatment for Patients with Pancreatic Cancer Using a Patient-Derived Tumour Explant Model</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">pancreatic cancer </subject>
<subject type="local">oncology</subject>
<subject type="local">chemotherapy</subject>
<subject type="local">stroma</subject>
<subject type="local">tumour biology</subject>
<description type="Chief Investigator">Dr Omali Pitiyarachchi</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Patients with pancreatic cancer (PC) have a poor prognosis. Our team has developed a world-first laboratory model of PC which we can use to test different chemotherapy drugs on a sample of a patient's tumour ("explant") with results available within 3 weeks. The overall aim of my PhD is to show our model can be used as a reliable indicator of how a patient will respond to different drug treatments, and search for reasons why some patients have tumours that don't respond ("chemoresistance").</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022167</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022167</identifier>
<identifier type="nhmrc">2022167</identifier>
<name type="primary"><namePart>Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation: The SAD-AF randomised controlled trial</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04z4kmw33</identifier><title>Melbourne Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </subject>
<subject type="local">atrial fibrillation </subject>
<subject type="local">depression</subject>
<subject type="local">serotonin</subject>
<subject type="local">cardiology</subject>
<subject type="local">quality of life</subject>
<description type="Chief Investigator">Dr Youlin Koh</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Hospitals and Health Services</description>
<description type="full">The SAD-AF study is trial of serotonin-based antidepressants in people with intermittent atrial fibrillation (AF) and at least moderate symptoms of depression, to improve AF-related quality of life. AF is an irregular rhythm arising from the upper chambers of the heart, and can cause symptoms of chest pain, breathlessness and feelings of depression or anxiety. We believe that commonly prescribed serotonin-based antidepressants may improve AF-related symptoms and reduce the time spent in AF.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022178</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022178</identifier>
<identifier type="nhmrc">2022178</identifier>
<name type="primary"><namePart>The role of the Gut Microbiome in Irritable Bowel Syndrome and its therapeutic potential</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03t52dk35</identifier><title>University of Western Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">irritable bowel syndrome (ibs) </subject>
<subject type="local">microbiology</subject>
<subject type="local">microbiological safety</subject>
<subject type="local">dietary factors</subject>
<subject type="local">clinical dietetic practice</subject>
<description type="Chief Investigator">Dr Yanna Ko</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. IBS patients have an altered gut microbiome, but the potential of targetting microbiome changes to treat IBS is unclear. This PhD will evaluate faecal microbiota transplantation as a novel method of restoring healthy gut bacteria in IBS treatment and the role of dietary modifications. It will also lead to the creation of Australia’s first microbiome bank for IBS patients.</description>
<description type="fundingAmount">$94,702.08</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022186</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022186</identifier>
<identifier type="nhmrc">2022186</identifier>
<name type="primary"><namePart>Investigating the effectiveness of systems-oriented implementation research and partnerships in malaria-endemic settings</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health systems | </subject>
<subject type="local">malaria </subject>
<subject type="local">health systems</subject>
<subject type="local">decision making</subject>
<subject type="local">collaboration</subject>
<subject type="local">population health</subject>
<description type="Chief Investigator">Miss Rachael Farquhar</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Malaria control interventions are falling short of impact and long-term sustainability as they lack systems integration and effective cross-program coordination. My research will provide evidence on; a) feasibility and acceptability of new vivax-specific tools, b) effectiveness of systems-oriented implementation research and c) impact of research partnerships in PNG. This research will be critical to embed the coordination and systems approach required to achieve malaria elimination.</description>
<description type="fundingAmount">$93,827.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022193</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022193</identifier>
<identifier type="nhmrc">2022193</identifier>
<name type="primary"><namePart>Saving sight: Novel stratification instruments for glaucoma</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </subject>
<subject type="local">glaucoma </subject>
<subject type="local">primary open angle glaucoma</subject>
<subject type="local">risk prediction</subject>
<subject type="local">risk factors</subject>
<subject type="local">clinical patient management</subject>
<description type="Chief Investigator">Dr Antonia Kolovos</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Glaucoma is the leading cause of irreversible blindness globally. Predictors of disease progression remain poorly understood, and monitoring is time and resource intensive. This project seeks to create an innovative predictive risk calculator which can be used to identify individuals at the highest risk of vision loss. The outcomes of this project will directly address existing gaps in knowledge and clinical practice, and propose new approaches to glaucoma monitoring and resource allocation.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022228</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022228</identifier>
<identifier type="nhmrc">2022228</identifier>
<name type="primary"><namePart>Digital health to assist recovery after critical illness</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care  | health sciences | allied health and rehabilitation science | physiotherapy | health sciences | health services and systems | digital health | </subject>
<subject type="local">patient outcomes </subject>
<subject type="local">survivorship</subject>
<subject type="local">recovery</subject>
<subject type="local">critical care</subject>
<subject type="local">telemedicine</subject>
<description type="Chief Investigator">Ms Nina Leggett</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">People who survive an Intensive Care Unit (ICU) admission often have physical and mental complications and poor health outcomes. Previous ICU recovery research is limited to in-person follow-up. Digital solutions may be a powerful mediator of ICU recovery by improving access to specialised recovery programs. This research aims to understand acceptability of digital programs, and develop and test these. This research will improve outcomes for ICU survivors, and will inform larger-scale research.</description>
<description type="fundingAmount">$99,112.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022235</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022235</identifier>
<identifier type="nhmrc">2022235</identifier>
<name type="primary"><namePart>Three-Dimensional (3D) Printing to Refine Cardiac Assessment and Procedures</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">arrhythmia </subject>
<subject type="local">cardiac disease</subject>
<subject type="local">cardiac electrophysiology</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">computed tomography</subject>
<description type="Chief Investigator">Juliana Kanawati</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">3D printing in cardiovascular medicine is still in its infancy. There is great scope for clinical applications of this technology and its use in developing the field of personalised medicine. First, this technique needs to be refined and established. Studies to demonstrate effectiveness are required before this technology can become implemented into guidelines and widely adopted. The proposed research is expected to establish the optimal 3D printing strategy in cardiovascular medicine.</description>
<description type="fundingAmount">$113,542.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022237</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022237</identifier>
<identifier type="nhmrc">2022237</identifier>
<name type="primary"><namePart>Defining the landscape of ANCA-associated vasculitides in Australia and providing a foundation for improved care</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </subject>
<subject type="local">vasculitis </subject>
<subject type="local">clinical epidemiology</subject>
<subject type="local">databases</subject>
<subject type="local">quality of care</subject>
<subject type="local">glomerular disease</subject>
<description type="Chief Investigator">Dr Justin Chua</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">ANCA-associated vasculitis is caused by the body attacking itself in small blood vessels affecting multiple organs, leading to deaths and ill health. A registry is being established to capture more information about this condition in Australia, to gain insight into the extent of the disease locally and identify improvements to treatment. The plan is to link the data with an existing European registry to attain more meaningful results, to investigate how to better treat this condition worldwide.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022238</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022238</identifier>
<identifier type="nhmrc">2022238</identifier>
<name type="primary"><namePart>Nanoparticle and gene therapy approaches to HIV cure</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | nanomedicine | </subject>
<subject type="local">human immunodeficiency virus (hiv) </subject>
<subject type="local">gene therapy</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">medical virology</subject>
<subject type="local">anti-latency drugs</subject>
<description type="Chief Investigator">Dr Michael Moso</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Current treatment for HIV is able to suppress but not eradicate HIV infection. This is because HIV is able to infect long-lived immune cells and maintain a reservoir of latent infection. One promising approach to target this reservoir is a form of gene therapy using CRISPR/Cas9. CRIPSR is able to target sequences of DNA, including HIV. This project aims to develop a therapeutic approach using CRISPR/Cas9 and explore novel mechanisms for gene therapy delivery using nanoparticle technology.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022240</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022240</identifier>
<identifier type="nhmrc">2022240</identifier>
<name type="primary"><namePart>Community, Country, and Cognition: A multi-jurisdictional assessment of dementia affecting Aboriginal and Torres Strait Islander Peoples</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | epidemiology | major global burdens of disease | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">dementia </subject>
<subject type="local">indigenous australians</subject>
<subject type="local">clinical epidemiology</subject>
<subject type="local">cardiovascular disease</subject>
<subject type="local">health service utilisation</subject>
<description type="Chief Investigator">Dr Antonia Clarke</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This study will be the first to evaluate nationwide dementia rates between Aboriginal and Torres Strait Islander and non-Aboriginal people. Guided by community-identified priorities, the study will evaluate risk factors for Aboriginal and non-Aboriginal Australians living with or developing dementia in NSW and Central Australia. This study will inform clinical practice and policy development to benefit dementia care for Aboriginal Australians across urban, regional, and remote settings.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022244</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022244</identifier>
<identifier type="nhmrc">2022244</identifier>
<name type="primary"><namePart>Platelet biomarkers of thrombotic risk in type 2 diabetes</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | </subject>
<subject type="local">diabetes mellitus </subject>
<subject type="local">platelet activation</subject>
<subject type="local">platelet function</subject>
<subject type="local">cardiovascular complications</subject>
<subject type="local">cardiovascular disease prevention</subject>
<description type="Chief Investigator">Dr Yvonne Kong</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Patients with diabetes face an increased risk of diseases linked to abnormal blood clotting, such as heart attacks and strokes. Our initial studies show platelets from patients with diabetes, which are hyperactive, produce more inflammatory proteins such as CXCL3. This opens new opportunities for drugs to block platelet inflammation to prevent heart attacks, with potentially fewer bleeding side-effects compared to traditional treatments.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022247</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022247</identifier>
<identifier type="nhmrc">2022247</identifier>
<name type="primary"><namePart>Coronary artery mimicking blood clot test: A point-of-care prothrombotic prediction device for patient-specific diagnosis</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | biomechanical engineering | </subject>
<subject type="local">coronary artery disease </subject>
<subject type="local">thrombosis</subject>
<subject type="local">haemodynamics</subject>
<subject type="local">platelets</subject>
<subject type="local">arterial flow dynamics</subject>
<description type="Chief Investigator">Mr Yunduo Zhao</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This biomedical engineering program aims to develop a patient-specific biochip to diagnose and predict blood clot tendency at an earlier stage. The point-of-care prothrombotic prediction device will be suitable for patients with high blood clot risks such as diabetes and, more recently, the COVID-19. It also serves as a testing platform for new anti-platelet and anti-coagulant drugs, and as a way for surgeons to screen patients for anti-thrombotic before operating to avoid uncontrolled bleeding.</description>
<description type="fundingAmount">$80,864.92</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022273</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022273</identifier>
<identifier type="nhmrc">2022273</identifier>
<name type="primary"><namePart>Understanding the phenotypic expression of early disease and genetics of cardiac amyloidosis</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">amyloid </subject>
<subject type="local">transthyretin</subject>
<subject type="local">clinical genetics</subject>
<subject type="local">heart failure</subject>
<subject type="local">ischaemic stroke</subject>
<description type="Chief Investigator">Dr Natasha Gorrie</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cardiac amyloid is a multi-system disorder with poor survival that presents as heart failure, rhythm issues or strokes. New treatments improving survival are available but costly. The prevalence of genetic mutations, the best test and how to diagnose early disease is unclear. Cardiac amyloid patients and families will have genetic testing and cardiac imaging to identify the prevalence of mutations, the best and earliest diagnostic tests and better explain heart changes associated with strokes.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022274</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022274</identifier>
<identifier type="nhmrc">2022274</identifier>
<name type="primary"><namePart>Predicting progression of intestinal metaplasia to gastric cancer</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">dysplasia </subject>
<subject type="local">gastric cancer</subject>
<subject type="local">surveillance</subject>
<subject type="local">cancer screening</subject>
<subject type="local">endoscopy</subject>
<description type="Chief Investigator">Dr Douglas Tjandra</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Stomach cancer is a rare type of cancer in Australia which is often diagnosed late and has a poor survival. Intestinal metaplasia is a change in the stomach which precedes cancer in some people. However, the best way to monitor patients with this condition is not known. This project will try to understand why some people develop stomach cancer, and how we should monitor patients with intestinal metaplasia. This will include developing a world-first model in the lab using cells from patients.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022279</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022279</identifier>
<identifier type="nhmrc">2022279</identifier>
<name type="primary"><namePart>Generating the trial evidence end-users prefer: adding value to the analysis of a randomised controlled trial of patient-led surveillance for subsequent melanoma (MEL-SELF)</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiological methods | mathematical sciences | statistics | biostatistics | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </subject>
<subject type="local">randomised controlled trial (rct) </subject>
<subject type="local">epidemiological research methods</subject>
<subject type="local">melanoma</subject>
<subject type="local">biostatistics</subject>
<subject type="local">public health</subject>
<description type="Chief Investigator">Ms Ellie Medcalf</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Common ways of determining the success of new treatments for health problems do not always offer the most useful knowledge to patients and doctors. This research explores new ways of analysing research results. In doing so, it aims to enhance the benefits of new treatments to patients, doctors, and policy makers.</description>
<description type="fundingAmount">$67,902.83</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022284</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022284</identifier>
<identifier type="nhmrc">2022284</identifier>
<name type="primary"><namePart>Understanding the interplay between eating disorders and weight management therapy</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | psychology | clinical and health psychology | counselling psychology | </subject>
<subject type="local">overweight/obesity </subject>
<subject type="local">eating disorders</subject>
<subject type="local">diets for weight loss</subject>
<subject type="local">behavioural intervention</subject>
<subject type="local">psychology</subject>
<description type="Chief Investigator">Rabia Khalid</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We need better evidence to make sure that weight management therapy for obesity does not lead to eating disorders development. We aim to (1) identify which persons are at risk of eating disorders (2) break down the building blocks of weight management therapies and compare if these ‘blocks’ increase eating disorder risk (3) describe what healthcare professionals and patients think about these issues (4) describe the pathway to eating disorder development during weight management therapy.</description>
<description type="fundingAmount">$85,964.17</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022301</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022301</identifier>
<identifier type="nhmrc">2022301</identifier>
<name type="primary"><namePart>Towards ending tuberculosis and leprosy in the Pacific – implementing the PEARL study in South Tarawa, Kiribati</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | major global burdens of disease | health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | </subject>
<subject type="local">tuberculosis </subject>
<subject type="local">population screening</subject>
<subject type="local">disease prevention</subject>
<subject type="local">epidemiology</subject>
<subject type="local">implementation</subject>
<description type="Chief Investigator">Dr Jeremy Hill</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">South Tarawa, the capital of Kiribati, has the highest rates of tuberculosis (TB) and leprosy in the Pacific. My project will partner with the Kiribati government to offer community-based screening, treatment and prevention for TB and leprosy to the entire population. We will measure the impact of this intervention on incidence and transmission rates of TB and leprosy in South Tarawa, demonstrating a pathway for future disease elimination in the whole of Kiribati and other remote settings.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022307</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022307</identifier>
<identifier type="nhmrc">2022307</identifier>
<name type="primary"><namePart>Precision diagnosis for children with hearing loss: optimising utilisation of imaging and genetic testing</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | public health | community child health  | </subject>
<subject type="local">child development </subject>
<subject type="local">congenital hearing loss</subject>
<subject type="local">genetic testing</subject>
<subject type="local">neuroimaging</subject>
<subject type="local">genetic counselling</subject>
<description type="Chief Investigator">Dr Karen Liddle</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hearing loss (HL) is relatively common in Australian newborns. Early and accurate detection and diagnosis of hearing loss optimizes care and developmental outcomes. Over 50% of HL is genetic with &gt;120 genes known. Imaging findings and genetic testing can enhance our understanding of the cause, providing families with precise diagnoses and family planning information. Up to 12% of genetic HL is due to an inner ear abnormality associated with specific genes, but genetic testing is rarely offered.</description>
<description type="fundingAmount">$113,542.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022340</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022340</identifier>
<identifier type="nhmrc">2022340</identifier>
<name type="primary"><namePart>Novel retinal imaging biomarkers for the assessment and prevention of diabetes complications</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sqdef20</identifier><title>Centre for Eye Research Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | vision science | </subject>
<subject type="local">diabetes </subject>
<subject type="local">diabetic retinopathy</subject>
<subject type="local">optical imaging</subject>
<subject type="local">retina</subject>
<subject type="local">diabetic complications</subject>
<description type="Chief Investigator">Dr Abera Saeed</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">PREDICT is a major study of type 2 diabetes complications. Whilst diabetes management has improved tremendously, our ability to identify those at risk of the sight- and life-threatening complications of the disease has not. Our goal is to develop better ways of estimating the risk of complications. We will use the rich data collected in PREDICT to determine if simple eye scans can be used for improved prediction. We will test new eye scanning technology and artificial intelligence methods.</description>
<description type="fundingAmount">$124,846.75</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022345</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022345</identifier>
<identifier type="nhmrc">2022345</identifier>
<name type="primary"><namePart>The effects of osteoanabolic pharmacotherapy and osteogenic exercise on bone and muscle outcomes in postmenopausal osteoporosis: exploring the bone/muscle interface</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | endocrinology | </subject>
<subject type="local">osteoporosis </subject>
<subject type="local">musculoskeletal disorders</subject>
<subject type="local">exercise</subject>
<subject type="local">bone mineral density</subject>
<subject type="local">muscle function</subject>
<description type="Chief Investigator">Dr Shejil Kumar</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bone fractures, particularly in women after menopause, result in significant health-related disability. We need to get more benefit from current therapies for osteoporosis (bone fragility). We will investigate the effects of combining exercise with bone-building medication on improving bone mass and whether bone-building medication can improve muscle and physical function, which may lend to reduction in falls. We are conducting a multi-centre study to help address these important questions.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022346</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022346</identifier>
<identifier type="nhmrc">2022346</identifier>
<name type="primary"><namePart>PhD Community Sentiment Tool</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | behavioural epidemiology | </subject>
<subject type="local">behavioural epidemiology </subject>
<subject type="local">public health</subject>
<subject type="local">cultural perceptions</subject>
<subject type="local">epidemiological research methods</subject>
<subject type="local">community</subject>
<description type="Chief Investigator">Danielle Hutchinson</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Widespread beliefs and opinions held by a community about a topic is known as "community sentiment". It is critical to understand community sentiment about public health measures as it will affect compliance. Artificial intelligence can be used to analyse sentences, phrases and words in open-source media and social media to measure community sentiment. This can be done in many languages and locations in real time to inform health policy. It can be adapted to any language, area or health issue.</description>
<description type="fundingAmount">$108,973.75</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022364</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022364</identifier>
<identifier type="nhmrc">2022364</identifier>
<name type="primary"><namePart>Comparing the Efficacy and Acceptability of Genomic Testing and Skin Biopsy in Diagnosing Monogenic Skin Disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | biomedical and clinical sciences | clinical sciences | dermatology | </subject>
<subject type="local">medical genomics </subject>
<subject type="local">dermatology</subject>
<subject type="local">cost-effectiveness</subject>
<subject type="local">attitudes</subject>
<subject type="local">patient preference</subject>
<description type="Chief Investigator">Dr Russell Gear</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">A skin biopsy is currently the first-line diagnostic-investigation for individuals with suspected genetic skin diseases. It would be valuable to determine whether this invasive procedure could be replaced with a saliva sample and genomic testing. This proposal aims to measure the cost-effectiveness, diagnostic yield and clinical impact of these test modalities, in addition to examining the attitudes of relevant stakeholders – including patients, families and clinicians.</description>
<description type="fundingAmount">$124,846.75</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022368</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022368</identifier>
<identifier type="nhmrc">2022368</identifier>
<name type="primary"><namePart>Assessing the cardiac arrhythmia profile of cancer therapeutics</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">action potential </subject>
<subject type="local">adverse drug reactions</subject>
<subject type="local">cardiac electrophysiology</subject>
<subject type="local">cardiovascular complications</subject>
<subject type="local">sudden cardiac death</subject>
<description type="Chief Investigator">Dr Justin Phan</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Heart rhythm disorders or arrhythmias can result from cancer treatment. A lab-based study will assess the mechanisms of cancer-treatment induced long QT syndrome, which can result in fatal arrhythmias. A clinical study will recruit patients treated with medications that use the immune system to fight cancer. A side effect of these medications includes heart inflammation and arrhythmias. This study will develop methods to diagnose heart inflammation and markers that indicate arrhythmia risk.</description>
<description type="fundingAmount">$113,542.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022377</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022377</identifier>
<identifier type="nhmrc">2022377</identifier>
<name type="primary"><namePart>Critical evaluation of the diagnostic utility of whole genome and transcriptome sequencing and the training of physicians in the deployment of frontier diagnostic technologies in healthcare</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </subject>
<subject type="local">genetic testing </subject>
<subject type="local">diagnostic methods</subject>
<subject type="local">genomics</subject>
<subject type="local">rna</subject>
<subject type="local">clinical competence / skills</subject>
<description type="Chief Investigator">Dr Smitha Kumble</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Rare diseases are largely uncommon but collectively, they result in significant morbidity. Most rare disease is genetic in origin and the majority of children with rare disease remain undiagnosed following genetic testing. This project focuses on increasing diagnoses in children with rare disease through novel testing strategies such as combined genome and RNA sequencing, as well as improving their overall care by upskilling and improving genomic literacy in medical specialists.</description>
<description type="fundingAmount">$94,702.08</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022380</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022380</identifier>
<identifier type="nhmrc">2022380</identifier>
<name type="primary"><namePart>Prescription Drug Monitoring Program in New South Wales: A mixed methods study of implementation processes, stakeholder experiences, and program impact</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health informatics and information systems | health sciences | health services and systems | primary health care | health sciences | health services and systems | implementation science and evaluation | </subject>
<subject type="local">health services research </subject>
<subject type="local">clinical decision making</subject>
<subject type="local">patient safety</subject>
<subject type="local">drugs of dependence</subject>
<subject type="local">medications</subject>
<description type="Chief Investigator">Dr Emma Tay</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Harm from high-risk prescription medicines including opioids is a public health concern. Prescription Drug Monitoring Programs (PDMP) are electronic systems that monitor these high-risk medicines and warn health care professionals when a patient is at risk. This research project will investigate how the NSW PDMP (SafeScript NSW) was implemented and will explore health care providers' and consumers' experiences and perceptions of the new PDMP tool in NSW.</description>
<description type="fundingAmount">$94,702.08</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022387</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022387</identifier>
<identifier type="nhmrc">2022387</identifier>
<name type="primary"><namePart>Functional connectivity-guided transcranial magnetic stimulation (TMS) treatment for young people with major depression</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </subject>
<subject type="local">transcranial magnetic stimulation (tms) </subject>
<subject type="local">functional imaging</subject>
<subject type="local">major depressive disorder</subject>
<subject type="local">adolescence</subject>
<subject type="local">psychiatric illness</subject>
<description type="Chief Investigator">Miss Nga Yan Tse</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Transcranial magnetic stimulation (TMS) is a Medicare-subsidised treatment for depression that normalises brain changes. However, neuroimaging studies of adolescent depression has generated inconsistent results, hindering the development of better TMS treatment for this age group. This study aims to establish a robust understanding of the neurobiology underlying adolescent depression and integrate this knowledge to improve TMS treatment efficacy for young people suffering from major depression.</description>
<description type="fundingAmount">$85,964.17</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022391</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022391</identifier>
<identifier type="nhmrc">2022391</identifier>
<name type="primary"><namePart>Evidence Supporting Strategies for Coronary Artery Revascularisation</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | surgery | </subject>
<subject type="local">coronary artery disease </subject>
<subject type="local">clinical outcome</subject>
<subject type="local">coronary artery bypass surgery</subject>
<subject type="local">mortality</subject>
<subject type="local">clinical research</subject>
<description type="Chief Investigator">Dr Aashray Gupta</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">My PhD project examines the quality and safety of treatments for coronary artery disease (CAD) and seeks to demonstrates the outcomes from these in various patient groups including in women and indigenous populations. New techniques in Coronary Artery Bypass Surgery (CABG) have been refined, but the comparisons between these and stenting is limited. With the help of artificial intelligence and medical machine learning, this project will provide novel data to improve patient survival globally.</description>
<description type="fundingAmount">$106,006.33</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022415</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022415</identifier>
<identifier type="nhmrc">2022415</identifier>
<name type="primary"><namePart>Predicting and preventing sepsis in patients with haematological malignancy</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">sepsis </subject>
<subject type="local">haematological malignancy</subject>
<subject type="local">supportive care</subject>
<subject type="local">prognostic indicators</subject>
<subject type="local">infection control</subject>
<description type="Chief Investigator">Dr Aleece MacPhail</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Sepsis is overwhelming reaction to severe infection. Patients with haematological malignancy (blood cancers) have reduced immunity to infection and many develop sepsis. The treatments available for blood cancers have improved in recent years, but the risk of dying from sepsis is still high. My research program will help understand which patients are at the highest risk of sepsis, and whether we can prevent sepsis with immunoglobulin (antibody) treatment or improved hospital hygiene strategies.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022417</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022417</identifier>
<identifier type="nhmrc">2022417</identifier>
<name type="primary"><namePart>Heart Failure Prevention in Cancer Survivors by Recognition and Treatment of Subclinical Disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">cardiovascular disease prevention </subject>
<subject type="local">heart failure</subject>
<subject type="local">cancer follow-up</subject>
<subject type="local">cardioprotection</subject>
<subject type="local">echocardiography</subject>
<description type="Chief Investigator">Dr Joshua Wong</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cancer survivors have an increased risk of heart failure (HF) due to chemotherapy toxicity &amp; shared risks between cancer &amp; heart disease. Subclinical heart failure (SBHF) are changes in echocardiography occurring prior to symptoms, allowing initiation of cardioprotective therapies (medications, exercise) - reducing the risk of overt HF. We aim to detect SBHF in cancer survivors &amp; evaluate impact of early cardioprotection. We expect this will improve functional capacity &amp; delay/prevent overt HF.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022424</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022424</identifier>
<identifier type="nhmrc">2022424</identifier>
<name type="primary"><namePart>Detection of autoantibodies using novel bioluminescent systems</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </subject>
<subject type="local">anti-receptor autoimmunity </subject>
<subject type="local">neuroimmunology</subject>
<subject type="local">autoimmune disease</subject>
<subject type="local">autoantibodies</subject>
<subject type="local">diagnostic assay</subject>
<description type="Chief Investigator">Dr Alex Stoyanov</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research aims to develop new and improved laboratory tests to identify and measure antibodies and other markers in the bloodstream that are associated with autoimmune diseases, including a number of different neurological conditions. More accurate detection of these markers is important to allow early diagnosis and treatment of autoimmune diseases, and prevent their complications including long term disability.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022453</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022453</identifier>
<identifier type="nhmrc">2022453</identifier>
<name type="primary"><namePart>Optimising Biologics in Inflammatory Bowel Disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">inflammatory bowel disease (ibd) </subject>
<subject type="local">crohn's disease</subject>
<subject type="local">ulcerative colitis</subject>
<subject type="local">therapeutic drug monitoring</subject>
<subject type="local">microbiology</subject>
<description type="Chief Investigator">Mr John Chetwood</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is no cure for inflammatory bowel disease (IBD), &amp; the underpinning mechanisms involved in disease development are poorly understood. Patients often progress on first line treatment and need ‘biologic’ therapy to control their disease, thereby keeping them healthy and improving their quality of life. My research aims to evaluate the clinical and cellular issues of IBD, and personalise treatments based on the individual which will help decide treatment strategies to keep patients healthy.</description>
<description type="fundingAmount">$124,846.75</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022454</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022454</identifier>
<identifier type="nhmrc">2022454</identifier>
<name type="primary"><namePart>Novel policy approaches to reduce the supply and availability of tobacco products</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">human society | policy and administration | health policy | health sciences | public health | public health not elsewhere classified | </subject>
<subject type="local">public health policy </subject>
<subject type="local">tobacco control</subject>
<subject type="local">tobacco</subject>
<subject type="local">smoking cessation</subject>
<subject type="local">policy analysis</subject>
<description type="Chief Investigator">Ms Georgia Carstensen</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This research aims to reduce tobacco smoking in Australia. Tobacco is widely available to purchase, making it difficult for smokers to quit and easy for young people to start. I will find new options for reducing availability of tobacco by looking at models used in other countries for harmful products. I will develop new policy options for reducing tobacco supply and gain feedback from the public and other stakeholders, which I will use to make policy recommendations.</description>
<description type="fundingAmount">$70,495.25</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022463</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022463</identifier>
<identifier type="nhmrc">2022463</identifier>
<name type="primary"><namePart>Targeted and stem cell therapeutics for Cystic Fibrosis sinus disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | otorhinolaryngology | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </subject>
<subject type="local">cystic fibrosis </subject>
<subject type="local">cystic fibrosis transmembrane regulator (cftr)</subject>
<subject type="local">rhinosinusitis</subject>
<subject type="local">stem cell transplantation</subject>
<subject type="local">endoscopic surgery</subject>
<description type="Chief Investigator">Catherine Banks</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite advances in treatment for Cystic Fibrosis, (CF) there is currently no cure. The sinonasal airway provides valuable insights into the lower airway. The impact of modulators on the sinonasal airway before and after treatment in the paediatric CF population will be studied. A rabbit sinus model will be developed to further define the essential preclinical steps to deliver rabbits own corrected airway stem-cells to renew the damaged cells within the sinus and lung.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022470</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022470</identifier>
<identifier type="nhmrc">2022470</identifier>
<name type="primary"><namePart>Investigating Novel Prevention and Treatment Strategies for for Gonococcal Control</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | venereology | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </subject>
<subject type="local">neisseria gonorrhoeae </subject>
<subject type="local">vaccination immunology</subject>
<subject type="local">treatment strategies</subject>
<subject type="local">disease prevention</subject>
<subject type="local">antibiotic resistance</subject>
<description type="Chief Investigator">Dr Chun Mei Thng</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Gonorrhoea infection can lead to long term health problems including infertility. Cases of gonorrhoea continue to increase and antibiotic-resistant strains have been reported, prompting WHO to declare an urgent need for new strategies to prevent the spread of untreatable gonorrhoea. My study focuses on this priority by generating new knowledge towards alternative strategies for gonococcal disease control including vaccine development and non-antibiotic strategies to treat gonorrhoea.</description>
<description type="fundingAmount">$117,310.58</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022471</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022471</identifier>
<identifier type="nhmrc">2022471</identifier>
<name type="primary"><namePart>Human amnion epithelial cell derived novel therapeutics in inflammatory bowel disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | </subject>
<subject type="local">inflammatory bowel disease (ibd) </subject>
<subject type="local">crohn's disease</subject>
<subject type="local">ulcerative colitis</subject>
<subject type="local">stem cell therapy</subject>
<subject type="local">regenerative medicine</subject>
<description type="Chief Investigator">Dr Adam Peterson</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will examine the potential therapeutic properties of extracellular vesicles, particles that carry messages between cells, that can be harvested from human amnion epithelial cells, a type of stem cell found in the amniotic membrane. We will then apply this as a treatment for perianal fistulising Crohn’s disease, a difficult to manage type of inflammatory bowel disease (IBD) with a higher risk of poor outcomes. Our goal is to establish a novel new therapy for patients suffering with IBD.</description>
<description type="fundingAmount">$106,006.33</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022495</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022495</identifier>
<identifier type="nhmrc">2022495</identifier>
<name type="primary"><namePart>Towards treatment of intellectual disability caused by errors in the chromatin machinery</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | </subject>
<subject type="local">behaviour genetics </subject>
<subject type="local">metabolomics</subject>
<subject type="local">acetylation</subject>
<subject type="local">biomarkers</subject>
<subject type="local">histone deacetylase</subject>
<description type="Chief Investigator">Sarah Donoghue</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Disorders that influence the expression of genes may be influenced by the metabolic environment in the cell. This research aims to characterise the metabolic environment and to see if there may be potential treatments for these metabolic disorders by supplementing deficient nutrients/substrates. In addition, we would be interested in characterising the biomarkers of these conditions to see if there are other chemicals that might be helpful to track treatment for these conditions.</description>
<description type="fundingAmount">$102,238.25</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022510</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022510</identifier>
<identifier type="nhmrc">2022510</identifier>
<name type="primary"><namePart>Vaccine Champions and Vaccine Communication program</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | health sciences | public health | health promotion | health sciences | health services and systems | implementation science and evaluation | </subject>
<subject type="local">vaccination </subject>
<subject type="local">community intervention</subject>
<subject type="local">social and behavioural research</subject>
<subject type="local">health promotion</subject>
<subject type="local">measurement</subject>
<description type="Chief Investigator">Yasmin Mohamed</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The Vaccine Champions and Vaccine Communication (VCVC) program aims to increase the number of people getting the COVID-19 vaccine and to build confidence in vaccines by empowering healthcare providers, community, faith, and industry leaders to become vaccine “champions” within their communities, in three Western Pacific countries. Champions will run vaccine information sessions in the community, addressing concerns and misconceptions. This research will assess the impact of the VCVC program.</description>
<description type="fundingAmount">$105,686.67</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022517</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022517</identifier>
<identifier type="nhmrc">2022517</identifier>
<name type="primary"><namePart>Novel bacteria as a therapy for inflammatory bowel disease</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">inflammatory bowel disease (ibd) </subject>
<subject type="local">mucosal immunology</subject>
<subject type="local">pathogenic bacteria</subject>
<subject type="local">translational research</subject>
<subject type="local">probiotics</subject>
<description type="Chief Investigator">Dr Patricia Khoo</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inflammatory bowel disease (IBD) is an incurable disease, affecting 1 in 200 Australians and is thought to be related to an imbalance between protective and harmful bacteria in our gut. Despite years of research, a large proportion of these bacteria remain unknown or poorly understood. Our team has succeeded in identifying a vast number of new species. I will use novel techniques to further understand the relationship between these bacteria and IBD, and lead the development of a new treatment.</description>
<description type="fundingAmount">$98,470.17</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022530</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022530</identifier>
<identifier type="nhmrc">2022530</identifier>
<name type="primary"><namePart>Application of novel personalised medicine tools to understand treatment mechanisms in Primary Ciliary Dyskinesia</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </subject>
<subject type="local">adult respiratory diseases </subject>
<subject type="local">mucociliary clearance</subject>
<subject type="local">functional magnetic resonance imaging (fmri)</subject>
<subject type="local">cell culture</subject>
<subject type="local">translational research</subject>
<description type="Chief Investigator">Dr Megan Frohlich</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Primary Ciliary Dyskinesia (PCD) is a rare genetic condition mostly affecting the respiratory tract, causing recurrent respiratory infections eventually leading to scarred and dilated airways. Research on the best treatment for patients with PCD is scarce. This study will use medical imaging and mini airway organs created in a lab from cells collected from the nose of PCD patients to measure the impact of treatments in patients with PCD.</description>
<description type="fundingAmount">$124,846.75</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022548</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022548</identifier>
<identifier type="nhmrc">2022548</identifier>
<name type="primary"><namePart>Better Vision for Patients with Ocular Toxoplasmosis</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </subject>
<subject type="local">eye </subject>
<subject type="local">retinal disease</subject>
<subject type="local">toxoplasmosis</subject>
<subject type="local">biological therapy</subject>
<subject type="local">clinical decision making</subject>
<description type="Chief Investigator">Dr Melissa Shields</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Toxoplasma gondii is a parasite that causes the eye disease called ocular toxoplasmosis. There are no medications that can rid the body of the parasite, and there is no vaccine that prevents an infection. The goal of my research is to improve vision outcomes in patients with ocular toxoplasmosis. I will investigate a new treatment that targets inflammatory molecules to protect the eye tissues, and I will develop clinical algorithms to identify patients who would benefit most from treatment.</description>
<description type="fundingAmount">$136,151.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022557</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022557</identifier>
<identifier type="nhmrc">2022557</identifier>
<name type="primary"><namePart>Designing Bayesian clinical trials to enhance clinician- and consumer-directed decision-making</namePart></name>
<name type="alternative"><namePart>Postgraduate Scholarships</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">mathematical sciences | statistics | biostatistics | health sciences | other health sciences | other health sciences not elsewhere classified | </subject>
<subject type="local">clinical trial </subject>
<subject type="local">biostatistics</subject>
<subject type="local">randomised controlled trial (rct)</subject>
<subject type="local">translational research</subject>
<subject type="local">informed decision making</subject>
<description type="Chief Investigator">Mr Michael Dymock</description>
<description type="Date Announced">2022-11-17T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Clinical trials are designed to answer scientific research questions. It is therefore hard for clinicians and consumers to use the trial results for their own decision-making. This is because the research question does not consider their individual preferences and so may not be helpful to them. To change this, we need a better way to evaluate and report trial results to make decision-making easier. This project will use advanced statistics to design better clinical trials.</description>
<description type="fundingAmount">$93,827.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018592</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018592</identifier>
<identifier type="nhmrc">2018592</identifier>
<name type="primary"><namePart>Reducing the impact of radiation on the heart for cancer and cardiac disease patients</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </subject>
<subject type="local">radiation </subject>
<subject type="local">cardiology</subject>
<subject type="local">ventricular tachycardia</subject>
<subject type="local">lung cancer</subject>
<subject type="local">radiotherapy</subject>
<description type="Chief Investigator">Prof Ricky O'Brien</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This program will develop the integrated technology and perform datamining, animal and human studies to provide a comprehensive understanding on the response of substructures in the heart to radiation. This work will benefits patients receiving radiation therapy for cancer treatments where we aim to minimise cardiac complications post treatment. Our work will also benefit patients with advanced ventricular tachycardia where radiation is being used to reduce the number of painful ICD shocks.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018642</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018642</identifier>
<identifier type="nhmrc">2018642</identifier>
<name type="primary"><namePart>Improving outcomes for high-risk child and adolescent cancer: from discovery to individualised treatment within a consumer partnership</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | psychology | clinical and health psychology | counselling psychology | </subject>
<subject type="local">cancer therapy </subject>
<subject type="local">experimental therapeutics</subject>
<subject type="local">consumer participation</subject>
<subject type="local">cancer biology</subject>
<subject type="local">mental health</subject>
<description type="Chief Investigator">Prof Glenn Marshall</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is the commonest disease causing death in children. New anticancer drugs are developed against one adult cancer gene target. Anticancer drugs work best in combination to overcome resistance. Our network of scientists and doctors have developed a diagnostic platform to better match the drug to the gene target for high risk child cancer. We will develop effective child cancer-specific combination therapy, accurate diagnostics for resistance and integrate consumers in the research pathway.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018654</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018654</identifier>
<identifier type="nhmrc">2018654</identifier>
<name type="primary"><namePart>Accelerating to zero: targeting roadblocks to achieve malaria elimination</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">malaria </subject>
<subject type="local">plasmodium</subject>
<subject type="local">malaria vaccine</subject>
<subject type="local">drug resistance</subject>
<subject type="local">surveillance</subject>
<description type="Chief Investigator">Prof James Beeson</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">This Synergy Grant addresses major knowledge and translation gaps that are key roadblocks to achieving malaria elimination. The new knowledge, tools, and strategies developed in this program through innovative and targeted research is responsive to global priorities and will directly inform policy and health practices, as well as driving future innovation.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018668</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018668</identifier>
<identifier type="nhmrc">2018668</identifier>
<name type="primary"><namePart>Synergise, Integrate and Enhance Sleep Research to Transform Brain Ageing (SIESTA)</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </subject>
<subject type="local">sleep disturbance </subject>
<subject type="local">alzheimer disease</subject>
<subject type="local">sleep disorders</subject>
<subject type="local">biomarkers</subject>
<subject type="local">treatment strategies</subject>
<description type="Chief Investigator">Prof Sharon Naismith</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Modifiable risk factors account for up to 40% of dementia risk, and sleep disturbance (SD) has emerged as a viable new target. This project will assess SD, cognitive decline and dementia pathology using methods including novel blood-based biomarkers. This project will also develop scalable digital health solutions addressing SD, and assess the impact of interventions on SD and dementia biomarkers, in order to translate findings into clinical practice and substantially reduce dementia risk.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018970</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018970</identifier>
<identifier type="nhmrc">2018970</identifier>
<name type="primary"><namePart>Improving Aboriginal health by understanding the influence of early life environments and contacts with health and social service systems over time and across generations</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </subject>
<subject type="local">indigenous health </subject>
<subject type="local">child development</subject>
<subject type="local">data linkage</subject>
<subject type="local">epidemiology</subject>
<subject type="local">family studies</subject>
<description type="Chief Investigator">Assoc Prof Francis Mitrou</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project is a partnership between researchers, the Aboriginal community and government to provide evidence for policy and practice addressing high priority health conditions for Aboriginal children and families. It will use a longitudinal linked dataset based on a population representative sample of Aboriginal children and their families (the 2000/02 Western Australian Aboriginal Child Health Survey) and government data across health, education, child protection, and justice domains.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019056</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019056</identifier>
<identifier type="nhmrc">2019056</identifier>
<name type="primary"><namePart>Advancing the treatment of brain cancer in children</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </subject>
<subject type="local">brain tumours </subject>
<subject type="local">blood-brain barrier</subject>
<subject type="local">drug delivery</subject>
<subject type="local">brain imaging</subject>
<subject type="local">child</subject>
<description type="Chief Investigator">Prof Maria Kavallaris</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Brain cancers are the number one cause of cancer related death in children. Treatment for this group of cancers is aggressive and includes chemotherapy, surgery and radiotherapy. This research will develop innovative nano-sized drug carriers to deliver therapies and imaging agents to detect and kill brain tumours. If successful, this work has the potential to markedly change treatment strategies to improve the survival of paediatric brain cancer patients.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019247</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019247</identifier>
<identifier type="nhmrc">2019247</identifier>
<name type="primary"><namePart>How can health districts and networks cultivate anti-racist hospitals?</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </subject>
<subject type="local">indigenous health </subject>
<subject type="local">hospitals</subject>
<subject type="local">health inequalities</subject>
<subject type="local">access to health care</subject>
<subject type="local">organisational processes</subject>
<description type="Chief Investigator">Assoc Prof Tamara Mackean</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The aim of this research is to enable local health networks and districts in Australia to tackle systemic racism in hospitals. Specifically, this research will use tools and frameworks to improve quality of hospital care and reduce health inequities for Aboriginal and Torres Strait Islander people. This work will be undertaken by a team of researchers with expertise and skills across public health, social science and Indigenous ways of working.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019251</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019251</identifier>
<identifier type="nhmrc">2019251</identifier>
<name type="primary"><namePart>Using complex models of human trophoblast to study placental biology and disease</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </subject>
<subject type="local">placenta </subject>
<subject type="local">stem cell biology</subject>
<subject type="local">epigenetics</subject>
<subject type="local">implantation</subject>
<subject type="local">transposons</subject>
<description type="Chief Investigator">Prof Jose Polo</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In this synergy grant, a multidisciplinary team of researchers in stem cell biology, placenta , epigenetics, embryonic implantation and computational science will work together to study the placenta using different artificial models. This will allow us to understand how early placenta is formed in humans, how it interacts with the cells of the uterus of the mother and unveil the genetic and toxicity insults that contribute to problems in pregnancy.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019252</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019252</identifier>
<identifier type="nhmrc">2019252</identifier>
<name type="primary"><namePart>The Interdisciplinary Tobacco Endgame Research Network (INTER-Net)</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified | economics | applied economics | behavioural economics | human society | policy and administration | health policy | </subject>
<subject type="local">tobacco control </subject>
<subject type="local">public health policy</subject>
<subject type="local">health economics</subject>
<subject type="local">behavioural science</subject>
<subject type="local">smoking</subject>
<description type="Chief Investigator">Assoc Prof Coral Gartner</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Tobacco smoking remains the leading preventable cause of early death and disease globally. Australia has been a global leader in implementing policies that have reduced smoking to one of the lowest rates in the world. This multidisciplinary research program will examine promising new approaches to minimising smoking in Australia using methods from epidemiology and applied statistics, health policy, law, the social sciences, and economics.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019260</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019260</identifier>
<identifier type="nhmrc">2019260</identifier>
<name type="primary"><namePart>Rhythms and blues: Personalising care for body clock dysfunction in mood disorders</namePart></name>
<name type="alternative"><namePart>Synergy Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </subject>
<subject type="local">circadian rhythms </subject>
<subject type="local">mental health</subject>
<subject type="local">clinical genetics</subject>
<subject type="local">biosensor</subject>
<subject type="local">psychiatry</subject>
<description type="Chief Investigator">Prof Ian Hickie</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to improve our knowledge about how problems with “body clocks” might lead to mood disorders like depression and bipolar disorder. We expect this research will (1) lead to better ways to measure body clock function, (2) reveal more clearly how body clocks are affected in mood disorders, (3) help clinicians predict whose mood disorder will persist or get worse over time, and (4) guide clinicians about what treatments can help improve people’s body clocks and mental health.</description>
<description type="fundingAmount">$5,000,000.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024704</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024704</identifier>
<identifier type="nhmrc">2024704</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05e4f1b55</identifier><title>Bionics Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr David Lane</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$175,939.06</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024700</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024700</identifier>
<identifier type="nhmrc">2024700</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00200ya62</identifier><title>National Ageing Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Marcia Fearn</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$269,730.58</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024693</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024693</identifier>
<identifier type="nhmrc">2024693</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sqdef20</identifier><title>Centre for Eye Research Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Raja Choudhury</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$601,540.31</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024706</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024706</identifier>
<identifier type="nhmrc">2024706</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b3dvp57</identifier><title>Garvan Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Sonja Bates</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$20,101.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024696</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024696</identifier>
<identifier type="nhmrc">2024696</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03a2tac74</identifier><title>Florey Institute of Neuroscience and Mental Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Andrea Richardson</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$1,292,024.30</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024689</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024689</identifier>
<identifier type="nhmrc">2024689</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Cherry Yu</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$1,883,201.91</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024690</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024690</identifier>
<identifier type="nhmrc">2024690</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Nadine Barnes</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$1,593,844.69</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024710</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024710</identifier>
<identifier type="nhmrc">2024710</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Callum Hensman</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$63,114.25</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024709</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024709</identifier>
<identifier type="nhmrc">2024709</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Catherine Hayden</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,934,493.84</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024708</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024708</identifier>
<identifier type="nhmrc">2024708</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/008cfxd05</identifier><title>The Sax Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Michael Frommer</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$184,164.39</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024707</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024707</identifier>
<identifier type="nhmrc">2024707</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/023331s46</identifier><title>The George Institute for Global Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Kerry Jenson</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$258,543.90</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024688</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024688</identifier>
<identifier type="nhmrc">2024688</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05kf27764</identifier><title>ANZAC Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mrs Julie Taranto</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$171,289.22</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024705</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024705</identifier>
<identifier type="nhmrc">2024705</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Marc Campitelli</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$3,331,279.62</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024703</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024703</identifier>
<identifier type="nhmrc">2024703</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02k3cxs74</identifier><title>St Vincents Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Colleen Elso</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$1,037,103.52</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024702</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024702</identifier>
<identifier type="nhmrc">2024702</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Leanne Sutherland</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$497,425.26</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024701</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024701</identifier>
<identifier type="nhmrc">2024701</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ftvnv05</identifier><title>Royal Brisbane and Women's Hospital Foundation</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Stephanie Miller</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Health</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$29,439.81</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024699</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024699</identifier>
<identifier type="nhmrc">2024699</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Nicole Donker</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$4,424,388.24</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024698</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024698</identifier>
<identifier type="nhmrc">2024698</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02jxrhq31</identifier><title>Melanoma Institute Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Valerie Jakrot</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$39,698.94</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024697</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024697</identifier>
<identifier type="nhmrc">2024697</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00ymae584</identifier><title>Institute for Breathing and Sleep</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Rosalba Drummond</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$95,889.16</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024695</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024695</identifier>
<identifier type="nhmrc">2024695</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02y0cs367</identifier><title>Family Planning NSW</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mrs Jane Estoesta</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Hospitals and Health Services</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$42,119.90</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024694</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024694</identifier>
<identifier type="nhmrc">2024694</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01bsaey45</identifier><title>Children's Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Ramona Grimm</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$25,035.49</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024692</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024692</identifier>
<identifier type="nhmrc">2024692</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05gvja138</identifier><title>Centenary Institute of Cancer Medicine and Cell Biology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Michelle Rutledge</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$57,851.71</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024691</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024691</identifier>
<identifier type="nhmrc">2024691</identifier>
<name type="primary"><namePart>IRIISS - 2022</namePart></name>
<name type="alternative"><namePart>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/023m51b03</identifier><title>Cancer Council VIC</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Alysha Cameron</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Charities and Philanthropic</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$90,363.19</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024644</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024644</identifier>
<identifier type="nhmrc">2024644</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Lucy Sheehan-Hennessy</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$102,012.25</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024674</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024674</identifier>
<identifier type="nhmrc">2024674</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Emilie Corrick</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$144,622.53</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024684</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024684</identifier>
<identifier type="nhmrc">2024684</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mrs Fiona Miotti</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$202,370.44</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024637</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024637</identifier>
<identifier type="nhmrc">2024637</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Nadine Barnes</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$57,829.43</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024660</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024660</identifier>
<identifier type="nhmrc">2024660</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006mbby82</identifier><title>Menzies School of Health Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Jodie Ellis</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$97,071.72</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024664</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024664</identifier>
<identifier type="nhmrc">2024664</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00200ya62</identifier><title>National Ageing Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Marcia Fearn</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$9,786.63</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024667</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024667</identifier>
<identifier type="nhmrc">2024667</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Leanne Sutherland</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$18,048.07</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024679</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024679</identifier>
<identifier type="nhmrc">2024679</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Debbie Docherty</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$602,991.01</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024636</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024636</identifier>
<identifier type="nhmrc">2024636</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006jxzx88</identifier><title>Bond University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Haley Jacobi</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$18,837.17</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024659</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024659</identifier>
<identifier type="nhmrc">2024659</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Erin Semon</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$71,925.76</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024638</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024638</identifier>
<identifier type="nhmrc">2024638</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sqdef20</identifier><title>Centre for Eye Research Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Raja Choudhury</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$21,825.67</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024641</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024641</identifier>
<identifier type="nhmrc">2024641</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02czsnj07</identifier><title>Deakin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Kara Spilstead</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$85,548.21</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024645</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024645</identifier>
<identifier type="nhmrc">2024645</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03a2tac74</identifier><title>Florey Institute of Neuroscience and Mental Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Andrea Richardson</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$46,878.49</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024635</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024635</identifier>
<identifier type="nhmrc">2024635</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Cherry Yu</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$68,328.17</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024669</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024669</identifier>
<identifier type="nhmrc">2024669</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/031rekg67</identifier><title>Swinburne University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Sheila Hamilton-Brown</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$13,942.99</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024687</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024687</identifier>
<identifier type="nhmrc">2024687</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03t52dk35</identifier><title>University of Western Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Manijah Hakim</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$8,983.15</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024686</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024686</identifier>
<identifier type="nhmrc">2024686</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04j757h98</identifier><title>Victoria University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Andrew Gaff</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,462.70</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024685</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024685</identifier>
<identifier type="nhmrc">2024685</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00jtmb277</identifier><title>University of Wollongong</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Monica Birrento</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$31,506.56</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024683</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024683</identifier>
<identifier type="nhmrc">2024683</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03f0f6041</identifier><title>University of Technology Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Katherine Waldron</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$46,186.43</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024682</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024682</identifier>
<identifier type="nhmrc">2024682</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Jodie Lamont</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$51,116.05</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024681</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024681</identifier>
<identifier type="nhmrc">2024681</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Nicole Makoviney</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$620,924.34</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024680</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024680</identifier>
<identifier type="nhmrc">2024680</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Mark Geier</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$77,776.86</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024678</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024678</identifier>
<identifier type="nhmrc">2024678</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Wade Moore</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$906,177.32</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024677</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024677</identifier>
<identifier type="nhmrc">2024677</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Catherine Hayden</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$251,604.08</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024676</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024676</identifier>
<identifier type="nhmrc">2024676</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ekaterina Ovsyanikova</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$481,962.12</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024675</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024675</identifier>
<identifier type="nhmrc">2024675</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Judy Alexander</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$130,703.58</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024673</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024673</identifier>
<identifier type="nhmrc">2024673</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/008cfxd05</identifier><title>The Sax Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Michael Frommer</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,682.03</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024672</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024672</identifier>
<identifier type="nhmrc">2024672</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/023331s46</identifier><title>The George Institute for Global Health</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Kerry Jenson</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$9,380.74</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024671</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024671</identifier>
<identifier type="nhmrc">2024671</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Marc Campitelli</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$120,868.74</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024670</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024670</identifier>
<identifier type="nhmrc">2024670</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05e4f1b55</identifier><title>Bionics Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr David Lane</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,383.59</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024668</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024668</identifier>
<identifier type="nhmrc">2024668</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02k3cxs74</identifier><title>St Vincents Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Colleen Elso</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$37,629.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024666</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024666</identifier>
<identifier type="nhmrc">2024666</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Jane Holt</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$30,889.62</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024665</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024665</identifier>
<identifier type="nhmrc">2024665</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03pnv4752</identifier><title>Queensland University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Katie York</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$37,493.21</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024663</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024663</identifier>
<identifier type="nhmrc">2024663</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00r4sry34</identifier><title>Murdoch University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Kerrie Carr</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$10,468.90</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024662</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024662</identifier>
<identifier type="nhmrc">2024662</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Nicole Donker</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$160,529.97</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024661</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024661</identifier>
<identifier type="nhmrc">2024661</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Michelle McMurtrie</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$791,822.05</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024646</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024646</identifier>
<identifier type="nhmrc">2024646</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Lynette Farquhar</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$64,069.82</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024632</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024632</identifier>
<identifier type="nhmrc">2024632</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05kf27764</identifier><title>ANZAC Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mrs Julie Taranto</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,214.88</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024650</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024650</identifier>
<identifier type="nhmrc">2024650</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Georgina Caruana</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$57,388.74</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024649</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024649</identifier>
<identifier type="nhmrc">2024649</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04gsp2c11</identifier><title>James Cook University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mr Javier Balanzategui</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$34,394.03</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024642</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024642</identifier>
<identifier type="nhmrc">2024642</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05jhnwe22</identifier><title>Edith Cowan University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Ms Sharon York</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$12,060.51</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024640</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024640</identifier>
<identifier type="nhmrc">2024640</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02n415q13</identifier><title>Curtin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Dr Jananee Raguragavan</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$36,015.20</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024639</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024639</identifier>
<identifier type="nhmrc">2024639</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048zcaj52</identifier><title>Charles Darwin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Mrs Hemali Seneviratne</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$6,363.38</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2024634</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2024634</identifier>
<identifier type="nhmrc">2024634</identifier>
<name type="primary"><namePart>2022 Equipment Grant</namePart></name>
<name type="alternative"><namePart>Equipment Grant</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Not Applicable</subject><subject type="anzsrc-for">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<subject type="local">Not Applicable</subject>
<description type="Chief Investigator">Katherine Hammersley</description>
<description type="Date Announced">2022-11-25T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Not Applicable</description>
<description type="fundingAmount">$95,923.66</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2016736</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2016736</identifier>
<identifier type="nhmrc">2016736</identifier>
<name type="primary"><namePart>Dental health, mental health and economic productivity; a child longitudinal study</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | community child health  | </subject>
<subject type="local">child health </subject>
<subject type="local">dental health</subject>
<subject type="local">dental health surveys</subject>
<subject type="local">population health</subject>
<subject type="local">health economics</subject>
<description type="Chief Investigator">Prof Lisa Jamieson</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Working with partners across each State and Territory to ensure local tailoring and national implementation, we will undertake NCOHS-2 – oral epidemiological examinations and questionnaire data on approximately 32,000 Australian children aged 5 to 14 years – then compare against NCOHS-1 data to test, model, evaluate and disseminate evidence that will enable important questions around child oral health, social and emotional wellbeing, school performance and economic productivity to be answered.</description>
<description type="fundingAmount">$1,499,998.80</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017219</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017219</identifier>
<identifier type="nhmrc">2017219</identifier>
<name type="primary"><namePart>Improving the health system’s response when patients are harmed: a mixed-methods study</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | patient safety | </subject>
<subject type="local">patient safety </subject>
<subject type="local">adverse events</subject>
<subject type="local">health services research</subject>
<subject type="local">injury</subject>
<subject type="local">health care evaluation</subject>
<description type="Chief Investigator">Assoc Prof Peter Hibbert</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">When patients are harmed, it is imperative that health care organisations respond to and learn from them and prevent other patients suffering a similar incident. However, there is no evidence that systems for managing incidents reduce more incidents causing harm to patients. We will work closely with four jurisdiction's health systems to research current practices, test interventions that are occurring in health services, and undertake a world-first simulation trial using artificial intelligence.</description>
<description type="fundingAmount">$1,496,179.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2017496</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2017496</identifier>
<identifier type="nhmrc">2017496</identifier>
<name type="primary"><namePart>Sleep for Strong Souls (3S): Multisectoral partnership and co-designed solutions to improve the sleep health of First Nations Adolescents</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </subject>
<subject type="local">indigenous australians </subject>
<subject type="local">sleep</subject>
<subject type="local">aboriginal health</subject>
<subject type="local">service delivery</subject>
<subject type="local">capacity building</subject>
<description type="Chief Investigator">Dr Yaqoot Fatima</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">1 in 3 Aboriginal and Torres Strait Islander adolescents struggle with poor sleep, yet their sleep health needs remains unmet. In collaboration with community members, the project team and partner organisations are working together to co-design a sleep health program and resources, build local capacity, and embed culturally responsive and context responsive sleep health care in preventive programs and health system to meet the sleep health needs of First Nations adolescents.</description>
<description type="fundingAmount">$783,055.32</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018981</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018981</identifier>
<identifier type="nhmrc">2018981</identifier>
<name type="primary"><namePart>NAVICARE: Implementing, scaling up and sustaining a co-designed care navigation model to improve mental health service access in regional Australia</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03pnv4752</identifier><title>Queensland University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | mental health services | human society | social work | counselling, wellbeing and community services | health sciences | health services and systems | rural and remote health services | </subject>
<subject type="local">mental health services </subject>
<subject type="local">mental health promotion</subject>
<subject type="local">implementation</subject>
<subject type="local">health economics</subject>
<subject type="local">rural and remote health services</subject>
<description type="Chief Investigator">Dr Zephanie Tyack</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">One in five Australians experience mental ill health each year. In regional Australia, mental health services are harder to access than in urban areas. We developed a new model of care with regional communities to address this. A local person assists people in navigating how to access the best mental health care, which has been shown to be beneficial. This project will evaluate the new model of care in multiple regional sites in Queensland and potential scaling up across Australia.</description>
<description type="fundingAmount">$727,470.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019034</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019034</identifier>
<identifier type="nhmrc">2019034</identifier>
<name type="primary"><namePart>Determining the impact of the Melbourne Supervised Injecting Rooms on health and social outcomess</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified | </subject>
<subject type="local">overdose </subject>
<subject type="local">injecting drug use</subject>
<subject type="local">heroin dependence</subject>
<subject type="local">drug use</subject>
<subject type="local">addiction</subject>
<description type="Chief Investigator">Prof Paul Dietze</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The Melbourne Supervised Injecting Room opened in North Richmond in 2018 and has since become one of the busiest in the world. A second MSIR will open in Melbourne's Central Business District. By establishing SIRX, a prospective cohort of MSIR service users, this study will provide new highest-quality evidence about the effectiveness of the MSIRS to inform ongoing policy and practice around supervised injecting facilities over the coming decade.</description>
<description type="fundingAmount">$1,499,966.40</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019085</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019085</identifier>
<identifier type="nhmrc">2019085</identifier>
<name type="primary"><namePart>Can an aftercare service reduce suicide risk in young people? An effectiveness-implementation evaluation</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">health sciences | health services and systems | implementation science and evaluation | </subject>
<subject type="local">suicide prevention </subject>
<subject type="local">suicide</subject>
<subject type="local">adolescent health</subject>
<subject type="local">evaluation</subject>
<subject type="local">health services research</subject>
<description type="Chief Investigator">Assoc Prof Jo Robinson</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project responds to rising rates of youth suicide. It will evaluate a youth aftercare service designed to support young people who have presented to the emergency department with suicide risk. The project will employ different methodologies to understand the acceptability and effectiveness of the service from the perspectives of young people, families and professionals. It represents a partnership between the University of Melbourne, Orygen and the Victorian Department of Health.</description>
<description type="fundingAmount">$1,225,326.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019735</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019735</identifier>
<identifier type="nhmrc">2019735</identifier>
<name type="primary"><namePart>Integrating mathematical modelling and public health surveillance to improve control of epidemic and pandemic respiratory infections in Australia</namePart></name>
<name type="alternative"><namePart>Partnership Projects</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | disease surveillance | health sciences | epidemiology | epidemiological modelling | </subject>
<subject type="local">covid-19 </subject>
<subject type="local">health surveillance</subject>
<subject type="local">mathematical modelling</subject>
<subject type="local">decision support</subject>
<subject type="local">respiratory viruses</subject>
<description type="Chief Investigator">Assoc Prof James Wood</description>
<description type="Date Announced">2022-12-05T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Australia has had a highly successful response to COVID-19 by global standards but this success relied on real-time development of public health responses including new surveillance of trends and interventions and analysis through newly developed models. We seek to embed efficient and relevant surveillance and real-time analysis within jurisdictional responses to COVID-19 and other important respiratory infections, through partnerships with NSW, ACT and QLD health departments.</description>
<description type="fundingAmount">$1,009,784.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018793</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018793</identifier>
<identifier type="nhmrc">2018793</identifier>
<name type="primary"><namePart>Engineered tumour-homing bacteria that safely turn up the heat on immunologically cold colorectal cancers</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | tumour immunology  | </subject>
<subject type="local">immunotherapy </subject>
<subject type="local">colorectal cancer treatment</subject>
<subject type="local">cd40/ cd40l interactions</subject>
<subject type="local">molecular microbiology</subject>
<subject type="local">acute liver injury</subject>
<description type="Chief Investigator">Dr Stephen Blake</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The most prevalent colorectal cancer subtype has a low mutational burden and does not respond well to immunotherapies. The immune agonist anti-CD40 can drive immune infiltration into this cancer subtype and can reduce tumour burden in a mouse model that faithfully recapitulates the disease, however induces severe toxicity. This project will determine if expressing CD40 agonists in probiotic bacteria can be used to reduce this toxicity and effectively suppress colorectal cancer growth.</description>
<description type="fundingAmount">$808,254.27</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018797</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018797</identifier>
<identifier type="nhmrc">2018797</identifier>
<name type="primary"><namePart>Targeting the hepatitis B e antigen as a novel therapeutic approach</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology  | </subject>
<subject type="local">hepatitis b virus </subject>
<subject type="local">hepatitis b infection</subject>
<subject type="local">novel therapeutic agents</subject>
<subject type="local">antibody therapy</subject>
<subject type="local">novel therapies</subject>
<description type="Chief Investigator">Prof Peter Revill</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is no cure for chronic hepatitis B virus disease. The secreted hepatitis B e antigen (HBeAg) is a major cause of chronic infection, and its removal by host immune responses improves patient health. Current antiviral therapy does not specifically target this protein. We have developed novel methods to reducing HBeAg levels in a mouse model of HBV persistence. This proposal will progress these findings towards a novel therapeutic approach to treat HBeAg-+ve chronic hepatitis B.</description>
<description type="fundingAmount">$1,400,226.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018825</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018825</identifier>
<identifier type="nhmrc">2018825</identifier>
<name type="primary"><namePart>Characterization of the Germline Regulatory Landscape</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | </subject>
<subject type="local">developmental biology </subject>
<subject type="local">developmental genetics</subject>
<subject type="local">genetics</subject>
<subject type="local">germ cells</subject>
<subject type="local">gene transcription</subject>
<description type="Chief Investigator">Prof Roger Pocock</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Human fertility requires the generation of gametes (oocytes and sperm) that combine to produce an embryo. The aim of this research program is to identify genes and proteins that control gamete production. The biochemical pathways under study could be targeted by drugs. Therefore, new knowledge generated in this project has the potential to identify processes and pathways that are directly relevant to reproduction-related disease, infertility and in vitro fertilization.</description>
<description type="fundingAmount">$1,156,248.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018833</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018833</identifier>
<identifier type="nhmrc">2018833</identifier>
<name type="primary"><namePart>Accelerating messenger RNA (mRNA) therapeutics by cracking the epitranscriptomic code</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | genomics and transcriptomics | information and computing sciences | machine learning | deep learning | biological sciences | biochemistry and cell biology | synthetic biology | </subject>
<subject type="local">messenger rna (mrna) </subject>
<subject type="local">rna processing</subject>
<subject type="local">sequencing</subject>
<subject type="local">artificial neural networks</subject>
<subject type="local">genomics</subject>
<description type="Chief Investigator">Prof Eduardo Eyras</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The remarkable efficacy of SARS-CoV-2 vaccines based on messenger RNA (mRNA) has highlighted the extraordinary potential of mRNA technologies and has secured the promise of mRNA as a therapeutic modality for multiple diseases. This research project builds on a recent breakthrough from my research that enables an unprecedented characterisation of the chemical composition of individual mRNA molecules to uphold this promise and accelerate mRNA exploration and design for therapeutic development.</description>
<description type="fundingAmount">$1,556,956.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018835</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018835</identifier>
<identifier type="nhmrc">2018835</identifier>
<name type="primary"><namePart>Molecular pathways that control platelet production</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </subject>
<subject type="local">platelets </subject>
<subject type="local">haematopoiesis</subject>
<subject type="local">thrombocytopenia</subject>
<subject type="local">ribosome biogenesis</subject>
<subject type="local">haemorrhage</subject>
<description type="Chief Investigator">Prof Elizabeth Gardiner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Platelets are small cells that circulate by the millions in the bloodstream and are primarily responsible for sealing a blood vessel when the vessel is damaged. The mechanisms controlling platelet production are not well understood. We have discovered that by inhibiting ribosomal biogenesis, we can rapidly increase platelet production. This will be of enormous benefit in clinical settings where platelets are low and catastrophic bleeding is likely.</description>
<description type="fundingAmount">$883,019.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018880</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018880</identifier>
<identifier type="nhmrc">2018880</identifier>
<name type="primary"><namePart>Dissecting the intracellular lifestyle of lethal Staphylococcus aureus</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | </subject>
<subject type="local">staphylococcus aureus </subject>
<subject type="local">intracellular bacterial infections</subject>
<subject type="local">cell death</subject>
<subject type="local">septicaemia</subject>
<subject type="local">antimicrobial resistance</subject>
<description type="Chief Investigator">Dr Abderrahman Hachani</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Staphylococcus aureus (golden staph) cause infection of the bloodstream, a serious condition with a high death toll in patients. Despite years of research, it is still unclear how these bacteria hide into human cells to escape our immune system and current antibiotics. Here, we propose a research programme to understand the molecular strategies used by golden staph to cause these serious infections. Our findings will help design new drugs to treat severe bacterial infections.</description>
<description type="fundingAmount">$870,337.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018888</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018888</identifier>
<identifier type="nhmrc">2018888</identifier>
<name type="primary"><namePart>Targeting molecular ageing pathways for the treatment of chronic pain</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">chronic pain </subject>
<subject type="local">neuropathic pain</subject>
<subject type="local">pain mechanisms</subject>
<subject type="local">pain minimisation</subject>
<subject type="local">pain transmission</subject>
<description type="Chief Investigator">Dr Arjun Muralidharan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">One in five Australians lives with chronic pain and this prevalence rises to one in three people over the age of 65. Available treatments for pain are often ineffective and associated with dose-limiting side effects. This project aims to explore a potential new avenue of pain research, and the knowledge gained is expected to provide a breakthrough understanding of the interplay between chronic pain and cellular ageing, and nonetheless will lay the groundwork for numerous applications.</description>
<description type="fundingAmount">$828,285.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018895</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018895</identifier>
<identifier type="nhmrc">2018895</identifier>
<name type="primary"><namePart>Unmask HIV latency through disruption of HIV synapses</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical virology  | biological sciences | biochemistry and cell biology | protein trafficking | information and computing sciences | computer vision and multimedia computation | computer vision | </subject>
<subject type="local">human immunodeficiency virus (hiv) </subject>
<subject type="local">protein trafficking</subject>
<subject type="local">synapse</subject>
<subject type="local">calcium</subject>
<subject type="local">image processing</subject>
<description type="Chief Investigator">Prof Johnson Mak</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">HIV synapses enable cell-cell transmission to overcome anti-retroviral therapeutics and broadly neutralising anti-HIV antibodies. Our ground-breaking report on the Ca2+-HIV synapse biology will: (i) improve efficiency of HIV therapeutics; and (ii) show how HIV latently infected cells can be sensitised for destruction. A cross-disciplinary approach involving molecular virology, cell biology, and machine learning will be used to accelerate our discovery for its application at the clinic.</description>
<description type="fundingAmount">$1,224,430.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018897</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018897</identifier>
<identifier type="nhmrc">2018897</identifier>
<name type="primary"><namePart>Preventing a nephron deficit in premature offspring</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </subject>
<subject type="local">premature birth </subject>
<subject type="local">nephron endowment</subject>
<subject type="local">maternal nutrition</subject>
<subject type="local">lactation</subject>
<subject type="local">kidney development</subject>
<description type="Chief Investigator">Prof John Bertram</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Many premature babies are born with a low number of functional units (nephrons) in their kidneys and an increased risk of developing chronic kidney disease. Strategies to prevent a nephron deficit in preterm offspring are required. We have found that manipulating maternal nutrition during lactation can rescue a nephron deficit. We will determine the multidimensional impact of dietary macronutrients on maternal milk composition and nephron endowment following premature birth.</description>
<description type="fundingAmount">$1,255,941.85</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018916</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018916</identifier>
<identifier type="nhmrc">2018916</identifier>
<name type="primary"><namePart>Assessing benefits of extended genomic newborn screening at population scale in infants from Generation Victoria</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </subject>
<subject type="local">newborn screening </subject>
<subject type="local">imprinting</subject>
<subject type="local">intellectual disability</subject>
<subject type="local">x linked disorder</subject>
<subject type="local">epigenetics</subject>
<description type="Chief Investigator">Assoc Prof David Godler</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">There are over 7,000 rare diseases with the average age of diagnosis being 4 years. Newborn screening using genomics could identify these children at a younger age and deliver new therapies at birth to offer the most chance of health benefits. We will test effectiveness of a novel genomic workflow called EpiGNs to detect harmful changes to genes on the whole-of-state birth cohort (GenV) of 100,000 infants. This will enable its implementation as a new model for genomic newborn screening.</description>
<description type="fundingAmount">$1,812,607.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018919</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018919</identifier>
<identifier type="nhmrc">2018919</identifier>
<name type="primary"><namePart>Regulators of Tau Pathology Induced by Exosomal and Vesicle-free Tau Seeds</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | cellular nervous system | </subject>
<subject type="local">alzheimer disease </subject>
<subject type="local">neuroscience</subject>
<subject type="local">molecular neuroscience</subject>
<subject type="local">protein aggregation</subject>
<subject type="local">vesicle-associated proteins</subject>
<description type="Chief Investigator">Dr Juan Carlos Polanco</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In Alzheimer’s disease, misfolded forms of the protein tau known as seeds propagate from neuron to neuron allowing for spreading and progression of tau pathology. We discovered novel genes that regulate this process. We will dissect how these regulators enable the disease, and whether their manipulation can modulate or stop tau pathology in cells and in brains. We expect that by understanding how different tau seeds cause tau pathology, our research will also reveal novel therapeutic targets.</description>
<description type="fundingAmount">$923,434.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018947</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018947</identifier>
<identifier type="nhmrc">2018947</identifier>
<name type="primary"><namePart>Personalising diagnosis and treatment of Pseudomonas aeruginosa infection</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | glycobiology | </subject>
<subject type="local">pseudomonas aeruginosa infection </subject>
<subject type="local">glycobiology</subject>
<subject type="local">immunoglobulin (ig)</subject>
<subject type="local">antibody therapy</subject>
<subject type="local">glycoproteins</subject>
<description type="Chief Investigator">Assoc Prof Daniel Kolarich</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will develop a novel blood test that measures the antibody glycocode and informs on the individual immune status of patients. This new test will improve and significantly accelerate personalised diagnosis and treatment of patients suffering from infection with Pseudomonas aeruginosa, a pathogen classified by the World Health Organisation at the highest threat level due to it becoming increasingly resistant to last resort antibiotics.</description>
<description type="fundingAmount">$880,844.25</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018951</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018951</identifier>
<identifier type="nhmrc">2018951</identifier>
<name type="primary"><namePart>New Approaches for Sensitising Metastatic Colorectal Cancer to Immunotherapy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">colorectal cancer </subject>
<subject type="local">colorectal cancer treatment</subject>
<subject type="local">cancer immunotherapy</subject>
<subject type="local">novel therapies</subject>
<subject type="local">cancer prognosis</subject>
<description type="Chief Investigator">Assoc Prof Vicki Whitehall</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Immunotherapy is an approach that takes advantage of the body’s own immune system to attack cancer cells. This therapy that has produced long term benefit for patients with many different types of advanced cancers, but has had limited benefit for patients with bowel cancer. In this application we are using cutting edge techniques to identify new ways to use immunotherapy to improve outcomes for patients with advanced bowel cancer.</description>
<description type="fundingAmount">$1,419,345.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018980</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018980</identifier>
<identifier type="nhmrc">2018980</identifier>
<name type="primary"><namePart>Defining the roles of O-linked glycosylation on Burkholderia virulence</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | infectious agents | </subject>
<subject type="local">glycosylation </subject>
<subject type="local">burkholderia</subject>
<subject type="local">proteomics</subject>
<subject type="local">protein modification</subject>
<subject type="local">mass spectrometry</subject>
<description type="Chief Investigator">Dr Nichollas Scott</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Burkholderia infections are associated with high mortality rates especially within immunocompromised individuals. Due to this there is an urgent need to identify bacterial factors which can be targeted to reduce the disease burden of these infections. Within this grant we aim to identify how a specific set of proteins, glycoproteins, contribute to Burkholderia virulence with the goal to identify next generation vaccines and anti-microbial targets.</description>
<description type="fundingAmount">$512,466.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018988</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018988</identifier>
<identifier type="nhmrc">2018988</identifier>
<name type="primary"><namePart>A novel brain circuit inhibiting airway interoceptive processing</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | sensory systems | biomedical and clinical sciences | neurosciences | autonomic nervous system  | </subject>
<subject type="local">vagus nerve </subject>
<subject type="local">cough</subject>
<subject type="local">sensory function</subject>
<subject type="local">autonomic nervous system</subject>
<subject type="local">airway diseases</subject>
<description type="Chief Investigator">Prof Stuart Mazzone</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The air passages and lungs are exposed to the external environment through the air that is breathed. It is therefore important that they can sense danger signals present in air, such as toxins or irritants, that might compromise breathing. This sensory system is poorly described. We will investigate brain circuits regulating airway irritant detection when air quality is compromised by smoke arising from bush fires. The findings will inform the severe health impacts of environmental pollutants.</description>
<description type="fundingAmount">$1,116,663.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018997</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018997</identifier>
<identifier type="nhmrc">2018997</identifier>
<name type="primary"><namePart>Novel biomarkers and drug targets for pharmacoresistant epilepsy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03pnv4752</identifier><title>Queensland University of Technology</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | biological sciences | genetics | neurogenetics | </subject>
<subject type="local">epilepsy </subject>
<subject type="local">drug resistant</subject>
<subject type="local">pharmacogenetics</subject>
<subject type="local">biomarkers</subject>
<subject type="local">antiepileptic drugs</subject>
<description type="Chief Investigator">Prof Dale Nyholt</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In one-third of epilepsy patients, currently available antiepileptic drugs (AEDs) do not control seizures. Recurrent seizures threaten life and impair its quality; hence, there is a clear need to discover new AEDs. In addition, there is currently no way to accurately predict which and how individuals will respond to a specific or any AED. The proposed research aims identify new AED targets and predict the right (and wrong) drugs for an epilepsy patient from the outset.</description>
<description type="fundingAmount">$1,967,753.56</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019011</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019011</identifier>
<identifier type="nhmrc">2019011</identifier>
<name type="primary"><namePart>Thalamic plasticity following cortical damage: recovery of vision</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">brain injury </subject>
<subject type="local">adult neurogenesis</subject>
<subject type="local">neural regeneration</subject>
<subject type="local">recovery</subject>
<subject type="local">task-related training</subject>
<description type="Chief Investigator">Dr Nafiseh Atapour</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will investigate how neuroplasticity can contribute to vision recovery in adult brain, following damage to one of its key nodes. Normally, such lesions render the person blind, but some slight improvement occurs over time. We will test the extent to which newborn neurons can be integrated to other parts of this circuit in a manner that explains the partial recovery of vision, and whether a rehabilitation therapy can boost this process.</description>
<description type="fundingAmount">$892,044.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019014</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019014</identifier>
<identifier type="nhmrc">2019014</identifier>
<name type="primary"><namePart>Engineering bone marrow-derived stromal cells to express anti-fibrotic cargo as a treatment for chronic kidney disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </subject>
<subject type="local">nephrology </subject>
<subject type="local">kidney disease</subject>
<subject type="local">therapeutics</subject>
<subject type="local">stem cell therapy</subject>
<subject type="local">combination therapy</subject>
<description type="Chief Investigator">Prof Chrishan Samuel</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Although a number of organs can repair themselves from mild injury, when subjected to persistent injury, they fail to do so. As a result, they undergo organ scarring (fibrosis) and a progressive loss of function. As current therapies fail to effectively stop this scarring process, we aim to engineer human bone marrow-derived stromal cells to express an anti-fibrotic agent (serelaxin), to deliver the therapeutic potential of this combination therapy as a treatment of chronic kidney disease.</description>
<description type="fundingAmount">$981,260.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019024</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019024</identifier>
<identifier type="nhmrc">2019024</identifier>
<name type="primary"><namePart>Harnessing and understanding Tr1 cells in inflammation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | cellular immunology | </subject>
<subject type="local">inflammation </subject>
<subject type="local">experimental autoimmune encephalomyelitis (eae)</subject>
<subject type="local">cd4</subject>
<subject type="local">airway inflammation</subject>
<subject type="local">regulatory t cells</subject>
<description type="Chief Investigator">Dr Iain Comerford</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inflammation that is inappropriately directed causes a range of important human diseases and current therapies for these diseases are limited. New methods or identification of new mechanisms that can be exploited to control persistent inflammation are therefore urgently required. In this project we will explore the biology of Type-I regulatory T cells (Tr1 cells), which appear to play an important role in the control of inflammation.</description>
<description type="fundingAmount">$866,880.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019032</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019032</identifier>
<identifier type="nhmrc">2019032</identifier>
<name type="primary"><namePart>Codon bias and the role of tRNA modifications in cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | </subject>
<subject type="local">protein synthesis </subject>
<subject type="local">rna processing</subject>
<subject type="local">messenger rna (mrna)</subject>
<subject type="local">proteome analysis</subject>
<subject type="local">cancer cell biology</subject>
<description type="Chief Investigator">Dr Luc Furic</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is characterised by high rate of cell growth and proliferation. Cancer cells need to increase their biomass to divide and this is dependent on the the synthesis of proteins. We have recently discovered that transfer RNAs, the small molecules carrying the building blocs required for protein synthesis, are chemicaly modified and that these modifications could be targeted to strongly inhibit tumour growth and progression in a wide array of cancers.</description>
<description type="fundingAmount">$934,787.32</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019058</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019058</identifier>
<identifier type="nhmrc">2019058</identifier>
<name type="primary"><namePart>How does metabolic conditioning of the host environment enhance persistence of Haemophilus influenzae infections?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | biological sciences | microbiology | infectious agents | </subject>
<subject type="local">bacterial respiratory diseases </subject>
<subject type="local">infectious diseases</subject>
<subject type="local">haemophilus influenzae</subject>
<subject type="local">metabolism</subject>
<subject type="local">host/pathogen interaction</subject>
<description type="Chief Investigator">Assoc Prof Ulrike Kappler</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">To thrive, bacterial pathogens infecting humans require access to high quality nutrients, but our understanding of pathogen nutrition is limited. We will examine how virulence of the respiratory pathogen Haemophilus influenzae (NTHi) is determined by nutrient availability in the human respiratory tract and how the presence of NTHi changes the way human cells detect infection. The project will identify targets for the development of novel types of antimicrobials that starve NTHi of key nutrients.</description>
<description type="fundingAmount">$786,583.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019079</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019079</identifier>
<identifier type="nhmrc">2019079</identifier>
<name type="primary"><namePart>Shedding new light on vagal nerve stimulation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | autonomic nervous system  | </subject>
<subject type="local">vagus nerve </subject>
<subject type="local">autonomic nervous system</subject>
<subject type="local">parasympathetic nervous system</subject>
<subject type="local">inflammation</subject>
<subject type="local">septic shock</subject>
<description type="Chief Investigator">Dr Lindsea Booth</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inflammation is a complex response to injury and overactivation of inflammation can lead to damage to the host. Stimulating the vagus nerve (VNS) is known to have powerful anti-inflammatory effects but the mechanisms are not well understood. We will use cutting-edge molecular tools in a pre-clinical model of inflammation to allow us to selectively target branches of the vagus nerve going to specific organs and will determine the contribution of each organ to the anti-inflammatory effect of VNS.</description>
<description type="fundingAmount">$853,380.10</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019087</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019087</identifier>
<identifier type="nhmrc">2019087</identifier>
<name type="primary"><namePart>Interrupting suicides in public places: Using CCTV to understand, detect, and respond to behaviours prior to a suicide attempt</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | public health not elsewhere classified | </subject>
<subject type="local">suicide prevention </subject>
<subject type="local">suicide</subject>
<subject type="local">image analysis</subject>
<subject type="local">artificial neural networks</subject>
<subject type="local">intervention</subject>
<description type="Chief Investigator">Dr Mark Larsen</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Suicide is a leading cause of death, and 30% of all suicides occur in public places. Despite this frequency, we lack an understanding of the key behaviours people exhibit prior to a suicide attempt in different public settings, and we lack the tools to identify these behaviours at the scale needed for those responsible for those public sites to meaningfully respond. This project will characterise, detect, and respond to behaviours which precede suicide attempts in public places in Australia.</description>
<description type="fundingAmount">$839,422.65</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019093</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019093</identifier>
<identifier type="nhmrc">2019093</identifier>
<name type="primary"><namePart>Improving estimates of antimalarial drug resistance</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">mathematical sciences | statistics | time series and spatial modelling | mathematical sciences | statistics | applied statistics  | </subject>
<subject type="local">applied statistics </subject>
<subject type="local">mathematical modelling</subject>
<subject type="local">disease modelling</subject>
<subject type="local">drug resistance</subject>
<subject type="local">falciparum malaria</subject>
<description type="Chief Investigator">Assoc Prof Jennifer Flegg</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Antimalarial drugs are essential for the elimination of malaria. Resistance to all currently available antimalarials, including the pivotal artemisinin derivatives, has emerged and is spreading. This project aims to generate the first data-driven, predictive maps of the changing landscape of artemisinin resistance in Asia. These maps fill in the gaps where no information is available and can be used by health agencies to guide new polices about where and when the drug is appropriate to use.</description>
<description type="fundingAmount">$866,114.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019097</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019097</identifier>
<identifier type="nhmrc">2019097</identifier>
<name type="primary"><namePart>A metabolic enzyme as a target for controlling tumourigenesis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | immunology | tumour immunology  | </subject>
<subject type="local">macrophages </subject>
<subject type="local">cd8 t cells</subject>
<subject type="local">t cell immunity</subject>
<subject type="local">lipid metabolism</subject>
<subject type="local">cancer control</subject>
<description type="Chief Investigator">Dr Brendon Chua</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is the leading cause of death in Australia and globally. The majority of cancers are associated with metabolic alterations in tumours. We have identified a key role for an enzyme involved in fatty acid metabolism which impairs immune responses involved in tumour-control and drives cancer. This research aims to investigate key mechanisms of how this enzyme promotes tumour progression and establish the development of inhibitors of this enzyme that can be applied to different cancers.</description>
<description type="fundingAmount">$1,131,088.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019100</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019100</identifier>
<identifier type="nhmrc">2019100</identifier>
<name type="primary"><namePart>Finding Biomarkers and Treatments for Vascular Dementia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </subject>
<subject type="local">vascular dementia </subject>
<subject type="local">neuroinflammation</subject>
<subject type="local">mild cognitive impairment</subject>
<subject type="local">neuronal cell death</subject>
<subject type="local">biomarkers</subject>
<description type="Chief Investigator">Prof Thiruma Valavan Arumugam</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Vascular dementia (VaD) occurs as a result of brain hypoperfusion and represents the second most common type of dementia after Alzheimer's disease. Currently, no specific treatments for VaD exist due to incomplete understanding of the underlying pathophysiology. We are studying inflammasomes as a new therapeutic target to treat VaD. In the next 5 years, this project expects to discover translatable preclinical targets and therapies to treat VaD, and novel biomarkers to diagnosis VaD in humans.</description>
<description type="fundingAmount">$1,229,540.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019101</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019101</identifier>
<identifier type="nhmrc">2019101</identifier>
<name type="primary"><namePart>Combining genetics and genomics to tackle ovarian cancer.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | </subject>
<subject type="local">molecular biology </subject>
<subject type="local">cancer genetics</subject>
<subject type="local">rna</subject>
<subject type="local">chromatin</subject>
<subject type="local">ovarian cancer</subject>
<description type="Chief Investigator">Assoc Prof Stacey Edwards</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Recent studies have identified DNA markers within the human genome that are associated with an increased risk of ovarian cancer. Most of these markers are located in noncoding regions, therefore the key genes driving risk are not known. This proposal will identify the target genes at all ovarian cancer risk regions and assess gene function in cancer development. Understanding how DNA variation contributes to ovarian cancer will provide new avenues for future prevention or treatment.</description>
<description type="fundingAmount">$1,129,198.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019139</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019139</identifier>
<identifier type="nhmrc">2019139</identifier>
<name type="primary"><namePart>Repurposing the in-clinic PCSK9 inhibitor evolocumab to enhance Gemcitabine/Abraxane chemotherapy in pancreatic cancer guided by single-cell intravital imaging</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">cancer cell biology </subject>
<subject type="local">pancreatic cancer</subject>
<subject type="local">imaging</subject>
<subject type="local">cancer metastasis</subject>
<subject type="local">biosensor</subject>
<description type="Chief Investigator">Dr Brooke Pereira</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">During pancreatic cancer development, cancer cells undergo metabolic rewiring in order to survive, grow and spread. This Ideas Grant will use advanced animal imaging and unique patient-derived pancreatic cancer specimens to explore targeting PCSK9 with drugs already in the clinic, in combination with chemotherapy. This new dual therapy could significantly improve treatment response in this devastating disease.</description>
<description type="fundingAmount">$532,570.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019152</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019152</identifier>
<identifier type="nhmrc">2019152</identifier>
<name type="primary"><namePart>Multi-species malaria transmission modelling to inform policy decisions</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006mbby82</identifier><title>Menzies School of Health Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">economics | applied economics | health economics  | health sciences | epidemiology | epidemiological modelling | biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">malaria transmission </subject>
<subject type="local">mathematical modelling</subject>
<subject type="local">economic evaluation</subject>
<subject type="local">malaria</subject>
<subject type="local">decision making</subject>
<description type="Chief Investigator">Dr Angela Devine</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Most malaria cases are caused by two parasite species. While many countries with malaria have both species, decisions about treatment and control of malaria rely on data and mathematical models on one species. Working with policy makers, we have built a novel model that includes both species. This model will explore how species interact and determine how to allocate money on strategies that will maximise health benefits, ensuring that we reach malaria elimination as quickly as possible.</description>
<description type="fundingAmount">$1,041,498.87</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019153</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019153</identifier>
<identifier type="nhmrc">2019153</identifier>
<name type="primary"><namePart>The newly-discovered splenic Plasmodium reservoir as a target to reduce global malaria burden</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/006mbby82</identifier><title>Menzies School of Health Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical parasitology  | </subject>
<subject type="local">malaria </subject>
<subject type="local">organ-specific</subject>
<subject type="local">genetics</subject>
<subject type="local">differential gene expression</subject>
<subject type="local">splenectomy</subject>
<description type="Chief Investigator">Dr Steven Kho</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">We have recently discovered that the spleen is the major reservoir for malaria parasites in natural human malaria infections. There are significant concerns that this previously-unrecognised reservoir underlies the major challenges we face to eliminate this disease. We will use the world’s only collection of spleen and blood samples from untreated human infections, to study the splenic malaria reservoir, uncover its biology and identify new ways to improve malaria elimination strategies.</description>
<description type="fundingAmount">$1,564,455.80</description>
<coverage><spatial type="text">NT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019160</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019160</identifier>
<identifier type="nhmrc">2019160</identifier>
<name type="primary"><namePart>Pharmaceutical Development of Innovative "Trojan Horse" Anti-Cancer Agents that Inhibit Desmoplasia by Reprogramming Signalling</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | </subject>
<subject type="local">pharmaceutical </subject>
<subject type="local">pharmaceutical treatment</subject>
<subject type="local">pharmaceutics</subject>
<subject type="local">molecular pharmacology</subject>
<subject type="local">anticancer drug action</subject>
<description type="Chief Investigator">Prof Des Richardson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We discovered the new PPPT agents that reprogram Sonic Hedgehog Signalling to Inhibit Desmoplasia. Another breakthrough is that these agents totally prevent myoglobin (Mb) oxidation, which was an issue with our clinically trialled agent, DpC Underlining Innovation, no other drug currently available prevents deleterious Mb oxidation, targets the deadly "Triad of Death" (metastasis, Pgp resistance, primary tumour growth), and &amp; inhibits bidirectional oncogenic signalling that leads to desmoplasia</description>
<description type="fundingAmount">$599,828.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019167</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019167</identifier>
<identifier type="nhmrc">2019167</identifier>
<name type="primary"><namePart>Oxidised Cholesterols as Key Regulators of Host Immunity to Tuberculosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | </subject>
<subject type="local">mycobacterium tuberculosis </subject>
<subject type="local">tuberculosis</subject>
<subject type="local">oxysterols</subject>
<subject type="local">granuloma</subject>
<subject type="local">bacterial respiratory diseases</subject>
<description type="Chief Investigator">Assoc Prof Katharina Ronacher</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite available antibiotics we have failed to eradicate TB. It is therefore critically important to elucidate the host immune factors that are required for effective containment of the bacteria that cause TB. We have identified that oxidised cholesterols play a critical role in attracting immune cells and containing the infection. This project will deliver further insights into this pathway which can ultimately be targeted with drugs to prevent the development of TB.</description>
<description type="fundingAmount">$1,515,176.90</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019196</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019196</identifier>
<identifier type="nhmrc">2019196</identifier>
<name type="primary"><namePart>The Mental Health Impact of Childhood SARS-CoV-2</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | social and affective neuroscience | biomedical and clinical sciences | paediatrics | infant and child health | </subject>
<subject type="local">sars-cov-2 </subject>
<subject type="local">brain development</subject>
<subject type="local">mental health</subject>
<subject type="local">depression</subject>
<subject type="local">amygdala</subject>
<description type="Chief Investigator">Prof Sarah Spencer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Children have key differences in ACE2, the receptor by which SARS-CoV-2 enters host cells, that may make them especially vulnerable to lasting brain damage. We show that a single ACE2 inhibition in juvenile rats leads to lasting anxiety- and depressive-like behaviour and associated brain changes. We hypothesize these effects will be worse the younger COVID-19 occurs. We will reveal the potential for COVID-19 to critically impact children, changing the approach to child health in this pandemic.</description>
<description type="fundingAmount">$765,560.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019231</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019231</identifier>
<identifier type="nhmrc">2019231</identifier>
<name type="primary"><namePart>Firing up oncolytic vectors: viral based strategies to repurpose necroptosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | molecular medicine | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">cell death </subject>
<subject type="local">tumour immunotherapy</subject>
<subject type="local">molecular virology</subject>
<subject type="local">herpes simplex virus (hsv)</subject>
<subject type="local">structural biology</subject>
<description type="Chief Investigator">Prof Margaret Sunde</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Necroptosis is an inflammatory form of cell death that could be harnessed to turn on the immune response and fight tumours. This research will study necroptosis signalling and adapt existing approved oncolytic viruses to deliver proteins that initiate necroptosis specifically within the tumour. Melanoma and colorectal cancer models will be used for proof-of-principle. These second-generation therapeutics could work in concert with existing immunotherapies to provide superior cancer control.</description>
<description type="fundingAmount">$748,283.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019254</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019254</identifier>
<identifier type="nhmrc">2019254</identifier>
<name type="primary"><namePart>Size matters: ECM regulation in pregnancy success</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | </subject>
<subject type="local">mouse models </subject>
<subject type="local">developmental genetics</subject>
<subject type="local">implantation</subject>
<subject type="local">extracellular matrix</subject>
<subject type="local">placentation</subject>
<description type="Chief Investigator">Dr Jessica Briffa</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Complications affect ~15% of pregnancies. Appropriate regulation of cellular environment is required for correct implantation and placental formation, but disease will occur if it is defective. To diagnose and treat pregnancy complications we must first understand how implantation and the placenta form. This project will investigate mouse models with abnormal implantation and placental development. It will determine how and why disease occurs and investigate potential therapeutic interventions.</description>
<description type="fundingAmount">$646,541.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019264</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019264</identifier>
<identifier type="nhmrc">2019264</identifier>
<name type="primary"><namePart>Novel Targeted Therapies for Chronic Pain</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | cellular nervous system | </subject>
<subject type="local">chronic pain </subject>
<subject type="local">pain mechanisms</subject>
<subject type="local">cell therapy</subject>
<subject type="local">targeted therapy</subject>
<subject type="local">gene silencing</subject>
<description type="Chief Investigator">Dr Lipin Loo</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Using single cell sequencing technology, we have identified several drivers underlying spinal hyperexcitability in neuropathic pain. Here we will confirm our findings with new spatial technology that reconstructs the spinal anatomical map and assess the effectiveness of 1) boosting inhibition via cell transplants and 2) suppressing hyperexcitability via CRISPR. Our work leverages new functional genomic technologies to rapidly deliver new safe, effective pain management approaches to the clinic.</description>
<description type="fundingAmount">$1,028,104.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019271</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019271</identifier>
<identifier type="nhmrc">2019271</identifier>
<name type="primary"><namePart>Neural circuits that control movement: from mice to humans</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">movement </subject>
<subject type="local">parkinson disease</subject>
<subject type="local">cellular nervous system</subject>
<subject type="local">neural pathways</subject>
<subject type="local">neural regulation</subject>
<description type="Chief Investigator">Prof Pankaj Sah</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting nearly 1% of individuals older than 60, one of the fastest growing neurological disorders, generating a substantial burden patients, and caregivers, with the total cost to the community in excess of $10 billion / year. Many patients with PD develop Freezing of gait. This grant aim to understand what causes freezing of gait in PD and new ways treat the effects of PD on gait and movement.</description>
<description type="fundingAmount">$1,070,796.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019296</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019296</identifier>
<identifier type="nhmrc">2019296</identifier>
<name type="primary"><namePart>An Achilles’ heel of ovarian cancer: targeting ARID1A mutant tumours</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03f0f6041</identifier><title>University of Technology Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">cancer biology </subject>
<subject type="local">cancer cell biology</subject>
<subject type="local">ovarian cancer</subject>
<subject type="local">gynaecological cancers</subject>
<subject type="local">molecular biology</subject>
<description type="Chief Investigator">Prof Deborah Marsh</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Five-year survival for most women with ovarian cancer is poor, with drug resistance a major problem, especially once relapsed. Outcomes are particularly dismal for the sub-type ovarian clear cell carcinoma that is particularly drug resistant. We are looking beyond the DNA to the “epigenome” to target factors involved in changing the landscape of DNA in order to identify new therapies to treat ovarian cancer, overcome chemoresistance and extend the lives of women with this malignancy.</description>
<description type="fundingAmount">$1,199,273.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019329</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019329</identifier>
<identifier type="nhmrc">2019329</identifier>
<name type="primary"><namePart>Exploiting the gene transfer synergies of AAV and LNP to achieve highly efficient genome editing in the human liver</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </subject>
<subject type="local">gene delivery </subject>
<subject type="local">adeno-associated virus</subject>
<subject type="local">liver disease</subject>
<subject type="local">hepatocytes</subject>
<subject type="local">messenger rna (mrna)</subject>
<description type="Chief Investigator">Dr Samantha Ginn</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Genome editing is set to revolutionise the face of modern medicine. This project will develop a cutting-edge genome editing treatment carefully designed for therapeutic readiness. The team will exploit privileged access to explanted patient and donor livers as well as elite gene delivery systems to advance an innovative approach that will provide the foundations for a future clinical trial in children with severe and potentially fatal urea cycle disorders without further preclinical studies.</description>
<description type="fundingAmount">$1,350,007.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019352</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019352</identifier>
<identifier type="nhmrc">2019352</identifier>
<name type="primary"><namePart>A therapeutic solution for respiratory RNA viruses that corrects the patient’s TLR7-dependent inflammatory response</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </subject>
<subject type="local">toll-like receptors </subject>
<subject type="local">acute inflammation</subject>
<subject type="local">acute lung injury</subject>
<subject type="local">influenza virus</subject>
<subject type="local">sars-cov-2</subject>
<description type="Chief Investigator">Prof Stavros Selemidis</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Respiratory virus infections such as COVID-19 and influenza cause mild to severe complications in humans, often resulting in patient death. With limitations in current treatments, there is an urgent need for novel therapeutics to combat these and other viruses. We propose a drug strategy that attacks a critical point in the viral pathogenesis process. With the knowledge of this control point, we developed a drug and will evaluate its efficacy for treating COVID-19, influenza and the common cold.</description>
<description type="fundingAmount">$1,448,333.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019360</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019360</identifier>
<identifier type="nhmrc">2019360</identifier>
<name type="primary"><namePart>Gene regulatory mechanisms by autoimmune risk loci in primary human cells</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genome structure and regulation | biological sciences | genetics | genetic immunology  | biomedical and clinical sciences | immunology | cellular immunology | </subject>
<subject type="local">functional genomics </subject>
<subject type="local">gene regulation</subject>
<subject type="local">complex genetic disease</subject>
<subject type="local">autoimmune disease</subject>
<subject type="local">b cells</subject>
<description type="Chief Investigator">Dr Hamish King</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The genetic causes of autoimmune disease (where the immune system attacks our own body) are poorly understood. While many small changes in patient DNA are linked with autoimmunity, for more than 90% of these mutations we do not know which genes or cells are affected. We will discover the genes controlled by autoimmune-specific DNA changes and how they disrupt immune cell function. This will discover how autoimmune diseases develop and provide information needed to develop new treatments.</description>
<description type="fundingAmount">$1,499,871.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019361</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019361</identifier>
<identifier type="nhmrc">2019361</identifier>
<name type="primary"><namePart>The Role of Salt in Obesity Development</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | biochemistry and cell biology | cell metabolism | </subject>
<subject type="local">hypothalamus </subject>
<subject type="local">neuropeptide y (npy)</subject>
<subject type="local">dietary salt</subject>
<subject type="local">energy balance</subject>
<subject type="local">obesity</subject>
<description type="Chief Investigator">Dr Yanchuan Shi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Modern diets high in sugar and fat have contributed significantly to the prevalence of obesity. However, tackling obesity by lowering dietary fat content in our diets has not succeeded to the degree that we expected. As a result, obesity is on the rise. Recently, my team has discovered that high salt intake, often present in a high fat diet, could be a key and overlooked factor that potentially contributes to the development and progression of obesity, especially combined with high fat feeding.</description>
<description type="fundingAmount">$860,943.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019372</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019372</identifier>
<identifier type="nhmrc">2019372</identifier>
<name type="primary"><namePart>Developing an in vitro human sleep system</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | </subject>
<subject type="local">neurodevelopment </subject>
<subject type="local">neurodevelopmental disorders</subject>
<subject type="local">gene regulation</subject>
<subject type="local">hypothalamus</subject>
<subject type="local">sleep</subject>
<description type="Chief Investigator">Prof Stefan Thor</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to understand the formation of cells in the brain that are critical for controlling sleep. These sleep neurons are often affected in sleep disorders such as narcolepsy, a condition involving sudden attacks of sleep that affects 1/2,000 humans. By understanding how sleep neurons develop within the brain we will be able to generate sleep neurons from stem cells. This will pave the way for future bench-to-clinic transplantation experiments to alleviate narcolepsy.</description>
<description type="fundingAmount">$599,036.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019383</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019383</identifier>
<identifier type="nhmrc">2019383</identifier>
<name type="primary"><namePart>Stimulating Biomimetic Neuroplasticity to Develop New Cell Therapy for Blindness.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | vision science | </subject>
<subject type="local">stem cell transplantation </subject>
<subject type="local">vision loss</subject>
<subject type="local">photoreceptors</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">neuroplasticity</subject>
<description type="Chief Investigator">Dr Anai Gonzalez Cordero</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The loss of light-sensing photoreceptors is a leading cause of blindness. Severe cases have no treatments, and we thus aim to develop effective cell therapy by transplantation of photoreceptors to restore vision. We can generate millions of these cells from stem cell generated mini-retinas (organoids), but transplantation outcomes are still ineffective. Here we will test whether electrical stimulation improves photoreceptor transplantation in animal models to rescue sight and treat blindness.</description>
<description type="fundingAmount">$790,265.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019404</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019404</identifier>
<identifier type="nhmrc">2019404</identifier>
<name type="primary"><namePart>Microelectrode recordings from the vagus nerve in awake humans</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | autonomic nervous system  | </subject>
<subject type="local">vagus nerve </subject>
<subject type="local">parasympathetic nervous system</subject>
<subject type="local">microneurography</subject>
<subject type="local">baroreceptors</subject>
<subject type="local">orthostatic hypotension</subject>
<description type="Chief Investigator">Prof Vaughan Macefield</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The vagus nerve is an important nerve that controls the heart, lungs and gut. It exits the brain and travels with the carotid arteries and jugular veins in the neck. As such it has defied direct investigation in humans, but here we have developed a means of inserting metal microelectrodes into this nerve and recording signals going to and from the brain. This approach promises to provide much needed information on how the organ control provided by the vagus nerve is affected in disease states.</description>
<description type="fundingAmount">$1,246,924.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019416</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019416</identifier>
<identifier type="nhmrc">2019416</identifier>
<name type="primary"><namePart>The Neurokinin 3 Receptor is a New Target for the Treatment of Autism Spectrum Disorder.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | cellular nervous system | </subject>
<subject type="local">autism </subject>
<subject type="local">neuron</subject>
<subject type="local">neuropeptides</subject>
<subject type="local">brain development</subject>
<subject type="local">electrophysiology</subject>
<description type="Chief Investigator">Dr Nathalie Dehorter</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">No treatment has been shown to be effective in treating the core symptoms of autism spectrum disorder. We have discovered a molecule, named NK3R, which plays a key role in the development of autism. Studying how this molecule works in mouse models of autism will help us to better understand the disorder and enable us to identify the signs of abnormal brain function. The outcomes of this 4-year research will ultimately enable us to propose new strategies to treat the symptoms of autism.</description>
<description type="fundingAmount">$996,128.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019420</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019420</identifier>
<identifier type="nhmrc">2019420</identifier>
<name type="primary"><namePart>Human anogenital mononuclear phagocytes in tranmission of HIV</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology  | </subject>
<subject type="local">human immunodeficiency virus (hiv) </subject>
<subject type="local">cellular immunology</subject>
<subject type="local">dendritic cell</subject>
<subject type="local">flow cytometry</subject>
<subject type="local">confocal microscopy</subject>
<description type="Chief Investigator">Prof Andrew Harman</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Dendritic cells (DC) are the first cells to interact with HIV and the program has discovered three that transmit the virus. This proposal will define the receptors these DCs use to bind HIV and how they activate the immune system which is important information for vaccine design. Using new technologies that the research program has pioneered, the proposal will also define how HIV transmission occurs in human inflamed tissue for the first time which will lead to better prophylactic treatments.</description>
<description type="fundingAmount">$802,780.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019437</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019437</identifier>
<identifier type="nhmrc">2019437</identifier>
<name type="primary"><namePart>Targeting phenotypic plasticity to treat chemotherapy-resistant cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </subject>
<subject type="local">breast cancer metastases </subject>
<subject type="local">cancer treatment</subject>
<subject type="local">cancer cell biology</subject>
<subject type="local">cancer chemotherapy</subject>
<subject type="local">epithelial-mesenchymal transition (emt)</subject>
<description type="Chief Investigator">Assoc Prof Christine Chaffer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Some cancer cells are very aggressive. Those cells are the reason why cancers become resistant to chemotherapy. If we can eradicate the aggressive cells we can improve survival outcomes for patients. We have identified a new target, SULF1, that is required for cancer cells to be aggressive and evade chemotherapy. We now aim to show that by targeting SULF1 we can stop cancers from spreading and make them susceptible to chemotherapy.</description>
<description type="fundingAmount">$929,996.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019442</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019442</identifier>
<identifier type="nhmrc">2019442</identifier>
<name type="primary"><namePart>Improving parent and child emotion regulation in early childhood to reduce population rates of child mental illness</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02czsnj07</identifier><title>Deakin University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">psychology | applied and developmental psychology | applied and developmental psychology not elsewhere classified | </subject>
<subject type="local">parenting </subject>
<subject type="local">mental health promotion</subject>
<subject type="local">child development</subject>
<subject type="local">community intervention study</subject>
<subject type="local">child behaviour</subject>
<description type="Chief Investigator">Dr Elizabeth Westrupp</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The project develops and trials a new smartphone intervention that will radically redesign models for parenting support and the prevention of child mental illness. We aim to engage both mothers and fathers of children 2-4 years, and will optimise parent and child outcomes: (a) tailoring parenting resources to be relevant to specific parenting situations; (b) including Indigenous-led, culturally-derived content; and (c) using machine learning to personalise the delivery of 3 types of support.</description>
<description type="fundingAmount">$1,392,462.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019447</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019447</identifier>
<identifier type="nhmrc">2019447</identifier>
<name type="primary"><namePart>Understanding clonal hierarchy and tissue reconstitution post injury</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </subject>
<subject type="local">experimental haematology </subject>
<subject type="local">adult stem cells</subject>
<subject type="local">epigenetics</subject>
<subject type="local">plasticity</subject>
<subject type="local">t cell development</subject>
<description type="Chief Investigator">Dr ALI MOTAZEDIAN</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Millions of blood cells are made by the body every day in specialised organ compartments. T-cells are white blood cells and make up an important part of the immune system that fights infections and cancer. In this study, we aim to find out how blood stem cells turn into T-cells as they move through different organ compartments. We are trying to understand how the blood system is regenerated after damage from cancer therapies by stem cell transplants to improve patient outcomes.</description>
<description type="fundingAmount">$691,296.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019455</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019455</identifier>
<identifier type="nhmrc">2019455</identifier>
<name type="primary"><namePart>Harnessing the therapeutic potential of mesenchymal stromal cells by priming via surface microtopographies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | engineering | biomedical engineering | biomaterials  | </subject>
<subject type="local">cell therapy </subject>
<subject type="local">autocrine/paracrine regulation</subject>
<subject type="local">biomaterials</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">biomedical engineering</subject>
<description type="Chief Investigator">Assoc Prof Jessica Frith</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mesenchymal stromal cells (MSCs) promote tissue repair, but lose their beneficial properties during the production process outside the body. We have found that culturing MSCs on surfaces with microscale patterns alters their properties. We will investigate how these surfaces improve the therapeutic activity of MSCs and develop a technology to allow this to be done at a large scale. Our discoveries will enable higher quality MSCs to be produced for therapies for a wide range of diseases.</description>
<description type="fundingAmount">$836,365.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019477</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019477</identifier>
<identifier type="nhmrc">2019477</identifier>
<name type="primary"><namePart>Developing PKCepsilon-Degrading PROTACs as Dual-Action Agents to Treat Type 2 Diabetes</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">medicinal chemistry </subject>
<subject type="local">protein kinase c (pkc)</subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">drug design</subject>
<subject type="local">ubiquitin-mediated proteolysis</subject>
<description type="Chief Investigator">Assoc Prof Carsten Schmitz-Peiffer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Type 2 diabetes (T2D) is reaching epidemic proportions worldwide, and involves poor insulin production and decreased insulin sensitivity. This collaboration between diabetes researchers and medicinal chemists will translate basic science, demonstrating that inhibiting one enzyme can improve both these defects, into the generation of lead compounds that block this target. We will test inhibitors in models of T2D, providing proof-of-principle for their further development.</description>
<description type="fundingAmount">$825,490.65</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019488</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019488</identifier>
<identifier type="nhmrc">2019488</identifier>
<name type="primary"><namePart>A calcium influx pathway regulates adaptive cancer drug tolerance</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </subject>
<subject type="local">molecular pharmacology </subject>
<subject type="local">pharmacology</subject>
<subject type="local">calcium signalling</subject>
<subject type="local">calcium imaging</subject>
<subject type="local">calcium channels</subject>
<description type="Chief Investigator">Prof Gregory Monteith</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">New drugs for the treatment of melanoma, lung and other cancers has revolutionised therapeutic approaches for many patients. However, in many cases, cancers become tolerant and eventually completely resistant to these new therapies. This project team has identified a specific new drug target that may hold the key to preventing or reversing the tolerance to these therapies. This grant will focus on defining the therapeutic opportunities that this new drug target offers.</description>
<description type="fundingAmount">$690,303.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019492</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019492</identifier>
<identifier type="nhmrc">2019492</identifier>
<name type="primary"><namePart>Hijacking enzymes that charge tRNAs: a new strategy for development of anti-malarials.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | enzymes | biological sciences | microbiology | infectious agents | </subject>
<subject type="local">infectious diseases </subject>
<subject type="local">medical parasitology</subject>
<subject type="local">antimalarial</subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">structural biology</subject>
<description type="Chief Investigator">Prof Leann Tilley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">New drugs are desperately needed to treat drug-resistant pathogens. We have discovered a class of inhibitor molecules, called “nukes”, that target enzymes powered by the energy molecule, ATP. “Nukes” induce the enzymes to generate their own inhibitors, via a mechanism that we call “reaction hijacking”. This project will investigate the design principles for making bespoke “nukes”, which will have applications in curing malaria, as well as infections with antimicrobial resistant bacteria.</description>
<description type="fundingAmount">$758,942.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019552</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019552</identifier>
<identifier type="nhmrc">2019552</identifier>
<name type="primary"><namePart>Unlocking the potential of cancer associated fibroblasts to defeat pancreatic cancer.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">pancreatic cancer </subject>
<subject type="local">fibroblasts</subject>
<subject type="local">cell metabolism</subject>
<subject type="local">cancer chemotherapy</subject>
<subject type="local">drug resistance</subject>
<description type="Chief Investigator">Dr Zaklina Kovacevic</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There are key knowledge gaps in understanding the complex metabolism of the pancreatic cancer tumour microenvironment and how this influences poor response to current therapies. My research will directly address this by characterizing how the pancreatic cancer tumour microenvironment evolves as cancer progresses and its response to current therapies. This will inform development of more effective treatment strategies that can overcome resistance and improve patient outcomes.</description>
<description type="fundingAmount">$636,920.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019558</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019558</identifier>
<identifier type="nhmrc">2019558</identifier>
<name type="primary"><namePart>Dysregulated lymphatic vasculature in the pathogenesis of bronchopulmonary dysplasia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology | </subject>
<subject type="local">bronchopulmonary dysplasia </subject>
<subject type="local">lymphangiogenesis</subject>
<subject type="local">angiogenesis</subject>
<subject type="local">lung development</subject>
<subject type="local">vascular endothelium</subject>
<description type="Chief Investigator">Assoc Prof Margaret Hibbs</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bronchopulmonary dysplasia is a severe lung disease that is a main cause of disability and death in premature infants and there is no cure. We have found that a factor that enhances the growth of lung lymphatic vessels, essential fluid channels, protects the lung from structural and functional damage. We will used advanced research methods to define the role of these vessels in this disease to turn our discovery into new treatments that can help these tiny lungs develop and function normally.</description>
<description type="fundingAmount">$1,490,644.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019572</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019572</identifier>
<identifier type="nhmrc">2019572</identifier>
<name type="primary"><namePart>Targeting pyroptosis to limit the severity of influenza virus infections</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">influenza virus </subject>
<subject type="local">host/pathogen interaction</subject>
<subject type="local">inflammation</subject>
<subject type="local">immunomodulation</subject>
<subject type="local">innate immunity</subject>
<description type="Chief Investigator">Assoc Prof Michelle Tate</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Highly pathogenic influenza A virus infections are associated with highly mortality rates. To facilitate the development of improved treatments for severe IAV infections, this project will advance our fundamental knowledge of the mechanisms by which the host and virus interact and elucidate how the host's immune system can be therapeutically modulated to limit disease severity. These studies are crucial to ensure we are better prepared for the next pandemic.</description>
<description type="fundingAmount">$1,062,685.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019595</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019595</identifier>
<identifier type="nhmrc">2019595</identifier>
<name type="primary"><namePart>The role of genetic compensation in modifying disease severity and potential therapeutic application</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">developmental biology </subject>
<subject type="local">developmental genetics</subject>
<subject type="local">transcriptional regulation</subject>
<subject type="local">disease modelling</subject>
<subject type="local">zebrafish</subject>
<description type="Chief Investigator">Dr Tamar Sztal</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Harmful mutations in the genome have significant impacts on health and survival. Recent studies have identified individuals with mutations, that are expected to cause disease, yet they are remarkably asymptomatic. Growing evidence suggests this is due to compensatory activation of other genes, masking the effects of damaging mutations. This project examines the trigger for this compensation to determine its relevance in preventing disease and potential use in genetic therapies.</description>
<description type="fundingAmount">$640,308.90</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019655</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019655</identifier>
<identifier type="nhmrc">2019655</identifier>
<name type="primary"><namePart>Tracking transcriptional evolution in breast cancer using circulating tumour DNA</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | </subject>
<subject type="local">solid tumours </subject>
<subject type="local">bioinformatics</subject>
<subject type="local">genomics</subject>
<subject type="local">gene expression</subject>
<subject type="local">drug resistance</subject>
<description type="Chief Investigator">Dr Dineika Chandrananda</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Tumours shed small amounts of DNA into the patient’s bloodstream. Therefore, a simple blood test gives us a window to study the cancer, offering a non-invasive alternative to tissue biopsies. This project will use circulating tumour DNA in blood to study how cancer evolves and becomes resistant to treatment in advanced breast cancer where only 25% of patients survive beyond five years. Our method is generalisable across tumour types and has the potential to transform real-time cancer monitoring.</description>
<description type="fundingAmount">$663,211.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019670</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019670</identifier>
<identifier type="nhmrc">2019670</identifier>
<name type="primary"><namePart>Novel methods to improve reporting and peer review of systematic reviews of health evidence</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | health sciences | epidemiology | epidemiological methods | mathematical sciences | statistics | biostatistics | </subject>
<subject type="local">meta-analysis </subject>
<subject type="local">evidence-based</subject>
<subject type="local">methodology</subject>
<subject type="local">guidelines</subject>
<subject type="local">intervention study</subject>
<description type="Chief Investigator">Dr Matthew Page</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Systematic reviews focus on the totality of available evidence on a given question, and often underpin healthcare decision making. However, the reporting of many systematic reviews is suboptimal. This amounts to wasted research effort, and systematic reviews that cannot reliably inform clinical and public health guidelines. This proposal will develop guidance and web apps to help researchers produce systematic reviews that better meet the needs of stakeholders, hence improving health outcomes.</description>
<description type="fundingAmount">$552,225.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019689</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019689</identifier>
<identifier type="nhmrc">2019689</identifier>
<name type="primary"><namePart>On target and on time, advancing molecular diagnosis of complicated childhood pneumonia for better patient outcomes and vaccine strategies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | </subject>
<subject type="local">pneumonia </subject>
<subject type="local">streptococcus pneumoniae</subject>
<subject type="local">molecular diagnosis</subject>
<subject type="local">antibiotics</subject>
<subject type="local">vaccine</subject>
<description type="Chief Investigator">Assoc Prof Catherine Satzke</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">During pleural infection fluid pools in the lung. Identifying the bacterial cause is important, so children can receive the right antibiotics. Our new laboratory test can better identify bacteria than traditional methods. We will use our test to determine which bacteria are causing pleural infection in Asian children and how our test will improve clinical care. We will apply other molecular methods to determine how many cases could be prevented by pneumococcal vaccines.</description>
<description type="fundingAmount">$1,133,729.65</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019722</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019722</identifier>
<identifier type="nhmrc">2019722</identifier>
<name type="primary"><namePart>Targeting Impaired Glucose Sensing in the Brain to Improve Glucose Homeostasis in T2D</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">hypothalamus </subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">obesity</subject>
<subject type="local">protein kinase c (pkc)</subject>
<subject type="local">molecular neuroscience</subject>
<description type="Chief Investigator">Assoc Prof Carsten Schmitz-Peiffer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">New drugs working in novel ways are needed to treat type 2 diabetes, because current treatments fail to prevent the progression of the disease. We showed that an enzyme, PKCe, interferes with the the sensitivity of the brain to glucose, so that it fails to respond to rising glucose levels. We will investigate how this enzyme prevents the brain from controlling blood glucose levels, and will also test whether blocking PKCe is able to improve glucose sensing, paving the way for drug development.</description>
<description type="fundingAmount">$961,576.40</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019729</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019729</identifier>
<identifier type="nhmrc">2019729</identifier>
<name type="primary"><namePart>Determination of “actionable vaccine targets” for breast cancer immunotherapy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">proteomics </subject>
<subject type="local">human leukocyte antigen (hla)</subject>
<subject type="local">antigen presentation</subject>
<subject type="local">breast cancer</subject>
<subject type="local">cancer immunotherapy</subject>
<description type="Chief Investigator">Dr Pouya Faridi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In recent years, immunotherapy brings hopes for treatment of incurable cancer. However, understanding the right target for immunotherapy is critical and challenging. We have developed new technologies and will explore new classes of antigens that can form targets of vaccines and immunotherapy in breast cancer.</description>
<description type="fundingAmount">$1,377,141.75</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019765</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019765</identifier>
<identifier type="nhmrc">2019765</identifier>
<name type="primary"><namePart>Harnessing metabolism to improve the outcomes of deadly fungal infections</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | mycology  | </subject>
<subject type="local">mycology </subject>
<subject type="local">medical mycology</subject>
<subject type="local">candida</subject>
<subject type="local">fungal infection</subject>
<subject type="local">fungal pathogenesis</subject>
<description type="Chief Investigator">Prof Ana Traven</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Life-threatening infections are complications of surgery, chemotherapy and organ transplantations. Therapies are limited and mortality is high. This project studies how metabolic adaptations could be harnessed to provide energy for effective immune responses and maintaining the function of vital organs during life-threatening fungal infection. We expect that the knowledge gained in this project will inform therapeutic innovations aimed at improving patient survival of serious fungal infections.</description>
<description type="fundingAmount">$955,684.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019767</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019767</identifier>
<identifier type="nhmrc">2019767</identifier>
<name type="primary"><namePart>Characterising a novel toxin regulatory mechanism from the new hypervirulent Streptococcal pyogenes M1uk lineage in Australia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00jtmb277</identifier><title>University of Wollongong</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | </subject>
<subject type="local">streptococcus pyogenes </subject>
<subject type="local">group a streptococcal disease</subject>
<subject type="local">bacterial pathogenesis</subject>
<subject type="local">bacterial virulence factors</subject>
<subject type="local">bacterial toxins</subject>
<description type="Chief Investigator">Assoc Prof Martina Sanderson-Smith</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Group A Streptococcus (GAS) is a strictly human pathogen that ranks among the top 10 infectious disease killers. A new variant of GAS expressing a novel set of bacterial toxins has emerged in the United Kingdom, known as M1UK. The M1UK lineage is associated with increases in invasive disease. We have now detected that this new GAS M1UK lineage has arrived in Australia. This proposal will define the disease mechanisms underlying this new health threat to Australian and global health.</description>
<description type="fundingAmount">$1,058,650.97</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019780</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019780</identifier>
<identifier type="nhmrc">2019780</identifier>
<name type="primary"><namePart>GABA-A receptor variants in developmental and epileptic encephalopathy: a bench to bedside approach.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | </subject>
<subject type="local">intractable epilepsy syndromes </subject>
<subject type="local">gamma-aminobutyric acid (gaba) receptors</subject>
<subject type="local">antiepileptic drugs</subject>
<subject type="local">genetic analysis</subject>
<subject type="local">pharmacological intervention</subject>
<description type="Chief Investigator">Assoc Prof Philip Ahring</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Developmental epileptic encephalopathies (DEE) are a group of severe brain disorders characterised by childhood seizures that are often treatment resistant. We identified that hyperactivity in GABA-A receptors (the major inhibitory protein of the brain) caused by novel mutations are responsible for treatment resistant DEE. With a team of scientists, geneticists, and neurologists we aim to decipher the role of these receptors in brain networks and translate our discoveries to the clinic.</description>
<description type="fundingAmount">$2,240,955.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019804</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019804</identifier>
<identifier type="nhmrc">2019804</identifier>
<name type="primary"><namePart>Testing a preventative strategy for sudden unexpected death in epilepsy (SUDEP) in mouse models based on human genetics</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | genetics | neurogenetics | </subject>
<subject type="local">epilepsy </subject>
<subject type="local">cardiac arrhythmia</subject>
<subject type="local">ion channels</subject>
<subject type="local">electrophysiology</subject>
<subject type="local">sudden death</subject>
<description type="Chief Investigator">Prof Christopher Reid</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">What causes sudden unexpected death in epilepsy (SUDEP) in unclear, although irregular heart rhythm is suspected to play a role. We recently found that genetic changes in the heart could help identify epilepsy patients who are at higher risk of SUDEP. By introducing these genetic changes in research models, we can understand how the heart responds in events leading up to SUDEP, and if improving heart function with currently available therapies can reduce SUDEP risk.</description>
<description type="fundingAmount">$917,002.71</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019818</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019818</identifier>
<identifier type="nhmrc">2019818</identifier>
<name type="primary"><namePart>Inspire the bright side of kidney fibroblasts to prevent and cure chronic kidney disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | nephrology and urology  | </subject>
<subject type="local">renal fibrosis </subject>
<subject type="local">fibroblasts</subject>
<subject type="local">drug delivery</subject>
<subject type="local">tissue regeneration</subject>
<subject type="local">cell therapy</subject>
<description type="Chief Investigator">Assoc Prof Xin-Ming Chen</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic kidney disease (CKD) is a worldwide public health problem. Current clinical strategies for CKD are largely ineffective. Kidney transplantation and dialysis are the only options for the management of end stage kidney disease (ESKD), which results in a significant personal and societal burden. This project will innovatively promote the good function but hinder the bad role of kidney fibroblasts thereby conferring renal protection in CKD through targeting En-1 gene function.</description>
<description type="fundingAmount">$895,653.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019831</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019831</identifier>
<identifier type="nhmrc">2019831</identifier>
<name type="primary"><namePart>Healing Spirit, Healing Minds: Co-designed healing program to promote social and emotional wellbeing of Aboriginal and Torres Strait Islander youth.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | indigenous studies | aboriginal and torres strait islander peoples, society and community | aboriginal and torres strait islander community-based research | </subject>
<subject type="local">indigenous health </subject>
<subject type="local">aboriginal mental health</subject>
<subject type="local">mental health promotion</subject>
<subject type="local">community-based</subject>
<subject type="local">participatory action research</subject>
<description type="Chief Investigator">Ms Hayley Williams</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The Healing Spirits, Healing Minds project will co-design and evaluate a healing program under the leadership of First Nations youth that are most at risk of suffering from undetected and under-supported suicidal ideations and behaviours. The resulting program is anticipated to incorporate peer mentorship with activities focused on 1) promoting empowerment and wellbeing, 2) building social connections, 3) facilitating emotional regulation, and 4) encouraging help seeking behaviours.</description>
<description type="fundingAmount">$886,931.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019843</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019843</identifier>
<identifier type="nhmrc">2019843</identifier>
<name type="primary"><namePart>Targeting metastatic pancreatic cancer via selective inhibition of oncogenic JNK</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">cell signalling </subject>
<subject type="local">cancer metastasis</subject>
<subject type="local">pancreatic cancer</subject>
<subject type="local">mouse models</subject>
<subject type="local">c-jun/jnk kinase</subject>
<description type="Chief Investigator">Assoc Prof David Croucher</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pancreatic cancer is one of the most lethal forms of human cancer. The current standard-of-care chemotherapies are known to be largely ineffective against advanced disease and new treatment options are urgently needed. We have developed a novel drug (K12) that selectively inhibits the metastatic function of JNK in breast cancer, and shown that this oncogenic pathway is conserved in pancreatic cancer. We will now test the utility of our novel drug as a treatment for metastatic pancreatic cancer.</description>
<description type="fundingAmount">$775,663.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019853</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019853</identifier>
<identifier type="nhmrc">2019853</identifier>
<name type="primary"><namePart>Developing novel therapeutic strategies and predictive biomarkers in Pancreatic Cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">pancreatic cancer </subject>
<subject type="local">targeted therapy</subject>
<subject type="local">biomarkers</subject>
<subject type="local">signalling pathways</subject>
<subject type="local">dna barcoding</subject>
<description type="Chief Investigator">Prof Frederic Hollande</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pancreatic cancers are frequent and have extremely poor outcomes. Very few treatments are available for patients with this disease. Candidate drugs have recently emerged to block specific genetic modifications found in this cancer, but tumour cells can often evade these treatments. Here, we will combine innovative genetic and cellular analyses to design specific drug combinations preventing the ability of pancreatic cancers to escape treatment and thus improving the treatment of this disease.</description>
<description type="fundingAmount">$1,230,897.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019859</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019859</identifier>
<identifier type="nhmrc">2019859</identifier>
<name type="primary"><namePart>Identifying modifiable health and social determinants of 'deaths of despair': learning from the past to shape new interventions</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | epidemiology | epidemiology not elsewhere classified | </subject>
<subject type="local">avoidable deaths </subject>
<subject type="local">suicide</subject>
<subject type="local">drug utilisation</subject>
<subject type="local">data linkage</subject>
<subject type="local">health care utilisation</subject>
<description type="Chief Investigator">Dr Natasa Gisev</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Deaths of despair (due to alcohol, other substances, and suicide) have risen dramatically in Australia and globally over the last 20 years. These are avoidable deaths given timely and targeted intervention. Using population-based data linkage, novel machine learning methods, and mathematical modelling, we will examine risk factors, and model the impact of potential interventions to reduce deaths of despair to inform targeted strategies and policies to prevent these premature deaths occurring.</description>
<description type="fundingAmount">$1,027,327.70</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019867</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019867</identifier>
<identifier type="nhmrc">2019867</identifier>
<name type="primary"><namePart>A new brain circuit of GPR75 to regulate metabolism</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical physiology | systems physiology  | </subject>
<subject type="local">overweight/obesity </subject>
<subject type="local">hypertension</subject>
<subject type="local">glucose homeostasis</subject>
<subject type="local">energy balance</subject>
<subject type="local">hypothalamus</subject>
<description type="Chief Investigator">Dr Yi Wang</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The increasing prevalence of obesity represents a major public health crisis worldwide. In Australia, almost two-thirds of adults are overweight or obese. GPR75 is a gene recently identified to play an important role in body weight regulation. Indeed, humans and mice carrying loss-of-function mutations of GPR75 are protected from obesity. This proposal will determine the specific site of action, and underlying mechanism of GPR75-induced protection against obesity, and its related hypertension.</description>
<description type="fundingAmount">$643,424.26</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019871</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019871</identifier>
<identifier type="nhmrc">2019871</identifier>
<name type="primary"><namePart>Novel regulation of a fundamental host defence pathway by human herpesviruses</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">herpes simplex virus (hsv) </subject>
<subject type="local">cytomegalovirus (cmv) infection</subject>
<subject type="local">virus pathogenesis</subject>
<subject type="local">immune evasion</subject>
<subject type="local">viral infection</subject>
<description type="Chief Investigator">Assoc Prof Barry Slobedman</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Human cytomegalovirus (HCMV) and herpes simplex virus (HSV) often cause serious disease. Eg, HCMV is the leading infectious cause of birth defects and a major complication in transplant patients, and HSV causes cold sores that can be life-threatening in those with a compromised immune system. We have identified a novel way that these viruses can control the host response to infection. This research proposal will investigate this control to identify potential ways to control viral disease.</description>
<description type="fundingAmount">$925,288.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019889</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019889</identifier>
<identifier type="nhmrc">2019889</identifier>
<name type="primary"><namePart>A novel therapeutic target for obesity: Salt-inducible kinase 3 (SIK3)</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02k3cxs74</identifier><title>St Vincents Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical physiology | cell physiology | biological sciences | biochemistry and cell biology | systems biology | </subject>
<subject type="local">protein kinases </subject>
<subject type="local">energy metabolism</subject>
<subject type="local">cell metabolism</subject>
<subject type="local">energy expenditure</subject>
<subject type="local">thermogenesis</subject>
<description type="Chief Investigator">Dr Kim Loh</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The overconsumption of high calorie foods together with sedentary lifestyle are key reasons for the obesity epidemic. The brain plays an important role in controlling the amount of energy intake and expenditure. However, how the brain controls these physiological processes remain poorly understood. In this proposal, we aim to study a new molecule in the brain to control appetite and body weight and establish this molecule as a potential new therapeutic target for the treatment of obesity.</description>
<description type="fundingAmount">$987,440.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019904</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019904</identifier>
<identifier type="nhmrc">2019904</identifier>
<name type="primary"><namePart>Endothelial origin of left ventricular non compaction</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | </subject>
<subject type="local">endothelial cells </subject>
<subject type="local">congenital heart disease</subject>
<subject type="local">transcription factor</subject>
<subject type="local">embryo development</subject>
<subject type="local">morphogenesis</subject>
<description type="Chief Investigator">Assoc Prof Mathias Francois</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Primary cardiac myopathies refers to inheritable heart diseases, characterised by weak heart muscles. A common form of these disorders is left ventricular non-compaction (LVNC). By enlarge our understanding of the cellular origin of these cardiac defects is still unknown. This proposal will investigate how defects in blood vessel formation during embryogenesis is a cause of LVNC. This work will help to risk-stratify patients with LVNC cardiac disease to better manage adverse outcome.</description>
<description type="fundingAmount">$1,094,172.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019912</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019912</identifier>
<identifier type="nhmrc">2019912</identifier>
<name type="primary"><namePart>Understanding how platelets prevent fetal and neonatal stroke</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | </subject>
<subject type="local">platelets </subject>
<subject type="local">abnormal embryogenesis</subject>
<subject type="local">stroke prevention</subject>
<subject type="local">neonatal survival</subject>
<subject type="local">intracerebral haemorrhage</subject>
<description type="Chief Investigator">Dr Samir Taoudi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Stroke is caused by either abnormal clotting or by unchecked bleeding; both result in devastating damage to the brain, causing death or life-long disability. Newborn children with low platelet numbers are at high risk of bleeding-associated stroke, yet we do not understand why. We hypothesize that the cause is rooted in early development. We will identify when these problems arise and define therapeutic strategies for the prevention or amelioration of neonatal stroke.</description>
<description type="fundingAmount">$744,803.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019920</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019920</identifier>
<identifier type="nhmrc">2019920</identifier>
<name type="primary"><namePart>Uncovering and detecting placental dysfunction in late-onset preeclampsia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </subject>
<subject type="local">placenta </subject>
<subject type="local">pregnancy complications</subject>
<subject type="local">hypertension</subject>
<subject type="local">biomarkers</subject>
<subject type="local">lipid metabolism</subject>
<description type="Chief Investigator">Dr Ellen Menkhorst</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Preeclampsia is a life-threatening disease of pregnancy with grave immediate and life-long consequences for the mother and baby. The root cause of preeclampsia is an unhealthy placenta which releases toxins into the maternal blood causing maternal organ damage. This project will identify early pregnancy biomarkers to detect women who are at risk of developing preeclampsia and discover the key molecular mechanisms which drive preeclampsia, leading to new preventative treatment options.</description>
<description type="fundingAmount">$1,222,195.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019925</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019925</identifier>
<identifier type="nhmrc">2019925</identifier>
<name type="primary"><namePart>Metformin, gut epithelium and microbiome in the prevention of colorectal cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | microbiology not elsewhere classified | biological sciences | biochemistry and cell biology | glycobiology | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">colorectal cancer </subject>
<subject type="local">molecular microbiology</subject>
<subject type="local">glycobiology</subject>
<subject type="local">proteome analysis</subject>
<subject type="local">neoplasia</subject>
<description type="Chief Investigator">Prof Nicolle Packer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Prevention of colorectal cancer (CRC) saves lives. Metformin, a safe drug clinically used as an anti-diabetic therapy, has been shown to suppress cancer. Yet, its successful implementation as a CRC preventative is limited by a lack of knowledge on how metformin elicits these anti-cancer effects. Our project will provide a holistic understanding of how metformin impacts the colon lining, its microbiome and CRC development.</description>
<description type="fundingAmount">$847,242.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019931</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019931</identifier>
<identifier type="nhmrc">2019931</identifier>
<name type="primary"><namePart>The first tool to quantify brain copper during life</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </subject>
<subject type="local">medical imaging </subject>
<subject type="local">positron emission tomography (pet)</subject>
<subject type="local">copper</subject>
<subject type="local">neurodegeneration</subject>
<subject type="local">parkinson disease</subject>
<description type="Chief Investigator">Prof Kay Double</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Copper is essential for brain health but serious diseases result from either too much, or too little, copper in the brain. Unfortunately we do not have a method to measure brain copper levels. This limits our ability to understand the role of copper in these disorders and to deliver safe, effective treatments to patients. We are developing a technology to directly measure brain copper levels during life to solve these important problems.</description>
<description type="fundingAmount">$1,087,644.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019934</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019934</identifier>
<identifier type="nhmrc">2019934</identifier>
<name type="primary"><namePart>Novel determinants of male fertility carried by seminal fluid extracellular vesicles</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | reproduction  | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </subject>
<subject type="local">reproductive biology </subject>
<subject type="local">male reproduction</subject>
<subject type="local">sperm function</subject>
<subject type="local">reproductive immunology</subject>
<subject type="local">fertility</subject>
<description type="Chief Investigator">Dr John Schjenken</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">A father's influence over reproductive outcome goes beyond the provision of sperm. Our research has shown that signals carried by seminal fluid influence the likelihood of conception and pregnancy, but the identity and regulation of these signals is unknown. This research will define novel drivers of fertility and expand our understanding of the biological events at conception. Ultimately, these findings will inform the development of therapeutics that address the rising burden of infertility.</description>
<description type="fundingAmount">$899,842.25</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019948</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019948</identifier>
<identifier type="nhmrc">2019948</identifier>
<name type="primary"><namePart>Harnessing a native corticosteroid-binding globulin to treat life-threatening septic shock</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | health services and systems | health services and systems not elsewhere classified | </subject>
<subject type="local">glucocorticoids </subject>
<subject type="local">septic shock</subject>
<subject type="local">binding protein</subject>
<subject type="local">morbidity</subject>
<subject type="local">mortality</subject>
<description type="Chief Investigator">Assoc Prof Richard Young</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Septic shock is a maladaptive response to overwhelming infection that leads to organ failure and death. Corticosteroid-binding globulin (CBG) is a blood protein with unique properties to deliver the body’s natural anti-inflammatory hormone, glucocorticoid, to threatened organs - but its excessive depletion in septic shock triples the risk of dying. Our experiments in mouse models of sepsis are important next steps towards the use of CGB therapy to prevent deterioration and death in patients.</description>
<description type="fundingAmount">$1,235,442.20</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019968</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019968</identifier>
<identifier type="nhmrc">2019968</identifier>
<name type="primary"><namePart>Developing Therapeutic Engineered Virus-Like Particles to Target Genetic Diseases of the Retina</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biomedical and clinical sciences | ophthalmology and optometry | vision science | </subject>
<subject type="local">gene therapy </subject>
<subject type="local">lentiviral vector</subject>
<subject type="local">retinal disease</subject>
<subject type="local">molecular biology</subject>
<subject type="local">genetic engineering</subject>
<description type="Chief Investigator">Assoc Prof Leszek Lisowski</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inherited retinal disease is a leading cause of blindness among working-aged adults. Advances in diagnosis have identified mutations in genes which can cause these diseases. The project aims to develop and construct personalised gene therapy treatments for patients with inherited retinal diseases. The team will combine customised gene editing tools to fix their particular gene mutation together with a delivery system that specifically target the affected cell type.</description>
<description type="fundingAmount">$1,094,135.32</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019970</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019970</identifier>
<identifier type="nhmrc">2019970</identifier>
<name type="primary"><namePart>The neural bases of inhibitory learning and disorders of action control</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | behavioural neuroscience | </subject>
<subject type="local">cognitive dysfunction </subject>
<subject type="local">basal ganglia</subject>
<subject type="local">striatum</subject>
<subject type="local">dopamine</subject>
<subject type="local">impulse control disorder</subject>
<description type="Chief Investigator">Dr Miriam Matamales</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Several mental disorders including Tourette syndrome and obsessive-compulsive disorder, share a common feature, that is, the repeated urge to engage in behavioural sequences that are counterproductive or damaging. This proposal will study the neural bases of naturally-occurring processes for behaviour change by which subjects learn to inhibit maladaptive actions. The findings will help develop effective therapeutic interventions that promote inhibitory learning in affected individuals.</description>
<description type="fundingAmount">$486,802.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019988</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019988</identifier>
<identifier type="nhmrc">2019988</identifier>
<name type="primary"><namePart>A human experimental model to assess whether the gut microbiota regulates specific and non-specific immune responses to vaccination</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified | biological sciences | biochemistry and cell biology | systems biology | biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">vaccine biology </subject>
<subject type="local">microbial ecology</subject>
<subject type="local">systems biology</subject>
<subject type="local">genomics</subject>
<subject type="local">vaccination immunology</subject>
<description type="Chief Investigator">Prof David Lynn</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Our hypothesis is that the gut microbiota is a critical and targetable factor regulating specific and non-specific immune responses to vaccination. To assess this, we will investigate the impact of depleting the human gut microbiota on protection mediated by the BCG vaccine against microbes specifically targeted by the vaccine and unrelated infections. This study will lead to new interventions to maximise vaccine mediated protection in vulnerable populations worldwide.</description>
<description type="fundingAmount">$1,579,475.25</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019991</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019991</identifier>
<identifier type="nhmrc">2019991</identifier>
<name type="primary"><namePart>Transforming the management of perinatal depression through precision medicine to improve outcomes for women and children</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </subject>
<subject type="local">antidepressants </subject>
<subject type="local">pharmacogenetics</subject>
<subject type="local">perinatal</subject>
<subject type="local">depression</subject>
<subject type="local">pregnancy</subject>
<description type="Chief Investigator">Prof Megan Galbally</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pharmacogenetics have increasingly been shown to be relevant to the understanding of outcomes associated with antidepressants. By using a study of 862 women, including 158 taking antidepressants in pregnancy, we propose to use a new novel approach to elucidate how better to manage depression in pregnancy for women and also predict vulnerability to adverse impacts for the infant following antidepressant exposure and whether this can be attributed to variation in pharmacogenetics.</description>
<description type="fundingAmount">$630,913.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2019993</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2019993</identifier>
<identifier type="nhmrc">2019993</identifier>
<name type="primary"><namePart>Tuning mitophagy in mitochondrial diseases</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">ubiquitin-mediated proteolysis </subject>
<subject type="local">mitochondrial disease</subject>
<subject type="local">mitochondrial dynamics</subject>
<subject type="local">cell signalling</subject>
<subject type="local">autophagy</subject>
<description type="Chief Investigator">Dr Julia Pagan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The accumulation of damaged mitochondria is detrimental to cells and results in diseases. This fundamental research addresses how cells maintain a healthy mitochondrial population. We have discovered a pathway that maintains healthy mitochondrial numbers in cells. This pathway does not function properly in a devastating disease called mitochondrial DNA depletion disease. In this proposal, we seek to determine strategies to restore mitochondrial function in this disease.</description>
<description type="fundingAmount">$684,080.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020010</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020010</identifier>
<identifier type="nhmrc">2020010</identifier>
<name type="primary"><namePart>Let there be light- Modified Serpin as a Dual Function Therapeutic Agent in Glaucoma</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | vision science | </subject>
<subject type="local">glaucoma </subject>
<subject type="local">biochemistry</subject>
<subject type="local">mouse models</subject>
<subject type="local">neurodegenerative disorders</subject>
<subject type="local">apoptosis</subject>
<description type="Chief Investigator">Assoc Prof Vivek Gupta</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Glaucoma causes blindness and despite our best treatment many patients continue to progress. A new and innovative approach is needed to protect the cells that die in the retina. We have engineered a protease inhibitor – neuroserpin – a protein that is deactivated in the disease. We aim to deliver this molecule to retinal cells using an “artificial virus” approach and determine its usefulness as a novel and innovative therapy in glaucoma.</description>
<description type="fundingAmount">$1,186,771.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020020</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020020</identifier>
<identifier type="nhmrc">2020020</identifier>
<name type="primary"><namePart>A novel approach to reducing the psychosocial burden of infertility treatment</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | reproduction  | psychology | clinical and health psychology | clinical psychology | </subject>
<subject type="local">in vitro fertilisation (ivf) </subject>
<subject type="local">psychosocial</subject>
<subject type="local">coping techniques</subject>
<subject type="local">social support</subject>
<subject type="local">behavioural intervention</subject>
<description type="Chief Investigator">Dr Katrina Moss</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">One in six Australian couples experience infertility. Up to 75% of patients will report anxiety or depression during reproductive treatment, but less than 20% will receive mental health support. This research will generate new evidence on how coping, social support and mood change across an in vitro fertilization cycle (IVF). It will produce an online coping intervention for patients and information resources for partners and families, leading to better mental health outcomes after IVF.</description>
<description type="fundingAmount">$652,078.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020035</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020035</identifier>
<identifier type="nhmrc">2020035</identifier>
<name type="primary"><namePart>Computational analysis and Artificial Intelligence in brain tumour imaging: towards the augmented diagnostics of the future</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | surgery | health sciences | health services and systems | digital health | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </subject>
<subject type="local">brain tumours </subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">artificial neural networks</subject>
<subject type="local">neurosurgery</subject>
<subject type="local">connectivity</subject>
<description type="Chief Investigator">Prof Antonio Di Ieva</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This work will apply computer models, including Artificial Intelligence techniques, to augment expert diagnosis of brain tumours with the aim of better predicting patients’ prognosis, optimising their treatment and thereby improving their outcomes. By the end of this research, a new diagnostic paradigm will be in place: computers will help clinicians and surgeons in their decision-making to ensure the best treatment of patients affected by brain tumours, throughout their journey.</description>
<description type="fundingAmount">$1,556,663.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020050</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020050</identifier>
<identifier type="nhmrc">2020050</identifier>
<name type="primary"><namePart>A Fat Chance for Melanoma</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">cutaneous melanoma </subject>
<subject type="local">targeted therapy</subject>
<subject type="local">map kinases</subject>
<subject type="local">cell signalling</subject>
<subject type="local">cancer immunology</subject>
<description type="Chief Investigator">Assoc Prof Karen Sheppard</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Recently a study in melanoma patients showed that overweight patients did much better on treatment than normal weight patients. This project aims to understand how body fat makes melanoma patients more responsive to therapy. By understanding the biological basis for this association, we can design new therapeutic strategies that will improve the outcomes for melanoma patients and not lead to adverse health effects associated with being overweight.</description>
<description type="fundingAmount">$1,173,377.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020077</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020077</identifier>
<identifier type="nhmrc">2020077</identifier>
<name type="primary"><namePart>Using genomic signatures of natural selection to elucidate the genetic architecture of multiple sclerosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | biological sciences | evolutionary biology | biological adaptation | </subject>
<subject type="local">multiple sclerosis (ms) </subject>
<subject type="local">population genetics</subject>
<subject type="local">adaptation</subject>
<subject type="local">complex genetic disease</subject>
<subject type="local">disease prevalence</subject>
<description type="Chief Investigator">Dr Bennet McComish</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Multiple sclerosis (MS) is more common in people of European descent, and more common further from the equator. It is likely that this pattern has been shaped by natural selection. Identifying genes that increase MS risk and have experienced natural selection will improve our understanding of what causes the disease. We will identify specific genes that are under local selection in response to environmental factors, helping to better target therapies aimed at these risk factors.</description>
<description type="fundingAmount">$764,770.65</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020078</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020078</identifier>
<identifier type="nhmrc">2020078</identifier>
<name type="primary"><namePart>New ways to treat fatty liver disease: a focus on lipid metabolism</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </subject>
<subject type="local">fat metabolism </subject>
<subject type="local">insulin resistance</subject>
<subject type="local">fatty liver disease</subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">mouse models</subject>
<description type="Chief Investigator">Prof Matthew Watt</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Individuals with obesity have increased risk of developing other metabolic diseases including non-alcoholic fatty liver disease and diabetes. This is partially due to impairments in the capacity to burn fat and excessive accumulation of fat in most tissues of the body. We have identified a new pathway by which cells of the body regulate fat breakdown. In this project, we aim to test whether activating this pathway is effective in slowing the development of fatty liver and diabetes.</description>
<description type="fundingAmount">$1,441,644.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020097</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020097</identifier>
<identifier type="nhmrc">2020097</identifier>
<name type="primary"><namePart>Unlocking the Therapeutic Potential of a New ‘Dual-Action’ Target for Bone and Joint Diseases</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | orthopaedics  | </subject>
<subject type="local">osteoclast </subject>
<subject type="local">bone biology</subject>
<subject type="local">osteolysis</subject>
<subject type="local">membrane transport</subject>
<subject type="local">drug discovery</subject>
<description type="Chief Investigator">Assoc Prof Nathan Pavlos</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Diseases affecting the bones and joints are devastating to physical function and human health and often feature bone destruction by osteoclasts, giant bone dissolving cells. However, treatments for these diseases remain inadequate. We have discovered a new molecule that blocks osteoclast function and helps build new bone when inhibited. This proposal evaluates the utility of this promising target for the development of new bone preserving drugs for the treatment of bone and joint diseases.</description>
<description type="fundingAmount">$848,048.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020111</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020111</identifier>
<identifier type="nhmrc">2020111</identifier>
<name type="primary"><namePart>Predict, prevent and treat bone metastases in prostate cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">prostate cancer </subject>
<subject type="local">bone metastasis</subject>
<subject type="local">neurotrophic factors</subject>
<subject type="local">brain-derived neurotrophic factor (bdnf)</subject>
<subject type="local">cancer treatment</subject>
<description type="Chief Investigator">Prof Hubert Hondermarck</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bone metastases are a fear development of prostate cancer that cannot be predicted and for which there is no effective treatment. In this translational and multidisciplinary project, we will develop an innovative strategy to predict, prevent and treat bone metastases. Our idea is based on cancer neurosciences and the targeting of nerves in prostate cancer.</description>
<description type="fundingAmount">$599,657.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020113</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020113</identifier>
<identifier type="nhmrc">2020113</identifier>
<name type="primary"><namePart>Network level decoding of touch and pain in the spinal cord</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | sensory systems | </subject>
<subject type="local">chronic pain </subject>
<subject type="local">spinal cord</subject>
<subject type="local">calcium imaging</subject>
<subject type="local">signal processing</subject>
<subject type="local">neural coding</subject>
<description type="Chief Investigator">Assoc Prof Brett Graham</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Understanding how touch and pain signals pass through the spinal cord is critical in pain treatment, especially for touch-evoked pain. Our current understanding focuses on small circuits of spinal nerve cells, even though we know touch and pain activate much larger networks to produce signals that reach our brain. This project will decode network-level signalling of touch and pain in the spinal cord by studying activity in large nerve cell networks using imaging and complex systems analysis.</description>
<description type="fundingAmount">$738,587.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020121</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020121</identifier>
<identifier type="nhmrc">2020121</identifier>
<name type="primary"><namePart>Test often, treat early: Are major changes in policy and practice needed to eliminate hepatitis C among people with HIV?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05ktbsm52</identifier><title>Burnet Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | preventative health care | </subject>
<subject type="local">hepatitis c infection </subject>
<subject type="local">mathematical modelling</subject>
<subject type="local">collaboration</subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">cohort study</subject>
<description type="Chief Investigator">Dr Rachel Sacks-Davis</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Hepatitis C treatment is highly effective, preventing liver-related morbidity and mortality for individuals, as well as onward transmission of hepatitis. However, current limitations on the number of tests per year and restrictions on treatment until chronic hepatitis C infection has been confirmed, mean that treatment is usually delayed for over a year after diagnosis. This proposal aims to estimate potential benefits from allowing more frequent testing and earlier treatment.</description>
<description type="fundingAmount">$618,088.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020137</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020137</identifier>
<identifier type="nhmrc">2020137</identifier>
<name type="primary"><namePart>In vivo genetic engineering of T-cells for cancer treatment using novel exosome mimetic nanoparticles</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">cancer therapy </subject>
<subject type="local">oncology</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">cancer biology</subject>
<subject type="local">biomedical engineering</subject>
<description type="Chief Investigator">Dr Sherry Wu</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite the promise of using genetically engineered T-cells for treatment of a variety of immune-mediated diseases, current methods are expensive, labour-intensive, result in significant side effects, and have limited availability. In this proposal, we will re-engineer naturally occurring vesicles that are present in our body to allow them to redirect T-cells to specific danger signals. We will examine the therapeutic efficacy of this novel nanotechnology in cancer.</description>
<description type="fundingAmount">$751,076.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020149</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020149</identifier>
<identifier type="nhmrc">2020149</identifier>
<name type="primary"><namePart>Spatial analysis to investigate cancer evolution as a complex ecosystem of interacting tumour populations</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </subject>
<subject type="local">gene expression </subject>
<subject type="local">bioinformatics</subject>
<subject type="local">prostate cancer</subject>
<subject type="local">data analysis</subject>
<subject type="local">genomics</subject>
<description type="Chief Investigator">Dr Anna Trigos</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cancer is a disease where cells grow rapidly, creating tumours. However, all tumour cells are not the same. There can be multiple cell types within a single tumour. These are likely interacting, helping each other grow. We aim to understand which tumour cells are cooperating with each other in prostate cancer that has spread using computational methods. With this, we hope to develop a new type of treatment that works by disrupting how tumour cells talk with each other and thus kill tumours.</description>
<description type="fundingAmount">$978,228.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020151</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020151</identifier>
<identifier type="nhmrc">2020151</identifier>
<name type="primary"><namePart>Development of new treatment options for post-sepsis acute lung injury (ALI).</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | innate immunity | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">acute inflammation </subject>
<subject type="local">inflammatory cytokines</subject>
<subject type="local">cell surface receptor</subject>
<subject type="local">cytokine signalling</subject>
<subject type="local">acute lung injury</subject>
<description type="Chief Investigator">Prof Nicodemus Tedla</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Acute lung injury (ALI) occurs due to uncontrolled inflammation and is a major cause of death in Australia because there are no treatments. We recently found treatment with a new protein called A3 protects mice from this condition. In this project, we will develop A3 into a new class of anti-inflammatory drug and test it in mouse models of ALI that resemble human ALI and validate our results in human cells. This invention will address one of the most important unmet clinical needs worldwide.</description>
<description type="fundingAmount">$989,098.96</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020152</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020152</identifier>
<identifier type="nhmrc">2020152</identifier>
<name type="primary"><namePart>Autoimmunity; Finding the key to chronic atherosclerotic inflammation and plaque rupture</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">atherosclerosis </subject>
<subject type="local">plaque rupture</subject>
<subject type="local">chronic inflammation</subject>
<subject type="local">human</subject>
<subject type="local">animal model</subject>
<description type="Chief Investigator">Dr Jonathan Noonan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Heart disease is the leading cause of death globally, and ~1/3 of all deaths in Australia. Inflammation has been identified as a major cause of heart disease. However, what drives inflammation in heart diseases is not well known. Our research will explore how T cells, a common white blood cell, might cause heart attacks and strokes. By doing so, we will identify new ways in which we can treat inflammation and thereby prevent the massive numbers of deaths caused by heart disease.</description>
<description type="fundingAmount">$982,020.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020164</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020164</identifier>
<identifier type="nhmrc">2020164</identifier>
<name type="primary"><namePart>Assessment and modulation of cortical sensorimotor control for recovery after stroke</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">stroke </subject>
<subject type="local">sensorimotor control</subject>
<subject type="local">mouse models</subject>
<subject type="local">neuromodulation</subject>
<subject type="local">cortical plasticity</subject>
<description type="Chief Investigator">Dr Matilde Balbi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Our goal is to promote the recovery of motor function after stroke. We will create a computational model of the effects of stroke on the motor control system throughout rehabilitation. We will determine whether electrical stimulation can enhance the effect of movement-based therapy on recovery after stroke. We will also adjust our stimulation based on ongoing brain activity. We hypothesise that feedback mediated rehabilitation is a more robust mechanism to activate affected areas.</description>
<description type="fundingAmount">$1,273,360.02</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020169</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020169</identifier>
<identifier type="nhmrc">2020169</identifier>
<name type="primary"><namePart>Protecting vitamin D levels to prevent chemotherapy-induced gastrointestinal mucositis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | toxicology (incl. clinical toxicology)  | </subject>
<subject type="local">intestine </subject>
<subject type="local">vitamin d</subject>
<subject type="local">cancer chemotherapy</subject>
<subject type="local">mucositis</subject>
<subject type="local">tissue damage</subject>
<description type="Chief Investigator">Dr Andrea Stringer</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Vitamin D deficiency is common in cancer patients, and is linked to the incidence of many cancers. Maintaining vitamin D levels is key for maximising therapeutic outcomes and preventing chemotherapy- induced mucositis. We will identify cancer patients as ‘at risk’ for vitamin D deficiency, leading to higher incidence and severity of chemotherapy-induced mucositis. We will investigate therapeutic options for maintaining vitamin D levels and preventing chemotherapy-induced mucositis.</description>
<description type="fundingAmount">$807,368.12</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020173</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020173</identifier>
<identifier type="nhmrc">2020173</identifier>
<name type="primary"><namePart>Bacteriophages: a new paradigm in caring for infected wounds.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </subject>
<subject type="local">diabetes mellitus </subject>
<subject type="local">bacteriophage</subject>
<subject type="local">staphylococcus aureus</subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">health economics</subject>
<description type="Chief Investigator">Assoc Prof Peter Speck</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We will develop wound dressings carrying bacteriophages (viruses that kill bacteria) as a safe, effective way to treat wound infections. This will have great impact on treatment of diabetic foot ulcer infections, which currently often lead to amputation, which carries extremely high mortality. This work will lead to a new paradigm in wound care and will dramatically improve the lives of people with diabetes.</description>
<description type="fundingAmount">$736,657.40</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020185</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020185</identifier>
<identifier type="nhmrc">2020185</identifier>
<name type="primary"><namePart>An accessible chronic pain therapeutic target in peripheral sensory nerves</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">chronic pain </subject>
<subject type="local">hyperalgesia</subject>
<subject type="local">dorsal root ganglia</subject>
<subject type="local">neuroinflammation</subject>
<subject type="local">translational research</subject>
<description type="Chief Investigator">Assoc Prof Jenny Gunnersen</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic pain is hugely debilitating and its prevention remains an area of unmet clinical need. Nerve injuries result in exaggerated responses to painful, and even mild, stimuli. In pre-clinical models, we have discovered that removing a single protein from neurons, either throughout the nervous system or only in the peripheral nervous system, significantly diminishes injury-induced pain. This research aims to find a way to interfere with the development of chronic pain by targeting this protein.</description>
<description type="fundingAmount">$677,696.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020192</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020192</identifier>
<identifier type="nhmrc">2020192</identifier>
<name type="primary"><namePart>Using Big Data to Engineer Highly Immunogenic Hepatitis C Virus Envelopes for the Induction of Broad Neutralising Antibodies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | sequence analysis | physical sciences | medical and biological physics | biological physics | biological sciences | microbiology | virology  | </subject>
<subject type="local">hepatitis c virus </subject>
<subject type="local">vaccine design</subject>
<subject type="local">sequence analysis</subject>
<subject type="local">antibody</subject>
<subject type="local">mathematical modelling</subject>
<description type="Chief Investigator">Prof Matthew McKay</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is an urgent need to develop a preventative vaccine against hepatitis C, a virus that causes chronic life-threatening disease in millions of people globally. This project will bring together intelligent big data design methods and innovative experimental models to engineer panels of viral antigens for eliciting antibodies capable of neutralising diverse virus strains. The findings can be used to design new hepatitis C vaccines aimed at preventing virus infection and chronic disease.</description>
<description type="fundingAmount">$1,143,599.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020197</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020197</identifier>
<identifier type="nhmrc">2020197</identifier>
<name type="primary"><namePart>A Bioengineered Model of Calcific Aortic Valve Disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | mechanobiology | </subject>
<subject type="local">biomedical engineering </subject>
<subject type="local">aortic valve</subject>
<subject type="local">disease modelling</subject>
<subject type="local">mechanotransduction</subject>
<subject type="local">haemodynamics</subject>
<description type="Chief Investigator">Dr Sara Baratchi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Calcific aortic valve disease is a common cause of mortality and morbidity in the elderly. Our limited knowledge of the mechanisms that drive the progression of aortic stenosis is a major obstacle in developing medical treatments for this disease. This project utilises a bioengineered aortic valve model that mimics features found in the early and late stages of this disease. It enables the systematic study of the complex pathology of this disease and serves as a platform for screening drugs.</description>
<description type="fundingAmount">$1,045,794.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020226</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020226</identifier>
<identifier type="nhmrc">2020226</identifier>
<name type="primary"><namePart>Understanding neurodegeneration caused by oligodendroglial dysfunction</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">neuropathology </subject>
<subject type="local">histology</subject>
<subject type="local">microtubule associated protein (map)</subject>
<subject type="local">behaviour change</subject>
<subject type="local">brain</subject>
<description type="Chief Investigator">Dr Shelley Forrest</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Globular glial tauopathy (GGT) is a recently described frontotemporal dementia, a debilitating early-onset neurodegenerative disorder. GGT is characterised by abnormal tau protein in oligodendroglia, the main neuron support cell. Previous research has focused on neurons, which cause neurodegeneration and clinical symptoms with little consideration of oligodendroglia. This study will investigate how dysfunction in oligodendroglia causes neurodegeneration in human and preclinical disease models.</description>
<description type="fundingAmount">$1,025,253.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020234</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020234</identifier>
<identifier type="nhmrc">2020234</identifier>
<name type="primary"><namePart>Community driven communication and engagement during health crisis periods: co-designing enhanced and transferable strategies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | health promotion | </subject>
<subject type="local">communications/social research </subject>
<subject type="local">population health</subject>
<subject type="local">infectious diseases</subject>
<subject type="local">communication skills</subject>
<subject type="local">public health policy</subject>
<description type="Chief Investigator">Assoc Prof Holly Seale</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Communicating crisis information with “hard-to-reach” culturally and linguistically diverse (CALD) communities is a significant challenge. Leveraging existing networks and actors can ensure that information reaches CaLD communities. We will fill a key gap via developing a: (1) communication and engagement strategy that outlines best practices around the identification and support of information intermediaries and (2) a training program that focuses on capacity building with CaLD communities.</description>
<description type="fundingAmount">$589,259.20</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020251</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020251</identifier>
<identifier type="nhmrc">2020251</identifier>
<name type="primary"><namePart>A Systems Genetics Approach to Defining the Sexual Dimorphism in Exercise-Induced Cardioprotection</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - lipids  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">exercise </subject>
<subject type="local">cardiovascular disease prevention</subject>
<subject type="local">metabolomics</subject>
<subject type="local">proteomics</subject>
<subject type="local">lipid metabolism</subject>
<description type="Chief Investigator">Assoc Prof Anna Calkin</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Men and women differ in their risk and development of cardiovascular disease (CVD) and their response to the protective effects of exercise; however, we do not fully understand the mechanisms underlying these differences. We propose to generate a cutting-edge research tool that characterises the changes in the heart at rest and in response to exercise in male and females. Using this tool, we will identify novel targets that we will test for their ability to treat CVD in a personalised manner</description>
<description type="fundingAmount">$1,426,825.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020253</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020253</identifier>
<identifier type="nhmrc">2020253</identifier>
<name type="primary"><namePart>The Burning Question – how safe is sun exposure at low-dose and intensity?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | preventative health care | </subject>
<subject type="local">skin cancer </subject>
<subject type="local">sun protection</subject>
<subject type="local">vitamin d</subject>
<subject type="local">solar ultraviolet (uv) radiation</subject>
<subject type="local">preventive medicine</subject>
<description type="Chief Investigator">Dr Elke Hacker</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Skin cancers are more common in Australia than all other cancers combined. To reduce their burden, Australians are advised to protect their skin when the sun is strong, but not when the sun is weak. We will test whether low-intensity sunlight is ‘harmless’ by exposing the skin of volunteers to non-burning doses of UV radiation, and then assessing the effects on their skin cells. The information from these experiments will inform sun protection policies.</description>
<description type="fundingAmount">$741,332.70</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020285</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020285</identifier>
<identifier type="nhmrc">2020285</identifier>
<name type="primary"><namePart>New approaches to enhance immunotherapy for brain tumours</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">sphingolipids </subject>
<subject type="local">g protein-coupled receptors</subject>
<subject type="local">t cells</subject>
<subject type="local">glioblastoma</subject>
<subject type="local">brain tumours</subject>
<description type="Chief Investigator">Prof Stuart Pitson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Primary brain tumours and brain metastases arising from other tumours both have extremely poor patient outcomes. Immunotherapy offers great promise for brain tumour therapy, but is currently limited due to brain tumour-induced immunosuppression. This proposal aims to overcome this problem to improve the potency of brain tumour immunotherapies. Successful outcomes in this work have the potential to dramatically improve the survival outcomes for glioblastoma patients.</description>
<description type="fundingAmount">$844,149.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020289</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020289</identifier>
<identifier type="nhmrc">2020289</identifier>
<name type="primary"><namePart>Modulation of the M4 muscarinic receptor for the treatment of schizophrenia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">muscarinic receptors </subject>
<subject type="local">schizophrenia</subject>
<subject type="local">molecular pharmacology</subject>
<subject type="local">rational drug design</subject>
<subject type="local">protein structure</subject>
<description type="Chief Investigator">Dr Celine Valant</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The M4 muscarinic receptor is a promising drug target for treating schizophrenia, with therapeutic outcomes above and beyond any current antipsychotics. Recently, two M4-targeting drugs, xanomeline and emraclidine, have progressed to advanced stages in clinical trials. This project aims to explore the pharmacological outcomes of xanomeline and emraclidine as a novel, first-in-class, dual therapy to ultimately assist in designing more effective and safer drugs for treating schizophrenia.</description>
<description type="fundingAmount">$1,807,677.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020303</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020303</identifier>
<identifier type="nhmrc">2020303</identifier>
<name type="primary"><namePart>Exploiting GPX2 deficiency to enhance radiation response in gastrointestinal cancers</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | </subject>
<subject type="local">colorectal cancer </subject>
<subject type="local">colorectal cancer treatment</subject>
<subject type="local">colorectal cancer risk</subject>
<subject type="local">irradiation</subject>
<subject type="local">biomarkers</subject>
<description type="Chief Investigator">Prof John Mariadason</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bowel cancer is a major global health problem. Here, we will investigate how loss of protein called GPX2 can on the one hand contribute to the development of this disease, but make cancers sensitive to radiotherapy on the other. By studying the role of this critical protein, this project will deliver important new knowledge into how colorectal cancers arise, enable us to identify patients most likely to benefit from radiotherapy, and to develop a new way to improve response to this treatment.</description>
<description type="fundingAmount">$696,211.55</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020305</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020305</identifier>
<identifier type="nhmrc">2020305</identifier>
<name type="primary"><namePart>HARNESSING TUMOUR SPECIFIC HOMING AND EVOLUTION OF PROBIOTIC BACTERIA TO ENGINEER NEXT-GENERATION BOWEL CANCER TREATMENTS</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">colorectal cancer treatment </subject>
<subject type="local">bacterial genetics</subject>
<subject type="local">probiotics</subject>
<subject type="local">mouse models</subject>
<subject type="local">gastroenterology</subject>
<description type="Chief Investigator">Assoc Prof Susan Woods</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Bowel cancer kills over 5000 Australians each year. This failure of current treatments shows that a very different approach is needed. We are investigating the use of probiotics engineered to selectively release drugs direct to tumours. This research will help us understand why the probiotics home to tumours and how they change once in the tumour, so that we can better design probiotic treatments to treat bowel cancer in the future.</description>
<description type="fundingAmount">$717,084.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020315</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020315</identifier>
<identifier type="nhmrc">2020315</identifier>
<name type="primary"><namePart>A novel algorithm for accurate and efficient alignment of long DNA and RNA sequencing reads</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | bioinformatics and computational biology | bioinformatic methods development | </subject>
<subject type="local">bioinformatics </subject>
<subject type="local">sequence analysis</subject>
<subject type="local">methodology</subject>
<subject type="local">genomics</subject>
<subject type="local">dna sequencing</subject>
<description type="Chief Investigator">Dr Yang LIAO</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Long-read sequencing is a new development in DNA/RNA sequencing. It helps to find mutations and other genomic features that can never be found before. Mapping read sequences to the genome is usually the first step in the analysis. We will use many novel concepts to develop a new tool for long-read mapping. Because of its high efficiency and accuracy compared with the current tools, it can strongly enhance the value of long-read sequencing in both research and clinical settings.</description>
<description type="fundingAmount">$153,131.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020316</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020316</identifier>
<identifier type="nhmrc">2020316</identifier>
<name type="primary"><namePart>Dissecting the role of group 2 innate lymphoid cells in gastric cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | innate immunity | </subject>
<subject type="local">gastric cancer </subject>
<subject type="local">innate immunity</subject>
<subject type="local">cancer immunology</subject>
<subject type="local">cancer metastasis</subject>
<subject type="local">cancer detection</subject>
<description type="Chief Investigator">Dr Michael Buchert</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Gastric inflammation and early gastric cancer (GC) development elicits a rapid expansion of specialised immune cells (ILC2) in the stomach and their dissemination into the bloodstream. This project aims to uncover the impact of the systemic spread of ILC2s on metastatic niche formation and metastatic cancer growth in the context of aggressive GC and to investigate the utility of circulatory ILC2 as diagnostic biomarker for GC in order to achieve better health outcomes.</description>
<description type="fundingAmount">$1,365,646.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020334</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020334</identifier>
<identifier type="nhmrc">2020334</identifier>
<name type="primary"><namePart>Functional impact of CTCF binding site mutations in 3D cancer genome regulation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genome structure and regulation | </subject>
<subject type="local">transcriptional regulation </subject>
<subject type="local">chromatin structure</subject>
<subject type="local">de novo mutations</subject>
<subject type="local">promoter analysis</subject>
<subject type="local">antisense rna</subject>
<description type="Chief Investigator">Prof Susan Clark</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Understanding what regulates gene expression in normal cells and how this goes wrong in cancer is still one of the biggest challenges in modern biology. This grant is focused on investigating two classes of non-coding somatic mutations in breast and prostate cancer, which we hypothesise disrupt binding of an important DNA regulator (CTCF) and results in deregulation of specific regions of gene expression. Unravelling mechanisms underpinning CTCF site mutations may lead to new cancer treatments.</description>
<description type="fundingAmount">$961,787.38</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020371</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020371</identifier>
<identifier type="nhmrc">2020371</identifier>
<name type="primary"><namePart>A novel molecular test to determine if a pathogen is alive or dead - a tool to transform infectious disease management and reduce the threat of antimicrobial resistance</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </subject>
<subject type="local">molecular diagnostics </subject>
<subject type="local">infectious diseases</subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">sexually-transmitted infections (sti)</subject>
<subject type="local">clinical diagnosis</subject>
<description type="Chief Investigator">Dr Tanya Applegate</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Antimicrobial resistance is threatening our ability to treat infections globally. Current molecular tests for infectious disease detect both living and dead pathogens contributing to overdiagnosis and treatment. We will use a novel real time molecular assay, adaptable across pathogens, to determine what proportion of sexually transmitted infections are viable as an exemplar. This study could transform our entire public health approach to infectious disease diagnosis and antimicrobial stewardship</description>
<description type="fundingAmount">$956,774.20</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020376</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020376</identifier>
<identifier type="nhmrc">2020376</identifier>
<name type="primary"><namePart>Improving therapeutic responses in oesophageal cancer by overcoming resistance to ferroptosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biological sciences | biochemistry and cell biology | cell metabolism | </subject>
<subject type="local">cancer therapy </subject>
<subject type="local">cell death</subject>
<subject type="local">metabolism</subject>
<subject type="local">functional genomics</subject>
<subject type="local">oesophageal cancer</subject>
<description type="Chief Investigator">Assoc Prof Nicholas Clemons</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Compared to normal tissues, oesophageal cancers increase their consumption of nutrients from the surrounding environment and change the way they use these nutrients in order to survive, grow, spread to other organs and resist treatments. This project will identify which nutrients oesophageal cancers depend on to survive, and develop strategies to exploit these dependencies and improve the efficacy of treatments used to combat this disease, thereby improving cure rates and long term outcomes.</description>
<description type="fundingAmount">$1,073,391.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020377</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020377</identifier>
<identifier type="nhmrc">2020377</identifier>
<name type="primary"><namePart>Elucidating the signalling functions of Transmembrane Pseudokinases as a strategy to develop novel therapeutics modalities</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">structural biology </subject>
<subject type="local">protein kinases</subject>
<subject type="local">eph receptors</subject>
<subject type="local">intracellular signal transduction</subject>
<subject type="local">electron microscopy</subject>
<description type="Chief Investigator">Assoc Prof Isabelle Lucet</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Cells require highly coordinated communication signals to grow and divide. Any improper signalling responses can lead to conditions, such as cancer and inflammation. Pseudokinases have recently been discovered to play a vital role in the coordination of signals that can lead to cancer. This program aims to elucidate how transmembrane receptor pseudokinases contribute to “out of control” signalling, which will provide novel therapeutic strategies to counteract pseudokinase-driven diseases.</description>
<description type="fundingAmount">$1,320,638.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020421</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020421</identifier>
<identifier type="nhmrc">2020421</identifier>
<name type="primary"><namePart>Overcoming antiseptic and disinfectant resistance in staphylococci</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01kpzv902</identifier><title>Flinders University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | </subject>
<subject type="local">multidrug resistance </subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">structural biology</subject>
<subject type="local">medicinal chemistry</subject>
<subject type="local">staphylococcus aureus</subject>
<description type="Chief Investigator">Prof Melissa Brown</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Strains of Staphylococcus aureus (Golden Staph), resistant to almost all available anti-staphylococcal agents, are responsible for serious infections among patients. Resistance has emerged to all classes of antimicrobial agents, including antiseptics and disinfectants. We will increase our understanding of proteins that confer resistance by pumping multiple compounds out of the cell to ultimately be able to block their action.</description>
<description type="fundingAmount">$941,905.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020423</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020423</identifier>
<identifier type="nhmrc">2020423</identifier>
<name type="primary"><namePart>Harnessing the protective effects of Interferon epsilon as a therapeutic for endometriosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | reproductive medicine | reproduction  | </subject>
<subject type="local">endometrium </subject>
<subject type="local">endometriosis</subject>
<subject type="local">women's health</subject>
<subject type="local">uterus</subject>
<subject type="local">cell proliferation</subject>
<description type="Chief Investigator">Dr Fiona Cousins</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Endometriosis is a chronic, debilitating condition that affects 1 in 9 menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFNe), which may exert protective effects against the development of endometriosis. We will investigate whether IFNe can be used as an innovative treatment for endometriosis.</description>
<description type="fundingAmount">$1,125,385.96</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020434</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020434</identifier>
<identifier type="nhmrc">2020434</identifier>
<name type="primary"><namePart>A human brain organoid model of acute prenatal hypoxia enables biomarker discovery and drug screening for hypoxic-ischemic encephalopathy.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">fetal hypoxia </subject>
<subject type="local">encephalopathy</subject>
<subject type="local">brain asphyxia</subject>
<subject type="local">neurological disturbance</subject>
<subject type="local">early brain development</subject>
<description type="Chief Investigator">Prof Ernst Wolvetang</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">A lack of oxygen supply to the baby before and during birth has devastating immediate and long term consequences for brain development. Quantifiying the severity of birth asphyxia in newborns is difficult, little is known about the molecular and cellular processes involved, and effective treatments beyond cooling the newborn do not exist. Here we will use innovative human brain organoid models to address and overcome each of these knowledge and capability gaps.</description>
<description type="fundingAmount">$1,361,482.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020443</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020443</identifier>
<identifier type="nhmrc">2020443</identifier>
<name type="primary"><namePart>Engineered Amphiregulin: A Novel Growth Factor to Promote Tissue Regeneration</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | </subject>
<subject type="local">regenerative medicine </subject>
<subject type="local">growth factor therapy</subject>
<subject type="local">protein engineering</subject>
<subject type="local">epidermal growth factor receptor (egfr)</subject>
<subject type="local">macrophages</subject>
<description type="Chief Investigator">Assoc Prof Mikael Martino</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Tissue regeneration is facilitated by key proteins that are released by immune cells in injured tissues. These proteins include growth factors, which are promising drugs for regenerative medicine. However, growth factors have found limited clinical success due to poor efficacy and/or side effects. We have developed a novel engineered growth factor that shows significant promise in promoting tissue healing. This project will confirm its safety and efficacy for regenerative medicine applications.</description>
<description type="fundingAmount">$652,046.52</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020452</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020452</identifier>
<identifier type="nhmrc">2020452</identifier>
<name type="primary"><namePart>Targeting interleukin-18-mediated inflammation to treat advanced kidney disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </subject>
<subject type="local">kidney disease </subject>
<subject type="local">hypertension</subject>
<subject type="local">renal fibrosis</subject>
<subject type="local">chronic inflammation</subject>
<subject type="local">pharmacological intervention</subject>
<description type="Chief Investigator">Prof Grant Drummond</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Kidney failure is a leading cause of death and morbidity worldwide. This project will use state-of-the-art technologies to characterise the role of a newly identified molecule (interleukin-18) that contributes to the pathological remodelling that precedes kidney failure. The therapeutic potential of interleukin-18 inhibition will also be tested. This research will define an entirely new mechanism of kidney disease and validate interleukin-18 as a target for new therapies.</description>
<description type="fundingAmount">$1,304,466.78</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020453</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020453</identifier>
<identifier type="nhmrc">2020453</identifier>
<name type="primary"><namePart>Nuclear mechanobiology in cell migration and metastasis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">mechanotransduction </subject>
<subject type="local">cancer metastasis</subject>
<subject type="local">control of gene expression</subject>
<subject type="local">epigenetics</subject>
<subject type="local">cell polarity</subject>
<description type="Chief Investigator">Assoc Prof Archa Fox</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Preventing, diagnosing, and treating metastasis (the appearance of secondary tumors within the body) is the key to reducing death in breast cancer patients. Yet we still do not know exactly how cancer cells leave their tumors and invade into blood vessels to metastasise. Here we will test a new idea that invading breast cancer cells control their genes differently to normal cells, by the cell sensing its environment. This new understanding will help develop new drugs and diagnostic tools.</description>
<description type="fundingAmount">$645,792.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020454</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020454</identifier>
<identifier type="nhmrc">2020454</identifier>
<name type="primary"><namePart>Stratifying low-calorie sweeteners for diabetes risk</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | nutrition and dietetics | nutritional science | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">metabolic syndrome </subject>
<subject type="local">diabetes prevention</subject>
<subject type="local">glucose homeostasis</subject>
<subject type="local">microbiology</subject>
<subject type="local">gut peptides</subject>
<description type="Chief Investigator">Prof Christopher Rayner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Low calorie sweeteners are not inert sugar supplements. Rather, they are emerging as a risk factor for the development of diabetes. They can enhance sugar absorption from the gut and disrupt bacteria that live there, which can raise blood sugar levels. However, sweeteners are all distinct and are likely to affect blood sugar differently. We will test these differences in innovative human and animal studies to identify which sweeteners are safer options, in an effort to prevent type 2 diabetes.</description>
<description type="fundingAmount">$1,612,729.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020455</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020455</identifier>
<identifier type="nhmrc">2020455</identifier>
<name type="primary"><namePart>CRACing the role of the Flavivirus NS1 protein</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology  | biological sciences | microbiology | infectious agents | </subject>
<subject type="local">dengue virus </subject>
<subject type="local">cholesterol</subject>
<subject type="local">flavivirus</subject>
<subject type="local">viral replication</subject>
<subject type="local">protein trafficking</subject>
<description type="Chief Investigator">Dr David Muller</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">In this proposal, we will investigate the mechanisms by which various forms of the dengue viral protein, NS1 physically interacts with lipids and cholesterol. This is a critically important interaction for efficient viral replication and so understanding the ways in which NS1 engages with these host cell components should provide important clues as to how we can disrupt this interaction and so design potential anti-viral strategies not only for dengue, but also other flaviviruses.</description>
<description type="fundingAmount">$814,543.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020482</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020482</identifier>
<identifier type="nhmrc">2020482</identifier>
<name type="primary"><namePart>Viral modulation of the host cell: The STAT3 Interface</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology  | </subject>
<subject type="local">virus </subject>
<subject type="local">host/pathogen interaction</subject>
<subject type="local">viral proteins</subject>
<subject type="local">immune evasion</subject>
<subject type="local">protein interactions</subject>
<description type="Chief Investigator">Dr Gregory Moseley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will examine how viruses that cause major human diseases are able to interact with and control the cells that they infect, specifically through targeting of a central cellular regulator protein called STAT3. We will examine precisely how viruses selectively regulate STAT3 to control multiple processes in our cells that support viral infection and spread, and hence disease. By understanding how viruses do this, the project will identify new potential strategies to combat infections.</description>
<description type="fundingAmount">$823,296.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020483</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020483</identifier>
<identifier type="nhmrc">2020483</identifier>
<name type="primary"><namePart>Discovery of eosinophil-derived thermogenic beiging factors to combat obesity</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell metabolism | </subject>
<subject type="local">eosinophils </subject>
<subject type="local">overweight/obesity</subject>
<subject type="local">innate immunity</subject>
<subject type="local">adipose tissue</subject>
<subject type="local">gene regulation</subject>
<description type="Chief Investigator">Assoc Prof Kate Quinlan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Obesity is a global problem. We study the signals that control the switch between the accumulation and the burning of fat. A new type of fat, beige fat, is important in burning rather than storing fuel. Our data show that signals from a specialised immune cell – the eosinophil – convert normal fat into beige fat. By identifying the signaling molecules eosinophils produce in mouse and human tissue, we seek to mimic their action, and therapeutically stimulate beige fat to combat obesity.</description>
<description type="fundingAmount">$518,569.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020501</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020501</identifier>
<identifier type="nhmrc">2020501</identifier>
<name type="primary"><namePart>Comparative human functional genomics of Island Southeast Asia</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | genetics | genomics | </subject>
<subject type="local">differential gene expression </subject>
<subject type="local">immune regulation</subject>
<subject type="local">population genetics</subject>
<subject type="local">papua new guinea</subject>
<subject type="local">health inequalities</subject>
<description type="Chief Investigator">Dr Irene Gallego Romero</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">To date nearly all studies of how DNA variants impact genes have been carried out in people of European descent. But insights gained from them do not always translate to other populations. By combining measurements of gene expression obtained at a single cell level with samples from Island Southeast Asia, this project will be the first to characterise the genetic differences that impact immune response in these populations, with implications for disease progression and personalised medicine.</description>
<description type="fundingAmount">$707,834.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020517</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020517</identifier>
<identifier type="nhmrc">2020517</identifier>
<name type="primary"><namePart>Examining the ‘how’ and ‘why’ of blood cell gene regulation at loci relevant to autoimmune disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01nfmeh72</identifier><title>University of Tasmania</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </subject>
<subject type="local">single nucleotide polymorphism (snp) </subject>
<subject type="local">genetic variation</subject>
<subject type="local">complex genetic disease</subject>
<subject type="local">molecular basis of disease</subject>
<subject type="local">molecular immunology</subject>
<description type="Chief Investigator">Dr Kirsten Fairfax</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Every person has a distinct DNA code, which is why some people get certain diseases and some don’t. This code is complex and we currently only understand a fraction of what it does. Our research aims to understand which bits of DNA code are important for causing autoimmune diseases. We will do this using new technologies, like subtly changing the DNA code and looking at the effect this has. Understanding how these changes influence disease can benefit clinical diagnosis and drug development.</description>
<description type="fundingAmount">$854,575.00</description>
<coverage><spatial type="text">TAS</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020532</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020532</identifier>
<identifier type="nhmrc">2020532</identifier>
<name type="primary"><namePart>New pooled CRISPR screening approaches to study pain and painful venoms</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell neurochemistry | biological sciences | genetics | neurogenetics | </subject>
<subject type="local">molecular neuroscience </subject>
<subject type="local">acute pain</subject>
<subject type="local">chronic pain</subject>
<subject type="local">neurotoxins</subject>
<subject type="local">pain</subject>
<description type="Chief Investigator">Prof Graham Neely</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">It is time to develop new, effective, and non-addictive ways to manage pain, but this can only come from a better basic understanding of pain biology. Here, we develop and apply new pooled CRISPR screening technologies to map the human genome for factors that control pain. Our work here will yield the first genome-scale basic understanding of human pain regulation, and will provide a foundation for rational new painkillers for the 21st century.</description>
<description type="fundingAmount">$1,343,958.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020540</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020540</identifier>
<identifier type="nhmrc">2020540</identifier>
<name type="primary"><namePart>Hypothermic machine perfusion of circulatory death hearts for transplantation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">heart transplantation </subject>
<subject type="local">organ preservation</subject>
<subject type="local">myocardial ischaemia</subject>
<subject type="local">cardiovascular physiology</subject>
<subject type="local">cardiothoracic transplantation</subject>
<description type="Chief Investigator">Prof David McGiffin</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Novel technology has been developed to mitigate injury associated with heart preservation during heart transplantation. Preliminary studies show this technology is effective, but its beneficial effects are poorly understood. This project will investigate at a functional and cellular level how this technology improves heart function during heart transplantation. Increasing use of this technology will increase the donor heart pool, and decrease the risk of death following heart transplantation.</description>
<description type="fundingAmount">$2,062,431.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020543</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020543</identifier>
<identifier type="nhmrc">2020543</identifier>
<name type="primary"><namePart>Characterising a novel molecular pathway to reduce penicillin failure for Strep throat</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | </subject>
<subject type="local">group a streptococcal disease </subject>
<subject type="local">antibiotic resistance</subject>
<subject type="local">antibiotic use</subject>
<subject type="local">intracellular bacterial infections</subject>
<subject type="local">bacterial pathogenesis</subject>
<description type="Chief Investigator">Dr Timothy Barnett</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Strep throat is a common bacterial infection caused by Group A Streptococcus (GAS). While GAS is sensitive to penicillin in vitro, 10-20% of infections recur after treatment. We have identified that some GAS strains can replicate in a penicillin-resistant intracellular niche. This project will define this mechanism of resistance to penicillin and other antibiotics, and develop a prototype test to detect resistant infections at the point of care. This will lead to better treatment outcomes.</description>
<description type="fundingAmount">$819,804.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020555</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020555</identifier>
<identifier type="nhmrc">2020555</identifier>
<name type="primary"><namePart>HORIZONTAL GENE TRANSFER TO DETECT MUTATION AND REACT TO COLONIC NEOPLASIA</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </subject>
<subject type="local">colorectal cancer </subject>
<subject type="local">bacterial genetics</subject>
<subject type="local">genetic engineering</subject>
<subject type="local">cancer detection</subject>
<subject type="local">bowel cancer</subject>
<description type="Chief Investigator">Assoc Prof Daniel Worthley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Bowel cancer is common and is defined by changes to our genetic material (DNA). In this project we will answer whether bacteria that naturally live in the bowel can be coerced to take up cancer DNA through cutting-edge synthetic design; and whether bacteria could, in the future, detect and then react to bowel polyps and cancer and thus facilitate the detection, prevention and treatment of bowel cancer.</description>
<description type="fundingAmount">$800,115.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020562</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020562</identifier>
<identifier type="nhmrc">2020562</identifier>
<name type="primary"><namePart>PRC-1 regulation of mature CD8+ T cell effector and memory responses</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | microbiology | virology  | </subject>
<subject type="local">cd8 t cells </subject>
<subject type="local">t cell memory</subject>
<subject type="local">epigenetics</subject>
<subject type="local">influenza virus</subject>
<subject type="local">t cell activation</subject>
<description type="Chief Investigator">Prof Stephen Turner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The programming of effective killer T cell immunity is associated requires appropriate gene regulation that ensures acquisition of the specific functions necessary for control of infection and cancer, as well as the establishment of effective immunity. This study will examine how a key factor called PRC1 regulates the induction of optimal protective virus and tumour T responses. This knowledge will contribute to the development of novel treatments for infection, cancer and autoimmune disease.</description>
<description type="fundingAmount">$997,141.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020563</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020563</identifier>
<identifier type="nhmrc">2020563</identifier>
<name type="primary"><namePart>The influence of genetic variation on foetal alcohol spectrum disorder</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | </subject>
<subject type="local">fetal alcohol syndrome </subject>
<subject type="local">teratology</subject>
<subject type="local">environmental influences</subject>
<subject type="local">cell signalling</subject>
<subject type="local">developmental genetics</subject>
<description type="Chief Investigator">Prof Ruth Arkell</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Drinking alcohol during pregnancy is the most common cause of environmentally induced human birth defects. But there is not a simple linear relationship between the amount of alcohol ingested and the consequence for the unborn child. In this research we will examine how the genetic makeup of an unborn child influences the consequence of maternal alcohol consumption.</description>
<description type="fundingAmount">$1,312,850.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020565</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020565</identifier>
<identifier type="nhmrc">2020565</identifier>
<name type="primary"><namePart>Therapeutic targeting of TLR7 in autoimmunity</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | autoimmunity  | </subject>
<subject type="local">toll-like receptors </subject>
<subject type="local">autoimmunity</subject>
<subject type="local">major histocompatibility complex (mhc) class ii</subject>
<subject type="local">oligonucleotide</subject>
<subject type="local">intracellular signal transduction</subject>
<description type="Chief Investigator">Assoc Prof Michael Gantier</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Autoimmune diseases, which are driven by self-reactive autoantibodies, affect approximately 5% of all Australians. While treatments are available to limit disease progression and morbidity, these are non-curative and can have numerous harmful side-effects. Here, we propose an innovative approach to thwart autoimmune disease by targeting how autoantibodies are generated. We have developed a new class of specific therapeutics that have the potential to help treat diverse autoimmune conditions.</description>
<description type="fundingAmount">$1,496,654.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020567</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020567</identifier>
<identifier type="nhmrc">2020567</identifier>
<name type="primary"><namePart>Reverse translation of a rodent cognitive flexibility task</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </subject>
<subject type="local">animal model </subject>
<subject type="local">cognition</subject>
<subject type="local">translational research</subject>
<subject type="local">metabolic disorders</subject>
<subject type="local">mental health</subject>
<description type="Chief Investigator">Assoc Prof Thomas Burne</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cognitive dysfunction is prominent in patients with neuropsychiatric and neurodegenerative disorders, yet current treatments have little effect on these symptoms. We need better treatments, but this requires better testing protocols. The goal is to provide a novel cognitive flexibility task for cognitive research in rodents that will help to develop initiatives to prevent, treat and rehabilitate patients with cognitive impairment.</description>
<description type="fundingAmount">$503,785.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020569</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020569</identifier>
<identifier type="nhmrc">2020569</identifier>
<name type="primary"><namePart>Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">cancer immunotherapy </subject>
<subject type="local">drug resistance</subject>
<subject type="local">liver metastases</subject>
<subject type="local">malignant melanoma</subject>
<subject type="local">lung cancer</subject>
<description type="Chief Investigator">Dr Ines Esteves Domingues Pires da Silva</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Drugs that stimulate immune cells to fight cancer (immunotherapy) have been used in melanoma and other cancers. The majority of melanoma patients resistant to immunotherapy have their melanoma spread to the liver; and we will study the effect of the presence of liver metastases on the immune response, in order to unveil novel mechanisms of resistance and therapeutic targets. Given the global finding across other cancers, our work has potential for impacting a broad range of cancer patients.</description>
<description type="fundingAmount">$852,279.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020579</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020579</identifier>
<identifier type="nhmrc">2020579</identifier>
<name type="primary"><namePart>A novel pharmaco-genetic treatment for auto-immune kidney disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </subject>
<subject type="local">gene therapy </subject>
<subject type="local">experimental glomerulonephritis</subject>
<subject type="local">adeno-associated virus</subject>
<subject type="local">vasculitis</subject>
<subject type="local">neutrophils</subject>
<description type="Chief Investigator">Dr Grant Logan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is mounting evidence that the enzyme DNase I is a novel non-toxic therapeutic for autoimmunity, an appealing alternative to long-term use of current sub-optimal immunosuppressive drugs that carry significant toxicities. This project will build the translational bridge for application of a “one shot” DNase I therapy in humans with autoimmune kidney disease.</description>
<description type="fundingAmount">$1,248,547.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020587</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020587</identifier>
<identifier type="nhmrc">2020587</identifier>
<name type="primary"><namePart>A novel proinflammatory mechanism reveals an innovative therapeutic strategy to treat hepatic inflammation in chronic liver disease.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">hepatic stellate cells </subject>
<subject type="local">hepatic fibrosis</subject>
<subject type="local">haemochromatosis</subject>
<subject type="local">ferritin</subject>
<subject type="local">inflammation</subject>
<description type="Chief Investigator">Prof Grant Ramm</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">We have generated considerable evidence for a role for tissue ferritin as a mediator of inflammation associated with liver fibrosis (scarring). These highly novel and innovative studies will identify the mechanisms associated with H-Ferritin-regulated liver inflammation in hepatic stellate cells (scar-forming cells in the liver) in chronic liver disease, which we will use to develop novel anti-inflammatory therapeutics to inhibit inflammation and fibrosis associated with chronic liver disease.</description>
<description type="fundingAmount">$950,912.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020590</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020590</identifier>
<identifier type="nhmrc">2020590</identifier>
<name type="primary"><namePart>Incubation of craving for alcohol: Is exercise a viable intervention?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | behavioural neuroscience | </subject>
<subject type="local">alcohol and behaviour </subject>
<subject type="local">neuroscience</subject>
<subject type="local">exercise therapy</subject>
<subject type="local">alcohol use disorders</subject>
<subject type="local">addiction treatment</subject>
<description type="Chief Investigator">Dr Christina Perry</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Environmental cues elicit strong craving in people with alcohol use disorder. These cravings increase over longer periods of abstinence, in many cases prompting relapse. In a preclinical model, we have found that increased compulsion to seek alcohol across abstinence can be prevented with voluntary exercise. In this project we will identify the neural changes responsible for both the increase in craving and the restorative effect of exercise, and test the longevity of exercise benefits.</description>
<description type="fundingAmount">$876,991.56</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020606</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020606</identifier>
<identifier type="nhmrc">2020606</identifier>
<name type="primary"><namePart>Monoclonal antibodies to placental malaria antigen VAR2CSA</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">plasmodium falciparum </subject>
<subject type="local">malaria</subject>
<subject type="local">antibody</subject>
<subject type="local">monoclonal antibody</subject>
<subject type="local">pregnancy</subject>
<description type="Chief Investigator">Prof Stephen Rogerson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Placental malaria parasites express VAR2CSA protein on the red blood cell surface. From the blood of pregnant women with strong antibody to VAR2CSA, we will isolate antibody-producing B cells. We will test the antibodies produced by the B cells to find antibodies which can block placental infection, can clear or kill infected cells, and react with many strains. The best ones will be tweaked to further improve activity. Optimised monoclonal antibody to VAR2CSA may prevent placental malaria.</description>
<description type="fundingAmount">$707,364.16</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020613</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020613</identifier>
<identifier type="nhmrc">2020613</identifier>
<name type="primary"><namePart>Dissecting the regulatory mechanisms controlling antigen processing and presentation in dendritic cells</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified | </subject>
<subject type="local">dendritic cell </subject>
<subject type="local">cell surface receptor</subject>
<subject type="local">antigen presenting cells</subject>
<subject type="local">ubiquitination</subject>
<subject type="local">immune regulation</subject>
<description type="Chief Investigator">Assoc Prof Mireille Lahoud</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Dendritic cells of the immune system utilise specific receptors to sense danger signals from their environment. We identified a DC danger receptor, Clec9A, which recognizes and induces immunity to “dangerous” dead cells eg. infected cells. We will investigate how dendritic cells regulate their responses to “dangerous” dead cells, and the checkpoints that control immune responses. We will use this knowledge to develop novel approaches for vaccines and immunotherapies for improved health outcomes</description>
<description type="fundingAmount">$1,482,413.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020624</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020624</identifier>
<identifier type="nhmrc">2020624</identifier>
<name type="primary"><namePart>Inhibition failure in Alzheimer’s disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01sf06y89</identifier><title>Macquarie University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">alzheimer disease </subject>
<subject type="local">neurofibrillary tangles</subject>
<subject type="local">amyloid beta-protein</subject>
<subject type="local">dementia</subject>
<subject type="local">mouse models</subject>
<description type="Chief Investigator">Prof Lars Ittner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Dementia is a leading cause of death in Australia with a huge socioeconomic burden. Network of the brains executive cells, the neurons, are critical for the normal function of the brain. We hypothesize that distinct populations of neurons are compromised or lost in dementia brains, resulting initially in mild cognitive impairment and progressing to severe dementia. This project aims at understanding how these network fail and will test novel way to prevent or treat the resulting deficits.</description>
<description type="fundingAmount">$1,212,345.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020626</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020626</identifier>
<identifier type="nhmrc">2020626</identifier>
<name type="primary"><namePart>Co-designing a consumer-focused digital health system to improve adverse drug event (ADE) detection, management and reporting</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | health services and systems | primary health care | health sciences | public health | health promotion | health sciences | health services and systems | digital health | </subject>
<subject type="local">drug safety </subject>
<subject type="local">adverse drug reactions</subject>
<subject type="local">surveillance</subject>
<subject type="local">patient outcomes</subject>
<subject type="local">patient/professional communication</subject>
<description type="Chief Investigator">Dr Renly Lim</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Medicines have many benefits, but can also cause harm. Currently the effects of medicines and any potential harms are not monitored for the majority of people taking medicines. This project will develop a new digital health system that enables consumers and health professionals to actively detect medicine harms, and to report the harms to the medicine regulatory authority in Australia. We will also develop new tools to better communicate medicine safety issues to the public.</description>
<description type="fundingAmount">$1,717,988.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020633</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020633</identifier>
<identifier type="nhmrc">2020633</identifier>
<name type="primary"><namePart>The use of Pro-apoptotic Drugs to Eliminate HIV in the Brain</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04ttjf776</identifier><title>RMIT University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">human immunodeficiency virus (hiv) </subject>
<subject type="local">viral infection</subject>
<subject type="local">central nervous system (cns)</subject>
<subject type="local">anti-latency drugs</subject>
<subject type="local">apoptosis</subject>
<description type="Chief Investigator">Prof Melissa Churchill</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">HIV affects &gt;37 M people worldwide and no scalable cure exists. Current approaches to cure HIV utilises drugs that are designed to target and kill HIV-infected cells in the blood. However, the efficacy and possible toxicity of these compounds in the brain is unclear. Our study will use novel animal cohorts and human brain cells to determine the ability of these drugs to target and kill HIV-infected cells in the brain, thus, informing on the suitability of these drugs in people with HIV.</description>
<description type="fundingAmount">$1,287,548.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020636</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020636</identifier>
<identifier type="nhmrc">2020636</identifier>
<name type="primary"><namePart>What Matters to First Nations Kids: Co-designing a wellbeing measure for First Nations children aged 5-11 years (WM2K Project)</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </subject>
<subject type="local">aboriginal mental health </subject>
<subject type="local">wellbeing</subject>
<subject type="local">measurement</subject>
<subject type="local">aboriginal child</subject>
<subject type="local">indigenous australians</subject>
<description type="Chief Investigator">Dr Kate Anderson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project gives First Nations Australian children the chance to have a say about what is important to their wellbeing. The project team will engage First Nations children and their primary carers from across the country to co-design a new wellbeing measure that asks questions about what makes a good life for them. The measure will be widely available for use by decision makers to better understand the real impacts of policies and programs to improve the lives of all First Nations children.</description>
<description type="fundingAmount">$1,779,065.70</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020646</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020646</identifier>
<identifier type="nhmrc">2020646</identifier>
<name type="primary"><namePart>Molecular mechanisms underlying NF1 dysfunction in tumour growth and disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | information and computing sciences | artificial intelligence | modelling and simulation | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | </subject>
<subject type="local">structural biology </subject>
<subject type="local">electron microscopy</subject>
<subject type="local">protein biochemistry</subject>
<subject type="local">gtp-binding protein</subject>
<subject type="local">protein function</subject>
<description type="Chief Investigator">Dr Andrew Ellisdon</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mutations of the neurofibromin tumour suppressor gene cause the common genetic disease neurofibromatosis type 1 and drive numerous cancers including melanoma, breast and brain cancer. We will apply new breakthrough technologies to uncover how the neurofibromin protein is dysregulated at the atomic level and inside the cell. This project will discover new pathways for therapeutic intervention for Australians living with NF1-linked disease.</description>
<description type="fundingAmount">$939,387.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020732</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020732</identifier>
<identifier type="nhmrc">2020732</identifier>
<name type="primary"><namePart>Next generation technology for paediatric blood pressure monitoring</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | medical devices | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </subject>
<subject type="local">blood pressure </subject>
<subject type="local">hypertension</subject>
<subject type="local">young children</subject>
<subject type="local">primary school-aged children</subject>
<subject type="local">hypotension</subject>
<description type="Chief Investigator">Assoc Prof Jonathan Mynard</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Blood pressure (BP) monitoring is critically important in hospitalised children and in those with hypertension, but is impeded by low tolerance to repeated cuff inflation. In this project, a novel cuffless BP device suitable for children will be developed and tested in real clinical settings. The device will overcome the distress and sleep disturbance caused by current devices, enabling more reliable and timely identification of high or low BP levels that can cause permanent brain/kidney damage.</description>
<description type="fundingAmount">$1,130,880.40</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020737</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020737</identifier>
<identifier type="nhmrc">2020737</identifier>
<name type="primary"><namePart>Targeting Bromodomain and Extra-Terminal (BET) Proteins for Preventing Preterm Birth</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </subject>
<subject type="local">parturition </subject>
<subject type="local">premature birth</subject>
<subject type="local">fetal membranes</subject>
<subject type="local">gene regulation</subject>
<subject type="local">chromatin</subject>
<description type="Chief Investigator">Dr Jonathan Paul</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Preterm birth is the biggest contributing factor to death and disease among newborns. This application explores the physiological mechanism that controls pregnancy length and is disrupted in preterm birth. We focus on the involvement of key regulatory proteins that can be targeted by drugs and will determine the potential of these drugs to block preterm parturition.</description>
<description type="fundingAmount">$529,026.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020743</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020743</identifier>
<identifier type="nhmrc">2020743</identifier>
<name type="primary"><namePart>How is immunogenic double-stranded RNA regulated in cells?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02k3cxs74</identifier><title>St Vincents Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | immunology | innate immunity | </subject>
<subject type="local">rna binding proteins </subject>
<subject type="local">rna</subject>
<subject type="local">inflammatory diseases</subject>
<subject type="local">epigenetics</subject>
<subject type="local">genetics</subject>
<description type="Chief Investigator">Dr Jacqueline Heraud-Farlow</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Fundamental to a functional immune system is the ability to correctly distinguish between material from our own cells and from a virus. Failure to do so results in auto-inflammation. We have identified three new genes that are important for regulating virus-like RNA in our own cells, to prevent inflammation. Understanding these genes provides crucial insights and potential new therapeutic targets for diverse settings from auto-inflammatory disease to cancer, viral immunity and RNA therapeutics</description>
<description type="fundingAmount">$1,086,607.70</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020750</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020750</identifier>
<identifier type="nhmrc">2020750</identifier>
<name type="primary"><namePart>Translating and field-validating an epigenetic blood test to predict TB infection and disease risk</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">tuberculosis </subject>
<subject type="local">diagnostic</subject>
<subject type="local">risk prediction</subject>
<subject type="local">longitudinal cohort study</subject>
<subject type="local">dna methylation</subject>
<description type="Chief Investigator">Assoc Prof Anna Coussens</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">We will deliver a validated DNA blood test which can be used to identify asymptomatic individuals in at-risk communities who are infected with the tuberculosis bacteria and at risk of developing symptomatic disease over 3 years. Community screening asymptomatic individuals with this test has the potential to have the greatest impact on reducing TB cases, by allowing us to better target preventative therapy to those most in need, before they develop disease and transmit the bacteria to others.</description>
<description type="fundingAmount">$785,406.75</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020757</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020757</identifier>
<identifier type="nhmrc">2020757</identifier>
<name type="primary"><namePart>Targeting hepatic amino acid transport to combat cardiometabolic disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell metabolism | </subject>
<subject type="local">amino acid transport </subject>
<subject type="local">lipoprotein metabolism</subject>
<subject type="local">hepatic metabolism</subject>
<subject type="local">lipid metabolism</subject>
<subject type="local">atherosclerosis</subject>
<description type="Chief Investigator">Dr Adam Rose</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The overarching idea of this proposal is to find a way to mimic the health benefits of dietary protein restriction while avoiding negative health consequences. To this end, we have invented a way to internally mimic a protein restricted state, and preliminary data have shown that such a strategy can reduce cardiometabolic disease biomarkers. This proposal seeks to thoroughly understand and to provide key evidence of the effectiveness of this novel drug target against cardiometabolic disease.</description>
<description type="fundingAmount">$1,363,478.79</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020758</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020758</identifier>
<identifier type="nhmrc">2020758</identifier>
<name type="primary"><namePart>A novel dual therapy approach to treatment of multidrug-resistant Gram-negative infections</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical microbiology | medical bacteriology  | </subject>
<subject type="local">multidrug resistance </subject>
<subject type="local">bacterial infection</subject>
<subject type="local">mouse models</subject>
<subject type="local">molecular imaging</subject>
<subject type="local">medical bacteriology</subject>
<description type="Chief Investigator">Dr Abiodun Ogunniyi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project will use multiple advanced approaches to pinpoint how new derivatives of the anticoccidial drug robenidine kill and exert their specific activities against different superbugs. This study is of utmost significance in the current era of inexorable rise in multidrug resistance. The project will generate critical data that will promote targeted and responsible use of new antimicrobials, in alignment with similar global approaches towards eliminating multidrug resistance development.</description>
<description type="fundingAmount">$981,046.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020762</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020762</identifier>
<identifier type="nhmrc">2020762</identifier>
<name type="primary"><namePart>Striatal population involvement in OCD symptom domains</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | behavioural neuroscience | </subject>
<subject type="local">obsessive-compulsive disorder (ocd) </subject>
<subject type="local">animal model</subject>
<subject type="local">behavioural science</subject>
<subject type="local">striatum</subject>
<subject type="local">calcium imaging</subject>
<description type="Chief Investigator">Dr Elizabeth Manning</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Obsessive compulsive disorder (OCD) is associated with disturbances in different areas of flexible behaviour, including flexible actions (compulsions), threat responses (obsessions) and decision making. The striatum is a brain region that is critical for flexible behaviour, and that is also over active in OCD. The current proposal will determine how the two distinct functional neural populations in the striatum contribute to different disturbances in flexible behaviour relevant to OCD.</description>
<description type="fundingAmount">$644,116.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020768</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020768</identifier>
<identifier type="nhmrc">2020768</identifier>
<name type="primary"><namePart>A new mechanism for targeting stress-related mental health disorders</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | behavioural neuroscience | </subject>
<subject type="local">stress </subject>
<subject type="local">hypothalamus</subject>
<subject type="local">calcium imaging</subject>
<subject type="local">depression</subject>
<subject type="local">motivation</subject>
<description type="Chief Investigator">Prof Christopher Dayas</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Australians have faced significant emotional trauma over the past two years. Unfortunately, treatments for stress-induced psychiatric illness remain poor. By establishing a causal role of hypothalamic PVN-CRH cells in stress-induced psychopathology independent of the stress hormones, these studies will significantly shift the current dogma in psychiatry, leading to new studies and therapeutic opportunities for the treatment of stress-related disorders including depression and PTSD.</description>
<description type="fundingAmount">$831,378.50</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020780</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020780</identifier>
<identifier type="nhmrc">2020780</identifier>
<name type="primary"><namePart>Does finite slowing of feeding cause artemisinin resistance in malaria?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | infectious agents | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">antimalarial </subject>
<subject type="local">malaria control</subject>
<subject type="local">drug resistance</subject>
<subject type="local">malaria</subject>
<subject type="local">malaria drug resistance</subject>
<description type="Chief Investigator">Prof Stuart Ralph</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Drug resistance to the frontline antimalarial artemisinin is a major challenge to addressing the global burden of malaria. Deteriorating artemisinin resistance could lead to this drug becoming unusable, or could be manageable if drug resistance doesn't worsen and spread. We have determined the mechanism that underlies resistance and will test whether this is a finite and manageable process or instead is an escalating system that likely presages worsening prospects for global artemisinin use</description>
<description type="fundingAmount">$859,736.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020782</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020782</identifier>
<identifier type="nhmrc">2020782</identifier>
<name type="primary"><namePart>Optimising sleep quality inside insecticide treated mosquito nets in hot overnight environments</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical physiology | human biophysics  | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </subject>
<subject type="local">heat stress </subject>
<subject type="local">climate change</subject>
<subject type="local">thermoregulation</subject>
<subject type="local">mosquito-borne disease</subject>
<subject type="local">sleep</subject>
<description type="Chief Investigator">Dr Yorgi Mavros</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Nine-five percent of all Malaria transmission occurs within the African region, causing approximately 600 000 deaths per year. Insecticide-treated bed nets are one of the primary interventions used to stop the spread of malaria. However, sensations of feeling too hot to sleep comfortably is the primary reason for not using bed nets. By simulating real-world conditions, this project will determine how fans can be used to improve thermal comfort and sleep quality within the bed net enclosure.</description>
<description type="fundingAmount">$1,244,248.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020814</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020814</identifier>
<identifier type="nhmrc">2020814</identifier>
<name type="primary"><namePart>Identification and functional characterisation of genomic enhancers in the human brain: a steppingstone to clinical translation of genetic data for brain disorders.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | genetics | genomics | </subject>
<subject type="local">functional genomics </subject>
<subject type="local">gene regulation</subject>
<subject type="local">schizophrenia and related disorders</subject>
<subject type="local">glioma</subject>
<subject type="local">autism spectrum disorders</subject>
<description type="Chief Investigator">Assoc Prof Irina Voineagu</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The genetic basis of brain disorders is incompletely understood. An important discovery over the last decade was that genetic variants associated with brain disorders are likely to impact gene expression regulation. The proposed project studies enhancers, the key regulatory elements of the genome that turn genes on and off. The project aims to identify enhancers that play functional roles in brain cells, thereby uncovering how genetic changes lead to brain disorders.</description>
<description type="fundingAmount">$503,855.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020822</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020822</identifier>
<identifier type="nhmrc">2020822</identifier>
<name type="primary"><namePart>4D molecular characterisation of C-RIP proteins required for malaria host-cell entry</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical parasitology  | </subject>
<subject type="local">malaria </subject>
<subject type="local">invasion biology</subject>
<subject type="local">malaria transmission</subject>
<subject type="local">protein-protein interaction</subject>
<subject type="local">drug targeting</subject>
<description type="Chief Investigator">Dr Danny Wilson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We have identified proteins that control the dynamic release of essential antigens required for malaria parasite infection of host red blood cells and will identify druggable interactions between these proteins that can be targeted to kill malaria.</description>
<description type="fundingAmount">$901,642.43</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020851</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020851</identifier>
<identifier type="nhmrc">2020851</identifier>
<name type="primary"><namePart>Targeting sympathetic nerves to treat metastatic triple negative breast cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | </subject>
<subject type="local">breast cancer </subject>
<subject type="local">chemotherapy</subject>
<subject type="local">cancer treatment</subject>
<subject type="local">relapse</subject>
<subject type="local">cancer biology</subject>
<description type="Chief Investigator">Assoc Prof Erica Sloan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Survival from metastatic triple negative breast cancer is terrible. Our new findings suggest that nerves within cancers undermine the beneficial effects of current treatments. This project investigates how blocking nerves improves response to treatment, and will determine how to optimally apply these findings so cancer patients benefit.</description>
<description type="fundingAmount">$1,109,795.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020861</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020861</identifier>
<identifier type="nhmrc">2020861</identifier>
<name type="primary"><namePart>New approaches to treating hemoglobinopathies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">transcription factor </subject>
<subject type="local">control of gene expression</subject>
<subject type="local">enhancer elements</subject>
<subject type="local">dna methylation</subject>
<subject type="local">histone deacetylase</subject>
<description type="Chief Investigator">Prof Merlin Crossley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The genetic disorders ß-thalassemia and sickle cell disease are caused by mutations in the adult globin gene. Fortunately, humans have a second globin gene, the fetal globin gene, which is expressed in utero but turned off after birth. Re-activating expression of this fetal globin gene can alleviate the symptoms of ß-thalassemia and sickle cell disease. We are using new strategies, including sophisticated gene editing, to boost fetal globin output to treat this disease.</description>
<description type="fundingAmount">$1,508,780.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020900</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020900</identifier>
<identifier type="nhmrc">2020900</identifier>
<name type="primary"><namePart>RNA-mediated regulation of chromatin compaction in development and disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genome structure and regulation | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </subject>
<subject type="local">rna binding proteins </subject>
<subject type="local">rna</subject>
<subject type="local">chromatin structure</subject>
<subject type="local">epigenetics</subject>
<subject type="local">gene regulation</subject>
<description type="Chief Investigator">Assoc Prof Chen Davidovich</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Polycomb repressive complexes are enzymatic complexes that safeguard the genome by preventing repressed genes from becoming active. The proposed study aimed at identifying how RNA regulate certain types of polycomb repressive complexes to maintain genes in a compacted state that prevent their expression. The project aims to determine how RNA regulates the formation of compact chromatin structure and to visualize this process in high resolution.</description>
<description type="fundingAmount">$774,339.26</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020902</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020902</identifier>
<identifier type="nhmrc">2020902</identifier>
<name type="primary"><namePart>Designing novel blood and MRI-based predictive tools to understand disease mechanisms, improve recovery and guide targeted interventions following neonatal arterial ischaemic stroke</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | neonatology | </subject>
<subject type="local">stroke </subject>
<subject type="local">neonatal</subject>
<subject type="local">proteomics</subject>
<subject type="local">brain imaging</subject>
<subject type="local">developmental outcomes</subject>
<description type="Chief Investigator">Assoc Prof Mark Mackay</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Around 120 Australian babies suffer a stroke every year but causes are unknown. Almost half experience long-term problems such as cerebral palsy, speech, learning or behavioural difficulties. The study aims to answer the two most important questions that parents ask their doctors: why did my baby have a stroke and how will the stroke affect my baby’s future development? We will do this by looking at blood signatures and use advanced MRI imaging to study brain networks in 50 babies with stroke.</description>
<description type="fundingAmount">$1,270,873.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020911</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020911</identifier>
<identifier type="nhmrc">2020911</identifier>
<name type="primary"><namePart>Targeting the 4Ms in cancer treatment – matrix, mechanics, microenvironment, metabolism</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | biomaterials  | </subject>
<subject type="local">extracellular matrix </subject>
<subject type="local">microenvironment</subject>
<subject type="local">cancer cell biology</subject>
<subject type="local">tissue engineering</subject>
<subject type="local">biomechanics</subject>
<description type="Chief Investigator">Assoc Prof Daniela Loessner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project addresses a clinical problem with an innovative approach. Pancreatic cancer is one of the deadliest cancers and only 10% of patients survive 5 years after diagnosis. To find better therapies, we need patient-specific models that mimic the biology of tumour tissues and target interactions between different cell types. We will develop a controllable platform for modelling the human disease in the laboratory. We will use our new platform to discover better ways of treating the disease.</description>
<description type="fundingAmount">$814,599.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020950</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020950</identifier>
<identifier type="nhmrc">2020950</identifier>
<name type="primary"><namePart>High-throughput ex vivo screening of human retinal cell specific delivery nanoparticles for gene therapy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | ophthalmology and optometry | vision science | </subject>
<subject type="local">macular disease </subject>
<subject type="local">nanotechnology</subject>
<subject type="local">ex vivo</subject>
<subject type="local">drug delivery</subject>
<subject type="local">retinal metabolism</subject>
<description type="Chief Investigator">Dr Ling Zhu</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Using nanoparticles as carriers of therapeutic payloads is one promising way to treat retinal diseases. They can carry significantly larger payloads than viruses. The project combine single-cell RNA sequencing with a barcoded library to perform high-throughput screening for the nanoparticles that will cell-specifically deliver genes. These identified carriers will be used as vectors to introduce the gene constructs or drugs specifically into the target retinal cells to treat retinal diseases.</description>
<description type="fundingAmount">$920,948.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020961</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020961</identifier>
<identifier type="nhmrc">2020961</identifier>
<name type="primary"><namePart>Targeting IL-6 trans-signalling in brain injury</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | cellular nervous system | </subject>
<subject type="local">microglia </subject>
<subject type="local">molecular neuroscience</subject>
<subject type="local">acquired brain injury</subject>
<subject type="local">glia-neuron relationship</subject>
<subject type="local">glia</subject>
<description type="Chief Investigator">Assoc Prof Jana Vukovic</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Acquired brain injury is a leading cause of ongoing disability worldwide. Although the damage caused by the primary insult is irreversible, a series of secondary events cause further nerve cell death and exacerbate brain dysfunction. My laboratory has recently uncovered a way to prevent these secondary events by targeting the brain’s immune cells - microglia. Here we will dissect as to how microglia can be manipulated to promote repair following brain injury.</description>
<description type="fundingAmount">$940,680.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020984</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020984</identifier>
<identifier type="nhmrc">2020984</identifier>
<name type="primary"><namePart>Identifying endometriosis risk and disease variability by mapping endometrial stem cell maturation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </subject>
<subject type="local">endometriosis </subject>
<subject type="local">endometrium</subject>
<subject type="local">adult stem cells</subject>
<subject type="local">gene transcription</subject>
<subject type="local">in vitro</subject>
<description type="Chief Investigator">Dr Brett McKinnon</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Endometriosis is a poorly categorised disease. Diagnosis is via surgery and patient outcomes are varied. Identifying markers for disease risk and sub grouping would greatly improve treatment for individual patients. Endometriosis grows from endometrial stem cells that enter the peritoneal cavity. We identified altered differentiation increases endometriosis risk and propose to identify factors that cause altered differentiation and the biological signatures that result to improve treatment.</description>
<description type="fundingAmount">$945,439.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020999</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020999</identifier>
<identifier type="nhmrc">2020999</identifier>
<name type="primary"><namePart>Neuroprotective benefit and safety of preterm neonatal sulphate supplementation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | intensive care  | </subject>
<subject type="local">cerebral palsy treatments </subject>
<subject type="local">very preterm birth</subject>
<subject type="local">neuroprotection</subject>
<subject type="local">neonatal intensive care (nicu)</subject>
<subject type="local">hyposulphataemia</subject>
<description type="Chief Investigator">Assoc Prof Paul Dawson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Preterm babies become sulphate deficient after birth, increasing the risk of cerebral palsy. Any intervention that prevents cerebral palsy in preterm infants, particularly a simple, low-risk, low-cost intervention would have considerable personal and economic benefits. In this study, we will investigate the impact of sulphate supplementation on brain development in preterm piglets, which will help develop future sulphate therapies in human preterm infants.</description>
<description type="fundingAmount">$966,906.60</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021009</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021009</identifier>
<identifier type="nhmrc">2021009</identifier>
<name type="primary"><namePart>Targeting desmoglein-2 to reinvigorate anti-tumour immunity</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </subject>
<subject type="local">cancer cell biology </subject>
<subject type="local">pancreatic cancer</subject>
<subject type="local">melanoma</subject>
<subject type="local">tumour immunology</subject>
<subject type="local">adhesion molecules</subject>
<description type="Chief Investigator">Prof Claudine Bonder</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Pancreatic cancer and melanoma are amongst the deadliest forms of cancer which continue to rise in prevalence. Despite clinical advances, once metastasised, cancer from any organ is universally fatal. The growth and spread of solid tumours requires access to the blood supply as well as control of the immune response. Our work on tumour vasculature, in these most difficult to treat tumours, has identified an adhesion protein on the cancer cells that may help fight this deadly disease.</description>
<description type="fundingAmount">$1,159,847.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021010</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021010</identifier>
<identifier type="nhmrc">2021010</identifier>
<name type="primary"><namePart>Muscle-directed gene therapy as an adjuvant to neuroprotection: Targeting both ends of the dysfunctional nerve-muscle axis to treat motor neurone disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">amyotrophic lateral sclerosis </subject>
<subject type="local">motor neuron disease (mnd)</subject>
<subject type="local">muscle degeneration</subject>
<subject type="local">treatment strategies</subject>
<subject type="local">skeletal muscle hypertrophy</subject>
<description type="Chief Investigator">Assoc Prof Peter Crouch</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Amyotrophic lateral sclerosis involves nerve cell death and deterioration of the muscles that the nerves control. Effective treatments are lacking. Capitalising on our team’s complementary expertise in neuroscience and muscle physiology, we are developing a multimodal treatment strategy designed to protect nerves and promote muscle re-growth. Targeting both ends of the ‘nerve-muscle axis’ will prevent premature death of people with this disease and stimulate functional recovery.</description>
<description type="fundingAmount">$1,122,472.40</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021029</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021029</identifier>
<identifier type="nhmrc">2021029</identifier>
<name type="primary"><namePart>Enabling remote screening of childhood hearing loss using artificial intelligence</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02swxtp23</identifier><title>National Acoustic Laboratories</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | otorhinolaryngology | </subject>
<subject type="local">congenital hearing loss </subject>
<subject type="local">conductive hearing loss</subject>
<subject type="local">health screening</subject>
<subject type="local">audiology</subject>
<subject type="local">artificial neural networks</subject>
<description type="Chief Investigator">Dr Jessica Monaghan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Hospitals and Health Services</description>
<description type="full">Children born in Australia are tested to check if they have a hearing loss. This newborn screening doesn't pick up some forms of hearing loss and can't detect a hearing loss that only appears later in life. This project will create a smartphone app parents can use to record their child speaking to check if they may have a hearing loss. The app will provide a simple way for parents, health workers, and teachers to help make sure all children with hearing loss are diagnosed as soon as possible.</description>
<description type="fundingAmount">$452,713.70</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021041</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021041</identifier>
<identifier type="nhmrc">2021041</identifier>
<name type="primary"><namePart>Exploiting sex differences in androgen action to advance a novel treatment for breast cancer.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">breast cancer </subject>
<subject type="local">androgen receptor</subject>
<subject type="local">oestrogen receptor</subject>
<subject type="local">endocrine therapy</subject>
<subject type="local">immune response</subject>
<description type="Chief Investigator">Prof Wayne Tilley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We have recently discovered that activation of the androgen receptor (AR) can redirect the cancer-promoting activity of the estrogen receptor (ER) to halt rather than promote breast cancer growth. The current study will establish if AR activating drugs influence the immune system to inhibit growth of ER-driven breast cancers to establish androgen therapy as a more effective treatment strategy.</description>
<description type="fundingAmount">$1,262,967.20</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021055</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021055</identifier>
<identifier type="nhmrc">2021055</identifier>
<name type="primary"><namePart>Reducing the burden of respiratory distress after caesarean delivery.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | paediatrics | infant and child health | </subject>
<subject type="local">respiratory physiology </subject>
<subject type="local">cardiovascular physiology</subject>
<subject type="local">airway oedema</subject>
<subject type="local">newborn</subject>
<subject type="local">respiratory diseases</subject>
<description type="Chief Investigator">Dr Kelly Crossley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. We have recently made a major break-through in understanding why and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of this breathing problem.</description>
<description type="fundingAmount">$1,240,465.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021057</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021057</identifier>
<identifier type="nhmrc">2021057</identifier>
<name type="primary"><namePart>SETDB1 Epigenetic checkpoint blockade: A new approach to enhance immune-mediated control</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </subject>
<subject type="local">cancer immunotherapy </subject>
<subject type="local">cancer immunology</subject>
<subject type="local">gene expression</subject>
<subject type="local">nuclear import</subject>
<subject type="local">novel therapeutic agents</subject>
<description type="Chief Investigator">Prof Sudha Rao</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">SETDB1 is a novel drug target that mediates immunotherapy resistance. We have shown that the nuclear form of SETDB1 is enriched in tissue and blood samples from immunotherapy-resistant metastatic cancers. We have designed a new drug targeting nuclear SETDB1 (MSETC) that targets both cancer cells and simultaneously re-invigorates the immune system. In this project, we will undertake critical molecular pre-clinical studies towards advancing our prototypic drug (MSETC) to the clinic.</description>
<description type="fundingAmount">$1,280,776.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021063</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021063</identifier>
<identifier type="nhmrc">2021063</identifier>
<name type="primary"><namePart>Understanding and targeting self-renewal in aggressive blood cancers</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </subject>
<subject type="local">chromatin </subject>
<subject type="local">targeted therapy</subject>
<subject type="local">gene transcription</subject>
<subject type="local">acute leukaemia</subject>
<subject type="local">drug resistance</subject>
<description type="Chief Investigator">Dr Omer Gilan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The epigenetic protein Menin, is critical for the ability of leukaemia cells to divide indefinitely. Therapies that target this protein are currently in clinical trials, however it is unclear how they work. By studying how resistance to these therapies emerges, we have unexpectedly discovered that they work differently to what was previously thought. This proposal will use new tools to elucidate these findings in order to develop ways to overcome resistance and improve their efficacy.</description>
<description type="fundingAmount">$976,222.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021074</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021074</identifier>
<identifier type="nhmrc">2021074</identifier>
<name type="primary"><namePart>Organ Transplantation as a Model of Reversible Frailty</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </subject>
<subject type="local">frailty </subject>
<subject type="local">renal transplantation</subject>
<subject type="local">microcirculation</subject>
<subject type="local">metabolomics</subject>
<subject type="local">ageing</subject>
<description type="Chief Investigator">Prof Ruth Hubbard</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">People with end-stage kidney failure often have low energy and muscle weakness. Clinically, they are “frail”. Since health status improves significantly post-transplant, organ transplantation is a model of reversible frailty. In this study, we’ll measure frailty and biological data in 3 groups: (1) people before and after a kidney transplant (2) people with kidney failure who don’t receive a transplant (3) older people who are frail. This will provide new insights into the causes of frailty.</description>
<description type="fundingAmount">$1,609,170.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021082</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021082</identifier>
<identifier type="nhmrc">2021082</identifier>
<name type="primary"><namePart>Defining the features of atypical T cell responses in Human Immunodeficiency Virus (HIV) controllers</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01rxfrp27</identifier><title>La Trobe University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | cellular immunology | </subject>
<subject type="local">t cells </subject>
<subject type="local">human immunodeficiency virus (hiv)</subject>
<subject type="local">cytotoxic t lymphocyte (ctl) activation</subject>
<subject type="local">human leukocyte antigen (hla)</subject>
<subject type="local">t cell receptor</subject>
<description type="Chief Investigator">Prof Stephanie Gras</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Human immunodeficiency virus (HIV) directly attacks our immune system, impairing our natural defence against infection and disease. HIV has infected ~76 million individuals worldwide, leading to a long-lasting pandemic with no vaccine or cure currently available. However, there are rare individuals able to control HIV infection. Our work focuses on understanding how these individuals’ immune system can control HIV, thereby aiding the design of novel treatments or potential vaccines against HIV.</description>
<description type="fundingAmount">$697,946.10</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021085</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021085</identifier>
<identifier type="nhmrc">2021085</identifier>
<name type="primary"><namePart>Modelling of mitochondrial disease in specific cell lineages to understand pathomechanisms and develop effective targeted therapies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/048fyec77</identifier><title>Murdoch Childrens Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | </subject>
<subject type="local">mitochondrial disease </subject>
<subject type="local">inherited metabolic disorders</subject>
<subject type="local">molecular pathogenesis</subject>
<subject type="local">stem cells</subject>
<subject type="local">drug screening</subject>
<description type="Chief Investigator">Prof David Thorburn</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Mitochondrial disorders are a group of inherited diseases that can cause severe, life-limiting disease in at least 60 children born in Australia each year. These disorders impact on the brain, heart and other organ systems and we lack effective treatments, partly because we don’t understand the disease mechanisms. We will use human cell model systems, including stem cells differentiated into heart cells, to study disease mechanisms and trial new treatment approaches.</description>
<description type="fundingAmount">$1,360,059.40</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021126</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021126</identifier>
<identifier type="nhmrc">2021126</identifier>
<name type="primary"><namePart>Reversing Neurofibrosis: A New Way to Treat Type-2 Diabetes</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">hypothalamus </subject>
<subject type="local">neuroendocrinology</subject>
<subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</subject>
<subject type="local">insulin resistance</subject>
<subject type="local">extracellular matrix</subject>
<description type="Chief Investigator">Dr Garron Dodd</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We aim to discover new treatments for type-2 diabetes (T2D), a national and global health priority. Brain cells that maintain blood glucose levels within a safe range, are encased within a specialised extracellular matrix. We have discovered that this matrix becomes augmented and defective in T2D, a process termed neurofibrosis. Neurofibrosis makes neurons insulin resistant, which results in high blood sugar levels. We will pioneer the very first drugs targeting neurofibrosis to treat T2D.</description>
<description type="fundingAmount">$1,594,830.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021130</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021130</identifier>
<identifier type="nhmrc">2021130</identifier>
<name type="primary"><namePart>Improving HPV vaccine rates for Aboriginal young people through social media</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05jhnwe22</identifier><title>Edith Cowan University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander epidemiology | </subject>
<subject type="local">aboriginal health </subject>
<subject type="local">human papillomavirus (hpv)</subject>
<subject type="local">vaccination</subject>
<subject type="local">public health</subject>
<subject type="local">young adults</subject>
<description type="Chief Investigator">Dr Natalie Strobel</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Human papillomavirus (HPV) is a common sexually transmitted infection that can lead to HPV-related cancers. HPV rarely produces symptoms and cannot be cured or treated; therefore, vaccination is essential to protect against HPV and HPV-related diseases. This project aims to improve HPV vaccination rates amongst young Aboriginal people. Our project will combine health messages co-created by young people and implemented by micro-Influencers to improve HPV vaccination.</description>
<description type="fundingAmount">$974,708.75</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021155</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021155</identifier>
<identifier type="nhmrc">2021155</identifier>
<name type="primary"><namePart>Investigating the morphological and molecular origin of non-compaction cardiomyopathy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </subject>
<subject type="local">congenital heart disease </subject>
<subject type="local">molecular basis of disease</subject>
<subject type="local">heart development</subject>
<subject type="local">systems biology</subject>
<subject type="local">artificial neural networks</subject>
<description type="Chief Investigator">Dr Gonzalo del Monte Nieto</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Every year, 1 in 100 Australian babies are born with heart malformations of a genetic origin stressing the need for further research. In this project, we will investigate one of the most recently classified genetic cardiac condition and therefore, one of the least understood. Our expert team will apply innovative approaches to better understand the condition and provide crucial insights to design customized genetic screening panels and treatments for patients suffering from this disease.</description>
<description type="fundingAmount">$1,825,840.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021163</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021163</identifier>
<identifier type="nhmrc">2021163</identifier>
<name type="primary"><namePart>Targeting Endosomal Receptor Signalling for Superior Pain Relief</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | biomedical and clinical sciences | medical biotechnology | nanomedicine | </subject>
<subject type="local">receptor signalling </subject>
<subject type="local">chronic pain</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">g protein-coupled receptors</subject>
<subject type="local">receptor trafficking</subject>
<description type="Chief Investigator">Dr Nicholas Veldhuis</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">G protein-coupled receptors (GPCRs) are important drug targets. A key feature of GPCR function is their ability to internalise when stimulated, and it is now appreciated that this can promote signalling events that are uniquely associated with diseases of global relevance, including chronic pain. This project will define signalling processes mediated from internalised GPCRs, and develop nanomedicines for targeted delivery of drugs to specific sites inside cells for superior pain relief.</description>
<description type="fundingAmount">$1,353,578.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021172</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021172</identifier>
<identifier type="nhmrc">2021172</identifier>
<name type="primary"><namePart>Indigenous telomere-2-telomere human reference genomes to enable discovery, translation and innovations</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | genetics | genome structure and regulation | </subject>
<subject type="local">indigenous australians </subject>
<subject type="local">medical genomics</subject>
<subject type="local">human genome project</subject>
<subject type="local">population variation</subject>
<subject type="local">bioinformatics</subject>
<description type="Chief Investigator">Dr Hardip Patel</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Our project will use the latest DNA sequencing technologies to generate, for the first time, indigenous telomere-2-telomere reference genomes. These genomes will account for ancestral diversity and underpin the implementation of precision medicine, enable discoveries and drive innovations using genomics. Critically, the project will foster existing and create new partnerships with Indigenous communities through mutually agreed benefits of the genomics revolution.</description>
<description type="fundingAmount">$2,549,487.00</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021176</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021176</identifier>
<identifier type="nhmrc">2021176</identifier>
<name type="primary"><namePart>The neuroprotective potential of exercise in individuals with motor neuron disease - a paradigm-changing idea</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/04j757h98</identifier><title>Victoria University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">health sciences | sports science and exercise | exercise physiology | biomedical and clinical sciences | medical physiology | systems physiology  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">motor neuron disease (mnd) </subject>
<subject type="local">exercise training</subject>
<subject type="local">neuroprotection</subject>
<subject type="local">muscle</subject>
<subject type="local">brain</subject>
<description type="Chief Investigator">Dr Alessandra Ferri</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Every day two Australians die from motor neuron disease (MND) - an incurable neurodegenerative disease. This project aims to discover if exercise can slow neurodegeneration in MND. Thanks to the interdisciplinary expertise of our international consortium, we will investigate the neuroprotective potential of exercise on the brain, spinal cord, and muscle of patients with MND. This research has the potential to change the role of exercise in the treatment of MND.</description>
<description type="fundingAmount">$648,621.55</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021181</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021181</identifier>
<identifier type="nhmrc">2021181</identifier>
<name type="primary"><namePart>Unravelling tumour plasticity via parallels with tissue regeneration</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | </subject>
<subject type="local">adult stem cells </subject>
<subject type="local">organogenesis</subject>
<subject type="local">colon</subject>
<subject type="local">colorectal cancer</subject>
<subject type="local">intestine</subject>
<description type="Chief Investigator">Prof Helen Abud</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Development of resistance to chemotherapy is a major challenge in the treatment of bowel cancer. We are exploring whether a new cell type that is produced when the lining of the gut is injured, is also produced as bowel cancers acquire drug resistance. We will characterise these cells and examine if approaches directed at targeting these cells are capable of eliminating bowel cancers. This work could provide a rational basis for the design of new combination treatments for bowel cancer.</description>
<description type="fundingAmount">$1,356,369.20</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021182</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021182</identifier>
<identifier type="nhmrc">2021182</identifier>
<name type="primary"><namePart>Unravelling the brain-lung communication pathway as a novel way of improving stroke outcome</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">stroke outcome </subject>
<subject type="local">bacterial infection</subject>
<subject type="local">neutrophils</subject>
<subject type="local">lung</subject>
<subject type="local">vesicle transport</subject>
<description type="Chief Investigator">Assoc Prof Connie Wong</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Lung infection is highly prevalent and often deadly in patients with stroke, raising the possibility of weakened antibacterial responses in the lung after stroke. The focus of this project is to investigate the mechanisms underlying impaired lung immunity following stroke onset. We will also assess the potential of exosome content as biomarkers to identify high-risk stroke patients who will require antibacterial therapy to limit infection development and improve patient outcomes.</description>
<description type="fundingAmount">$1,104,980.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021183</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021183</identifier>
<identifier type="nhmrc">2021183</identifier>
<name type="primary"><namePart>Fluent Mobility for the Blind Individual Using Multimodal Auditory Sensory Augmentation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03f0f6041</identifier><title>University of Technology Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | medical devices | biomedical and clinical sciences | neurosciences | sensory systems | information and computing sciences | graphics, augmented reality and games | virtual and mixed reality | </subject>
<subject type="local">blindness </subject>
<subject type="local">sensory aids</subject>
<subject type="local">mobility</subject>
<subject type="local">functional magnetic resonance imaging (fmri)</subject>
<subject type="local">electroencephalography</subject>
<description type="Chief Investigator">Prof Chin-Teng Lin</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Fluency in blind users' mobility arises from access to an appropriate flow of sensory information, subtle control over the sensory information flow, and natural interaction. Any unimodal sensory augmentation system will fail to provide sufficient fluency, therefore we propose a multimodal sensory augmentation system using smart glasses and gesture control to improve fluency in mobility and orientation for blind individuals.</description>
<description type="fundingAmount">$1,604,198.75</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021186</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021186</identifier>
<identifier type="nhmrc">2021186</identifier>
<name type="primary"><namePart>Developing and applying a world-first alcohol market monitoring system</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | public health | health promotion | </subject>
<subject type="local">alcohol </subject>
<subject type="local">alcohol and behaviour</subject>
<subject type="local">alcohol consumption</subject>
<subject type="local">harm reduction</subject>
<subject type="local">consumer information</subject>
<description type="Chief Investigator">Prof Simone Pettigrew</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The alcohol market is evolving rapidly, with new products being brought to market and creative marketing strategies being implemented, often targeting younger drinkers. This project will deliver a world-first system of monitoring marketplace changes and providing timely data to policy makers to enable them to implement effective policy responses. A sustainable system of product monitoring and data reporting will be delivered to assist with alcohol harm-reduction strategies long term.</description>
<description type="fundingAmount">$790,147.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021208</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021208</identifier>
<identifier type="nhmrc">2021208</identifier>
<name type="primary"><namePart>UNIVERSAL NEUROPHOTONIC INTERFACE: A REVOLUTION IN MEDICAL BIONICS</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">physical sciences | atomic, molecular and optical physics | photonics, optoelectronics and optical communications | engineering | biomedical engineering | neural engineering | engineering | biomedical engineering | biomedical engineering not elsewhere classified | </subject>
<subject type="local">stem cell biology </subject>
<subject type="local">neurobiology</subject>
<subject type="local">photobiology</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">gene knockout</subject>
<description type="Chief Investigator">Assoc Prof Stefano Palomba</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to deliver the proof-of-concept of a universal nerve interface, which eventually will bidirectionally connect any bionic device to the peripheral nervous system. This would allow the brain to directly control any bionic device and also to receive sensory feedback, i.e. to “feel”. We will achieve this by combining permanently photoactive neurons, located on pre-determined areas on a photonic chip and addressed by light. Their axon will form a nerve-like structure.</description>
<description type="fundingAmount">$1,474,420.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021218</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021218</identifier>
<identifier type="nhmrc">2021218</identifier>
<name type="primary"><namePart>A Faster Cure for Tuberculosis: Revealing Adjunctive Antimicrobial Solutions</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical bacteriology  | </subject>
<subject type="local">mycobacterium tuberculosis </subject>
<subject type="local">adjunctive therapies</subject>
<subject type="local">antimicrobial resistance</subject>
<subject type="local">antimicrobial therapy</subject>
<subject type="local">bacterial pathogenesis</subject>
<description type="Chief Investigator">Assoc Prof Nicholas West</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The world urgently needs effective solutions for TB, a bacterial infection that claims more lives than any other. We have identified a "weak link" in the defences of the bacteria responsible and aim to find ALL such vulnerabilities, enabling the development of the next generation of therapy for TB. We will identify ways to weaken these bacterial defences, enhancing potency of existing antibiotics, and rescuing antimicrobial resistance, delaying the need for development of new TB antibiotics.</description>
<description type="fundingAmount">$1,395,113.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021228</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021228</identifier>
<identifier type="nhmrc">2021228</identifier>
<name type="primary"><namePart>Making next-generation dendritic cell vaccines a reality</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | immunology not elsewhere classified | </subject>
<subject type="local">dendritic cell </subject>
<subject type="local">innate immunity</subject>
<subject type="local">anti-tumour vaccine</subject>
<subject type="local">immunotherapy</subject>
<subject type="local">cancer immunotherapy</subject>
<description type="Chief Investigator">Dr Cindy Audiger</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Dendritic cells (DCs) kickstart the immune response to fight infections and cancer. Considering their power, they are also being harnessed for immunotherapy for use as ‘DC vaccines’ for the treatment of solid cancers and other immune disorders. We have found a novel way to make DCs in a petri dish in the large amounts required for such an approach. If we can demonstrate this approach is feasible in mice, it will provide the impetus to seek translational studies for use in humans.</description>
<description type="fundingAmount">$598,229.80</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021247</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021247</identifier>
<identifier type="nhmrc">2021247</identifier>
<name type="primary"><namePart>Understanding non-genetic inheritance in health and disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </subject>
<subject type="local">germ cells </subject>
<subject type="local">epigenetics</subject>
<subject type="local">inheritance</subject>
<subject type="local">fetal origins of disease</subject>
<subject type="local">fetal growth restriction</subject>
<description type="Chief Investigator">Assoc Prof Patrick Western</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Eggs provide genetic and non-genetic (epigenetic) information that is critical for offspring development. While we understand how genes transmit instructions that regulate offspring development, epigenetic inheritance is poorly understood. This project will determine how an essential epigenetic mechanism acting in eggs controls formation of tissues in offspring and grand-offspring and how dysregulation of this mechanism results in disease. Outcomes will help understand disease inheritance.</description>
<description type="fundingAmount">$1,433,936.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021260</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021260</identifier>
<identifier type="nhmrc">2021260</identifier>
<name type="primary"><namePart>Investigating the application of targeted therapeutics for the treatment of complex lymphatic vascular anomalies</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">lymphatic disease </subject>
<subject type="local">lymphatics</subject>
<subject type="local">transcriptional regulation</subject>
<subject type="local">signal transduction</subject>
<subject type="local">developmental biology</subject>
<description type="Chief Investigator">Prof Natasha Harvey</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Complex lymphatic anomalies arise due to defects in the development of lymphatic vessels during embryogenesis and result in stillbirth or chronic disease. We have identified pathogenic variants in the MDFIC gene underlying a complex lymphatic anomaly termed CCLA. Here, we will investigate the signalling pathways affected by pathogenic MDFIC variants and determine whether small molecule inhibitors of these signalling pathways might provide novel therapeutics able to effectively treat CCLA.</description>
<description type="fundingAmount">$694,856.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021267</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021267</identifier>
<identifier type="nhmrc">2021267</identifier>
<name type="primary"><namePart>Antibody based therapeutic development for coronaviruses</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </subject>
<subject type="local">structural immunology </subject>
<subject type="local">antibody</subject>
<subject type="local">coronavirus</subject>
<subject type="local">antiviral</subject>
<subject type="local">electron microscopy</subject>
<description type="Chief Investigator">Dr Phillip Pymm</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">The first human coronavirus was isolated from individuals suffering from the common cold in the 1960’s. Since then, three highly pathogenic human coronaviruses have arisen in the last two decades; SARS in 2002, MERS in 2012 and the devastating COVID-19 pandemic. It is critical we understand how current and emerging coronaviruses infect humans and more importantly, develop therapeutic agents to tackle current disease, resist future SARS-CoV-2 variants and new coronavirus-origin pandemics.</description>
<description type="fundingAmount">$1,103,723.30</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021271</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021271</identifier>
<identifier type="nhmrc">2021271</identifier>
<name type="primary"><namePart>Structurally informed vaccines and therapies to resist and counter JEV emergence</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical virology  | biological sciences | microbiology | virology  | biomedical and clinical sciences | clinical sciences | infectious diseases | </subject>
<subject type="local">flavivirus </subject>
<subject type="local">structural biology</subject>
<subject type="local">vaccine</subject>
<subject type="local">antibody</subject>
<subject type="local">japanese encephalitis</subject>
<description type="Chief Investigator">Dr Daniel Watterson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Flaviviruses such as JEV are arthropod-borne human pathogens that infect over 200 million annually. The current JEV vaccines are based on &gt;50 year old strains, raising the question of whether these are still optimal against modern emerging strains including the recent Australian outbreak. In this project we will reveal the molecular differences that define JEV strains. This will provide framework for a new generation of JEV vaccines as well as identify new antivirals to treat JEV infection.</description>
<description type="fundingAmount">$1,127,596.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021272</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021272</identifier>
<identifier type="nhmrc">2021272</identifier>
<name type="primary"><namePart>Dissecting the mechanisms of flavivirus neuro-pathogenesis using the systems biology approach</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | virology  | </subject>
<subject type="local">flavivirus </subject>
<subject type="local">flavivirus encephalitis</subject>
<subject type="local">flavivirus infection</subject>
<subject type="local">systems biology</subject>
<subject type="local">viral infection</subject>
<description type="Chief Investigator">Dr Andrii Slonchak</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Flaviviruses are important pathogens that Include West Nile, Japanese encephalitis and Zika viruses. They can infect human brain causing severe neurological diseases. This project is aimed to identify the cells in the brain vulnerable to viral infection and elucidate the molecular processes affected by the viruses in the brain. This will explain why flaviviruses cause neurological disease and identify the molecules that can be targeted to prevent or mitigate infection in the brain.</description>
<description type="fundingAmount">$971,941.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021286</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021286</identifier>
<identifier type="nhmrc">2021286</identifier>
<name type="primary"><namePart>Medulloblastoma plasticity, persistence, relapse and resistance</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biological sciences | biochemistry and cell biology | systems biology | </subject>
<subject type="local">medulloblastoma </subject>
<subject type="local">plasticity</subject>
<subject type="local">relapse</subject>
<subject type="local">systems biology</subject>
<subject type="local">cdk inhibitor</subject>
<description type="Chief Investigator">Dr Laura Genovesi</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Childhood cancer is devastating. For young children with medulloblastoma the outlook is bleak and if the cancer comes back after treatment it is lethal. We will identify cancer cells that survive treatment with a new drug, Palbociclib, and show how they lead to relapse. We will find out if the presence of these cells predicts relapse in patients, and develop a map of how cells develop tolerance to the drug that will help us to identify ways we might target these cells to prevent relapse.</description>
<description type="fundingAmount">$990,845.63</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021290</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021290</identifier>
<identifier type="nhmrc">2021290</identifier>
<name type="primary"><namePart>Functional genetic screen of osteoclasts targeted to risk loci for osteoporosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | </subject>
<subject type="local">osteoporosis </subject>
<subject type="local">fragility fracture</subject>
<subject type="local">osteoclast</subject>
<subject type="local">gene regulation</subject>
<subject type="local">functional genomics</subject>
<description type="Chief Investigator">Assoc Prof Scott Wilson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Numerous genetic risk variants for osteoporosis, which have been identified through genome-wide association studies and are specifically relevant to osteoclast function, have been partially characterised by our group. We will now use targeted Perturb-seq, which involves pooled CRISPR screens that couple targeted genetic perturbations relevant to the risk loci, with single-cell transcriptomics of the osteoclasts to definitively delineate the mechanism of effect of the variants.</description>
<description type="fundingAmount">$743,278.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021292</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021292</identifier>
<identifier type="nhmrc">2021292</identifier>
<name type="primary"><namePart>Selective Modulation Of Brain Circuits In Obsessive-Compulsive Disorder</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </subject>
<subject type="local">obsessive-compulsive disorder (ocd) </subject>
<subject type="local">functional magnetic resonance imaging (fmri)</subject>
<subject type="local">neuromodulation</subject>
<subject type="local">neuroscience</subject>
<subject type="local">treatment-resistant</subject>
<description type="Chief Investigator">Dr Philip Mosley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Obsessive-compulsive disorder (OCD) is a mental illness that can be very difficult to treat and causes significant disability and suffering. In this research, we plan to understand how focussed electricity delivered through permanent stimulating electrodes (deep brain stimulation) works in the brain to treat OCD and how we can translate this knowledge into new therapies that can be used without the requirement for surgery - thereby increasing acceptability and accessibility for more people.</description>
<description type="fundingAmount">$1,117,972.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021305</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021305</identifier>
<identifier type="nhmrc">2021305</identifier>
<name type="primary"><namePart>Bioengineering of next-generation adeno-associated viral vectors for gene therapy clinical applications using whole human liver explant preclinical model</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biomedical and clinical sciences | paediatrics | infant and child health | </subject>
<subject type="local">gene therapy </subject>
<subject type="local">liver disease</subject>
<subject type="local">adeno-associated virus</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">animal model</subject>
<description type="Chief Investigator">Assoc Prof Leszek Lisowski</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The recent exciting advancements in gene therapies targeting genetic conditions of the liver, eye and brain rely on viral vectors that enable delivery of the therapeutic cargo to the targeted cells. Unfortunately, vector utilised for therapeutic delivery to human liver lack in efficacy, which increases therapeutic cost and lowers safety. Most advanced preclinical model of human liver, the human liver itself, will be used to develop the next generation of vectors for clinical implementation.</description>
<description type="fundingAmount">$1,163,794.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021307</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021307</identifier>
<identifier type="nhmrc">2021307</identifier>
<name type="primary"><namePart>Modulators of T cell signaling: mechanism of pathogen virulence factors and design of synthetic immunomodulatory constructs</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">membrane signalling </subject>
<subject type="local">t cell activation</subject>
<subject type="local">t cell receptor</subject>
<subject type="local">intracellular signalling</subject>
<subject type="local">signalling pathways</subject>
<description type="Chief Investigator">Dr Jesse Goyette</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">T cells are immune cells critical for clearing infections and fighting cancer. They can distinguish healthy from infected or cancerous cells by sensing cues in their environment and encoding this information into networks of biochemical reactions, which are integrated into a functional decision. We will use cutting edge microscopy techniques to decode this information processing mechanism so that we may better intervene when T cells make incorrect decisions and fail to perform their function.</description>
<description type="fundingAmount">$834,168.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021322</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021322</identifier>
<identifier type="nhmrc">2021322</identifier>
<name type="primary"><namePart>Improving CNS copper availability to mitigate permanent neurological disability in progressive cases of multiple sclerosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - inorganic elements and compounds | </subject>
<subject type="local">multiple sclerosis (ms) </subject>
<subject type="local">copper</subject>
<subject type="local">copper deficiency</subject>
<subject type="local">neuroprotection</subject>
<subject type="local">treatment strategies</subject>
<description type="Chief Investigator">Assoc Prof Peter Crouch</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The accumulation of permanent neurological disability in progressive cases of multiple sclerosis represents a major, unmet medical need. New treatment options are required, but their production to date has been limited by incomplete knowledge of the underpinning biological factors and events. This application presents our discovery of a treatable feature of progressive multiple sclerosis and outlines our plan to develop novel compounds that can produce life-changing outcomes.</description>
<description type="fundingAmount">$847,286.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021360</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021360</identifier>
<identifier type="nhmrc">2021360</identifier>
<name type="primary"><namePart>A gut feeling about new therapies for glioma treatment: lessons from the enteric nervous system</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">enteric nervous system </subject>
<subject type="local">glioma</subject>
<subject type="local">glial cells</subject>
<subject type="local">dna repair</subject>
<subject type="local">cancer immunology</subject>
<description type="Chief Investigator">Dr Marlene Hao</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Gliomas are the most aggressive form of brain cancer. Gliomas come from glial cells, a type of support cell in the nervous system. Glial cells are found in the brain and also in the enteric nervous system, which is located in the gut. However, gliomas are rarely found in the gut and are generally benign. In this study, we aim to identify factors that protect enteric glial cells from forming aggressive cancers in order to develop new treatments for brain cancer.</description>
<description type="fundingAmount">$985,233.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021380</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021380</identifier>
<identifier type="nhmrc">2021380</identifier>
<name type="primary"><namePart>Protecting hearts from trastuzumab-induced cardiomyopathy</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | </subject>
<subject type="local">erbb receptors </subject>
<subject type="local">cell surface receptor</subject>
<subject type="local">erbb2-mediated cell signalling</subject>
<subject type="local">antibody cancer therapy</subject>
<subject type="local">anti-tumour drugs</subject>
<description type="Chief Investigator">Prof Walter Thomas</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Heart failure is a serious side-effect of an antibody-based therapy for breast cancer. The antibody targets a growth receptor called HER2, which is also present in hearts cells where it is critical for normal cardiac structure/function. We propose to mutate the HER2 receptor so it is no longer recognised by antibody, but where it retains functionality. In a mouse model of Herceptin-based cardiac toxicity, we will use viruses to deliver the resistant HER2 receptor to heart and rescue function.</description>
<description type="fundingAmount">$818,191.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021396</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021396</identifier>
<identifier type="nhmrc">2021396</identifier>
<name type="primary"><namePart>Genomic Autopsy of Pregnancy loss Study (GAPS): genomic investigations to help solve unexplained pregnancy loss at all gestations.</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | genomics | biomedical and clinical sciences | reproductive medicine | reproduction  | biological sciences | genetics | developmental genetics (incl. sex determination) | </subject>
<subject type="local">stillbirth </subject>
<subject type="local">miscarriage</subject>
<subject type="local">genomics</subject>
<subject type="local">genetics</subject>
<subject type="local">placenta</subject>
<description type="Chief Investigator">Prof Hamish Scott</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite scientific and medical advances, the rate of miscarriage and stillbirth has not declined in Australia over the past 20 years. Our project aims to better understand the underlying causes of pregnancy loss across all gestations. We will use novel genomic techniques and for the first time study variation in the placenta that may contribute to pregnancy loss. Accurate diagnosis is essential for counselling, and offers families reproductive choices to avoid future recurrence.</description>
<description type="fundingAmount">$1,489,454.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021404</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021404</identifier>
<identifier type="nhmrc">2021404</identifier>
<name type="primary"><namePart>Pregnancy and early life virome dynamics: contribution to chronic diseases</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | infant and child health | biological sciences | bioinformatics and computational biology | sequence analysis | biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </subject>
<subject type="local">allergy</subject>
<subject type="local">coeliac disease</subject>
<subject type="local">medical virology</subject>
<subject type="local">prospective cohort study</subject>
<description type="Chief Investigator">Dr Ki Wook Kim</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Viral infections during pregnancy and early life can majorly impact on maternal and infant health, and cause lifelong health issues, especially among those at risk of chronic disease. However, little is known about the early life virome of Australians, and whether it is a risk factor for pregnancy complications and chronic diseases. We will use the most comprehensive, sensitive and unbiased methods to assess pregnancy/early exposure to all viruses and their association with chronic diseases.</description>
<description type="fundingAmount">$1,441,627.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021463</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021463</identifier>
<identifier type="nhmrc">2021463</identifier>
<name type="primary"><namePart>Targeting novel cellular protagonists of cardiac fibrosis</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03rke0285</identifier><title>Baker Heart and Diabetes Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | biochemistry and cell biology | systems biology | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </subject>
<subject type="local">stromal cells </subject>
<subject type="local">cell activation</subject>
<subject type="local">cell differentiation</subject>
<subject type="local">systems biology</subject>
<subject type="local">cardiac fibrosis</subject>
<description type="Chief Investigator">Dr Alexander Pinto</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Heart failure is a leading cause of death. We have recently discovered two new heart cell types that emerge after cardiac stress to drive fibrosis—a key precursor for the development of heart failure. This project aims to determine what genes support the development of these cells and whether targeting these cells prevents the development of fibrosis after cardiac stress. This project may reveal novel approaches to prevent or treat heart failure by targeting these new fibrosis-promoting cells.</description>
<description type="fundingAmount">$1,492,287.62</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021475</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021475</identifier>
<identifier type="nhmrc">2021475</identifier>
<name type="primary"><namePart>Understanding novel ways that bacteria drive virulence by subverting metal ion intoxication</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02sc3r913</identifier><title>Griffith University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | </subject>
<subject type="local">bacterial pathogenesis </subject>
<subject type="local">streptococcal infection</subject>
<subject type="local">bacterial pathogenicity</subject>
<subject type="local">bacterial infection</subject>
<subject type="local">microbial pathogenesis</subject>
<description type="Chief Investigator">Prof Glen Ulett</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The pathogen Group B streptococcus (GBS) is a significant risk to human health, an ageing Australian population and is a major cause of severe infections in babies. This project will define fundamental aspects of streptococcal biology, revealing how bacteria survive in the human body. The outcomes will highlight novel strategies for disease prevention and treatment. Ultimately, this work could reduce the economic and social burdens imposed by GBS infections on our healthcare.</description>
<description type="fundingAmount">$910,641.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021495</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021495</identifier>
<identifier type="nhmrc">2021495</identifier>
<name type="primary"><namePart>A neural metabolic memory of diet restriction influences rebound weight gain</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </subject>
<subject type="local">neuropeptide y (npy) </subject>
<subject type="local">dopamine</subject>
<subject type="local">diets for weight loss</subject>
<subject type="local">neurobiology</subject>
<subject type="local">obesity</subject>
<description type="Chief Investigator">Prof Zane Andrews</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The overconsumption of high calorie foods in today’s society is a primary reason for the obesity epidemic. In this proposal we argue that periods of repetitive hunger program a metabolic memory of food shortage, which exacerbates feeding responses, motivation and food reward, especially high energy foods. A strong metabolic memory of food shortage may precipitate compulsive overeating, which is a major cause of obesity in today’s society.</description>
<description type="fundingAmount">$1,035,486.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021510</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021510</identifier>
<identifier type="nhmrc">2021510</identifier>
<name type="primary"><namePart>Exploring the anti-apoptotic and apoptosis-unrelated functions of MCL-1 during embryonic and blood cell development to advance MCL-1 inhibitors in clinical trials for cancer</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | </subject>
<subject type="local">apoptosis </subject>
<subject type="local">embryo development</subject>
<subject type="local">cancer chemotherapy</subject>
<subject type="local">bcl-2</subject>
<subject type="local">haematopoiesis</subject>
<description type="Chief Investigator">Dr Kerstin Brinkmann</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">In a healthy organism damaged or autoreactive cells kill themselves by a controlled cell death program, called apoptosis. Pro-survival proteins (e.g. MCL-1) block apoptosis, and their enhanced expression causes cancer. Some pro-survival inhibitory drugs (e.g. Venetoclax) are effective and well tolerated, whereas the highly effective MCL-1 inhibitors cause intolerable side effects in clinical trials. This project aims to determine the differences of these proteins to improve cancer therapy.</description>
<description type="fundingAmount">$771,528.10</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021525</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021525</identifier>
<identifier type="nhmrc">2021525</identifier>
<name type="primary"><namePart>Defining the mechanisms that underpin the environmental contribution to Parkinson’s disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </subject>
<subject type="local">parkinson disease </subject>
<subject type="local">xenobiotic metabolism</subject>
<subject type="local">glutathione</subject>
<subject type="local">oxidative stress</subject>
<subject type="local">environmental risk factors</subject>
<description type="Chief Investigator">Assoc Prof Kevin Barnham</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The number of people with Parkinson’s disease (PD) is doubling every 20 years as a consequence of exposure to environmental stressors from an industrialised world. These stressors increase the risk of developing PD, however, the underlying biology is poorly understood limiting our ability to intervene. We will characterise the link in this pathway and its association with PD. This knowledge will enable us to develop new intervention strategies that can attenuate the rising incidence of disease.</description>
<description type="fundingAmount">$1,820,255.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021560</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021560</identifier>
<identifier type="nhmrc">2021560</identifier>
<name type="primary"><namePart>Predicting disease progression in patients with myeloid neoplasms to enable early intervention</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | signal transduction | </subject>
<subject type="local">risk prediction </subject>
<subject type="local">cytokine receptor</subject>
<subject type="local">transformation</subject>
<subject type="local">stem cell biology</subject>
<subject type="local">haematological malignancy</subject>
<description type="Chief Investigator">Prof Angel Lopez</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Myelodysplastic and myeloproliferative neoplasms (MDS/MPN) are blood cancers with multiple genetic mistakes that have a risk of progressing to acute myeloid leukaemia (AML), a rapid and fatal disease. There are no reliable approaches to predict who is going to develop AML. Based on the idea that a skewed hormone receptor is the cause of the problem we propose to identify its genetic fingerprint that can predict when MDS and MPN will transform to AML to enable faster and better treatments.</description>
<description type="fundingAmount">$1,283,269.20</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021564</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021564</identifier>
<identifier type="nhmrc">2021564</identifier>
<name type="primary"><namePart>Unveiling the modulators of scarless wound healing</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">engineering | biomedical engineering | biomaterials  | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </subject>
<subject type="local">wound healing </subject>
<subject type="local">cell biology</subject>
<subject type="local">biomaterials</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">cell differentiation</subject>
<description type="Chief Investigator">Prof Alan Rowan</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Aberrant wound healing, scarring and fibrosis results in a tremendous burden on public health to treat or have them surgically removed. After injury a fibrin clot forms, this project aims to understand the properties of fibrin clots, that drive scarless, as observed in foetuses, or positive wound healing outcomes. Then engineer these key properties into smart fibrin biomaterials to improve the management of injuries to promote scarless wound healing to improve patient outcomes.</description>
<description type="fundingAmount">$994,636.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021586</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021586</identifier>
<identifier type="nhmrc">2021586</identifier>
<name type="primary"><namePart>Optimising treatment of Hepatitis B with novel predictive biomarkers</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | virology  | </subject>
<subject type="local">hepatitis b virus </subject>
<subject type="local">hepatitis b infection</subject>
<subject type="local">diagnostic assay</subject>
<subject type="local">diagnostic algorithms</subject>
<subject type="local">antiviral therapy</subject>
<description type="Chief Investigator">Assoc Prof Mark Douglas</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Hepatitis B is treatable but most people have to take medicine for life. Some people can safely stop treatment after a few years but it is difficult to predict for each person whether or not the virus will come back. We have developed a new test to measure different forms of virus in the liver. This test should identify people who can safely stop treatment and those who need to continue. In this grant we will study how to use our test to improve quality of life for people living with hepatitis B.</description>
<description type="fundingAmount">$1,210,387.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021587</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021587</identifier>
<identifier type="nhmrc">2021587</identifier>
<name type="primary"><namePart>Combining multi-omic causal-prediction networks from large patient datasets with a human intestinal organoid pipeline to identify new therapies for IBD</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00eae9z71</identifier><title>University of Newcastle</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">inflammatory bowel disease (ibd) </subject>
<subject type="local">wound repair</subject>
<subject type="local">functional genomics</subject>
<subject type="local">colonic epithelium</subject>
<subject type="local">bioinformatics</subject>
<description type="Chief Investigator">Dr Gerard Kaiko</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Inflammatory Bowel Diseases are an increasingly prevalent cause of morbidity worldwide. Therapies that induce mucosal healing are a key unmet clinical need required to improve disease remission. Using a form of artificial intelligence on genomic networks from large patient datasets we have identified novel drug targets in the intestinal epithelium. In this project we will use human 'mini-guts' to investigate the potential of these drug targets to improve healing and reduce disease severity.</description>
<description type="fundingAmount">$984,565.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021595</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021595</identifier>
<identifier type="nhmrc">2021595</identifier>
<name type="primary"><namePart>Sleep Disruption and Alzheimer’s Disease Pathology – Investigating Mechanisms via Acoustic Stimulation of Slow Wave Sleep</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | psychophysiology  | psychology | biological psychology  | behavioural neuroscience | </subject>
<subject type="local">sleep </subject>
<subject type="local">biomarkers</subject>
<subject type="local">brain ageing</subject>
<subject type="local">healthy ageing</subject>
<subject type="local">cognition</subject>
<description type="Chief Investigator">Assoc Prof Clare Anderson</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">A change in the sleep-wake system, particularly reduced deep sleep, is associated with impaired memory and cognition, and other aspects of brain health in later life. We will use exciting new technology and never-before-used ways of understanding the brain to reveal the causal role of deep sleep in brain and cognitive health. This will provide critical evidence for the use of sleep therapeutics which increase deep sleep to enhance brain health and promote cognition in older adults.</description>
<description type="fundingAmount">$1,275,717.60</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021623</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021623</identifier>
<identifier type="nhmrc">2021623</identifier>
<name type="primary"><namePart>Sensitivity to BH3 mimetics identified by BCL2 family interactions</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | cell development, proliferation and death | chemical sciences | medicinal and biomolecular chemistry | molecular medicine | </subject>
<subject type="local">bcl-2 </subject>
<subject type="local">anticancer drug action</subject>
<subject type="local">apoptosis</subject>
<subject type="local">protein complexes</subject>
<subject type="local">monoclonal antibody</subject>
<description type="Chief Investigator">Assoc Prof Ruth Kluck</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">BH3 mimetics are small molecule therapeutics which have resulted in paradigm shifts in the management of several cancers, although they are not curative and patients inevitably develop resistance. The mimetics bind to prosurvival BCL2 family members and displace proapoptotic members, indicating that sensitivity can be predicted by measuring complexes formed by BCL2 members. This project will develop the first antibodies to those complexes to measure responses of cancer cells to BH3 mimetics.</description>
<description type="fundingAmount">$596,069.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021638</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021638</identifier>
<identifier type="nhmrc">2021638</identifier>
<name type="primary"><namePart>A genomics-powered ultrahigh-throughput pipeline for rapid antibiotic discovery</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | genetics | genomics | </subject>
<subject type="local">bacteriology </subject>
<subject type="local">antibiotics</subject>
<subject type="local">microbiology</subject>
<subject type="local">organic chemistry</subject>
<subject type="local">genomics</subject>
<description type="Chief Investigator">Dr Sacha Pidot</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Antibiotic resistant bacterial infections are becoming increasingly common in both hospitals and the community. A key strategy to overcome resistant bacteria is to identify new antibiotics. However, we must do this faster and more creatively or we risk rediscovering already known antibiotics. This project will miniaturise and accelerate the antibiotic discovery process, allowing us to investigate previously unseen bacteria and find antibiotics to combat multi-drug resistant infections.</description>
<description type="fundingAmount">$897,480.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021644</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021644</identifier>
<identifier type="nhmrc">2021644</identifier>
<name type="primary"><namePart>Genomic medicine for Indigenous Australians</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/019wvm592</identifier><title>Australian National University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | genetics | gene mapping | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | </subject>
<subject type="local">genetic variation </subject>
<subject type="local">genetic association</subject>
<subject type="local">demography</subject>
<subject type="local">renal disease</subject>
<subject type="local">genetic mapping</subject>
<description type="Chief Investigator">Dr Ashley Farlow</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Whole genome sequencing of individuals from four remote Indigenous communities uncovered genomic patterns that suggest why previous studies failed to identify the genetic basis of two important diseases. We will use this information to develop a novel approach to find the causes of chronic kidney disease in people from the Tiwi Islands. These genetic patterns also allow us to recommend guidelines that increase the chance of success for future mapping projects in other Indigenous communities.</description>
<description type="fundingAmount">$885,257.50</description>
<coverage><spatial type="text">ACT</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021675</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021675</identifier>
<identifier type="nhmrc">2021675</identifier>
<name type="primary"><namePart>Harnessing Endogenous Opioids to Treat Gut Motility Disorders and Pain</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | autonomic nervous system  | </subject>
<subject type="local">opioid receptors </subject>
<subject type="local">enteric nervous system</subject>
<subject type="local">molecular pharmacology</subject>
<subject type="local">protein structure</subject>
<subject type="local">rational drug design</subject>
<description type="Chief Investigator">Dr Daniel Poole</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Opioids are highly effective pain killers and anti-diarrheal drugs, but their use can be severely limited by serious side-effects. An alternative therapeutic strategy that largely avoids these side-effects is to harness the actions of opioids produced by the body. This project explores a new approach to enhance the effects of these opioids to provide natural pain relief and a new approach to regulate the movement of contents through the intestine.</description>
<description type="fundingAmount">$1,260,809.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021687</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021687</identifier>
<identifier type="nhmrc">2021687</identifier>
<name type="primary"><namePart>Blocking harmful lung damage during acute exacerbations of chronic obstructive pulmonary disease (COPD) caused by infections</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </subject>
<subject type="local">chronic obstructive pulmonary disease (copd) </subject>
<subject type="local">acute exacerbations</subject>
<subject type="local">respiratory infection</subject>
<subject type="local">lung disease</subject>
<subject type="local">drug efficacy</subject>
<description type="Chief Investigator">Assoc Prof Jane Bourke</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Chronic obstructive pulmonary disease (COPD) affects over 2 million Australians and acute attacks, triggered by viruses or bacteria, can be fatal. Standard treatment with steroids is highly damaging to the lungs and safer treatments are urgently needed. Our team of leading clinical and basic science COPD researchers has identified a new drug with the potential to improve patient outcomes. Our pioneering studies will break the connection between COPD attacks, infections, lung damage and death.</description>
<description type="fundingAmount">$938,417.91</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021704</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021704</identifier>
<identifier type="nhmrc">2021704</identifier>
<name type="primary"><namePart>Mechanisms of regulatory T cell function</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | cellular immunology | </subject>
<subject type="local">regulatory t cells </subject>
<subject type="local">bone marrow transplantation</subject>
<subject type="local">graft versus host disease (gvhd)</subject>
<subject type="local">knockout mouse</subject>
<subject type="local">flow cytometry</subject>
<description type="Chief Investigator">Prof Barbara Fazekas de St Groth</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Normal regulation of the immune system is vital to human health, especially after bone marrow transplantation, but we still do yet not know exactly how it is achieved. In this project we will study one of the most important molecules used to regulate immune responses, CTLA-4. We aim to show that secreted CTLA-4, rather than CTLA-4 on the surface of immune cells, is responsible for immune regulation. Secreted CTLA-4 may hold promise as a new therapy for graft-versus host disease after transplant.</description>
<description type="fundingAmount">$1,179,644.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021732</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021732</identifier>
<identifier type="nhmrc">2021732</identifier>
<name type="primary"><namePart>The Development of splice-switching oligonucleotides for the management of kidney disease</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </subject>
<subject type="local">alternative splicing </subject>
<subject type="local">antisense oligonucleotides</subject>
<subject type="local">kidney disease</subject>
<subject type="local">diabetic nephropathy</subject>
<subject type="local">nephropathy</subject>
<description type="Chief Investigator">Prof Merlin Thomas</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">RNA can now be used to treat human diseases. It can be used as a template to make a new protein, such as in mRNA vaccines. But RNA can also be used change how coding elements are spliced together and the protein that results from them. This strategy has been used to great effect in difficult-to-treat diseases like muscular dystrophy and spinomuscular atrophy. We will apply this same technology to target pathways critically involved in the development and progression of chronic kidney disease.</description>
<description type="fundingAmount">$892,640.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021749</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021749</identifier>
<identifier type="nhmrc">2021749</identifier>
<name type="primary"><namePart>Pre-emptive targeted therapy to optimise high-risk neuroblastoma treatment</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </subject>
<subject type="local">neuroblastoma </subject>
<subject type="local">targeted therapy</subject>
<subject type="local">pre-clinical studies</subject>
<subject type="local">drug resistance</subject>
<subject type="local">tumour progression</subject>
<description type="Chief Investigator">Dr Jamie Fletcher</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Despite intensive and prolonged treatment, half of all children diagnosed with high-risk neuroblastoma either do not respond, or subsequently relapse. There are no curative therapies for these patients. Current approaches are clearly inadequate for these children, and experimental therapies are being introduced too late. This study aims to change this paradigm through comprehensive pre-clinical evidence supporting earlier intervention with targeted agents.</description>
<description type="fundingAmount">$524,147.63</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021763</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021763</identifier>
<identifier type="nhmrc">2021763</identifier>
<name type="primary"><namePart>What codes the development of asthma in children?</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/047272k79</identifier><title>University of Western Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | paediatrics | infant and child health | </subject>
<subject type="local">asthma </subject>
<subject type="local">allergic asthma</subject>
<subject type="local">epigenetics</subject>
<subject type="local">biomarkers</subject>
<subject type="local">allergic airways disease</subject>
<description type="Chief Investigator">Prof Peter Le Souef</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Wheezing in children is very common. At present, we cannot predict which young children who wheeze will progress to develop the lung disease asthma. Thus, we cannot prevent asthma and treatment for asthma is broadly the same for everyone. We will analyse skin cells from inside the nose and blood cells from children who wheeze. Changes in these cells will help predict who will go on to develop asthma. Better, more specific treatments can also be developed.</description>
<description type="fundingAmount">$1,139,644.00</description>
<coverage><spatial type="text">WA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021811</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021811</identifier>
<identifier type="nhmrc">2021811</identifier>
<name type="primary"><namePart>Wnt Signalling in Oligodendroglia: A missing link in MS neuroinflammation</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | central nervous system  | </subject>
<subject type="local">oligodendrocytes </subject>
<subject type="local">remyelination</subject>
<subject type="local">demyelinating disease</subject>
<subject type="local">neuroinflammation</subject>
<subject type="local">wnt signalling</subject>
<description type="Chief Investigator">Dr David Gonsalvez</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Multiple Sclerosis (MS) is a disease in which a person’s immune system incorrectly attacks a specific group of cells within the central nervous system (CNS) called oligodendroglia. Destruction of these cells causes neurodegeneration that leads to devastating functional deficits. Oligodendrogila have the capacity for regeneration, but it is insufficient. We aim identify new therapeutic targets that boost the ability of oligodendroglia to regenerate and thus limit the neurodegneration in MS.</description>
<description type="fundingAmount">$1,220,251.91</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2021864</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2021864</identifier>
<identifier type="nhmrc">2021864</identifier>
<name type="primary"><namePart>Establishing caffeine as a potential new treatment option for circadian misalignment</namePart></name>
<name type="alternative"><namePart>Ideas Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/023q4bk22</identifier><title>Central Queensland University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">psychology | biological psychology  | biological psychology not elsewhere classified | </subject>
<subject type="local">circadian rhythms </subject>
<subject type="local">sleep/wake patterns</subject>
<subject type="local">caffeine</subject>
<subject type="local">melatonin</subject>
<subject type="local">temperature</subject>
<description type="Chief Investigator">Prof Greg Roach</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The aim of this project is to examine the effects of caffeine on the human internal body clock. In particular, we will assess the extent to which a moderate amount of caffeine, equivalent to a double-shot espresso, can shift the timing of the body clock. The results of this project will enable practitioners to use caffeine to treat disorders and behaviours that seriously disrupt the body clocks of 20% of Australian adults (e.g., delayed sleep onset, night work, international flight).</description>
<description type="fundingAmount">$666,986.50</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022034</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022034</identifier>
<identifier type="nhmrc">2022034</identifier>
<name type="primary"><namePart>Development of bivalent degraders targeting Aurora kinase A for the treatment of polycystic kidney disease</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </subject>
<subject type="local">drug development </subject>
<subject type="local">kidney disease</subject>
<subject type="local">medicinal chemistry</subject>
<subject type="local">pharmaceutical treatment</subject>
<subject type="local">pharmacokinetics</subject>
<description type="Chief Investigator">Prof Jonathan Baell</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Autosomal dominant polycystic kidney disease (ADPKD) affects &gt;1:1000 people and is a leading cause of kidney failure. There are no useful treatments. We have shown this disease is driven by a protein called AURKA. We have discovered a drug candidate that potently degrades this disease-driving protein in cells. This grant will support development of potency and selectivity to give a patented drug candidate for a potential safe and effective treatment for ADPKD.</description>
<description type="fundingAmount">$891,093.09</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022040</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022040</identifier>
<identifier type="nhmrc">2022040</identifier>
<name type="primary"><namePart>Development of a New Class of Formyl Peptide Receptor 1 (FPR1) Biased Agonists for the Treatment of Myocardial Infarction</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </subject>
<subject type="local">medicinal chemistry </subject>
<subject type="local">g-protein coupled receptors</subject>
<subject type="local">acute myocardial infarction (ami)</subject>
<subject type="local">drug development</subject>
<subject type="local">cardiovascular pharmacology</subject>
<description type="Chief Investigator">Prof Jonathan Baell</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Cardiovascular disease is the leading cause of death, accounting for 30% of all global deaths. We have discovered a highly potent and novel compound that is unique in boosting a particular signalling pathway in heart tissue that can greatly improve recovery from heart attack, but this compound needs further optimization of properties that will enable it to be taken as a pill. This Development Grant will resource optimization of this novel drug candidate for the treatment of heart attack.</description>
<description type="fundingAmount">$944,924.64</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022050</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022050</identifier>
<identifier type="nhmrc">2022050</identifier>
<name type="primary"><namePart>Breaking drug resistance in community-acquired bacterial pneumonia (CABP)</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | bacteriology  | </subject>
<subject type="local">streptococcus pneumoniae </subject>
<subject type="local">bacterial respiratory diseases</subject>
<subject type="local">antibiotic resistance</subject>
<subject type="local">antibiotic therapy</subject>
<subject type="local">zinc</subject>
<description type="Chief Investigator">Prof Christopher McDevitt</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">There is an urgent and critical need to develop new ways to treat infections caused by drug resistant bacterial pathogens (superbugs). Our new therapeutic approach using an antibiotic potentiator is an entirely new strategy to disrupt the antibiotic resistance mechanisms of multidrug-resistant bacteria. Our treatment using the antibiotic potentiator renders drug-resistant superbugs sensitive to existing, frontline antibiotics and will restore the efficiency of existing treatment regimens.</description>
<description type="fundingAmount">$1,098,502.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022057</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022057</identifier>
<identifier type="nhmrc">2022057</identifier>
<name type="primary"><namePart>StandingTall: Digital Fall Prevention Solution</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">health sciences | allied health and rehabilitation science | physiotherapy | </subject>
<subject type="local">falls prevention </subject>
<subject type="local">exercise</subject>
<subject type="local">healthy ageing</subject>
<subject type="local">aged care</subject>
<subject type="local">allied health</subject>
<description type="Chief Investigator">Prof Kim Delbaere</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Falls in older people worldwide are common, with one in three older people experiencing one or more falls per year. StandingTall is a tailored and progressive digital exercise program designed for older people to do at home by themselves. We will leverage the experience and intellectual resources of leading industry providers and consumers using a co-design partnership approach to ensure the successful commercialisation and implementation of StandingTall into clinical practice.</description>
<description type="fundingAmount">$1,296,922.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022075</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022075</identifier>
<identifier type="nhmrc">2022075</identifier>
<name type="primary"><namePart>Mechanistically and chemically novel reaction-hijacking pro-inhibitors for malaria</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | biochemistry and cell biology | enzymes | biological sciences | microbiology | infectious agents | chemical sciences | medicinal and biomolecular chemistry | medicinal and biomolecular chemistry not elsewhere classified | </subject>
<subject type="local">malaria </subject>
<subject type="local">drug action</subject>
<subject type="local">mechanism of action</subject>
<subject type="local">antimalarial</subject>
<subject type="local">enzyme inhibitors</subject>
<description type="Chief Investigator">Prof Leann Tilley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Diseases caused by drug-resistant infectious agents, such as the malaria parasite, represent an enormous global health threat. New drugs are desperately needed to overcome drug resistance. We have discovered a new "Trojan horse" method to induce malaria parasites to make their own toxic molecules – making them the instruments of their own demise. In this project we will work with a major pharmaceutical company toward developing these new therapeutics.</description>
<description type="fundingAmount">$514,089.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022121</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022121</identifier>
<identifier type="nhmrc">2022121</identifier>
<name type="primary"><namePart>Developing a new type of drug for inflammatory lung disease</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </subject>
<subject type="local">medicinal chemistry </subject>
<subject type="local">lung inflammation</subject>
<subject type="local">allergic asthma</subject>
<subject type="local">pulmonary fibrosis</subject>
<subject type="local">chronic obstructive pulmonary disease (copd)</subject>
<description type="Chief Investigator">Prof David Fairlie</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Millions of Australians have breathing difficulties due to viral/bacterial infections or environmental allergens/pollutants (dust mites, pollen, food, smoke) that trigger inflammation leading to lung disease (e.g. asthma, COPD, fibrosis). We have discovered a new type of drug that blocks inflammation in human cells and damage in mouse models of lung disease. This study can improve drug potency, selectivity and effectiveness and provide proof of concept preclinical data to enable clinical trials.</description>
<description type="fundingAmount">$981,805.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022218</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022218</identifier>
<identifier type="nhmrc">2022218</identifier>
<name type="primary"><namePart>Development of a novel optical stimulation therapy for Obstructive Sleep Apnoea</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </subject>
<subject type="local">obstructive sleep apnoea </subject>
<subject type="local">gene therapy</subject>
<subject type="local">sleep apnoea</subject>
<subject type="local">biomedical engineering</subject>
<subject type="local">adeno-associated virus</subject>
<description type="Chief Investigator">Prof Lynne Bilston</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Obstructive sleep apnoea is a common sleep disorder where the upper airway collapses repeatedly during sleep, interrupting breathing. It is associated with accidents and elevated risk of cardiovascular disease. Current treatments are poorly adhered to by patients, and there is a substantial market for new therapies that are patient-friendly. This project aims to bring a new minimally invasive light-stimulation therapy, Optosleep, to the stage where it can be tested in human patients.</description>
<description type="fundingAmount">$1,137,447.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022337</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022337</identifier>
<identifier type="nhmrc">2022337</identifier>
<name type="primary"><namePart>Hybrid 3D-printed imaging catheter for more accurate cardiovascular disease detection</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00892tw58</identifier><title>University of Adelaide</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </subject>
<subject type="local">diagnostic imaging </subject>
<subject type="local">acute myocardial infarction (ami)</subject>
<subject type="local">instrumentation</subject>
<subject type="local">plaque rupture</subject>
<subject type="local">atherosclerosis</subject>
<description type="Chief Investigator">Dr Jiawen Li</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Most heart attacks are caused by high-risk plaques. A significant unmet need in cardiology is to reliably detect high-risk plaques before they are life-threatening. This project will deliver the first-in-human study and commercialisation of our novel hybrid 3D-printed imaging catheter. This novel device is likely to enable accurate detection of high-risk plaques and prevent (recurrent) heart attacks. This high-tech device is ideal for manufacturing in Australia and has great export potential.</description>
<description type="fundingAmount">$905,058.50</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022449</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022449</identifier>
<identifier type="nhmrc">2022449</identifier>
<name type="primary"><namePart>Development of nanomedicine for non-alcoholic steatohepatitis</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | nanomedicine | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </subject>
<subject type="local">liver regeneration </subject>
<subject type="local">fatty liver disease</subject>
<subject type="local">nonalcoholic steatohepatitis</subject>
<subject type="local">end-stage liver disease</subject>
<subject type="local">cell therapy</subject>
<description type="Chief Investigator">Assoc Prof Rebecca Lim</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Non-alcoholic steatohepatitis (NASH) is a leading cause for liver cancer. The failure of promising drugs is due to their inability to address all aspects of this complex disease. In this proposal, we provide compelling evidence that nanoparticles shed by amniotic epithelial cells (a perinatal stem-like cell) have multivalent properties in the context of NASH. We propose the development of these ‘amniotic exosomes’ as a regenerative medicine for NASH.</description>
<description type="fundingAmount">$890,458.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022583</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022583</identifier>
<identifier type="nhmrc">2022583</identifier>
<name type="primary"><namePart>EarGenie: A diagnostic system to transform the management of infants with hearing loss</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/05e4f1b55</identifier><title>Bionics Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | sensory systems | </subject>
<subject type="local">deafness </subject>
<subject type="local">hearing aid fitting</subject>
<subject type="local">cochlear implant</subject>
<subject type="local">speech and language development</subject>
<subject type="local">diagnostic algorithms</subject>
<description type="Chief Investigator">Prof Colette McKay</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">After an infant is diagnosed with a hearing loss via new-born screening, it is critically important that a hearing aid or cochlear implant is provided as soon as possible: otherwise language development is significantly and permanently impacted. In this project we develop a novel hearing assessment system that will reduce the delay between diagnosis and provision of the optimal hearing solution for each infant from 9-24 months down to 2-6 months, thus leading to improved quality of life.</description>
<description type="fundingAmount">$1,176,999.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022585</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022585</identifier>
<identifier type="nhmrc">2022585</identifier>
<name type="primary"><namePart>Development of novel GPR52 agonists for the treatment of schizophrenia</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </subject>
<subject type="local">medicinal chemistry </subject>
<subject type="local">drug development</subject>
<subject type="local">g-protein coupled receptors</subject>
<subject type="local">schizophrenia and related disorders</subject>
<subject type="local">neuropharmacology</subject>
<description type="Chief Investigator">Prof Jonathan Baell</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">We are developing a novel class of drug candidates as better treatments for schizophrenia, a debilitating psychiatric disorder. Current therapeutics address only one component of the disorder and cause significant side-effects, often leading to discontinuation of treatment. There is a well-recognized and significant unmet need for novel, effective treatment options with fewer side effects that also address the negative symptoms and cognitive impairments core to schizophrenia.</description>
<description type="fundingAmount">$779,955.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022625</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022625</identifier>
<identifier type="nhmrc">2022625</identifier>
<name type="primary"><namePart>Development of a therapeutic monoclonal antibody</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b3dvp57</identifier><title>Garvan Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </subject>
<subject type="local">antibody engineering </subject>
<subject type="local">antibody production</subject>
<subject type="local">antibody therapy</subject>
<subject type="local">protein engineering</subject>
<subject type="local">monoclonal antibody</subject>
<description type="Chief Investigator">Prof Daniel Christ</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">This project specifically relates to the development of a product - a humanised monoclonal antibody. The project has now reached an early proof-of-principle-stage of product development and represents a highly promising commercial opportunity for Australia, with annual sales of monoclonals exceeding $100 billion in 2021. To be able to progress our basic discoveries into a commercial product a humanised antibody is required.</description>
<description type="fundingAmount">$867,242.00</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022635</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022635</identifier>
<identifier type="nhmrc">2022635</identifier>
<name type="primary"><namePart>Splice switching oligonucleotides for the treatment of chronic kidney disease</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </subject>
<subject type="local">antisense oligonucleotides </subject>
<subject type="local">alternative splicing</subject>
<subject type="local">rna processing</subject>
<subject type="local">kidney disease</subject>
<subject type="local">diabetic nephropathy</subject>
<description type="Chief Investigator">Prof Merlin Thomas</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">RNA can now be used to safely and selectively treat human diseases. RNA can be used as a template to make a new protein, such as in mRNA vaccines. But RNA can also be used change how coding elements are spliced together and the protein that results from them. This strategy has recently been used to great effect in difficult-to-treat diseases, like muscular dystrophy. We will now apply this same disruptive RNA technology to develop a novel treatment for chronic kidney disease.</description>
<description type="fundingAmount">$998,513.10</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022674</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022674</identifier>
<identifier type="nhmrc">2022674</identifier>
<name type="primary"><namePart>Development of a Plasmodium vivax multi-analyte lateral flow assay to accelerate malaria elimination</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | public health | public health not elsewhere classified | </subject>
<subject type="local">plasmodium </subject>
<subject type="local">serology</subject>
<subject type="local">treatment strategies</subject>
<subject type="local">diagnostic test</subject>
<subject type="local">exposure assessment</subject>
<description type="Chief Investigator">Prof Ivo Mueller</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">To efficiently eliminate Plasmodium vivax (Pv), malaria control programs require novel, easy-to-use tools to identify and treat people with hidden dormant Pv liver-stage infections. We have developed the first test to meet this requirement: a novel serological test that recognises specific patterns in a person's immune response to malaria. We are now developing a field-deployable rapid diagnostic test to ensure translation of this public health opportunity to accelerate malaria elimination.</description>
<description type="fundingAmount">$945,940.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022693</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022693</identifier>
<identifier type="nhmrc">2022693</identifier>
<name type="primary"><namePart>The development of DMX8.1 as a novel treatment for immunotherapy-refractory cancers</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/004y8wk30</identifier><title>QIMR Berghofer Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </subject>
<subject type="local">anticancer drug </subject>
<subject type="local">epigenetics</subject>
<subject type="local">drug resistance</subject>
<subject type="local">drug development</subject>
<subject type="local">cancer immunotherapy</subject>
<description type="Chief Investigator">Assoc Prof Jason Lee</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Optimal treatment is critical for cancer patient outcome, however, a significant proportion of patients fail to respond and relapse. Using clinically-relevant tumour models, this proposal is aimed at validating the efficacy of a novel drug that can be used either alone or in combination with other therapeutic agents to define the best combination and sequence of treatments to allow immunotherapies to be more effective in more patients.</description>
<description type="fundingAmount">$915,215.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022723</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022723</identifier>
<identifier type="nhmrc">2022723</identifier>
<name type="primary"><namePart>Preclinical Validation of a Targeted Theranostic Agent for MRI Guided Radiotherapy and Radiosensitisation of Aggressive Brain Tumours</namePart></name>
<name type="alternative"><namePart>Development Grants</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01p93h210</identifier><title>University of South Australia</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </subject>
<subject type="local">radiotherapy </subject>
<subject type="local">radiosensitivity</subject>
<subject type="local">magnetic resonance imaging (mri)</subject>
<subject type="local">nanotechnology</subject>
<subject type="local">brain tumours</subject>
<description type="Chief Investigator">Prof Benjamin Thierry</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">This project aims to validate preclinically FerroTrace-FAPi, a theranostic agent designed to improve and facilitate image guided radiotherapy. Successful outcomes would enable and improve aggressive image-guided treatment of brain tumours with acceptable neurological toxicity, including in the near future with proton beam radiotherapy. It would also pave the way to rapid commercialisation of FerroTrace-FAPi via the FDA orphan-drug designation pathway.</description>
<description type="fundingAmount">$837,678.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018644</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018644</identifier>
<identifier type="nhmrc">2018644</identifier>
<name type="primary"><namePart>Small Steps for Big Changes: Implementing an Evidence-Based Diabetes Prevention Program into Diverse Urban Communities</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | preventive medicine | </subject>
<subject type="local">community intervention study </subject>
<subject type="local">diabetes prevention </subject>
<subject type="local">physical activity </subject>
<subject type="local">health promotion </subject>
<subject type="local">implementation </subject>
<description type="Chief Investigator">Prof Genevieve Healy</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Small Steps for Big Changes is an evidence-based type 2 diabetes prevention program. Following initial success, we are now scaling up the program to deliver it in community settings across both Canada and Australia. Our trial will investigate how community-, organisation-, provider-, and patient-level factors contribute to implementation outcomes when organisations deliver the same program in different contexts. We will also examine cost-effectiveness and program impacts on diabetes prevention.</description>
<description type="fundingAmount">$1,169,612.20</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018862</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018862</identifier>
<identifier type="nhmrc">2018862</identifier>
<name type="primary"><namePart>Choose To Move Sydney</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/0384j8v12</identifier><title>University of Sydney</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">physical activity </subject>
<subject type="local">behaviour change </subject>
<subject type="local">implementation </subject>
<subject type="local">healthy ageing </subject>
<subject type="local">older people </subject>
<description type="Chief Investigator">Prof Anne Tiedemann</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Physical activity is crucial for health across the lifespan and is key to healthy ageing. Choose To Move (CTM) was developed by researchers in British Columbia, Canada, in collaboration with older adults and community-based organisations and is effective in supporting older people to increase physical activity. This research will adapt CTM to suit the needs of older Arabic speaking people in Sydney, who are particularly inactive and not well supported by existing physical activity programs.</description>
<description type="fundingAmount">$1,212,853.25</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2020155</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2020155</identifier>
<identifier type="nhmrc">2020155</identifier>
<name type="primary"><namePart>Building CapaCITY/É for Sustainable Transportation</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | public health and health services not elsewhere classified | </subject>
<subject type="local">implementation </subject>
<subject type="local">transport </subject>
<subject type="local">road safety </subject>
<subject type="local">physical activity </subject>
<subject type="local">health promotion </subject>
<description type="Chief Investigator">Assoc Prof Ben Beck</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Active and sustainable transport (such as walking and bike riding) are critical to supporting health, mobility and equity outcomes. However, cities globally are struggling to implement infrastructure to enable greater uptake of these modes of transport. Through partnerships with Australian government agencies and Canadian collaborators, we will develop a novel framework that will support governments in successfully implementing interventions to enable active and sustainable transportation.</description>
<description type="fundingAmount">$1,249,675.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2023127</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2023127</identifier>
<identifier type="nhmrc">2023127</identifier>
<name type="primary"><namePart>Supporting Healthy Lifestyle Choices to Promote Mental Health &amp; Wellbeing of Indigenous Youth Aging-Out-of-Care in Urban Settings</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Public Health Research</subject><subject type="anzsrc-for">public health and health services | aboriginal and torres strait islander health | </subject>
<subject type="local">indigenous health </subject>
<subject type="local">wellbeing </subject>
<subject type="local">social and cultural issues </subject>
<subject type="local">youth </subject>
<subject type="local">implementation </subject>
<description type="Chief Investigator">Prof Gail Garvey</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">First Nations children and young people comprise one third of children living in out-of-home care and for many the time spent in care undermines their connection to culture and community. Young people transitioning from care are vulnerable and often have limited capacity to connect with their culture and community. This project will apply a strengths-based approach to co-design culturally-grounded programs to support and improve the wellbeing of First Nations youth (12-17 years) in care.</description>
<description type="fundingAmount">$1,249,997.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018589</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018589</identifier>
<identifier type="nhmrc">2018589</identifier>
<name type="primary"><namePart>Development of Innovative Antimicrobials for Combatting Multidrug-resistant Gram-negative Bacteria: An integrated multi-disciplinary approach</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/02bfwt286</identifier><title>Monash University</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | </subject>
<subject type="local">antibiotic resistance </subject>
<subject type="local">drug discovery </subject>
<subject type="local">drug design </subject>
<subject type="local">transporters </subject>
<subject type="local">pharmacokinetics </subject>
<description type="Chief Investigator">Prof Jian Li</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">The World Health Organization (WHO) has highlighted antibiotic resistance as a major global health crisis. Gram-negative bacteria top the WHO priority pathogen list due to the lack of therapeutic options, and toxic polymyxins are often the last resort. This project will be the first to integrate cutting-edge computational and experimental approaches to develop novel, safer polymyxins and their inhalation formulations. Our study targets the urgent global medical need for new antibiotics.</description>
<description type="fundingAmount">$749,920.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018677</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018677</identifier>
<identifier type="nhmrc">2018677</identifier>
<name type="primary"><namePart>Gut leak and microbiome contribution to severe dengue disease</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Clinical Medicine and Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | medical microbiology | medical infection agents (incl. prions) | biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | medical microbiology | medical virology  | </subject>
<subject type="local">dengue fever </subject>
<subject type="local">gastrointestinal symptoms </subject>
<subject type="local">enteric bacteria </subject>
<subject type="local">mucosal inflammation </subject>
<subject type="local">viral disease </subject>
<description type="Chief Investigator">Prof Katryn Stacey</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Mosquito-borne dengue virus is a major health threat in tropical areas. When some patients are recovering from fever, their condition suddenly deteriorates with life-threatening bleeding and shock. We propose that severe disease is the result of virus-induced damage to the gut, allowing entry of bacterial products into the body. Together with collaborators in Thailand and Japan, we will investigate the impact of gut bacteria on dengue disease and possible probiotic treatments.</description>
<description type="fundingAmount">$669,503.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2018695</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2018695</identifier>
<identifier type="nhmrc">2018695</identifier>
<name type="primary"><namePart>Applying novel serological exposure markers to quantify residual malaria transmission in the Philippines</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01b6kha49</identifier><title>Walter and Eliza Hall Institute of Medical Research</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biological sciences | microbiology | infectious agents | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </subject>
<subject type="local">malaria </subject>
<subject type="local">serology </subject>
<subject type="local">surveillance </subject>
<subject type="local">plasmodium </subject>
<subject type="local">epidemiology </subject>
<description type="Chief Investigator">Dr Rhea Longley</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Malaria is an infectious disease that still affects millions of people worldwide, including in the East Asian region. In the Philippines, recent outbreaks of malaria caused by Plasmodium vivax have occurred. Plasmodium vivax is difficult to eliminate due to hidden liver-stage parasites, known as hypnozoites. We will apply our novel surveillance tools to understand how these outbreaks are occurring; to identify the hidden hypnozoite reservoir; and to accelerate malaria elimination.</description>
<description type="fundingAmount">$361,876.50</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022885</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022885</identifier>
<identifier type="nhmrc">2022885</identifier>
<name type="primary"><namePart>Taking steps against the burden of Parkinson’s disease</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03r8z3t63</identifier><title>University of New South Wales</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">parkinson disease </subject>
<subject type="local">gait disorders</subject>
<subject type="local">brief intervention</subject>
<subject type="local">biomechanics</subject>
<subject type="local">neurophysiology</subject>
<description type="Chief Investigator">Dr Andrew Brodie</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Parkinson’s disease (PD) affects over 10 million people worldwide. Unstable gait and falls affect 70% of PD patients. This EU Joint Project investigates the mechanistic changes underpinning successful treadmill intervention that are enhanced by mechanically or virtual-reality triggered gait adaptations. Four clinical centers (Sydney, Tel Aviv, Bolongna and Kiel) will recruit 168 PD patients randomized 1:1 to intervention or control groups. Outcomes will improve fall prevention in people with PD.</description>
<description type="fundingAmount">$471,454.80</description>
<coverage><spatial type="text">NSW</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022997</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022997</identifier>
<identifier type="nhmrc">2022997</identifier>
<name type="primary"><namePart>Facilitating focused ultrasound-mediated Tau clearance in Alzheimer's disease and other Tauopathies by understanding the underlying autophagic mechanisms</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/00rqy9422</identifier><title>University of Queensland</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </subject>
<subject type="local">alzheimer disease </subject>
<subject type="local">ultrasound</subject>
<subject type="local">autophagy</subject>
<subject type="local">antibody</subject>
<subject type="local">neuromodulation</subject>
<description type="Chief Investigator">Prof Juergen Goetz</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Ultrasound (US) is routinely used for diagnostic imaging, but applicability of this non-invasive technology extends far beyond bio-imaging. We have shown that US clears toxic Tau typical of Alzheimer’s disease (AD). With a team of experts in AD, US technology and multimodal imaging we aim to understand the underlying Tau clearance mechanisms and monitor the process in relation to blood flow. The proposed work constitutes an important step towards developing an US therapy for AD patients.</description>
<description type="fundingAmount">$483,493.00</description>
<coverage><spatial type="text">QLD</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2023333</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2023333</identifier>
<identifier type="nhmrc">2023333</identifier>
<name type="primary"><namePart>The role of microglia in the effects of environmental enrichment in neurodegenerative disorders</namePart></name>
<name type="alternative"><namePart>International Collaborations</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/01ej9dk98</identifier><title>University of Melbourne</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Basic Science Research</subject><subject type="anzsrc-for">biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </subject>
<subject type="local">alzheimer disease </subject>
<subject type="local">amyotrophic lateral sclerosis</subject>
<subject type="local">neurodegeneration</subject>
<subject type="local">environmental intervention</subject>
<subject type="local">amyloid beta-protein</subject>
<description type="Chief Investigator">Assoc Prof Bradley Turner</description>
<description type="Date Announced">2022-12-14T00:00:00</description>
<description type="Sector">University</description>
<description type="full">Environmental enrichment (EE) is a powerful preclinical manipulation with remarkable therapeutic promise for neurodegenerative diseases, however its molecular mechanisms remain elusive. Here, we will study the role of inflammatory brain cells in mediating clinical and pathological benefits of EE in models of Alzheimer’s disease (AD) and motor neuron disease (MND). Gene targets in microglia mediating benefits of EE will be identified which could be therapeutically exploited in neurodegeneration.</description>
<description type="fundingAmount">$486,525.00</description>
<coverage><spatial type="text">VIC</spatial></coverage>
</activity>
</registryObject>
    <registryObject group="National Health and Medical Research Council">
<key>http://purl.org/au-research/grants/nhmrc/2022398</key>
<originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
<activity type="grant">
<identifier type="purl">http://purl.org/au-research/grants/nhmrc/2022398</identifier>
<identifier type="nhmrc">2022398</identifier>
<name type="primary"><namePart>It’s time to flourish: Co-designed perinatal and early years care, self-determined by Aboriginal and Torres Strait Islander women, Resulting in policy and practice transformation and Exceptional service (ICARE).</namePart></name>
<name type="alternative"><namePart>Targeted Call for Research</namePart></name>
<relatedInfo type="party"><identifier type="doi">10.13039/501100000925</identifier><title>National Health and Medical Research Council</title><relation type="isFundedBy"/></relatedInfo>
<relatedInfo type="party"><identifier type="uri">https://ror.org/03e3kts03</identifier><title>South Australian Health and Medical Research Institute</title><relation type="isManagedBy"/></relatedInfo>
<subject type="local">Health Services Research</subject><subject type="anzsrc-for">indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander mothers and babies health and wellbeing | </subject>
<subject type="local">aboriginal health </subject>
<subject type="local">maternal and child health </subject>
<subject type="local">child development </subject>
<subject type="local">wellbeing </subject>
<subject type="local">decolonization </subject>
<description type="Chief Investigator">Assoc Prof Yvonne Clark</description>
<description type="Date Announced">2023-02-24T00:00:00</description>
<description type="Sector">Research Institutes</description>
<description type="full">Close the Gap targets and the consistent voices of Aboriginal and Torres Strait Islander people want our babies to be strong and healthy with the best start to life. This begins in pregnancy. This multi-faceted research will provide culturally appropriate and strength-based tools and supports during pregnancy and the early years to empower families. The study will generate new knowledge about empowerment, health system responses and improved data to track and understand the parent’s journey.</description>
<description type="fundingAmount">$4,973,482.00</description>
<coverage><spatial type="text">SA</spatial></coverage>
</activity>
</registryObject>
</registryObjects>